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5-HTTP: 5-hydroxytryptophan 92 
a.u.: Arbitrary Units 131 
ADC 2: Automatic Development Chamber 2 30 
AHP: American Herbal Pharmacopoeia 53 
ATR-IR: Attenuated Total Reflection Infrared 15 
ATS 4: Automatic TLC Sampler 4 30 
BC: Black cohosh 30 
BHMA: British Herbal Medicine Association III 
bp: base pairs 14 
BWH: Buckwheat herb 92 
CAD: Charged Aerosol Detector 18 
CDER: Center for Drug Evaluation and Research 7 
CHF: Swiss Francs 158 
CL: Chemiluminescence Detector 18 
CMC: Chemistry, Manufacturing, and Controls 7 
COI: Cythochrome Oxidase I 14 
COSY: Correlation Spectroscopy 16 
CPNP: Cosmetic Products Notification Portal 10 
CRAFT: Complete Reduction to Amplitude Frequency Table 16 
CV: Coefficient of Variation 78 
CYR: Corydalis rhizome 99 
DA: Decursinol Angelate 61 
DAD: Diode Array Detector 18 
DER: Drug/Extract Ratio 36 
DS: Dietary Supplements 9 
DSC: Dietary Supplements Compendium of the USP 31 
DSHEA: The Dietary Supplement Health and Education Act of 1994 9 
ECH: Coneflower 30 
EDQM: European Directorate for Quality of Medicines III 
EFSA: The European Food Safety Authority 8 
ELSD: Evaporative Light Scattering Detector 18 
EMA: European Medicines Agency 6 
EU: European Union 8 
FDCA: Federal Food, Drug, and Cosmetic Act 9 
FHH: Forum for the Harmonization of Herbal Medicines III 
FID: Flame Ionization Detector 17 
FPLA: Fair Packaging and Labeling Act 10 
FS: Food Supplement 34 
FSMA: Food Safety Modernization Act 9 
FTB: Fritillaria thunbergii bulbs 99 
GACP: Good Agricultural and Collection Practice 7 
GAP: Good Agricultural Practice 54 
GB: Ginkgo biloba 86 
GBE: Ginkgo Leaf Refined Dry Extract 74 
GC: Gas chromatography 17 
GE: Other types of ginkgo dry extract 89 
GL: Samples of Ganoderma lucidum fruiting body 126 
GLe: USP G. lucidum fruiting body extract 130 
GLFB: Ganoderma lucidum fruiting body 122 
GLm: G. lucidum fruiting body, pooled sample 130 
GMP: Good Manufacturing Practice 7 
GP: Ginkgo Products 75 
GRAS: Generally Recognized as Safe 9 






GRASE: Generally Recognized as Safe and Effective 8 
HDP: Herbal Drugs / Herbal Preparations 39 
HDRI: High-Dynamic-Range Imaging 162 
HKCMMS: Hong Kong Chinese Materia Medica Standards 123 
HMBC: Heteronuclear Multiple Bond Correlatio 16 
HMP: Herbal Medicinal Products 5 
HMPC: The Committee on Herbal Medicinal Products 6 
HPLC: High-Performance Liquid Chromatography 18 
HPTLC: High-Performance Thin-Layer Chromatography 19 
HRM: herbal Reference Material 52 
HSQC: Heteronuclear Single Quantum Coherenc 16 
Hue: Color Appearance Value 163 
I: Isorhamnetin 80 
IND: Investigational New Drug Application 7 
IR: Infrared 15 
K: Kaempferol 80 
LC: Liquid Chromatography 17 
MC: Minimum Content 60 
MS: Mass spectrometry 17 
MT: Milk thistle 30 
NDA: New Drug Application 7 
NDI: New Dietary Ingredient 9 
NF: National Formulary 8 
NGS: Next-Generation Sequencing 15 
NIFDC: National Institute of Food and Drug Control 53 
NIFDS: National Institute of Food and Drug Safety Evaluation 52 
NIMM: National Institute of Medicinal Materials 53 
NIR: Near Infrared 15 
NLEA: Nutrition Labeling and Education Act 9 
NLT: Not less than 80 
NMR: Nuclear Magnetic Resonance 16 
NP: Natural Products Reagent 31 
OTC: Over-the-Counter 7 
PCR: Polymerase Chain Reaction 14 
PEG: Polyethylene Glycol Reagent 31 
Ph. Eur.: European Pharmacopoeia 52 
PMA: Premarket Approval 10 
PPI: Peak Profiles from Images 54 
PPSD: Peak Profiles from Scanning Densitometry 58 
Q: Quercetin 80 
qNMR: Quantitative Nuclear Magnetic Resonance 17 
R: Correlation Coefficient 59 
RMPM: Reference Material of Medicinal Plant Material 52 
SJfl: Sophora flower bud 92 
SJfr: Sophora fruit 92 
SST: System Suitability Test 104 
TCM: Traditional Chinese Medicine III 
THMP: Traditional Herbal Medicinal Products 6 
THP: Tetrahydropalmatine 108 
THR: Traditional Herbal Registration 29 
TLC: Thin Layer Chromatography 19 
UHPLC: Ultra-HPLC 18 
USP: The United States Pharmacopeia 8 
UV: Ultraviolet 16 
WEU: Well-Established Medicinal Use 6







Quality control of herbals has its roots in the study of morphoanatomic and organoleptic 
characters. Nevertheless, in the last century, with the evolution of analytical chemistry, the 
quality control rapidly evolved from elementary tests to the use of sophisticated 
instruments combined with software for data management. In the current days, many 
authorities and organizations recommend a suite of tests, featuring many of these 
instruments, to evaluate quality of herbal products. HPTLC offers a comprehensive set of 
data that can be used not only for identification but also to evaluate the purity and content 
of herbal drugs, herbal preparations, and herbal products.  
The objective of this doctoral thesis was to explore in-depth the capacities of HPTLC and 
develop applications for quality control of herbals, far beyond simple identification of the 
herbal drugs, preparations, and products. For that, five studies were developed.  
In the first study, the quality of herbal drugs, preparations, and products from milk thistle 
fruit, coneflower root and aerial parts and black cohosh root, regulated under food 
supplements or medicines were evaluated with existing HPTLC methods. The suitability 
of these methods, using the entire fingerprint and several detection modes, as a tool for 
detecting quality problems, mainly adulterations, was confirmed.  
In the second study, the comprehensive HPTLC fingerprinting concept was developed with 
the goal of simplifying the quality control process. This concept combines the qualitative 
and quantitative information of HPTLC images, obtained in a single analysis, to evaluate 
the identity, purity and content of herbals. The possibilities of applying it to identify an 
herbal drug, detect mixtures with related species (purity), and develop a minimum content 
test of an analytical marker were demonstrated in Angelica gigas root.  
In the third study, the application of comprehensive HPTLC fingerprinting aimed to go one 
step beyond in the test for adulterants and to evaluate the use of the HPTLC for purity limit 
tests. This approach was evaluated with samples of ginkgo leaf and extracts, 
commercialized as food supplements in different countries. This study demonstrated that 
the information contained in the HPTLC fingerprints was suitable for verifying levels of rutin 
and quercetin, providing results similar to that of the HPLC limit test. It was also useful for 
detecting mixtures of ginkgo products not only with rutin and quercetin but also with 
buckwheat herb and sophora (flower bud or fruit).  
In the fourth study, it was evaluated the use of comprehensive HPTLC fingerprinting as an 
alternative method to the current HPLC assay of markers of TCM drugs in the Ph. Eur. 
The goal of this project was to simplify the determination of content and thus reducing the 
number of tests to be performed during quality control. For this evaluation, two TCM herbal 
drugs were chosen by the experts of the TCM working party of the Ph. Eur.: Fritillaria 
thunbergii bulbs and corydalis rhizome. In both cases, comprehensive HPTLC 
fingerprinting was proven useful for identification and minimum content testing in one 
single analysis. 
The fifth study goes one step beyond in the content determination. While the previous 
studies focused in the quantification of single markers, this study aimed to apply 
comprehensive HPTLC fingerprinting to quantify a group of constituents in an herbal drug, 
as an example of a more holistic assessment of quality. This determination was combined 
with the tests for purity and identity. To illustrate this concept, Ganoderma lucidum fruiting 
body was chosen. 
In this work, HPTLC proved to be a useful technique for routine quality control of herbal 
drugs, preparations and products. As demonstrated, it can simplify this process by 
applying the concept of comprehensive HPTLC fingerprinting. A detailed guideline of how 
to develop, validate and apply comprehensive HPTLC fingerprinting methods for routine 
quality control of herbals has been elaborated and is also included in the thesis. 








Anàlisi integral de l'empremta dactilar per cromatografia en capa fina d'alta 
resolució (HPTLC) en el control de qualitat de drogues  
i preparats vegetals i productes a base de plantes 
 
El control de qualitat dels productes a base de plantes té les seves arrels en l'estudi dels 
caràcters morfoanatòmics i organolèptics. No obstant això, al segle passat, amb l'evolució 
de la química analítica, el control de qualitat va evolucionar ràpidament des de proves 
elementals a l'ús d'instruments sofisticats combinats amb programari per a la gestió de 
dades. Actualment, moltes autoritats i organitzacions recomanen un conjunt de proves, 
amb molts d'aquests instruments, per avaluar la qualitat dels productes a base de plantes. 
La HPTLC ofereix un conjunt complet de dades que poden usar-se no només per a la 
identificació, sinó també per avaluar la puresa i el contingut de drogues i preparats 
vegetals i productes a base de plantes. 
L'objectiu d'aquesta tesi doctoral va ser explorar en profunditat les capacitats de la HPTLC 
i desenvolupar aplicacions per al control de qualitat dels productes de plantes medicinals, 
molt més enllà de la simple identificació de drogues vegetals, preparats vegetals i 
productes finals comercialitzats. Per això, es van desenvolupar cinc estudis. 
En el primer estudi, es va avaluar la qualitat de les drogues vegetals, preparats vegetals i 
productes a base de plantes del fruit de card marià, l'arrel i la part aèria de equinàcia i 
l'arrel de cimicífuga, regulats com complements alimentosos o medicaments, amb els 
mètodes existents de HPTLC. Es va confirmar la idoneïtat d'aquests mètodes, utilitzant 
l'empremta dactilar completa i diversos formes de detecció, com una eina per a detectar 
problemes de qualitat, principalment adulteracions. 
En el segon estudi, es va desenvolupar el concepte d'anàlisi integral de l'empremta 
dactilar per HPTLC (comprehensive HPTLC fingerprinting) amb l'objectiu de simplificar el 
procés de control de qualitat. Aquest concepte combina la informació qualitativa i 
quantitativa de les imatges d’HPTLC, obtingudes en una única anàlisi, per avaluar la 
identitat, la puresa i el contingut dels productes a base de plantes. La seva aplicabilitat 
per identificar una droga vegetal, detectar mescles amb espècies relacionades (puresa) i 
desenvolupar un assaig de contingut mínim d'un marcador analític es van demostrar en 
l'arrel d'Angelica gigas. 
En el tercer estudi, l'aplicació de l'anàlisi integral de l'empremta dactilar per HPTLC va 
tenir com a objectiu anar un pas més enllà en l'assaig de adulterants i avaluar l'ús de 
l’HPTLC per a l'assaig límit de puresa. Aquest enfocament es va avaluar amb mostres de 
fulla i extracte de ginkgo, comercialitzats com a complements alimentosos en diferents 
països. Aquest estudi va demostrar que la informació continguda en les empremtes 
dactilars per HPTLC era adequada per verificar els nivells de rutina i quercetina, 
proporcionant resultats similars als de l'assaig límit per HPLC. També va ser útil per 
detectar mescles de productes de ginkgo no només amb rutina i quercetina, sinó també 
amb part aèria de blat sarraí i sòfora (botó floral i fruit). 
En el quart estudi, es va avaluar l'ús de l'anàlisi integral de l'empremta dactilar per HPTLC 
com un mètode alternatiu a l'actual valoració de marcadors per HPLC en drogues vegetals 
de la medicina tradicional xinesa (MTC) a la Ph. Eur. L'objectiu d'aquest projecte era 
simplificar la determinació del contingut i, per tant, reduir el nombre de proves a realitzar 
durant el control de qualitat. Per a aquesta avaluació, dues drogues vegetals de la MTC 
van ser elegides pels experts del grup de treball TCM de la Ph. Eur.: bulb de Fritillaria 
thunbergii i rizoma de coridalis. En tots dos casos, es va demostrar que l'empremta dactilar 
completa per HPTLC era útil per a la identificació i l'assaig de contingut mínim en una sola 







El cinquè estudi va un pas més enllà en la determinació del contingut. Si bé els estudis 
anteriors es van centrar en la quantificació de marcadors individuals, aquest estudi va 
tenir com a objectiu aplicar l'anàlisi integral de l'empremta dactilar per HPTLC a la 
quantificació d'un grup de components en una droga vegetal, com un exemple d'una 
avaluació més holística de la qualitat. Aquesta determinació es va combinar amb els 
assajos d'identitat i puresa. Per ilꞏlustrar aquest concepte, es va triar el carpòfor de 
Ganoderma lucidum. 
En aquest treball, s'ha demostrat que la HPTLC és una tècnica útil per al control de qualitat 
rutinari de drogues i preparats vegetals i productes a base de plantes, i que es pot 
simplificar aquest procés aplicant el concepte d'anàlisi integral de l'empremta dactilar per 
HPTLC. S'ha elaborat una guia detallada sobre com desenvolupar, validar i aplicar 
mètodes d'anàlisi integral de l'empremta dactilar per HPTLC per al control de qualitat 












Análisis integral de la huella dactilar por cromatografía en capa fina de alta 
resolución (HPTLC) en el control de calidad de drogas  
y preparados vegetales y productos a base de plantas 
 
El control de calidad de los productos a base de plantas tiene sus raíces en el estudio de 
los caracteres morfoanatómicos y organolépticos. Sin embargo, en el siglo pasado, con 
la evolución de la química analítica, el control de calidad evolucionó rápidamente de las 
pruebas elementales al uso de instrumentos sofisticados combinados con software para 
la gestión de datos. Actualmente, muchas autoridades y organizaciones recomiendan un 
conjunto de pruebas, con muchos de estos instrumentos, para evaluar la calidad de los 
productos a base de plantas. La HPTLC ofrece un conjunto completo de datos que pueden 
usarse no sólo para la identificación, sino también para evaluar la pureza y el contenido 
de drogas y preparados vegetales y productos a base de plantas. 
El objetivo de esta tesis doctoral fue explorar en profundidad las capacidades de HPTLC 
y desarrollar aplicaciones para el control de calidad de los productos de plantas 
medicinales, mucho más allá de la simple identificación de drogas vegetales, preparados 
vegetales y productos finales comercializados. Para eso, se desarrollaron cinco estudios. 
En el primer estudio, se evaluó la calidad de las drogas vegetales, preparados vegetales 
y productos a base de plantas del fruto del cardo mariano, la raíz y la parte aérea de 
equinácea y la raíz de cimicífuga, regulados como complementos alimenticios o 
medicamentos, con los métodos existentes de HPTLC. Se confirmó la idoneidad de estos 
métodos, utilizando la huella digital completa y varios modos de detección, como una 
herramienta para detectar problemas de calidad, principalmente adulteraciones. 
En el segundo estudio, se desarrolló el concepto de análisis integral de la huella dactilar 
por HPTLC (comprehensive HPTLC fingerprinting) con el objetivo de simplificar el proceso 
de control de calidad. Este concepto combina la información cualitativa y cuantitativa de 
las imágenes de HPTLC, obtenidas en un único análisis, para evaluar la identidad, la 
pureza y el contenido de los productos a base de plantas. Su aplicabilidad para identificar 
una droga vegetal, detectar mezclas con especies relacionadas (pureza) y desarrollar un 
ensayo de contenido mínimo de un marcador analítico se demostraron en la raíz de 
Angelica gigas. 
En el tercer estudio, la aplicación del análisis integral de la huella dactilar por HPTLC tuvo 
como objetivo ir un paso más allá en el ensayo de adulterantes y evaluar el uso de la 
HPTLC para el ensayo límite de pureza. Este enfoque se evaluó con muestras de hoja y 
extracto de ginkgo, comercializados como complementos alimenticios en diferentes 
países. Este estudio demostró que la información contenida en las huellas dactilares por 
HPTLC era adecuada para verificar los niveles de rutina y quercetina, proporcionando 
resultados similares a los del ensayo límite por HPLC. También fue útil para detectar 
mezclas de productos de ginkgo no sólo con rutina y quercetina, sino también con parte 
aérea de trigo sarraceno y sófora (botón floral y fruto). 
En el cuarto estudio, se evaluó el uso del análisis integral de la huella dactilar por HPTLC 
como un método alternativo a la actual valoración de marcadores por HPLC en drogas 
vegetales de la medicina tradicional china (MTC) en la Ph. Eur. El objetivo de este 
proyecto era simplificar la determinación del contenido y, por lo tanto, reducir el número 
de pruebas a realizar durante el control de calidad. Para esta evaluación, dos drogas 
vegetales de la MTC fueron elegidas por los expertos del grupo de trabajo TCM de la Ph. 
Eur.: bulbo de Fritillaria thunbergii y rizoma coridalis. En ambos casos, se demostró que 
la huella digital completa de HPTLC era útil para la identificación y el ensayo de contenido 






mínimo en un solo análisis. 
El quinto estudio va un paso más allá en la determinación del contenido. Si bien los 
estudios anteriores se centraron en la cuantificación de marcadores individuales, este 
estudio tuvo como objetivo aplicar el análisis integral de la huella dactilar por HPTLC a la 
cuantificación de un grupo de componentes en una droga vegetal, como un ejemplo de 
una evaluación más holística de la calidad. Esta determinación se combinó con los 
ensayos de identidad y pureza. Para ilustrar este concepto, se eligió el carpóforo de 
Ganoderma lucidum. 
En este trabajo, se ha demostrado que la HPTLC es una técnica útil para el control de 
calidad rutinario de drogas y preparados vegetales y productos a base de plantas, y que 
se puede simplificar este proceso aplicando el concepto de análisis integral de la huella 
dactilar por HPTLC. Se ha elaborado una guía detallada sobre cómo desarrollar, validar 
y aplicar métodos de análisis integral de la huella dactilar por HPTLC para el control de 





























Herbal drugs are the oldest source of medicines known to mankind. For hundreds of centu-
ries, the knowledge in the herbal medicines field was gained instinctively by trial and error 
through ingestion of herbal drugs and observations of their activity or toxicity [1] [2]. This 
process was the base for the traditional herbal medicinal practices, such as Traditional 
Chinese Medicine (TCM), Ayurveda, Kampo, amongst others [3], and later on, for the 
modern Western herbal medicines.  
Because the chemistry of the herbal drugs was not known at that time, humans have iden-
tified and selected medicinal plants and foods based on sensorial characteristics (ap-
pearance, smell, taste, and texture) [4]. Therefore, botanical morphology and organoleptic 
testing was the root of quality control of herbal drugs.  
The first scientific reference to quality of herbal drugs are the collections of books named 
“De Causis Plantarium” (Plant Etiology) and “De Historia Plantarium” (Plant History), 
written by Theophrastus. In these books, Theophrastus describes and classifies more than 
500 medicinal plants [1]. Another important work in ancient history was “De Materia 
Medica”, written by Dioscorides (77 BC), the father of pharmacognosy. In his collection, 
the plant names, outward appearance, locality, mode of collection, preparation of 
medicines, and their therapeutic effect are described for about 600 medicinal plant 
species. No or short descriptions were included, but additional data were included in later 
editions, along centuries, especially in those of Mattioli and Laguna in the 16th century [1] 
[5]. 
From ancient times to early modern age, the morphological and organoleptic identity re-
mained the principal way of assessing the quality of herbal drugs. Over time, descriptions 
and illustrations of morphological characters where gaining precision and became the 
basis for the identification of herbal drugs in the pharmacopoeias in the 19th century [6] [7].  
One of the first chemical methods used in the quality control of herbal drugs were tests for 
the detection of functional groups by color reaction [4]. The Pharmacopoea Wirtenbergica 
(1741) was the first pharmacopoeia to introduce chemical testing of drugs, which later 
have been adopted in Western pharmacopoeias [6]. Nevertheless, it was only along the 
second half of the 19th century and the beginning of the 20th century, with the evolution of 
analytical chemistry, that the study of chemical compounds of the herbal drugs started [1] 
[4] [6]. This may be considered the birth of modern medicine and the beginning of scientific 
pharmacy.  
During the 19th century, after successful isolation of morphine by Friedrich Sertürner [8], 
herbal drug research was concentrating on the extraction, isolation, and purification of 
substances (e.g., quinine, caffeine, nicotine, and so forth) [1] [4]. These studies also led to 
the first synthetic medicines derived from herbal drugs, such as acetylsalicylic acid [2].  
With the emergence of the pharmaceutical science and industry in the mid-19th century, 
pure compounds isolated from plants and synthetic compounds started to be produced on 
a large scale. They became popular for treating diseases and took over the medicinal 
market. In the middle of the 20th century, companies started to invest more in the synthetic 
chemistry. Together with this shift, between 1930 and 1960, new analytical techniques, 
such as X-ray crystallography, ultraviolet and infrared spectroscopy, have emerged on the 
market for structural determination. Consequently, more  knowledge was gained regarding 
the relation between the molecular structure and the biological activity [9].  
Between 1937 and 1950s, the first regulations concerning drug safety started to appear in 
the US, Germany, and the UK. These were the base for the formal standards for testing 
and manufacture of medicines. Between 1960 and 1980, new analytical techniques, such 
as nuclear magnetic resonance and chromatography, and the beginnings of computers 
drove drug discovery and drug regulation. From this time, a more comprehensive and strict 
medicines law was implemented in many countries [9]. 
Because adverse effects and contraindications were increasingly detected in synthetic 






drugs, the interest in natural remedies was slowly restored [1]. At the last third of the 20th 
century, the consumption of herbal medicines began to increase again. This change was 
driven by the belief that herbal medicines are "natural", and thus, are safer than drugs 
because of their long history of use [3]. However, one of the impediments to its widespread 
acceptance as medicines was the lack of standards for safety, efficacy and quality control, 
as these applied to medicines [10]. 
In 1992, the WHO Regional Office for the Western Pacific recognized the importance of 
herbal medicines, and the need for their scientific study. They were one of the first to create 
a guideline defining the basic criteria for assessing quality, safety and efficacy of herbal 
medicines [3]. This document became the base for herbal medicines assessment and 
regulation in different countries.  
Molded by the conventional drugs path, quality control of herbal medicines has been 
adapted to meet the standards of the pharmaceutical industry. This means that the quality 
of an herbal is defined through several specifications, which are a set of morphological, 
chemical or biological tests that will confirm the identity, purity, and content of the material 
[11] [12] [13]. While quality control of synthetic drugs usually involves monitoring of one or 
few constituents, obtained under controlled conditions, herbal medicines have an extra 
challenge. They often present a complex chemical composition, containing numerous 
substances to be monitored, and to which the acceptance criteria need to be established 
[10] [12] [14]. Additionally, certain substances can be qualitatively and quantitatively 
influenced by environmental, genetic, and growth factors (e.g. UV radiation, different 
genetic material, different maturity/ripening stages, etc.) [12] [15], and post-harvesting 
processing. In order to simplify the quality control of herbal medicines, usually one or few 
markers of the herbal drug are chosen for monitoring during this process, rather than the 
entire range of constituents. However, based on this approach, a holistic understanding is 
set aside.  
With the years and evolution of analytical techniques, the legal requirements for herbal 
medicines became stricter, more complex and expensive, which discouraged many 
companies to pursue this path. This caused the herbal products manufacturers to fit their 
products into other regulation categories, such as medical devices and dietary 
supplements, as a faster way to reach the market. Nevertheless, many of these regulatory 
categories do not have a specific guideline for the assessment of herbal drugs, preparation 
and products. They also have different requirements for testing quality, safety and efficacy. 
These differences are discussed in the following section. 
Before discussing the regulation of herbals, definitions of the “herbal” terms commonly 
used in this work are provided. These are: 
 Herbal drugs: are mainly whole, fragmented or broken plants or parts of plants in 
an unprocessed state, usually in dried form but sometimes fresh. In this definition, 
the word ‘plant' is used in the broader sense to also include algae, fungi and 
lichens. [16].  
 Herbal preparations: are homogeneous products obtained by subjecting herbal 
drugs to treatments such as extraction, distillation, expression, fractionation, 
purification, concentration or fermentation. Herbal drug preparations include, for 
example, extracts, essential oils, expressed juices, processed exudates, and 
herbal drugs that have been subjected to size reduction for specific applications, 
for example herbal drugs cut for herbal teas or powdered for encapsulation [17]. 
 Herbal products: any product, containing as active ingredients one or more herbal 
drugs and/or one or more herbal preparations. When registered as medicines, they 
are herbal medicinal products [18]. 
For matter of terminology, this work refers to “herbals” as those materials being herbal 
drug(s) or herbal preparation(s) or herbal product(s). 






1.1 The fitting regulation  
Regulation of herbals is a complex topic because these products do not have a single 
regulatory category. Depending on their intended use, preparations, and dosages, herbals 
can fall under different definitions [19]. The main are medicinal products, food (dietary) 
supplements, medical devices, cosmetics and foodstuff. Each of them can have different 
levels of requirements for quality, safety, and efficacy. 
The second factor that complicates regulation of herbals is that the legal situation of the 
same herbal drug, preparation and product can vary from country to country. For example, 
an herbal product can be regulated as dietary supplements in the USA and as medicine in 
the European Union [20] [21]. The sales of herbals through the internet further complicates 
this scenario. Consumers can easily purchase products from anywhere in the world. Con-
sequently, products of different grades, or even unregulated items, have entered different 
markets endangering the user’s safety [21]. 
The diversity of specifications and lack of harmonization between the regulatory categories 
led to the reflection that different regulatory framework may be expected to result in 
products of different quality. To investigate this hypothesis, a literature review was 
conducted. It aimed at understanding the five main regulatory categories, for which herbals 
are eligible, and their requirements. In this review, the regulations of the EU and US were 
compared. These two regions were chosen due to their economic importance in the herbal 
market. 
1.1.1 Which are the most common regulatory classifications for herbals?  
Generally, medicinal products are any substance or combination of substances used for 
treating or preventing disease, diagnosing or restoring, correcting or modifying 
physiological functions in human beings [22].  
Food is any substance under different degrees of process, intended to be ingested by 
humans [23]. Food includes drink, chewing gum and any substance, including water. 
Herbal ingredients and products are often included in this regulatory class. They can be 
either conventional food (e.g., vegetables, spices) or food supplements. Food (dietary) 
supplements is considered as a subcategory of food in different countries, and thus, 
follows the same rules as the food category [24]. Food supplements are intended to 
supplement a diet, maintain physiological functions or correct nutritional deficiencies with 
concentrated sources of nutrients or other substances with nutritional or physiological 
effect. They can be prepared from a single substance or a combination thereof, and are 
presented in a dosage form (e.g., liquid extract, capsule, etc.) [25].  
Medical devices are any instrument, apparatus, software, implant, reagent, or other 
article (alone or in combination), intended to be used to diagnose, prevent, mitigate, and 
treat disease, injury, health condition, etc. In this case, the principal intended action is not 
achieved by any pharmacological, immunological or metabolic means, but rather by 
physical means, or the pharmacological activity is ancillary to the physical means [26] 
(e.g., propolis spray to remove mucus deposit from the nasal cavity).  
Cosmetics are any substance or mixture intended to be applied on the external parts of 
the human body, teeth and the mucous membranes of the oral cavity, with the intent of 
cleaning, perfuming, changing their appearance, protecting, keeping in good condition or 
correcting body odors [27]. Other categories, such as biocidal, scents, color additives, 
etc., are not considered in this work. 
Borderline products are those for which the boundary between the regulatory categories 
is not well-defined [28]. Usually, these types of products fall within the scope of at least 
two regulatory categories. For example, a shampoo is considered cosmetic if it is intended 
use is to clean the hair. However, if the shampoo is intended to treat dandruff, it is 
considered as medicine due to its health claims [29]. It is often the case with herbal 






products, particularly among the medicines, medical devices, cosmetics, and food 
supplements categories. For determining the classification of a product, its primary mode 
of action, its intended use, and the claims made are considered.  
1.1.2 Requirements of the five main herbals regulation categories in the EU 
and the US 
Generally, the classification of herbals depends on (1) route of administration, (2) 
formulation, (3) safety and efficacy evidences, and (4) intended use and indication. In this 
section, the typical requirements of the main regulatory categories for herbals in the EU 
and US are discussed. 
1.1.1.1 Medicinal products 
Medicinal products in EU 
In the EU, herbals can be market as medicines through a specific regulatory category 
named Herbal Medicinal Products (HMP). According to the Directive 2004/24/EC [18], 
herbal medicines can be marked as “new” herbal medicinal products, products with a well-
established medicinal use, and traditional herbal medicinal products. A comparison of the 
requirements of the three categories is shown in Figure 1.1. 
 
 
Figure 1.1 Overview of the requirements of the three categories of herbal medicinal products in the 
EU. New herbal medicinal products (HMP); well-established medicinal use products (WEU); 
Traditional Herbal Medicinal Products (THMP). Modified from [30] 
New HMP  
To obtain a license to market a new HMP, the manufacturer must submit to the authorities 
a dossier containing details about the quality, safety, and efficacy of its product through a 
process called marketing authorization [24]. The requirements and acceptance criteria for 
HMP are very similar to those of synthetic medicinal products. HMP are allowed to make 
major therapeutic claims, depending on the levels of clinical efficacy demonstrated [31] 
(Figure 1.1). The application for marketing authorization can be made through three 
different levels, from national to EU levels [30]. These procedures rely on the mutual 






recognition of the scientific evaluations of the Member States [31]. 
The marketing authorization of medical products can be very lengthy and costly, which 
demotivates many manufactures to pursue registration of their products in this category. 
Nevertheless, over the past years, manufacturers of herbal products have become more 
eager to qualify their products as medicine, mainly because several countries implemented 
strict limitations on therapeutic claims for other regulation categories such as food supple-
ments. 
HMP with well-established medicinal use (WEU) 
The WEU subcategory was created to facilitate the authorization procedure of medicinal 
products. It is applied to any type of medicine, including HMP. Products which fall in this 
category must show evidence of at least one decade of use, starting from its first 
systematic and well-documented use, recognized efficacy and acceptable levels of safety 
[32]. In this category, the applicant may not be required to perform efficacy and safety 
tests, if these can be demonstrated through a detailed scientific bibliography (Figure 1.1). 
However, quality still needs to be assessed, as for new HMP. Further aspects to be 
considered for the classification of an HMP as WEU are quantitative aspects of the use of 
the active substance, the degree of scientific interest in the use of the substance, and the 
coherence of scientific assessments and published scientific literature [24] [30]. As for new 
HMP, WEU can make major to minor therapeutic claims, depending on the levels of clinical 
efficacy.  
The Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency 
(EMA) prepared a guideline (EMEA/HMPC/ 104613/05), providing detailed instructions 
regarding the documentation needed for marketing authorization/registration of all types 
of HMP. This committee is also responsible for the elaboration of Community Herbal 
Monographs that may be used to support the full marketing authorizations of WEU. Those 
monographs reflect the scientific opinion from the HMPC concerning the safety and 
efficacy of a determined preparation of an HMP. Bibliographic application is only possible 
if the scientific information contains at least one controlled clinical study (clinical trial, post 
marketing study, epidemiological study) of good quality to substantiate the efficacy of the 
HMP [24] [30] [33]. Additionally, if the scientific bibliography does not provide sufficient 
data, it is possible to obtain marketing authorization though a mixed application (hybrid 
form) [24]. 
Traditional Herbal Medicinal Products (THMP) 
The Traditional Herbal Medicinal Products subcategory is applied exclusively for herbal 
drugs, preparation, and products for human use. This category was created to overcome 
the difficulties of manufactures to meet requirements to prove safety and principally 
efficacy of certain herbal products as medicine [18] [24]. It was first introduced in the EU 
and UK in 2004 by the Directive 2004/24/EC [18]. Some other countries, e.g., Saudi 
Arabia, Malaysia, Brazil and the Philippines, adopted a similar concept [34].  
In the EU, this category offers a simplified mechanism in which the herbal product can be 
registered as medicine based on its traditional use for specific minor indications (e.g., 
relieve the symptoms of upper respiratory tract infections), appropriated to the traditional 
use (Figure 1.1) [30] [35]. In this case, they are exempt from proofing efficacy through 
clinical trials. Eligible products should have been in medicinal use for a sufficiently long 
time, its pharmacological effects or efficacy are plausible and proved based on long-
standing use and experience (based on bibliographical or expert evidence), and are 
considered not to be harmful under normal conditions of use [18]. They are designated for 
use without supervision, have limited route of administration (oral, external, and or 
inhalation preparation), their strength and posology is specified and derived from the 
tradition, and have restrictive therapeutic claims [18] [24] [35]. Furthermore, a full expert 
report on safety and quality needs to be provided [35].   






Instead of a marketing authorization procedure, a simplified registration can be used for 
THMP. The required documentation should provide sufficient evidence of the medicinal 
use of the product during at least 30 years, including at least 15 years within the European 
Community [19] [18] [24] [35]. Safety can be proven through scientific bibliography, but 
additional tests may be required. Nevertheless, there are no exemptions for the quality 
dossier and it has to fulfill the same requirements as any other medicinal product. To 
further facilitate and harmonize the registration authorization of THMP, the HMPC has 
created a list of herbal substances, which have been in medicinal use for a sufficiently long 
time, and are considered not to be harmful under normal conditions of use. Also, 
monographs on herbal drugs and the accepted indications for the traditional use of their 
preparations are elaborated by the HMPC. The applicants can refer to this list and the 
monographs to address the safety and efficacy of a THMP [19] [30]. 
Botanical drugs regulation in the US 
Unlike various regulatory systems, the USA does not have a “traditional herbal medicinal 
product” or any particular category for herbal medicinal products. Herbal medicinal 
products are classified as “Botanical drugs”, and thus all requirements of the Federal Food, 
Drug and Cosmetic Act for drugs should apply [36] [37]. Botanical drugs may be classified 
as “new botanical drug” or “over-the-counter (OTC)”. Existing dietary supplements can 
also apply for botanical drugs.  
New botanical drugs 
According to Tamayo et al. [36], most of the botanical drugs entering in the US market will 
be considered as new, which is defined as any drug that has not been marketed before 
1938 and therefore is not generally recognized as safe and effective under the conditions 
prescribed, recommended or suggested in the labeling [36] [38]. The first regulatory step 
to obtain marketing approval is the filing of an investigational new drug application (IND). 
This document is required when a botanical drug is studied in the US for drug use. The 
final step is the submission of a new drug application (NDA) for marketing approval, which 
includes the quality control tests, clinical and non-clinical trials, and safety studies [36] [39] 
[38]. 
To encourage botanical drug development, FDA’s Center for Drug Evaluation and 
Research (CDER) published a guideline for botanical drugs, considering their complexity 
and the practical difficulties in quality control. The initial document (chemistry, 
manufacturing, and controls (CMC)), include additional information about the Good 
Agricultural and Collection Practice (GACP) and Good Manufacturing Practice (GMP) of 
the herbal drug, proper identification of the raw material, as well as information on any 
human use that can support the safety of the botanical drug. These documents are 
significantly reduced compared to those of synthetic drugs. For example, manufacturers 
are not required to purify or identify the active ingredients [36]. Nevertheless, additional 
animal studies may be requested, and the evidence required for safety and efficacy are 
not less stringent than those for synthetic drugs [36] [37] [38]. In CMC, clinical and non-
clinical data are the base documentation for the IND application [40]. 
There has been only a limited number of botanical drugs approved by the FDA due to 
stringent criteria for this regulation category. For example, between 2004 and 2016, the 
FDA received more than 600 INDs notifications for New Botanical Drugs. Only two NDA 
have been approved: Veregen® (an extract of Camellia sinensis Kuntze) and FulyzaqTM 
(an extract of dragon’s blood, the blood-red latex of Croton lechlerii Müll. Arg) [39] [41] 
[42]. 
Over-the-counter (OTC) drug 
According to the FDA’s guideline, any drug that does not fall within the definition of a 
prescription drug is a nonprescription or OTC drug. This subcategory is further divided into 
OTC New Drug Application and OTC Drug Monograph. The first sub class follows the 






same path as for new botanical drugs. For being eligible as OTC Drug Monograph, an 
herbal drug must generally be recognized as safe and effective (GRASE) and have been 
market for a long time for a specific indication. Furthermore, a botanical drug substance 
must be recognized in an official USP (USP) monograph and show compliance with the 
quality acceptance criteria of this monograph [38]. Any product that complies with an OTC 
monograph may be manufactured and sold without FDA’s approval [43]. If the botanical 
drug is not included in the USP or OTC monograph, the manufacturer should submit a 
proposal standard for inclusion in this pharmacopoeia, or a petition/Time and Extent 
Application (TEA) to amend a monograph in order to include a botanical drug substance 
[38]. Examples of herbal drugs present in OTC drugs review and OTC Drug Monograph in 
the USA are psyllium seed, senna, slippery elm bark, witch-hazel leaf/bark, etc. [38] [44].  
1.1.1.2 Herbal food and food supplements  
Herbal food and food supplements regulation in the EU 
Food supplements are regulated as a specific category of food under Directive 2002/46/EC 
in the EU. This directive has a harmonized rule for vitamins and minerals supplements, 
but it does not include considerations for herbal food supplements. Therefore, the general 
requirements of food law under the regulation [EC] N° 178/2002, and for novel food under 
regulation [EC] N° 258/97 and [EU] 2015/2283 shall apply to herbal food supplements in 
the EU [19]. The European Food Safety Authority (EFSA) is the agency responsible for its 
regulation together with the national authorities.  
The main focus of these laws is regarding the safety of the foodstuff. Besides that, they 
oblige food business operators to ensure compliance with the law and enforce the mutual 
recognition concept [19]. They also require that all kinds of food, that fall under the 
definition of novel foods (not used for human consumption within the EU before 15 May 
1997), and their claims must be authorized by the EFSA before they reach the market. For 
that, manufacturers need to submit documentation to EFSA, proving their safety through 
centralized authorization procedure [19] [45].  
Health claims can only be made if they are included in one of the EU health claims positive 
lists. The European Commission provides a list of examples of health claims for food and 
food supplements (other than herbals) that were granted in the EU [46]. Herbals have only 
“on hold” or rejected health claims. 
Unlike novel foods, the EU has no centralized authorization procedure for food 
supplements. Instead, the member states enforce their own or European laws, which may 
have different criteria. Often, this results in a lack of specifications for herbal products and 
even in their regulation classification. For example, products can have different limits for 
toxic substances such as pyrrolizidine alkaloids. They can also be regulated as food 
supplements in one member state and as THMP in another.  
Some of the member states have created their list of allowed plants (positive list) and/or a 
list of plants banned from foodstuffs (negative list), which are not consistent across the 
countries. Other information, such as the common name, plant part, restrictions, 
contraindications, interactions, etc. may be present or not [19]. Attempting to harmonize 
the safety and quality evaluation of herbal foodstuff, Belgian, French and Italian authorities 
have launched the “BELFRIT” project, which integrates the positive lists of each member 
state in a common positive list [19]. Even though the mutual recognition mechanism of 
non-harmonized EU legislation ensures free trade on the EU market, such inconsistency 
in the regulatory approaches still created barriers in the trade of those products at the 
European level. 
Dietary supplements (DS) regulation in the US 
Unlike food, dietary supplements (DS) are regulated in the US by the Dietary Supplement 
Health and Education Act of 1994 (DSHEA). The definition of DS is similar to that of EFSA 






for food supplements. However, it excludes any “highly purified ingredients derived from 
plants, products of fermentation, or homeopathic drugs [36] [47]. 
According to DSHEA, only health claims (relation between an ingredient and reduced risk 
of a disease), structure/function claims (relation between an ingredient and the typical 
structure or function of the human body) or nutrient content claims (level of a nutrient in an 
ingredient) are allowed [48]. Those claims may be submitted to FDA for approval (the 
agency can be notified up to 30 days after marketing). In case the company has not notified 
the FDA, they should include a disclaimer that the FDA has not evaluated the claim. DS 
can only be marketed in limited administration forms such as tablets, capsules, liquids, 
and others, which is different from conventional food [36] [47], and are for self-prescription. 
Furthermore, they are required to be labeled as “dietary supplement” [49].  DSHEA states 
that DS products need to be manufactured under GMP to ensure that the product meets 
quality standards [50]. Currently, a list of pre-DSHEA ingredients (positive list for DS non-
NDI) is being discussed in the US. 
The manufactures of DS are prohibited from marketing products that are adulterated or 
misbranded, and the FDA can take legal actions against fraudulent companies [51]. 
Generally, DS products do not require pre-marketing approval from the FDA because they 
are generally recognized as safe (GRAS). It means that the manufacturer is responsible 
for the safety and quality of its product. However, if the product contains “new dietary 
ingredient” (NDI) (any ingredient that has not being marketed in the USA before 1994), a 
notification should be filed to the FDA. This notification should contain information 
regarding the manufacturing process, identity, and safety of the new ingredient [20] [52], 
and it should be received at least 75 days before the product is marketed.  
Food regulation in the US 
In the US, food products are controlled by the FDCA. Products of this regulatory category 
are also allowed to make health, structure/function, or nutrition claims if derivate from their 
nutritive value. Food claims are controlled by the Nutrition Labeling and Education Act 
(NLEA) of 1990. Unlike the dietary supplements, the FDA does not require notifications 
from food manufacturers about their structure/function and nutrition claims, and 
disclaimers are not required in their labels [44]. Health claims in food have to be authorized 
by the FDA [53].  
FDCA requires that the substances used in foods are generally recognized as safe (or is 
authorized by a prior sanction), clean, and that the food product labeling should be truthful 
and not misleading [53]. Furthermore, food products should follow GMP. Any imported 
food should be adequate to the FDCA rules through the Food Safety Modernization Act 
(FSMA). 
The FDA recognizes different categories of foods: conventional food (the most common 
foods in the general food supply, such as vegetables and fruits), medical foods (intended 
for the specific dietary management of a disease), and dietary supplements [53]. 
1.1.1.3 Medical devices 
Medical devices regulation in the EU 
In the EU, medical devices do not undergo an official authorization procedure like 
medicinal products. Instead, a simpler CE-marketing document, which indicates that a 
device conforms with the applicable requirements set out in the Regulation (EU) 2017/745, 
is required [26]. The competent national authorities, and in some specific cases the EMA, 
are responsible for the regulation of medical devices in each country. According to Fan et 
al. [54], registration of products in this category may be more desirable because it is 
generally quicker than the ‘traditional’ route, and some limited therapeutic claims are 
allowed. Nevertheless, the documentation should present comprehensive clinical data 
demonstrating the product’s action by physical means or that it is ancillary to the physical 






action. Quality and safety should also be proven [26]. The quality guideline for medical 
devices provides no specific quality control information for herbal products. Not all 
European countries accept herbal products as medical devices. Italy is one exception, in 
which many herbal products were approved in this class. 
Medical devices regulation in the US 
Medical devices are classified as Class I, II, and III. Class I are considered low risk and 
subject only to general controls such as tests of sterility. Therefore, they do not require 
premarketing notification. Class II are considered moderate-risk and, thus, must file a pre-
marketing notification to FDA. Class III (e.g., defibrillators) require clinical studies 
evaluating the safety and effectiveness of the device and must file a Premarket Approval 
(PMA) application to the FDA [55].  
One of the very few examples of herbal used as a medical device is the gutta-percha. This 
product is a dental device, made from coagulated sap of some tropical trees and used to 
fill the tooth root canal. It is classified as class I and thus, exempt from premarketing 
notification [56]. FDA does not specify the test required for herbals classified as medical 
devices.  
1.1.1.4 Cosmetics  
Cosmetics regulation in the EU 
Cosmetic (herbal) products are regulated by competent national authorities in the EU, 
based on the regulation (EC) N° 1223/2009. The EU regulation requires these products to 
undergo notification procedure before marketing, via EU Cosmetic Products Notification 
Portal (CPNP), in which the safety and quality are assessed [27] [57]. This process is less 
expensive and complicated when compared to the medicinal products category [58]. 
Furthermore, cosmetic products should be accompanied by information such as purpose, 
warnings, and instructions for use, etc. [57]. The regulation (EC) N° 1223/2009 also 
includes a list of substances prohibited in cosmetic products. Some of them are plant 
species such as Monk’s hood (Aconitum napellus) [27]. 
Cosmetics regulation in the US 
In the US, cosmetic (herbal) products are regulated by the FDA under the FDCA and the 
Fair Packaging and Labeling Act (FPLA). Soaps are excluded from cosmetics definition 
and are controlled by another agency than FDA. Some products regulated as cosmetics 
in other countries, such as sunscreen, anti-aging, or products used for the treatment of 
acne, dandruff, etc., or any cosmetic product that claims therapeutic action are considered 
as drugs or as both, cosmetics and drugs in the US. In this case, the product should comply 
with both regulations. Cosmetics do not require pre-marketing approval from FDA (except 
color additives). Furthermore, the law does not require cosmetics to follow GMP, or specify 
the minimum GMP requirements [59] [60]. 
According to the FDA, the manufactures of cosmetics are prohibited from marketing prod-
ucts that are adulterated or misbranded (e.g., therapeutic claims in cosmetic only 
products). The manufacturers have the legal responsibility to ensure the safety of their 
products. No specific test to demonstrate safety is described in the regulation. The 
cosmetic companies are neither obliged to share their safety information with FDA or 
required to register their establishments or file their product formulations with FDA [61]. 
FDA has a brief list of prohibited substances in cosmetics, but none of them are of plant 
origin [62]. 
1.2 General considerations regarding regulation of herbals 
Currently, the world seems to have a fragmented approach to the regulation of herbals. 
There is no agreement on a standard classification of this type of ingredient. Instead, 
herbal products may be fitted into either medicine, food, food supplements, medical 






devices, cosmetics, or other categories. As shown in section 1.1.2, each category has 
different requirements regarding quality, safety, efficacy, where the medicine category has 
the most stringent criteria compared to unclear criteria in others. 
In this review, it was observed that excluding medicines, which are generally not 
considered as safe and thus require exhaustive control, the herbal products of other 
regulatory categories may not be thoroughly controlled by the national authorities. In these 
cases, the manufacturers are still responsible for the quality, safety and efficacy of their 
products. However, in practice, they are not always performing the corresponding tests, 
particularly because the process can quickly become very expensive when several tests 
are involved.  
In the quality control framework, the non-medicines regulations require herbal products 
manufacturers to be compliant with the laws. Nevertheless, many of them do not offer clear 
guidance on how to do that, which tests are to be performed, what to monitor and which 
acceptances criteria to select. Other regulations may define just minimum requirements, 
such as those for dietary supplements in the US, where the manufacturers should follow 
GMP and conduct at least one appropriate examination to verify the identity. However, 
concrete instructions are still lacking.   
So, manufacturers have the freedom to develop their own methods and specifications or 
use those described in a pharmacopoeia. In the latter case, they are neither obliged to 
perform all prescribed tests nor to be in agreement with the pharmacopoeia’s 
specifications as long as they do not claim compliance. Therefore, it is often observed that 
manufacturers chose only 1-2 tests from a monograph to analyze their product’s quality, 
e.g., the assay of markers. When these tests are taken out of a monograph’s context, the 
entire “quality picture” cannot be seen, but only fragments of it. This fact frequently led to 
adulteration, safety, and quality issues.  
Another problem frequently observed is the lack of information regarding the type of 
product used and how it was prepared. Led by the believe that more analytical markers 
yield more efficacious products, the manufacturers limit themselves to monitor and mainly 
report the content of a marker as the synonym of good quality products instead of 
monitoring the entire composition of the herbal drug/preparation or products.  
In order to address quality and other problems, it is inevitable to increase regulatory 
oversight of herbals in different non-medicine categories and to improve their regulation. 
Nevertheless, as mentioned by Low et al. [20], the regulatory burden cannot be ignored.  
1.3 Which are the tests required for quality control of herbals 
according to the pharmacopoeias? 
Pharmacopoeias and non-official compendia are crucial instruments for quality assurance 
and quality control of herbals. Most of the time they are enforced for herbal medicines but 
can also be applied to other regulations. Their role is to provide quality specifications, 
establish the test methods and acceptance criteria (as part of quality assurance) that are 
likely to be used by independent analysts for quality control and regulation of herbals [13] 
[146]. According to WHO [13], pharmacopoeias are legally binding collections, prepared 
by an authority, of standards and quality specifications for medicines used within its 
territory.  
The official compendia are particularly crucial for harmonizing and standardizing the 
quality of herbals within a country or region. Examples of the main pharmacopoeias and 
their number of herbal monographs are shown in Table 1.1. Currently, the European and 
the US Pharmacopoeias contain state-of-art monographs and are references for quality 
assurance and control of herbals. They are broadly accepted and also used outside of 
their region (e.g., Ph. Eur. is often used in countries that have no specific monograph 
available or no pharmacopoeia [13]).  






Table 1.1. Examples of some (non)compendial collections of herbal monographs. The listed herbal 
monographs include single and multi- herbal formulations, herbal drugs, preparations, products, 
and tinctures, sometimes of the same species.  
Region Official* compendia 
N° of herbal 
monographs 
Year/Edition/vol 
Brazil Brazilian Pharmacopoeiaa 58 2014/5th 
China The Pharmacopoeia of the People’s Republic of 
Chinab 
610 2015/10th 
Europe European Pharmacopoeiaa,b 346 2017/9th 
France French Pharmacopoeiab  52d 2005/10th  
Germany German Pharmacopoeia (DAB)b 19d 2018 
Germany German Homeopathic Pharmacopoeia (HAB)b 441 2012 
India Indian Pharmacopoeia [63] 165 2018 
India Ayurvedic Pharmacopoeia of Indiab 847 2017/ Parts I-II 
India Siddha Pharmacopoeia of Indiab 139 2011/ vol I and II 
India Unani Pharmacopoeia of India 448 2016/ Vol I-III 
Japan Japanese Pharmacopoeiab 122 2016/17th 
ROK Korean Herbal Pharmacopoeiaa 561 2019 
ROK Korean Pharmacopoeiaa 200 2014/11th 
Russia The State Pharmacopoeia of the Russian 
Federationb 
107 2018/ 14th 
CH Pharmacopoea Helveticab 24d 2012/11th  
Thailand Thai Material Medicaa ≥ 200 NI 
Thailand Thai Herbal Pharmacopoeiaa 80 2018 
UK British Pharmacopoeia (BP) 265c 2009/vol III 
US United States Pharmacopoeia (USP)b 214 2017/USP41NF36 
Vietnam Vietnamese Pharmacopoeiab 330 2017/5th Edition 
Region Non-official compendia 
N° of herbal 
monographs 
Year/Edition/vol 
Africa African Herbal Pharmacopoeiab 52 2010 
Brazil Brazilian Homeopathic Pharmacopoeiab 34 2011/3rd  
Germany German Pharmaceutical Codex (DAC)b 82 2012 
India Indian Herbal Pharmacopoeia [64] 40 NI 





Indonesia Pharmakope Herbal Indonesiab 171 2008-2011/EDISI 
I 
Inter. WHO monographsb 117 2007/Vol 1-4 
Japan 
The Japanese standards for non-
pharmacopoeial crude drugs 
56 2012 
Malaysia Malaysian Herbal Monograph 60 1990-2013/ Vol 1-
3 
Taiwan Taiwan Herbal Pharmacopoeiab 301 2015 
USA Dietary Supplement Compendium (DSC-USP)b  69 2015 
USA Herbal Medicinal Compendium (HMC-USP)b  106 2018 
UK British Herbal Pharmacopoeia (BHP)b 169 1996/2nd  
Hong 
Kong 




NI: Not informed; CH: Switzerland; EU: European Union; Inter: International; UK: United Kingdom; 
ROK: Republic of Korea. aData obtained from Presentation in TradReg congress 2017, Bonn-
Germany; bData obtained either from the pharmacopoeia’s website or in the pharmacopoeia’s 
index; ccorresponds to a combined number of monographs from the European Pharmacopoeia and 
National Pharmacopoeia. dNumber of monographs corresponding only to the national 
Pharmacopoeia (excluding those that are from Ph. Eur.).  
The quality of an herbal is defined through specifications, which will confirm the identity, 
purity, and content of the material [11] [12] [13]. Identification is performed to ensure that 






the article under examination agrees with the name on its label [65]. For that, the 
morphoanatomic and chemical characteristics of the herbal ingredient are evaluated.  
Purity tests are performed to verify whether the examined material contains undesired 
components such as adulterants, microbiological contamination, foreign matter, heavy 
metals, mycotoxins, pesticide residue, or other contaminants, and to ensure that the 
material is safe for use [66].  
Finally, the content of active principle(s) or markers is determined in order to ensure that 
the strength of the herbal drug, preparation, and product in a batch is within the defined 
specifications, and that the amount of herbal ingredient per dosage unit of a product is 
correct  [12] [66] [67]. Because herbals are chemically complex, tests for content are 
commonly based on the quantification of one or a few constituents [12].  
Analytical methods and criteria of acceptance, together with other information about the 
herbal drug/preparation and in some cases its dosage form, are described in the individual 
monographs, general monographs and general chapters of the pharmacopoeias.  
Table 1.2 shows the typical content of individual pharmacopoeial herbal monographs of 
the European Pharmacopoeia. The presence of some tests will depend on the nature of 
the material (whether it is an herbal drug, herbal extract, essential oils, etc.).  
Table 1.2 General descriptions of the content of herbal monographs, based on [63] [65] [68]  
Definition Includes at least Latin binomial (genus, species, subspecies, 
variety, author), plant part, state of the drug, minimum 
content (or limits) of quantified constituent(s)* 
Characters Few physical and organoleptic characteristics (color and, 
sometimes, odor). This section is not mandatory in the Ph. 
Eur. 
Production** - Information on harvesting, drying, etc.  
- Accepted extraction solvent, in the case of extracts 
Identification - Macroscopic and microscopic characters (may include 
images or illustrations) 
- Chromatographic profile (TLC, HPTLC, HPLC, GC) 
- Chemical reactions for identification 
- Other tests 
Purity (tests for 
impurities/contaminants) 
- Adulterants 
- Foreign matter, loss on drying, water content 
- Total ash, ash insoluble in hydrochloric acid 
- Heavy metals, pesticides, aflatoxins  
- Pyrrolizidine alkaloids 
- Microbiological quality 
Assay (tests for minimum 
content or strength) 
- Quantification of active principles or markers 
Other tests* - Extractable matter, swelling index, bitterness value 
- Matter insoluble in ethanol  
- Residual solvent in dry extract** 
Storage* Storage conditions 
Labeling* The general monograph covers most labeling items 
*Not applicable to all monographs or not required by all pharmacopoeias; **Mainly in case 
of herbal preparations 
1.4 What are the existing analytical techniques for performing 
quality control of herbals?  
In order to perform the tests required by Pharmacopoeias, a combination of different 






morphoanatomic, genomic, spectroscopic, and chromatographic techniques is used to 
assess the chemical, biological or physical parameters of an herbal drug, preparation or 
product. In this scenario, all analytical techniques are important for the evaluation of quality 
of herbals and are usually used in combination. As stated by Upton et al. [7], “the scientific 
validity of a technique depends on the analytical goal and is reflected in the concept of 
“fitness-for-purpose”. This means that each technique should be used for its correct 
purpose or function. In this section, different analytical techniques used in routine tests for 
identity, purity, and content, are briefly presented and discussed.  
1.4.1 Organoleptic analysis 
According to Dentali [69], the gross organoleptic analysis uses the sensorial impressions 
to examine and characterize the quality of a material, such as aroma, flavor/taste, texture, 
and appearance. It is applicable to identify mainly unprocessed herbal drugs, and only in 
some cases for herbal preparations. It is a low-cost alternative for identification, does not 
depend on expensive instruments and is still present in many pharmacopoeias. However, 
due to ethical reasons, nowadays tests for odor and taste are increasingly excluded from 
mandatory sections. 
1.4.2 Macroscopy and microscopy 
Macroscopy and microscopy are the oldest methods of identification of herbal drugs of 
economic and medicinal importance. They are part of nearly all pharmacopoeias 
worldwide and are one of the first identification tests required for pharmacopoeial 
compliance. They are used for the evaluation of the anatomical features of the examined 
herbal drug and are less often used for the analysis of herbal preparation [70]  [71]. 
Due to their long history of use, extensive literature is available as reference for 
comparison [70] [71]. Moreover, those techniques are relatively inexpensive and 
straightforward to use. Macroscopy and microscopy can also be useful in the purity test 
for detecting adulterants of plant origin, inert inorganic material (such as sand, salts) and 
other foreign matter, which may have been added to increase the weight of a material [7] 
[70]. 
1.4.3 DNA barcoding 
DNA barcoding emerged less than half a century ago, and, in recent decades, has been 
widely in the scientific literature for the quality control of herbals. It has been progressively 
adopted by different pharmacopoeias as a routine method. The DNA barcode of plants 
consists of characteristic combinations of nucleotides, generally extracted from the nuclear 
DNA, which allows the identification of the herbal drug species. DNA barcoding refers to 
the technique where numerous copies of DNA base-pair sequences are made using a 
primer in a polymerase chain reaction (PCR). Those copies are then identified using a 
sequencing method [72].  
This powerful and sensitive technique is also applied to distinguish animals, plant, fungal, 
and bacteria species [72] and thus, is useful for purity test of the biological source. Being 
a not quantitative technique, it is not applicable for tests of content. 
DNA barcoding is mainly applicable to the evaluation of herbal drugs with preserved 
genetic material. There are some difficulties in evaluating herbal preparations by DNA 
barcoding due to the fragmentation of the genetic material through extraction, exposure to 
high temperatures and other processes. Unlike the genome sequencing of animals, that 
uses the cythochrome oxidase I (COI) region of the mitochondrial genome to distinguish 
species, the DNA sequencing of herbals involves a combination of two or three shorter 
chloroplast regions (with 200-300 bp), called mini-barcode, to distinguish plant species 
(e.g., ITS2 and psbA-trnH) [72] [73] [74]. Such length can be easily retrieved from 
processed material and sometimes extracts. 






Due to its exceptional sensitivity, next-generation sequencing (NGS) or DNA 
metabarcoding allows parallel sequencing of multiple DNA fragments from different 
material in a single run and thus permitting the analysis of poly-herbal formulation, and 
detection of adulterants even in trace amounts [7] [72]. Besides that, the DNA content is 
independent of the physical and seasonal variation. Different plant parts cannot be 
distinguished.  
A successful identification of the botanical material by DNA barcoding relies on a solid 
DNA library, containing a large population of the target herbal drug and closely related 
species and adulterants [7].  
As mentioned by DeSalle [75], the chemical constituents of herbals are mainly responsible 
for their biological activity. Thus, relying only on the genome-based authentication will be 
insufficient for their quality control. Nevertheless, DNA barcoding can be a beneficial 
complementary method [73]. Some examples of successful identification and test for 
adulteration have been shown in [76] [77] [78] [79] and [80]. 
1.4.4 Spectroscopic techniques 
Different forms of spectroscopy create signatures or fingerprints without separation of sub-
stances. Those techniques are viewed as ‘holistic’ methods because they generate 
spectra that contain information of the entire sample. In the following sections, the use of 
infrared, UV/visible, and nuclear magnetic resonance spectroscopy for quality control of 
herbals are discussed. 
1.4.4.1 Infrared (IR) spectroscopy 
Infrared (IR) spectroscopy includes the wavelengths between the visible (700 nm) and the 
microwave (1 mm) range of the electromagnetic spectrum and is divided into three regions: 
near IR (750 - 2500 nm), mid IR (2.5 – 25 μm), and far IR (25 – 1000 μm). Spectroscopic 
techniques in the infrared (IR) wavelengths have been widely used in the fields of food, 
agriculture, and pharmaceuticals, and is also recommended by different pharmacopoeias 
in monographs. The NIR is the IR technique most frequently used for the quality control 
due to its higher energy, facilitating deeper penetration and thus easier analysis of the 
samples. However, absorption bands in the NIR are much broader than in the mid IR and 
therefore often overlap [81] [82]. 
NIR spectroscopy can be used for the identification and quantification of ingredients, all in 
a single analysis. One of its significant advantages is very little or no need for sample 
preparation. Measurements can be performed in various types of samples, from solid to 
liquid. The instrumentation is also very flexible, portable and provides a rapid analysis 
(about 30 s in the case of NIR) with a relatively low running cost. It is considered a holistic 
method, capable of detecting different classes of compounds such as carbohydrates, 
amino acids, lipids, fatty acids, proteins, polysaccharides, etc. [83].  
In the herbals field, the most commonly applied techniques are the Attenuated Total 
Reflection (ATR-IR, the most sensitive) and near IR (NIR, the least sensitive). Generally, 
IR is mainly used as a qualitative method. Besides the chemical information, other 
anatomical characteristics of the herbal drug surface can be obtained (e.g., hairy 
epidermis) [7]. It has been also applied for the assay of either a group of substances or 
specific markers. Huck [82] listed some publications that use NIR for the assay of, for 
example, total polyphenols in grape seed, blueberries, primula, and total catechins in 
green tea, bamboo leaves. Huck [82] also reported the use of NIR for the assay of specific 
markers. Some examples are the quantification of hypericin plus hyperforin in St. John’s 
wort, verbenalin plus verbascoside in Verbena officinalis, kavalactones in kava, and 
ginsenosides in ginseng root [82]. The polyphenol quantification is particularly attractive 
because it does not require pre-treatment of the sample, as in the classic Folin Ciocalteau 
method. This can reduce errors during an assay. Several publications have shown the use 
of NIR for the identification of herbals and discrimination of related species and plant parts, 






geographic origins, etc. as an alternative to the current pharmacopoeial identification 
methods [7]. However, reliability of the IR results depends on well-developed reference 
spectral library [7]. 
In summary, IR spectroscopy is suitable for the rapid evaluation of the chemical and 
physical properties of herbal samples. Nevertheless, the lack of well-established herbal 
drugs IR data bases and the need of chemometric methods to interpret the data limits its 
applicability as an identity method. 
1.4.4.2 Ultraviolet (UV) spectroscopy 
The use of UV spectroscopy has only a very limited number of publications in the field of 
identification, species discrimination, and test for purity of herbals. Some examples are 
shown in [84] [85] and [86]. Leung [87] presented an interesting application of UV 
spectroscopy for the identification of herbal drugs. In his approach, he combined the 
holistic information of the UV-Vis spectroscopy (UV spectra) with that of HPTLC 
fingerprints, obtained with different solvent systems, to develop as many identification 
features as possible. The set of data was compared to that of a characterized botanical 
reference material. This approach was successfully used to properly identify three Chinese 
herbal drugs. 
In contrast, UV-visible spectrophotometry is a well-established methodology, which is 
often described and recommended by different pharmacopoeias as a quantitative method. 
It is regarded as moderately sensitive and robust. In the quantitative analysis of herbals, 
spectrophotometry typically groups similar compounds. For example, it is used to assay 
total flavonoids and phenolic compounds, hydroxyanthracene glycosides, anthocyanins, 
coumarins, lignans, sugars, etc. [88] [89]. In many cases, these assays require a 
colorimetric reaction (e.g., Folin-Ciocalteau) to either make saturated compounds absorb 
UV-vis light by  adding a chromophore, or to change the absorbance wavelength of a 
molecule to make the assay more selective [90]. Due to its “grouping” characteristic, UV-
visible spectrophotometry often gives a more comprehensive representation of the totality 
of the herbals’ composition. However, such a general approach has a disadvantage of 
being easily fooled by admixtures of adulterants [6]. In a review publication, Foster and 
Blumenthal [91] reported that the UV assay of total anthocyanins in bilberry extract could 
be misled by the addition of anthocyanins-reach material, yielding a false-positive result. 
Kupina and Gafner [92] mentioned that one of the main reasons for adulterating grape 
seed with peanut skin is due to manufactures relying on the lack of specificity of the UV 
spectrophotometric assay of proanthocyanidins. 
1.4.4.3 Nuclear Magnetic Resonance (NMR) spectroscopy 
NMR is widely used for the analysis of natural products and is the benchmark technique 
for structure elucidation of organic compounds [93]. NMR can detect a broad range of 
substances due to its universality (detects all compounds with NMR-active nuclei), is non-
destructive, does not require elaborate sample preparation and can be used without 
separation techniques.  
In the field of identification, NMR has been used for fingerprint analysis through two main 
approaches: targeted and non-targeted. The targeted approach involves the evaluation of 
specific analytes [93]. The non-targeted approach involves the analysis of the entire 
chemical profile (approximately 30–150 metabolites), generally of the 1H-NMR spectrum. 
Data interpretation with chemometric methods is often required for this case [93] [94]. This 
combination is widely applied for assessing adulteration in foodstuff [7]. Other types of 
NMR analysis, such as 2D NMR (e.g., COSY, HMBC, HSQC, 2D J-resolved, CRAFT) is 
less often applied for the quality control of herbals. 
Because in NMR, the intensity and frequency of the signals are proportional to the number 
of atoms (molar concentration) and strength of the magnetic field, NMR provides absolute 
measurements for quantification. Quantitative analysis by NMR (qNMR), can be done with 






an internal calibration (addition of a known amount of reference substance to the sample) 
or external calibration (reference standard with known concentration and samples are 
analyzed separately). [95] [96] [93] [97]. For complex herbal mixtures, quantification of 
multiple substances can be performed simultaneously [98]. Examples of its applicability 
for the quantitative assessment of herbals is extensively reviewed by Pauli et al. in [99] 
and [100]. 
The suitability of NMR for routine quality control of herbal drugs is limited by the high costs 
of non-portable instruments, when compared to other techniques [7]. Nevertheless, 
several publications show the usability of this technique for identification, determination of 
purity, and assay of herbals. Since 2018, the US Pharmacopoeia has been introducing 
qNMR for the evaluation of the composition and simultaneously quantification of multiple 
compounds of herbal medicines and dietary supplements [101]. 
1.4.5 Mass spectrometry (MS) 
Mass spectrometry is extensively used in the fields of pharmaceutical, environmental, food 
analyses, clinical diagnostics, forensics, and protein research [102], and is mainly 
hyphenated with separation techniques (GC, LC, HPTLC and capillary electrophoresis 
(CE). The application in the quality control of herbals of the hyphenated techniques will be 
discussed in the following sections.  
MS spectrometry is very sensitive, provides high resolution, has an extensive dynamic 
range (ratio of the largest to smallest detectable signal) [103], and it does not depend on 
chromophores or functional groups for the detection of compounds [104]. Even though it 
less universal than NMR, hyphenated MS is a very selective method capable of 
distinguishing compounds with highly similar structures. Additionally, it can perform 
structural confirmation by comparing the masses of the fragments with those from a 
spectral library or the literature [102].  
MS instruments can be very costly, depending on the selected configuration, which may 
prevent them from being used in routine analysis [105] 
1.4.6 Chromatographic techniques 
Chromatography has been extensively used in the quality control of herbals and is the 
“golden standard” of most of the pharmacopoeias and non-official compendia [106]. It 
represents a significant advantage for the analysis of complex mixtures, because it 
increases the resolution of the data, and can detect different classes of compounds when 
hyphenated with different detectors or submitted to chemical reaction(s). In this work, the 
main chromatographic techniques (gas, liquid, and planar) used for the quality control of 
herbals will be discussed.  
Beside identification and tests for content, chromatography techniques are used to detect 
and quantify over 250 different pesticides [12] [107], and detect (and in some cases, 
quantify) mycotoxins [108] and pyrrolizidine alkaloids as part of the purity test. 
1.4.6.1 Gas chromatography (GC) 
The use of gas chromatography (GC) is well established in different fields, such as phar-
maceuticals, cosmetics, environmental, forensic, petrochemical, and others analyses 
[109]. GC is recommended by many pharmacopoeias and compendia for the analysis of 
essential oils and essential oil-containing herbal drugs. There exists a vast literature on 
this topic.  
Gas chromatography can be hyphenated with different detectors. The most common is the 
flame ionization detector (FID), while the MS detector is less common in routine quality 
control analysis. Hyphenated GC analysis offers some advantages such as very low 
detection limits and high separation power [106] [110] [111]. GC is the technique of choice 
for the quality control of essential oils in the pharmacopoeias, giving information relative 






to the identification, purity, and content of constituents. An example is the use of GC-FID 
for anise oil in the Ph. Eur. In this monograph, the identification of anise oil is made by 
comparing the retention times of the peaks of 7 specific constituents in the chromatograms 
of the sample and reference solutions. Relative content for these constituents is also 
obtained from the same chromatogram through normalization procedure. GC-FID is also 
used for a limit test for foeniculin and fenchone (two markers for dulterantion). Samples 
should not contain more than 0.01% of them [112]. 
GC-MS offers the advantage of reproducible spectra, particularly due to the standardized 
MS ionization energy. Due to its availability, reliability, effectiveness, and reproducibility, 
GC-MS has a long history of use in metabolomic studies. Thus numerous databases and 
libraries are available, also for secondary metabolites of herbals [106] [113] [110] [111].  
Regarding quantitative analysis, the most common approaches in the pharmacopoeias 
and routine quality control are normalization and absolute quantification. The first 
approach quantifies the relative % abundances of the detected peaks, as in the example 
of anise oil. It is accepted as a semi-quantitative method and is prescribed in many 
monographs. The second approach quantifies some markers through calibrations with 
internal or external standards [114]. It is less observed in the monographs using GC. 
Besides these applications, GC hyphenated with MS is often used for the analysis of non-
polar and semi-polar pesticides [115] [116].  
1.4.6.2 High-performance liquid chromatography (HPLC) 
HPLC is one of the principal chromatographic methods and is the technique of choice for 
quality control in different fields such as environment, food, drugs, cosmetics, forensic, 
detection of mycotoxins, etc.. In the herbal field, pharmacopoeial monographs use HPLC 
mainly as a quantitative technique [117] for determination of active principles, markers, or 
contaminants and, to a lesser extent, for identification or detection of adulterants. 
Furthermore, there exist a vast literature using hyphenated HPLC for identification, 
determination of purity, and content of herbals, based on targeted analysis [118].  
This technique has many advantages, such as easy and fully automated operation, 
suitablility to analyze almost all secondary metabolites from herbals, as well as high 
precision, resolution, selectivity, and sensitivity [119][118][117]. The most advanced form 
of HPLC is ultra-HPLC (UHPLC), featuring even smaller particles in shorter, narrow 
columns, and stronger pumps, which substantially increased the chromatographic 
resolution and peak capacity compared with HPLC, and may shorten the time of analysis. 
Nevertheless, such advance is associated with higher prices and less equipment available 
worldwide [111]. Therefore, it is not yet often applied to routine quality control of herbals.  
To detect different classes of secondary metabolites, HPLC can be coupled with different 
detectors. The most frequently used is a UV detector (e.g., diode array detector (DAD)). 
Other detectors are evaporative light scattering detector (ELSD), charged aerosol detector 
(CAD), chemiluminescence detector (CL) for non-UV absorbing compounds, NMR, and 
mass spectrometry (MS) for universal detection and identification of substances [117] 
[119]. Coupling HPLC with NMR is not an economical alternative, and thus not feasible for 
routine analysis. 
In the pharmacopoeias and compendial methods, quantitative analysis of non-volatile sub-
stances in herbals is mainly performed by HPLC. Some approaches are: (1) direct quan-
tification of one or fewer compounds, using reference substances at single concentration 
level; (2) quantification of the sum of peaks against a reference substance; and (3) group 
assays using hydrolysis reactions of the test solution for reducing the number of 
compounds to be separated (e.g., total flavonoids after hydrolysis, converting complex 
mixtures of glycosides into fewer aglycones) [6].  
Besides that, HPLC-MS is often applied for the analysis of a wide range of pesticides and 






mycotoxins in herbals [115] [116]. USP also recommends the use of a HPLC-fluorescence 
detector together with post-chromatographic column derivatization for the analysis of afla-
toxins [120].  
1.4.6.3 High-performance thin-layer chromatography (HPTLC) 
Thin layer chromatography (TLC) was the first chromatographic method used for herbal 
screening and identification in pharmacopoeias, and is still recommended by most of these 
compendia [121]. However, because of its non-instrumental and non-standardized 
characteristics, this technique has low resolution and reproducibility, high detection limits, 
and is not suitable for quantitative analysis [119]. Nevertheless, TLC saw significant 
improvements after the introduction of high-performance thin-layer chromatography 
(HPTLC) [122]. 
TLC and HPTLC share the same basic principle. HPTLC is the High-Performance version 
of TLC, which focuses on better reproducibility, sensitivity, separation power, data tracea-
bility, and GMP compliance. It relies on the use of a stationary phase with smaller particle 
size, automation of all steps through instruments controlled by software, optimized and 
standardized parameters, well-defined, and validated methods. Such advance leads to 
reliable analytical results with good intra- and inter-laboratory reproducibility [123] [122] 
[119]. The HPTLC concept and its specific parameters for the analysis of herbals are 
described in the main pharmacopoeias, such as Ph. Eur. and USP, in general chapters:  
 2.8.25 (High-performance thin-layer chromatography of herbal drugs and herbal 
drug preparations) in the 9th edition of the European Pharmacopoeia [122]. 
 Chapters <203> (High-Performance Thin-Layer Chromatography Procedure for 
Identification of Articles of Botanical Origin) and <1064> (Identification of Articles 
of botanical origin by High-Performance Thin-layer Chromatography procedure) in 
the USP 38 – NF 33 [122]. 
Some of the advantages of HPTLC for the analysis of herbals are simplicity, the possibility 
of combining a large number of stationary and mobile phases, and different choices of 
chamber configuration. It requires simpler sample preparation (no need to remove 
substances that bind irreversibly to the stationary phase, which is disposable), has low 
solvent consumption (no need for pre-equilibration of the system), and has the capacity of 
analyzing a large number of samples simultaneously (15 per plate) [121] [124]. The 
possibility of multiple detection and derivatizations gives flexibility to TLC/HPTLC and 
allows detecting compounds of different phytochemical groups in a single analysis [122]. 
The characteristic fingerprint of herbal drugs and preparations is one of the highlights of 
this technique, which relies not only on the RF values of the zones and their intensities but 
also on their specific colors prior to and after derivatization.  
Due to its long history of use as a method for the identification of herbals, a vast number 
of TLC/HPTLC methods are available worldwide. According to Reich et al. [125], in 2015, 
there were at least 1666 methods only from compendial sources applying TLC/HPLTC for 
the identification of plant material. This number tends to grow towards HPTLC with the 
modernization of the monographs for herbals in the most important pharmacopoeias 
worldwide [122].  
When HPTLC data is generated under standardized and reproducible conditions, it is pos-
sible to compare images of tracks from different plates and laboratories side-by-side, with 
the support of software (e.g., Figure 1.2). For example, Booker et al. [126] compared 40 
different samples of turmeric analyzed on 4 different plates. This feature is a good basis 
for data exchange. According to Cañigueral et al. [122], images can be stored in an 
electronic atlas or even in a cloud, which can be accessed by different labs, enabling global 
exchange and collaboration. 







Figure 1.2 Images of the fingerprints of 40 turmeric samples, arranged according to their 
similarities, after derivatization under white light. Mobile phase toluene, acetic acid 4:1 
(curcuminoids determination). Image adapted from [126]. 
HPTLC is a useful tool for determining the purity of herbals. Several pharmacopoeias in-
cluded in their specific monographs the use of HPTLC and TLC for distinguishing close 
related species, confounding material, and adulterants [122].  
Quantitative HPTLC is less often used by Pharmacopoeias. However, there exists a vast 
number of publications reporting absolute quantification of markers (with chemical 
standards and calibration curves) by HPTLC, using validated methods with good accuracy 
and precision. Examples are shown in [127] and [128].  
In addition to these features, HPTLC is also applied to stability studies of herbal products. 
Cañigueral et al. [122] stated that stability studies are necessary for the market 
authorization of an herbal medicinal product, and HPTLC can be straightforwardly applied, 
particularly to analyze the variation of the entire fingerprint, rather than of a single marker. 
Stability studies usually combine analysis of fingerprints with quantification of markers. 
Besides these applications, HPTLC is also recommended for the analysis of aflatoxins by 
the USP [120].  
1.4.7 General considerations regarding analytical techniques used for 
quality control of herbals  
As observed in this review, some techniques such as spectroscopy can look into the 
chemical composition of herbals in a less specific but more holistic way, considering its 
entire composition. On the other hand, chromatographic techniques allow to zoom into 
specific classes or individual compounds, being more selective but less holistic. Biological 
identification have irreplaceable features, such as detection of material invisible to 
chemical techniques or morphologic and genomic characterization of herbal drugs. 
Therefore, there is no absolute method capable of evaluating all quality parameters for 
herbals. Instead, a combination of them is often applied. 
Nevertheless, it is important to consider that the chemical composition of an herbal is 
responsible for its pharmacological activity and its safety. Thus, the focus of the quality 
control and assurance should be on the chemical characteristics of the herbal. In this 
context, chromatographic and spectroscopic techniques are irreplaceable. 
Chromatographic methods have the main advantage of separating complex mixtures and 
looking into the different potions of the chemical composition. They are particularly 
powerful when coupled with spectroscopic detectors. The main advantages and limitations 
of all discussed techniques are shown in Table 1.3. 
However, if a large number of tests have to be performed for quality control, the associated 
costs increase dramatically. Instead, if some techniques could be better explored for their 
entire potential, the number of analyses and the costs could be reduced. In this context, 
HPTLC proved to be a simple, visual, and pragmatic technique, capable of delivering 
reliable and reproducible results based on standardized methodology [122]. The 
improvements introduced with the instrumentation and software open a whole new field in 
herbal analysis. The unique characteristics of HPTLC fingerprints (position of the zones, 
their intensities, and colors in multiple detections), allow visual or software-based 
comparison with other samples and simpler interpretation of the chromatogram. 






Additionally, HPTLC results generated on different plates and laboratories can be directly 
compared. HPTLC also offers several advantages in comparison to other chromatographic 
and spectroscopic techniques, by combining features of both. For example, besides 
offering the separation of compounds, with HPTLC, the entire test solution is detected on 
the plate and is part of the fingerprint, including substances at the application position. 
With GC or HPLC, not everything that is injected in the instrument will be eluted or 
detected. With HPTLC, it is possible to detect several classes of substances in a single 
analysis, with the support of derivatization steps. For achieving this detection, different 
spectroscopic techniques may be used. The use of universal detectors (e.g., NMR) may 
offer a comprehensive detection. Nevertheless, most of the time, it is not coupled with a 
separation technique, and simpler instruments lack sensitivity.  







 Does not require expensive 
instruments 
 Applicable to the identification 
of herbal drugs and detection 
of adulterations 
 Limited applicability for identification 
of herbal extracts and products  
 Requires well-trained personnel 
 Sensorial description subjected to 
personal interpretation 
 Odor and taste are not considered 
ethically suitable as mandatory tests 
Macroscopy 
 Does not require expensive 
instruments  
 Applicable to the identifica-
tion of intact herbal drugs 
and detection of adulterants 
 Can identify different parts 
of the plant 
 Low cost 
 Not suitable for powdered herbal 
drugs 
 Limited application for extracts and 
products 
 Criteria of acceptance as written des-
criptions 
Microscopy 
 Does not require expensive 
instruments  
 Applicable to the identifica-
tion of intact and powdered 
herbal drugs 
 Can identify different parts 
of the plant  
 A large amount of referential 
information available  
 Digital images available 
 Relatively low cost 
 Powdered material can lead to 
misidentification of herbal drugs from 
close species  
 Limited applicability for the 
identification of herbal extracts, 
tinctures, and products  






 Useful for species identifica-
tion of herbal drugs 
 Independent from the sea-
sonal variations and age of 
the plant 
 Analysis in products contai-
ning multiple plant species is 




 Requires expensive instrumentation 
 Presence of some plant constituents 
and excipients may interfere with the 
analysis, leading to false results 
 Not suitable for identification in pro-
cessed herbal preparations and pro-
ducts 
 Universal DNA barcoding may be dif-
ficult for accurate species identifica-
tion  
 Identification based on a combination 
of two or more small regions (e.g., 
ITS2 and psbA-trnH) leads to higher 
costs 






 Problems to identify hybrids  
 Cannot distinguish the different plant 
parts of the same species 
 Cannot detect adulteration with che-
micals and addition of exhaustively 
extracted material  
 Lack of reliable information from data 






 Low to high-cost instrumenta-
tion 
 Flexible and portable instru-
mentation 
 Very simple or no sample 
preparation is required 
 Short analysis time 
 Analyze full spectrum pattern 
 Simultaneous quantification of 
different constituents is possi-
ble 
 A number of samples are required to 
calibrate the instrument and 
identification system. 
 Interpretation of data from complex 
samples requires chemometric 
methods.  
 Quantification methods are not very 
robust 
 Quantification methods have a low 
sensibility 
 Existing spectral libraries are not 
suitable for identification of species 
UV-Visible 
 Low to high-cost instrumenta-
tion 
 Simple and easy to use 
 Analyze full spectrum pattern 
 Allows quantification 
 
 Limited applicability as an identifica-
tion method due to unspecific charac-
teristics of the UV-Vis spectrum  
 Only substances with chromophores 
are detected 
 Substances without chromophores re-
quire chemical derivatization 
 Low specificity (substances can have 
similar spectrum) 
NMR 
 Is a non-destructive method 
 Robust instrumentation 
 Highly reproducible technique 
if all the parameters are care-
fully maintenance 
 Simple or no sample prepara-
tion required 
 Does not require separation 
technique 
 Can analyze the total chemi-
cal composition and detects a 
high number of metabolites 
 Suitable for ID and detection 
of adulterants 
 Can quantify without stan-
dards (using pre-established 
calibration curve) or internal 
standard 
 Is a universal detector for or-
ganic molecules 
 Very high-cost instrumentation  
 Maintenance and consumable costs 
are very high  
 Low sensitivity compared to other 
spectroscopy techniques  
 Requires experienced personal 
 1H-NMR provides complex spectra 
with overlaying peaks, hampering the 
use for identification and quantifica-
tion  
 13C-NMR provides simpler spectra 
than 1H-NMR but requires a longer 
time for acquisition and is less sen-
sitive than 1H-NMR.  
 Interpretation of data from complex 






 Low to high-cost instrumenta-
tion 
 High separation efficiency  
 Sensitive detection 
 Not suitable for thermo-labile com-
pounds 
 Non-volatile compounds require deri-
vatization 






 Robust technique 
 Well established MS libraries 
for GC-MS analysis  
 Suitable for quantification 
 It may be difficult to compare spectra 
of derivatized samples with an exis-
ting data base 
 
HPLC 
 Well-established technique  
 Large literature available in 
the herbal field 
 Fully automated  
 Suitable to analyze a wide 
range of constituent classes  
 Relatively robust methods 
 Suitable for quantification 
 UHPLC increases resolution 
and reduces analysis time  
 Medium to very high-cost instrumen-
tation. 
 Uses large volumes of solvents 
 HPLC has lower resolution power 
than GC  
 Columns lack long term reproducibility  
 Samples may require clean-up  
 A most common detector, UV-vis, is 
not universal  
HPTLC 
 Low to medium cost instru-
mentation. 
 Simple sample preparation 
 Well-defined and validated 
methods provide good intra- 
and inter-laboratory reprodu-
cibility. 
 Suitable for identification, pu-
rity test, and quantification 
 Lower solvent consumption 
than HPLC 
 Multiple detections possible in 
a single analysis 
 Instruments require very little 
maintenance 
 Data from different laborato-
ries can be compared through 
image library 
 Limited resolution and separation ca-
pability 
 Limited sensitivity 
 Absence of fully automated systems.  
 Detection may require chemical deri-
vatization 
 Lower precision and linearity range 
than HPLC and GC in quantitative 
analysis 
 Plates from a different manufacturer 













As reviewed in the introduction, quality control of herbals is a complex process that 
involves several steps, performed by a combination of methods. This assessment is often 
associated with high costs, which can discourage medium-small business to perform 
proper quality control of their material. Maybe, the number of analyses and cost could be 
reduced if the full potential of some techniques would be utilized.  
Some analytical techniques, such as chromatography, offers a comprehensive set of data, 
which can be used for different assessments. Among chromatographic techniques, the 
thin-layer chromatography (TLC) has been used for years as initial screening and 
identification of herbals. High-performance thin-layer chromatography (HPTLC) is the 
modern version of TLC. When the full potential of HPTLC is unlocked, quality control could 
be performed in a straightforward, very cost-efficient way because qualitative and 
quantitative information about the sample can be obtained in a single HPTLC analysis.  
Based on this hypothesis, the general objective of this work was to explore in-depth the 
capacities of HPTLC and develop pragmatic applications of HPTLC for quality control of 
herbals far beyond simple identification of the herbal drug, preparation, and product. 
Fitness for purpose and scalability to the different needs of different regulatory frameworks 
have been the key elements of the work. 
The specific objectives, developed from the general objective, were the following: 
1. Experimentally develop different case studies to investigate current quality 
problems of herbals regulated under different categories.  
2. Show the usefulness of the HPTLC, as described in the pharmacopoeias and with 
enlarged interpretation, as a tool for detecting quality problems, such as 
adulteration.  
3. Develop a new concept, named comprehensive HPTLC fingerprinting, taking 
advantage of the quantitative aspects of the HPTLC fingerprint, and its application 
to the quality control of herbal products, particularly to identity, purity and the 
content of markers. 
4. Demonstrate the usefulness of comprehensive HPTLC fingerprinting in the test 
for adulterants and use the quantitative aspects of the electronic images to 
perform limit tests on purity.    
5. Evaluate the use of comprehensive HPTLC fingerprinting as an alternative 
method to the current HPLC assay of markers, in order to simplify the quality 
control of TCM herbal drugs of the Ph. Eur.  
6. Evaluate the applicability of comprehensive HPTLC fingerprinting to determine 
the content of a group of constituents in an herbal drug. In addition, evaluate the 
use of pattern recognition tools to automate the identification of the samples. 
7. Develop a practical guideline on how to develop a comprehensive HPTLC 
fingerprinting method. 
The specific objectives are addressed in the different chapters as follows. Current quality 
problems of marketed herbal products (objective A) is studied in the chapter 3 (milk thistle, 
coneflower and black cohosh products) and chapter 5 (ginkgo products). Chapter 3 also 
addresses objective B. 
The concept of comprehensive HPTLC fingerprinting (objective C) is developed in chapter 
4, using the case of the root of Angelica gigas as a proof of concept. The application of 
comprehensive HPTLC fingerprinting to a better assessment of adulterations, including to 
performing limit tests for adulterants (objective D) is investigated in chapter 5 using 
products of Ginkgo biloba leaf and extracts. 
The objective E, this is the application of comprehensive HPTLC fingerprinting to perform 
a test for minimum content of markers as an alternative for the assay in TCM herbal drugs 





of the Ph. Eur. has been developed for Fritillaria thunbergii bulbs and corydalis rhizome in 
the chapter 6. The applicability of comprehensive HPTLC fingerprinting to determine the 
content of a group of constituents in an herbal drug and the use of pattern recognition tools 
for identification (objective F) has been studied in the case Ganoderma lucidum fruiting 
body and the triterpenic acids group (ganoderic and ganoderenic acids) were the 
constituents analysed. 
Finally, after the general discussion of results and taking advantage of the experience 
gained along the development of the different methods of the thesis, a guidance for future 
comprehensive HPTLC fingerprinting methods development has been elaborated 












Chapter 3: Investigation of market herbal products 
regulated under different categories: how can HPTLC 
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Investigació de productes a base de plantes del mercat regulats en diferents 
categories: com pot ajudar l’HPTLC a detectar problemes de qualitat? 
 
Antecedents: S’ha trobat que els productes a base de plantes regulats en diferents 
categories són de diferent qualitat. Això ho demostra el nombre creixent de publicacions 
sobre la qualitat dels productes a base de plantes a la literatura científica. Una adequada  
identificació és una manera eficaç d’abordar aquesta qüestió de forma precoç en el procés 
de fabricació d’un producte.  
Objectius: Avaluar la qualitat de drogues vegetals, preparacions i productes a base de 
card marià, equinàcia i cimicífuga comercialitzats en diferents categories regulatòries, i 
ilꞏlustrar la utilitat de l’HPTLC com a eina d’avaluació de la qualitat. 
Mètodes: Els mètodes HPTLC es van adaptar a partir de les monografies de la 
Farmacopea Europea per al fruit de card marià, el rizoma de cimicífuga i l’equinàcia 
purpúria. Es van utilitzar modes de detecció addicionals més enllà dels descrits a les 
monografies i es van fer servir les empremtes dactilars completes de HPTLC per a 
l'examen de la identitat i la puresa de les mostres investigades. 
Resultats: Tots els productes regulats com a medicaments tradicionals a base de plantes 
van mostrar una bona qualitat: les seves empremtes dactilars eren consistents i sense 
zones inesperades. Un nombre significatiu de complements alimentosos van mostrar 
problemes de qualitat (principalment adulteracions): el 52,4% per al card marià, el 33,3% 
per a les equinàcies i el 45,5% per als productes de cimicífuga. El mateix es va observar 
en el 66,6% de drogues i preparats vegetals de cimicífuga.  
Punts destacats: s’ha demostrat que els mètodes per HPTLC optimitzats i normalitzats, 
juntament amb l'avaluació de l'empremta dactilar complerta mitjançant diversos modes de 
detecció, constitueixen una tècnica rendible per a la detecció ràpida de diversos 
problemes de qualitat en drogues, preparats i productes a base de plantes. Els nostres 
resultats suggereixen que regulacions menys estrictes poden afectar negativament la 
qualitat dels productes a base de plantes comercialitzats. 
 
  







Investigación de productos a base de plantas comercializados en diferentes 
categorías regulatorias: ¿cómo puede ayudar la HPTLC a detectar problemas de 
calidad? 
 
Antecedentes: Se ha encontrado que los productos a base de plantas regulados en 
diferentes categorías son de diferente calidad. Esto lo demuestra el número creciente de 
publicaciones sobre la calidad de los productos a base de plantas en la literatura científica. 
Una adecuada identificación es una manera eficaz de abordar esta cuestión de forma 
precoz en el proceso de fabricación de un producto.  
Objetivos: Evaluar la calidad de drogas vegetales, preparados y productos a base de 
cardo mariano, equinácea y cimicífuga comercializados en diferentes categorías 
regulatorias, e ilustrar la utilidad de la HPTLC como herramienta de evaluación de la 
calidad. 
Métodos: Los métodos por HPTLC se adaptaron a partir de las monografías de la 
Farmacopea Europea para el fruto de cardo mariano, el rizoma de cimicífuga y la 
equinácea purpúrea. Se utilizaron modos de detección adicionales más allá de los 
descritos en las monografías y se usaron las huellas dactilares completas de HPTLC para 
el examen de la identidad y la pureza de las muestras investigadas. 
Resultados: Todos los productos regulados como medicamentos tradicionales a base de 
plantas mostraron una buena calidad: sus huellas dactilares eran consistentes y sin zonas 
inesperadas. Un número significativo de complementos alimenticios mostraron problemas 
de calidad (principalmente adulteraciones): el 52,4% para el cardo mariano, el 33,3% para 
las equináceas y el 45,5% para los productos de cimicífuga. Lo mismo se observó en el 
66,6% de drogas y preparados vegetales de cimicífuga.  
Puntos destacados: se ha demostrado que los métodos por HPTLC optimizados y 
normalizados, junto con la evaluación de la huella dactilar completa mediante diversos 
modos de detección, constituyen una técnica rentable para la detección rápida de varios 
problemas de calidad en drogas y preparados vegetales, así como productos a base de 
plantas. Nuestros resultados sugieren que regulaciones menos estrictas pueden afectar 
negativamente la calidad de los productos a base de plantas comercializados. 
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3.1  Abstract 
Background: Herbal products regulated under different categories were found to be of 
different qualities. This has been demonstrated by the increasing number of reports on the 
quality of herbal products in the scientific literature. Proper identification is an effective way 
to address this concerning issue early on in a products’ manufacturing process. 
Objectives: To assess the quality of milk thistle, coneflower and black cohosh herbal drugs, 
preparations and products commercialized under different regulatory categories, and to 
illustrate the usefulness of HPTLC as a tool for evaluating quality. 
Methods: HPTLC methods were adapted from the European Pharmacopeia’s monographs 
for milk thistle fruits, black cohosh and purple coneflower. Additional detection modes 
beyond those described in the monographs were employed, and the entire HPTLC 
fingerprints were used for the examination of identity and purity of the investigated 
samples.  
Results: All products regulated as Traditional Herbal Medicinal Products showed good 
quality: their fingerprints were consistent and without unexpected zones. A significant 
number of food supplements showed quality issues (mainly adulterations): 52.4% for the 
milk thistle, 33.3% for the coneflowers, and 45.5% for the black cohosh products. The 
same was observed in 66.6% of black cohosh herbal drugs and preparations. 
Highlights: Optimized and standardized HPTLC methods along with the evaluation of the 
entire fingerprint using several detection modes, proved to be a cost-efficient technique 
for quick detection of a range of quality issues in herbal drugs, preparations and products. 
Our findings suggest that less stringent regulations can negatively affect the quality of 
marketed herbal products.  
3.2  Introduction 
Herbal products containing the same ingredient and regulated under different categories 
can be of different quality, because regulatory evaluations do not require the same 
scientific scrutiny. Although companies producing food supplements are obliged to comply 
with GMP, in many countries, those products do not undergo pre-evaluation/approval by 
a national authority. According to Low et al. (1), mandatory pre-marketing evaluation of 
products regulated under non-drug categories can increase the burden on both regulators 





and business, and thus seem to be an unrealistic solution. A reason that could explain the 
variation in qualities of herbal products in different markets. Cost of analysis and use of 
expensive equipment can further exacerbate this burden.  
Quality control of herbal products starts with the proper identification of their herbal 
ingredients. By using the right set of tools, additional quality parameters (beyond 
establishing the correct identity) can be assessed within the same analysis (e.g., purity of 
the material). Techniques such as HPTLC, recommended by pharmacopoeias to evaluate 
the identity of herbals, can deliver supplementary valuable data without the need for 
additional analyses. In addition, multiple samples can be tested at the same time and 
under the same exact conditions on one plate.  With the proper resources, multiple 
samples can be compared across HPTLC plates that have been developed at different 
times and / or in different laboratories. In addition, the entire fingerprint of a sample, 
sometimes in multiple detection modes, can be utilized for assessment instead of looking 
at only a few zones as described in the acceptance criteria of typical monographs. Such 
extended evaluation of a single HPTLC analysis, in comparison to other tools, is useful for 
detecting zones that may indicate quality problems (2). 
To illustrate this concept, three case studies have been conducted: milk thistle, coneflower, 
and black cohosh. The first two case studies were conducted in collaboration with the 
British Herbal Medicine Association (BHMA). The examples were chosen based on their 
market importance. According to Smith et al. (3), in 2016, these three herbal ingredients 
were listed among the top-20 selling products in the U.S. mainstream market. They are 
also well-known ingredients in the European market. 
Milk thistle, the dried fruit of Silybum marianum (L.) Gaertn., is one of the most frequently 
sold herbal products for treatment and relief of dyspepsia and digestive complaints of 
hepatic origin. Its preparation is usually standardized to contain 70-80% of three 
flavonolignans (silybin, silychristin, and silydianin), collectively known as silymarin. A high 
concentration of flavonolignans in milk thistle extract is recommended because of their 
poor absorption in the gastrointestinal tract (4). Therefore, many products in the market 
declare to be standardized to contain high levels of silymarin. Another major constituent 
of milk thistle is the flavonoid taxifolin. Milk thistle is recognized as a Traditional Herbal 
Medicinal Product (THMP) and as a Traditional Herbal Registration (THR) medicinal 
product In the European Union (EU) and the United Kingdom (UK), respectively (5). 
However, it is also sold as a food supplement. 
The term coneflower refers to several Echinacea species. In particular, the aerial parts and 
or roots of three species are used as medicinal: E. purpurea (L.) Moench (purple 
coneflower), E. angustifolia DC. (narrow-leaf coneflower) and E. pallida (Nutt.) Nutt (pale 
purple coneflower). The roots of the three species and aerial parts of E. purpurea are used 
mainly for preventing and treating the common cold. The roots of E. purpurea are also 
used for the relief of spots and pimples due to mild acne, and the aerial parts for the 
treatment of small superficial wounds. Proposed active constituent groups of these 
coneflowers include polysaccharides, glycoproteins, caffeic acid derivatives, and 
alkylamides (6). In the EU, the preparations of the roots of the three species are recognized 
as THMP and those from the fresh aerial parts of the purple coneflower are accepted, both 
as THMP and for Well Established Use (WEU) medicinal products (4)(7)(8)(9)(10). In the 
UK, medicinal products containing coneflower preparations are sold as THMP/THR. Both, 
in the EU and the UK, coneflower products are also sold as food supplements. They often 
contain one or more Echinacea sp. or different parts of the same or different species. 
Preparations of black cohosh, the dried root and rhizome of Actaea racemosa L., are 
widely used in the United States, Canada, Europe, Australia, and elsewhere, principally 
for the treatment of menopausal symptoms. The two main compound classes of this herbal 
drug are triterpene glycosides and polyphenolic derivatives (11). 
For economic reasons, black cohosh, growing in North America, is known to be adulterated 





with related species from China. The most common of those are Actaea cimicifuga L. and 
Actaea dahurica (Turcz. ex Fisch. & C.A.Mey.) Franch. Intentional adulteration happens 
mainly because of the price of Chinese powdered material and extract, which may be as 
low as one-quarter of that of the authentic black cohosh. Accidental adulteration with 
Chinese material happens because of the confusion in the nomenclature. For example, 
Chinese species of Actaea and Serratula chinensis S.Moore are sold under the name, 
black cohosh, through internet shops. Admixture with American species (e.g., A. 
podocarpa DC., A. pachypoda Elliott, A. rubra (Aiton) Willd., and A. cordifolia DC.) occurs 
because they share the same habitat and resemble black cohosh (12) when the 
underground parts are harvested in the fall. In the EU, black cohosh products are sold as 
WEU medicinal products (13) and as THR products in the UK, or as food supplements, 
while in the US, they are considered dietary supplements. 
The objective of these three case studies was to evaluate the quality of the different 
herbals as a function of their regulation category and to show the usefulness of the HPTLC 
fingerprint as a tool for detecting quality issues, particularly adulteration. Samples were 
evaluated following the HPTLC methods in the Ph. Eur. monographs with modifications. 
The interpretation was based on the entire fingerprint (beyond the table description of the 
Ph. Eur.) and we used additional detection modes. 
3.3  Experimental 
3.3.1 Chemical reference standards, reagents, and apparatus  
The chemical reference standards silybin (98% pure) and caffeic acid (98% pure) were 
purchased from Sigma Aldrich (St. Louis, United States). Taxifolin (85% pure) was 
purchased from Extrasynthese (Genay, France). Silydianin, chlorogenic acid (97% pure), 
caftaric acid (90% pure), and chicoric acid (97% pure) were purchased from USP 
(Rockville, United States). Silychristin (97.9% pure), dodec-2-ene-8,10-diynoic acid 
isobutylamide, and isoferulic acid (97% pure) were purchased from Chromadex (Los 
Angeles, United States). β-sitosterol (95% pure), ursolic acid (97% pure), echinacoside 
(95% pure), dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (93% pure), cynarin 
(96% pure), actein (95% pure), and cimifugin (97% pure) were purchased from Phytolab 
(Vestenbergsgreuth, Germany). 
Solvents (≥95% pure) and reagents were purchased from Roth (Karlsruhe, Germany), 
Acros (Gent, Belgium), Fisher Scientific (Hampton, United States), and Merck (Darmstadt, 
Germany). Silica gel 60 F254 HPTLC glass plates (20 x 10 cm) were obtained from Merck 
(Darmstadt, Germany).  
HPTLC instruments from CAMAG (Muttenz, Switzerland) were used, including Automatic 
TLC Sampler (ATS 4), Automatic Development Chamber (ADC 2) with humidity control, 
Plate Heater 3, TLC Visualizer 2, and Immersion Device 3. 
3.3.2 Samples  
Thirty-one products of milk thistle (MT) and twenty-three products of coneflower (ECH) 
were acquired from the internet, local shops, and pharmacies in the UK. They included 
tablets, chewable tablets, capsules, tinctures, and liquid extracts, sold as food 
supplements or traditional herbal medicinal products. Their labels claimed contents of 
either standardized extract, extract, a mixture of extracts and herbal drug, or dried herbal 
drug.  
Sixty samples of products, herbal drugs and herbal preparations (e.g., extracts) labeled as 
black cohosh (BC), including tea bags, capsules, tablets of plant material and/or extracts, 
and herbal ingredients (powdered herbal drug and extracts) were acquired from the 
internet, and the market in the U.S.  
A list of samples and their specifications is presented in the supplementary information 





(Tables 3S1 – 3S3). 
3.3.3  Preparation of test solutions 
3.3.3.1  Milk thistle and coneflower products 
Products were extracted with methanol to contain the equivalent of 100 mg of dried herbal 
drug, dried or liquid extract per mL of solution. If the drug extract ratio (DER) of extracts 
was declared, it was used to calculate the equivalent amount of herbal drug used in the 
preparation. The mixtures were sonicated for 10 minutes, centrifuged, and the 
supernatants used as the test solutions. For analysis of alkylamides in coneflower 
products, the test solutions were prepared in dichloromethane following the same 
procedure.  
Milk thistle tinctures (MT20 and MT14), which did not declare the DER were directly 
applied onto the plate. Samples MT12, 13 and 30 were prepared at 5 mg/mL, MT8 at 25 
mg/mL and ECH16 at 20 mg/mL. These concentrations were adopted due to the 
overloaded fingerprints or matrix disturbance, observed in these samples during initial 
experiments.  
3.3.3.2  Black cohosh products, herbal drugs and preparations  
Products were extracted with ethanol and water (50:50 v/v) to contain the equivalent of 50 
mg of herbal drug, extract, or combined herbal drug and extract per mL of solution. The 
mixtures were sonicated for 10 minutes, centrifuged, and the supernatants were used as 
the test solutions. 
3.3.4  HPTLC parameters 
HPTLC was performed with general parameters specified in Ph. Eur. 2.8.25 
3.3.4.1  Milk thistle products 
The HPTLC method was adapted from the Ph. Eur. monograph for milk thistle fruits (14). 
It was published by the HPTLC Association (15) and adopted in the United States 
Pharmacopeia (USP) Dietary Supplements Compendium (DSC) 2019 (16). Specific 
parameters are described in  
Table 3.1 HPTLC parameters for identification of milk thistle 
Parameters Description 
Stationary phase 20x10 cm glass plates Si 60 F254 (Merck) 
SST 0.5 mg/mL of taxifolin, 0.2 mg/mL of silybin, 0.1 mg/mL of silychristin and 
silydianin, individually prepared in methanol 
Application volume 2 μL of test and reference solutions 
Developing solvent Toluene, ethyl formate, formic acid 40:50:5 (v/v/v) 
Development 20 min saturation (with filter paper), 10 min conditioning at 33% relative 
humidity (with MgCl2), 70 mm distance from lower edge, room temperature = 
23-27 ⁰C 
Derivatization reagent 1 Natural Product (NP) reagent: 1 g of diphenylboric acid 2-aminoethyl ester 
was dissolved in 200 mL of ethyl acetate 
Derivatization reagent 2 Polyethylene glycol (PEG) reagent: 10 g of polyethylene glycol (Macrogol) 400 
were dissolved in 200 mL of dichloromethane. 
Derivatization 
procedure 
Plates were heated at 100 ⁰C for 5 min and then derivatized by dipping 
(speed: 3, time: 0) in NP reagent and subsequently in PEG reagent. Plates 
were heated again for 5 minutes at 100°C. Images were taken one hour after 
derivatization 
Documentation  White light, UV 254 nm, and UV 366 nm prior to derivatization; UV 366 nm 
and white light after derivatization 
3.3.4.2  Echinacea products 
Two HPTLC methods for the identification of coneflowers roots and aerial parts were used 





to evaluate the coneflower products. These methods were adapted from the Ph. Eur. 
monograph for purple coneflower root (17) and published by the HPTLC Association, with 
modifications of the sample preparation, application volume, developing distance and 
derivatization (18), were used to evaluate the coneflower products. The parameters are 
described in Table 3.2 and Table 3.3. For the alkylamides fingerprints, the image after the 
second heating step was used because it yields stronger zones. 
Table 3.2 HPTLC parameters for identification of coneflowers roots and aerial parts, phenolic 
compounds fingerprint. 
Parameters Description 
Stationary phase 20x10 cm glass plates Si 60 F254 (Merck) 
SST 0.5 mg/mL of cynarin and echinacoside, 0.1 mg/mL of chlorogenic acid and 
caffeic acid, individually prepared in methanol 
Application volume 2 μL of reference solutions and 4 µL of the test solution 
Developing solvent Ethyl acetate, ethyl methyl ketone, water, formic acid 5:3:1:1 (v/v/v/v) 
Development 20 min saturation (with filter paper), 10 min conditioning at 33% relative 
humidity (with MgCl2), 70 mm distance from lower edge, room temperature = 
23-27 ⁰C 
Derivatization reagent 1 NP reagent: 1 g of diphenylboric acid 2-aminoethyl ester was dissolved in 
200 mL of ethyl acetate 
Derivatization reagent 2 PEG reagent: 10 g of polyethylene glycol (Macrogol) 400 were dissolved in 
200 mL of dichloromethane. 
Derivatization 
procedure 
Plates were heated at 100 ⁰C for 3 min and derivatized by dipping (speed: 3, 
time: 0) into NP reagent and then into PEG reagent. 
Documentation  White light, UV 254 nm, and UV 366 nm prior to derivatization; UV 366 nm 
and white light after derivatization 
Table 3.3 HPTLC parameters for identification of coneflowers roots and aerial parts, alkylamides. 
Parameters Description 
Stationary phase 20x10cm plates Si 60 F254 (Merck) 
SST 
0.2 mg/mL ursolic acid, β-sitosterol and dodec-2-ene-8,10-diynoic
acid isobutylamide and 0.4 mg/mL of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid
isobutylamide, individually prepared in methanol 
Application volume 2 μL of reference solutions and 10 µL of the test solution 
Developing solvent Toluene, ethyl acetate, cyclohexane, formic acid 80:20:10:3 (v/v/v/v) 
Development 20 min saturation, 10 min conditioning at 33% relative humidity (with MgCl2), 
70 mm distance from lower edge, room temperature = 23-27 ⁰C 
Derivatization reagent  Anisaldehyde reagent: 20 mL of acetic acid and 10 mL of sulfuric acid was 
slowly added to 170 mL of ice-cooled methanol and mixed well. The mixture 
was allowed to cool to room temperature, and then 1 mL of anisaldehyde was 
added. 
Derivatization procedure The plates were dipped (speed: 3, time: 0) into anisaldehyde reagent and 
then heated 3 minutes at 100°C. After documentation, the plates were heated 
for another 15 min and then documented again 
Documentation  White light, UV 254 nm, and UV 366 nm prior to derivatization; UV 366 nm 
and white light after derivatization and after second heating 
3.3.4.3  Black cohosh products 
The HPTLC method for identification of Cimicifuga racemosa (syn. of A. racemosa) from 
Ph. Eur. (19) was used to evaluate the black cohosh products, herbal drugs and 
preparations. The monograph includes three HPTLC methods, which share the same 
parameters except for the application volume and derivatization reagent. These 
parameters are summarized in Table 3.4.  
Table 3.4 HPTLC parameters for identification of black cohosh. 
Parameters Description 
Stationary phase 20x10 cm glass plates Si 60 F254 (Merck) 





SST 0.1 mg/mL of actein, isoferulic acid and cimifugin are individually prepared in 
methanol 
Application volume 2 μL of reference and test solution for identification and 20 µL of test solution 
for test for the presence of A. podocarpa, A. dahurica, and A. cimicifuga 
Developing solvent Toluene, ethyl formate, formic acid 50:30:20 (v/v/v) 
Development 20 min saturation (with filter paper), 10 min conditioning at 0% relative 
humidity (with molecular sieve), 70 mm distance from lower edge, room 
temperature = 23-27 ⁰C 
Derivatization reagent 1 
(identification) 
Sulfuric acid reagent: 20 mL of sulfuric acid was mixed with 180 mL of 
methanol. The plate is dipped (time: 0, spped:3) and then heated at 100°C for 
5 minutes 
Derivatization reagent 2 
(test for adulteration 
with A. dahurica) 
Antimony trichloride reagent: 8 g of Antimony trichloride were mixed with 200 
mL of chloroform and shaken until completely dissolved. The plates were 
immersed (time: 1s, speed: 3) into the solution and then heated at 120°C for 
10 minutes.  
Derivatization reagent 3 
(test for adulteration 
with A. cimicifuga) 
Boric acid, oxalic acid reagent: 4 g of boric acid and 5 g of oxalic acid were 
individually dissolved in 150 mL and 50 mL of ethanol absolute, respectively, 
and then shaken until completely clear. The solutions were combined before 
derivatization. The plates were dipped (time: 1s, speed: 3) into the solution 
and heated at 120°C for 5 minutes. 
Documentation  White light, UV 254 nm and UV 366 nm prior to derivatization, UV 366 nm and 
white light after derivatization 
3.4 Results and discussion 
3.4.1  Milk thistle case study 
Silybum marianum fruits have unique macroscopic and chemical characteristics. 
Therefore, quality problems of milk thistle products (MT) are rarely related to substitution 
or mixing with other species. There is a limited number of publications referring to poor 
quality and adulteration of MT products. Fenclova et al. (20) analyzed twenty-six MT food 
supplements purchased in the U.S. and the Czech market. Mycotoxins, pesticides, and 
microbiological contamination were detected in all tested preparations. Furthermore, the 
authors identified significant differences in the silymarin content between the products, 
often contradicting the information provided on the labels.  
The products analyzed in the present study claimed to contain different plant parts of S. 
marianum, the herbal drug and/ or its extracts. The present HPTLC method, based on the 
analysis of flavonolignans and flavonoids, can differentiate between these ingredient 
types. As shown in Figure 3.1, fingerprints of MT fruit and fruit extract show a sequence 
of four green zones after derivatization, three of which are due to silybin, silydianin, and 
silychristin. Additionally, an orange zone due to taxifolin is observed just below silybin. 
Fingerprints of fruit show a blue zone at RF 0.13 (yellow arrows) before and after 
derivatization, which is absent in the extract. Milk thistle herb show two very faint green 
zones, one of them at the position of silybin, and prior to derivatization, it shows an intense 
red zone due to chlorophylls (green arrow), absent in the fruit and fruit extract. 
MT products were evaluated with the same HPTLC method. In Figure 3.2, the products 
are grouped by their regulatory category and their tracks were then re-arranged based on 
similarity upon visual inspection. The evaluation of quality is summarized in Figure 3.3. All 
THMP products (tracks 1-10) show homogeneous and consistent fingerprints in regard to 
the number of zones and their intensities, including those due to flavonolignans and 
taxifolin. Only one sample declared to contain milk thistle fruit, and as expected, it showed 
a blue zone at RF 0.13. These ten products were concluded to be of good quality. Of the 
twenty-one food supplement (FS) products, two were declaring to contain MT fruit (tracks 
11-12) and eight declaring to contain MT extracts (tracks 13-18, 28-29). Fingerprints for 
these ten FS products conform with the labeled information and were deemed of good 
quality. Two of them (tracks 28-29) show an additional zone at RF 0.55, which is suspected 
to be curcuminoids from turmeric extract, declared on the product label.  







Figure 3.1 HPTLC Fingerprints of milk thistle fruit, fruit extract, and herb prior to (right image) and 
after derivatization (left image). Yellow arrows: blue zone characteristic of MT fruit, absent in MT 
fruit extract; Green arrow: chlorophyll zone characteristic of MT herb. 
 
Figure 3.2 Fingerprints of the 31 milk thistle products in different detection modes, grouped by 
regulatory categories. Track A: silydianin, silychristin, taxifolin, and silybin in increasing RF values. 
Blue arrows: red zone due to chlorophyll detected in some products; red arrow: an unidentified 
yellow-white zone detected in some products. 
The rest of the MT FS (11) had questionable quality. Nine of them (tracks 19-27) showed 
the four green zones due to flavonolignans but lacked taxifolin (orange zone). Additionally, 
some of them have a faint fingerprint under UV 254 nm, in which the zones due to silybin 
and silychristin are not detected due to their low concentration. These findings are in 
agreement with the statement of Fenclova et al. (20). Finally, two samples (tracks 30 and 
31) lack zones characteristic of MT fruit or its extracts, which suggest the absence of MT 
in these products.  
The fingerprints of some samples of both the good or questionable quality feature 
additional zones that are not characteristic of MT, but related to other declared ingredients 
in the product. In particular, eight samples presented red zone(s) due to chlorophyll 
(Figure 3.2, blue arrows), which could be caused by the declared MT herb, spirulina 
(biomass of Arthrospira platensis and A. maxima), alfalfa (Medicago sativa L.), artichoke 
(Cynara cardunculus L.), dandelion (Taraxacum officinale F.H.Wigg.), boldo (Peumus 
boldus Molina) and peppermint leaf (Mentha × piperita L.). Five samples show an 
unidentified yellow-white zone just above the application position under UV 366 nm prior 





to derivatization (Figure 3.2, red arrows), which could indicate a quality issue. Common 
excipients were ruled out as source of this zone by additional experiments. The origin of 
this zone continues to be unclear.  
 
Figure 3.3 Summary of the quality of milk thistle products MT. THMP: Traditional Herbal Medicinal 
Product; FS: Food supplement. The number after the back slash represents the total number of 
products analyzed per category. 
3.4.2 Coneflower case study 
Poor quality of coneflowers (ECH) products has been reported for a long time. At the end 
of the last century, ECH products in the U.S. market often contained Parthenium 
integrifolium L. as a substitute, which is no longer happening for most cases (21). Species 
mix up can also happen between members of the Echinacea genus. According to 
Ardjomand-Woelkart and Bauer (22), the roots of E. angustifolia and E. pallida are often 
confused due to their physical similarities. The first species is endangered in the wild. 
Nowadays, the most found ingredient in ECH products is E. purpurea root. Spelman stated 
that confusion of species is almost certainly still occurring for researchers and companies 
that do not have proper identification procedures in place (23). 
The current HTPLC methods for identification of coneflowers, published by the HPTLC 
Association (18), include HPTLC fingerprints for phenolic compounds and alkylamides. 
While the phenolic fingerprint is used to distinguish the plant parts and species, the 
alkylamides fingerprint is used to indicate the quality of the herbal ingredients. According 
to Wills and Stuart (24), alkylamides can suffer degradation if the herbal drug when stored 
in the milled form at room temperature. 
Figure 3.4 shows the characteristic fingerprints of the three coneflowers roots and the 
purple coneflower herb obtained with the two HPTLC methods. Some HPTLC 
characteristics allows to clearly distinguish the four herbal drugs. The most prominent are: 
(1) echinacoside is present in the roots of E. angustifolia and E. pallida as a very intense 
zone, but absent in the roots and the aerial parts of E. purpurea; (2) cynarin is present in 
the roots of E. angustifolia, but not in the other 3 herbal drugs; (3) the zone due to chicoric 
acid is very intense in the root and aerial parts of E. purpurea, but far less intense in the 
root of E. pallida and absent in the root of E. angustifolia (although there is a faint zone 
below that position), and (4) E. purpurea aerial parts show red zones due to chlorophylls 
and some yellow zones due to flavonoids, which are not present in the three roots. 
Chlorogenic acid appears mainly in the root of E. angustifolia, and caftaric acid mainly in 
the root and aerial parts of E. purpurea, but these two compounds are less helpful for 







Figure 3.4 HPLTC fingerprints of standards and coneflowers herbal drugs: phenolic compounds 
(left image); alkylamides (after second heating step, right image). Yellow arrows: zones 
characteristic of E. purpurea herb; black arrows: zones due to alkylamides of E. angustifolia root; 
purple arrow: zones characteristic of E. pallida root; blue arrow: zone due to alkylamides in E. 
purpurea root. 
The alkylamide fingerprint (Figure 3.4, image to the right) of E. angustifolia root shows 
one pink and one brown zone at the positions of the alkylamides dodec-2-ene-8,10-diynoic 
acid isobutylamide and dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide, 
respectively (black arrows). E. purpurea root shows the upper alkylamide co-eluting with 
another pink zone due to another unidentified alkylamide (blue arrow), and these zones 
are absent in the other species and E. purpurea aerial parts. E. pallida root shows a brown 
zone absent in all other fingerprints (purple arrow).  
In Figure 3.5, the products are separated by the regulatory category and their tracks were 
then re-arranged based on similarity upon visual inspection of the fingerprint due to 
phenolic compounds. A summary of the quality of ECH products is presented in Figure 
3.6.  
In Figure 3.5, all THMP (tracks 1-11) and nine of the twelve FS products (tracks 12-18, 20 
and 23) show fingerprints compliant with their labels. Regarding their phenolic fingerprint, 
nine THMP present a composition similar to E. purpurea root (tracks 1-9), one THMP 
shows zones characteristic of E. angustifolia root (track 10), one THMP (track 11) and 
seven FS (tracks 12-18) show zones similar to E. purpurea aerial parts. These herbal 
drugs were declared on the labels. Two FS products (tracks 20 and 23) declared to contain 
E. purpurea aerial parts plus E. angustifolia root show no zones characteristic of 
chlorophyll. These samples were prepared in glycerin and water, which could have 
affected the extraction of chlorophyll. Therefore, they were also considered compliant with 
their labels. Regarding the alkylamides profile, two THMP products (tracks 1 and 11) and 
four FS products (tracks 12, 13, 20 and 23) showed very faint zones under UV 254 nm 
prior to derivatization and under white light after derivatization. The possible reasons may 
be that: (1) the extract used in samples at tracks 1, 20 and 23 were prepared using low 
percentages of ethanol (e.g., 30%) or in water/glycerin, leading to lesser amounts of the 
lower-polarity constituents, such as alkylamides; and (2) due to lack of information 
regarding the drug/extract ratio (DER) for samples on tracks 11-13, the selected sample 
preparation may not be optimal thus yielding overall faint fingerprints. 






Figure 3.5 Alkylamide fingerprints of standards and Echinacea spp., in different detection modes. 
Tracks A: echinacoside and cynarin, B: chlorogenic and caffeic acids, C: Ursolic acid and β-
sitosterol and D: dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide and dodec-2-ene-8,10-
diynoic acid isobutylamide (with increasing RF); 1-23: ECH products 1-23. 
The remaining three of the twelve FS samples are of questionable quality. Two products 
(tracks 21-22) show no zones due to coneflower in either fingerprint. Sample on track 19 
declared to contain E. purpurea aerial parts but showed no zones due to chlorophyll in the 
phenolic compounds fingerprint. This zone is expected to be seen in tinctures. 
Furthermore, its alkylamide fingerprint was very faint.  
 
Figure 3.6 Summary of the quality of coneflower products ECH. THMP: Traditional Herbal 
Medicinal Product; FS: Food supplement. The number after the back slash represents the total 
number of products analyzed per category. 





3.4.3  Black cohosh case study 
The HPTLC method for black cohosh of the Ph. Eur. (19) is capable of discriminating the 
four main adulterants: A. cimicifuga, A. dahurica, A. podocarpa, and Serratula chinensis 
root. The typical fingerprints of these species and black cohosh are shown in Figure 3.7. 
Under UV 254 nm, A. podocarpa (tracks 9 -10) shows quenching zones absent in black 
cohosh and other Actaea species (blue arrows). Under white light after derivatization, A. 
dahurica (tracks7-8) fingerprint lacks zones due to actein (black arrow) and 26-
deoxyactein (purple arrow), while A. cimicifuga (tracks 5-6) lacks only 26-deoxyactein. 
Under UV 366 nm after derivatization, all four Actaea species show distinctive fingerprints, 
and S. chinensis (track 11) shows mainly an intense blue zone above the application 
position, absent in the other fingerprints. Even though, these four Actaea species can be 
distinguished with the identification method, the presence of the adulterants in a mixture 
cannot be detected in this test.  
Therefore, Ankli et al. (25) proposed an additional HPTLC test for the detection of adultera-
tion, which was adopted in the Ph. Eur. monograph for black cohosh. In this test, 20 µL of 
the samples are applied twice onto the plate (once in each half. After development, the 
plate is cut in the middle. One half is derivatized with antimony trichloride reagent (reagent 
2), and the other half with boric acid and oxalic acid reagent (reagent 3). As shown in 
Figure 3.8, adulteration of A. racemosa with ≥ 10% of A. podocarpa shows a quenching 
zone (black arrow, track 2) under UV 254 nm prior to derivatization, absent in pure A. 
racemosa (track 1). Under UV 366 nm after derivatization with antimony trichloride 
reagent, A. racemosa adulterated with ≥ 5% of A. dahurica shows two green zones, one 
above and one below actein (orange arrows, track 4), absent in pure A. racemosa (track 
3). Under UV 366 nm after derivatization with boric acid and oxalic acid reagent, A. 
racemosa adulterated with ≥ 5% of A. cimicifuga shows one blue zone due to cimifugin 
(green arrow, track 6), and another blue zone above the application position. These zones 
are absent in A. racemosa (track 5). 
The black cohosh food supplements and herbal drugs / herbal preparations (HDP) were 
analyzed with the two described methods above. The HPTLC fingerprints are presented 




Figure 3.7 Fingerprints of Actaea racemosa and common adulterants prior to (top) and after deriva-
tization (bottom). Blue arrows: zones characteristic of A. podocarpa root; black arrow: zone due to 
actein in A. racemosa; purple arrow: zone due to 26-deoxyactein in A. racemosa.  






Figure 3.8 Test for adulteration of A. racemosa with A. podocarpa, A. dahurica, and A. cimicifuga. 
Tracks 1, 3 and 5: A. racemosa; tracks 2, 4 and 6: A. racemosa mixed with 10% of A. podocarpa, 
5% of A. dahurica and 5% of A. cimicifuga, respectively. Black arrow: zones characteristic of A. 
podocarpa root; orange arrows: zones characteristic of A. dahurica root; green arrow: zone due to 
cimifugin characteristic of A. cimicifuga root. 
Of the sixty food supplement and HDP, eighteen FS (BC2-5, 7-9, 11, 13-15, 18, 22-24, 26, 
30, and 32) and nine HDP (BC34-40, and 49-50) showed fingerprints characteristic of A. 
racemosa (e.g., BC37, Figure 3.9 A and B). Of these samples, the fingerprints of eight are 
fainter than those of reference herbal drug (BCRHD) and reference extract (BCRE) (e.g., 
BC24, Figure 3.9 A, and B). Nevertheless, these samples were considered compliant with 
their labels concerning identity, but were likely of low potency. 
The remaining thirty-three samples are of questionable quality. None of them were con-
cluded to be adulterated with A. podocarpa or S. chinensis. Fifteen products contained A. 
racemosa adulterated with other Actaea species. Of these, six FS (BC1, 16, 19, 20, 21, 
27 and 28) and seven HDP (BC 45, 48, 51-53, 56-57) showed zones due to A. cimicifuga 
and A. dahurica in addition to those of A. racemosa (e.g., BC16, 19 and 20, Figure 3.9). 
Ten of the fifteen samples (BC1, 12, 17, 45, 48, 51-53, 56-57) have the green zones 
characteristic for adulteration with A. dahurica fainter than the 5% accepted by the Ph. Eur. 
(e.g., BC19 and 16, Figure 3.9 C). Samples BC16 and 41 are adulterated with A. 
cimicifuga only.  
The other eighteen samples show no traces of black cohosh. Of these, two FS (BC12 and 
17) have zones due to A. dahurica and A. cimicifuga (e.g., similar to BC1, Figure 3.9 C-
D). Four FS (BC10, 25, 29, 31) and two HDP (BC44, 47) presented faint fingerprints, in 
composition similar to that of A. cimicifuga (e.g., BC44, Figure 3.9 A, B and D), indicating 
the presence of this species alone. Seven HDP (BC42, 43, 46, 55, 58-60) contained only 
A. dahurica (e.g., BC58, Figure 3.9 A-C). The three remaining samples (BC6, 33, and 54) 
show fingerprints different from all Actaea species (e.g., BC6, Figure 3.9 A-B) or only 
barely detectable zones.  
In this case study, more than half of the analyzed black cohosh samples were found to be 
adulterated. A summary of the quality of all black cohosh samples is presented in Figure 
3.10. 






Figure 3.9 HPTLC fingerprint of 11 black cohosh products (BCP) and ingredients (BCI). STD1: 
actein and isoferulic acid (increasing RF); STD2: cimifugin; RBCR: reference black cohosh root; 
RBCE: reference black cohosh root extract; 5% AD: A. racemosa mixed with 5% of A. dahurica; 
5% AC: A. racemosa mixed with 5% of A. cimicifuga. Fingerprints A and B are used for identification 
of black cohosh root, while fingerprints C and D are used for detecting adulteration with A. dahurica 
and A. cimicifuga, respectively. 
 
Figure 3.10 Summary of the quality of black cohosh FS and (HPD) analyzed in this case study. 
AC: A. cimicifuga; AD: A. dahurica; AR: A. racemosa; HDP: black cohosh herbal drugs and 
preparations; FS: black cohosh food supplement products.  
3.5  Conclusions 
These three case studies showed that evaluating the entire HPTLC fingerprints in several 
detection modes is very helpful for uncovering adulterations and other quality issues in 





herbal drugs, preparations and products.  
Significant quality differences were observed between the tested products commercialised 
under different regulatory frameworks. All products marketed as medicinal products were 
compliant with label statements. Their fingerprints were consistent, without unexpected 
zones observed. This may not be the case with food/dietary supplements products. Quality 
issues were found in 52% of the milk thistle products, 25% of the coneflowers products, 
and 46% of the black cohosh food supplement products. Also, 67% of herbal drugs and 
preparations labelled as black cohosh presented quality issues. Several quality issues 
were found, including absence of the herbal ingredient declared on the label of the product, 
lower concentration of the herbal ingredient per unit pharmaceutical form, and presence 
of undeclared herbal drugs and adulterants, especially related species. These case 
studies support the theory that less stringent regulations can negatively affect the quality 
of herbal products.  
The cost for the HPTLC analysis per sample, if only one sample were to be analyzed on 
one plate and in one run, is approximately $46 for coneflower (because two methods were 
used), and $21 for black cohosh and milk thistle. A detailed calculation of the cost is shown 
in the supplementary information. It is important to highlight that the analysis cost per 
sample is reduced drastically when more than one sample is analyzed on the same plate. 
HPTLC using optimized and standardized methods and evaluating the entire fingerprint 
under several detections, proves to be a cost-efficient technique for proper identification 
and quick detection of a range of quality issues in herbal drugs, preparations and products. 
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3.7  Supplementary information 
Table 3S1 Description of the milk thistle products analyzed in this work, their pharmaceutical 
dosage form and regulatory status. MTE: Milk thistle extract; MTS: Milk thistle fruit; MTHP: Milk 
thistle herb powder; MTT: Milk thistle tincture; THMP: traditional herbal medicinal product. 
Sample 
N° 






MTE 300 mg equivalent to 7.2-8.1 g of fruit (DER: 24-27:1). 
Standardized to contain 174 mg of silymarin. Extraction 
solvent: Acetone 95% 
Tablet THMP 
MT2 
MTE 137.5-165 mg equivalent to 2.75-6.60 g of fruit (DER: 
20-40:1). Standardized to contain 82.5 mg of silymarin. 
Extraction solvent: Ethyl acetate 
Tablet THMP 
MT3 
MTE 100 mg equivalent to 3 g of fruit (DER: 30:1). 




MT4 MTS 450 mg  Capsules THMP 
MT5 
MTE 83.3 mg equivalent to 3 g of herbal drug (DER: 36:1). 





MTE 100 mg equivalent to 4 g of herbal drug (DER: 40:1), 
MTHP 325 mg and MTS 25 mg. Each dosage form is 





MTE 83.3 mg equivalent to 3 g of herbal drug (DER: 36:1). 





MTE 100 mg standardized to contain 80 mg of silymarin, and 





MTE 300 mg equivalent to 7.2-8.1 g of fruit (DER: 24-27:1). 
Standardized to contain 174 mg of silymarin. Extraction 
solvent: Acetone 95% 
Tablets THMP 
MT10 
MTE equivalent to 485 mg of milk thistle complex tincture. 
Other ingredients: artichoke leaves 46%, dandelion herb 





MTE 86 mg equivalent to 3 g of seeds (DER: 35:1). 





MTE 40 mg standardized to 32 mg of silymarin. Other 
ingredients: dandelion root 100 mg, curcumin extract 25 mg, 





MTE 40 mg standardized to 32 mg of silymarin. Other 
ingredients: dandelion root 100 mg, curcumin extract 25 mg, 





MT dried fruit complex tincture 32%, artichoke leaves 46%, 
dandelion herb 12%, boldo leaf 7% and peppermint leaf 3%. 





MTE 125 mg equivalent to 2.5-5 g of fruit (DER: 20-40:1). 
Standardized to contain 62.5-75 mg of silymarin.  
Tablets THMP 
MT16 





















MT dried fruit complex tincture 32%, artichoke leaves 46%, 
dandelion herb 12%, boldo leaf 7% and peppermint leaf 3%. 

















MTE of seeds 100 mg standardized to contain 80 mg of 


















MTE 193-261 mg equivalent to 3.725-10.818 g of fruit (DER: 
19.3-41.4:1). Standardized to contain 108 mg of silymarin. 
Extraction solvent: Acetone 95% 
Capsules THMP 
MT26 
MTE 89-121 mg equivalent to 1.721-5.0 g of fruit (DER: 
19.3-41.3:1). Standardized to contain 50 mg of silymarin. 
Extraction solvent: Acetone 95% 
Capsules THMP 
MT27 
MTE 193-261 mg equivalent to 3.725-10.818 g of fruit (DER: 
19.3-41.4:1). Standardized to contain 108 mg of silymarin. 
Extraction solvent: Acetone 95% 
Capsules THMP 
MT28 
MTE 89-121 mg equivalent to 1.721-5.0 g of fruit (DER: 
19.3-41.3:1). Standardized to contain 50 mg of silymarin. 
Extraction solvent: Acetone 95% 
Capsules THMP 
MT 29 
MTE 100 mg equivalent to 4 g of fruit (DER: 40:1). 
Standardized to contain 80 mg of silymarin. MT seeds and 





MTE seed 175 mg standardized to contain 140 mg of 





MTE 133-324 mg equivalent to 3.325-9.720 g of fruit (DER: 
25-30:1). Standardized to contain 108 mg of silymarin. 
Extraction solvent: Acetone 99% 
Capsule THMP 
 
Table 3S2 Description of the coneflower products analyzed in this work, their pharmaceutical 
dosage form and regulatory status. ECHE: coneflower dried extract; ECHT: coneflower tincture; 
ECHHD:  coneflower herbal drug; THMP: traditional herbal medicinal product. 
Sample 
N° 






ECHE 380 mg from fresh E. purpurea herb (DER: 7.5-
14.6:1), ECHE 20 mg from fresh E. purpurea root 
(DER: 7.1-12.5:1) Extraction solvent: ethanol 65% 
Tablets Food supplement 
ECH2 
ECHE 70 mg from fresh E. purpurea root equivalent to 
460-530 mg of root (DER: 6.6-7.6:1) Extraction solvent: 
ethanol 30% 
Tablets THMP  
ECH3 
 
ECHE 128 mg of E. angustifolia (part of the herbal drug 
not declared) per mL of extract (DER: 1:1). Extraction 
solvent: ethanol 45%. Other ingredients: wild indigo (35 
mg of extract DER 1:1, per mL) and fulmitory (32 mg of 
extract DER 1:1, per mL) 
Oral Liquid THMP 
ECH4 
ECHE 380 mg from fresh E. purpurea herb (DER: 
12:1), ECHE 20 mg from fresh E. purpurea root (DER: 
11:1). Extraction solvent: ethanol 65% 
Chewable Tablets THMP 
ECH5 
ECHE 65 mg from E. purpurea root (DER: 4:1) and 
ECHHB 265 mg of E. purpurea aerial parts  
Capsules Food supplement 
ECH6 
 
ECHT 860 mg of E. purpurea herb per mL of tincture 
(DER: 7.5-14.6:1). ECHT 45 mg of E. purpurea root per 
mL of tincture (DER: 7.1-12.5:1) Extraction solvent: 
ethanol 65% 
Oral Liquid Food supplement 
ECH7 
ECHE 70 mg from fresh E. purpurea root equivalent to 




ECHE 140 mg from fresh E. purpurea root equivalent 
to 838-1177 mg of root (DER: 6-8.4:1) Extraction 
solvent: ethanol 75% 
Capsules THMP 
ECH9 
ECHE 71.5 mg from fresh E. purpurea root equivalent 
to 429-500 mg of root (DER: 6-7:1)  
Tablets THMP 
ECH10 
ECHT 250 mg of E. purpurea herb per mL of tincture 
(DER: 5:1). Extraction solvent: ethanol 66% 
Oral Liquid Food supplement 
ECH11 
ECH standardized extract 160 mg equivalent to 3200 
mg of herb (DER: 45:1). Note: 160 mg of extract is 
equivalent to 7200 mg of fresh herb and not 3200 mg, 
as declared in the label. 
Tablets Food supplement 
ECH12 ECHE 56 mg from fresh E. purpurea root equivalent to Tablets THMP  












338-450 mg of root (DER: 6-7:1) Extraction solvent: 
ethanol 75% 
ECH13 ECHT 480 mg of E. purpurea herb per mL of tincture  Oral Liquid Food supplement 
ECH14 
ECHE 71.5 mg from fresh E. purpurea root equivalent 
to 429-500 mg of root (DER: 6-7:1) 
Tablets THMP 
ECH15 
ECHE 71.5 mg from fresh E. purpurea root equivalent 
to 429-500 mg of root (DER: 6-7:1) 
Tablets THMP 
ECH16 
ECHT 1 mL contains 1 g of E. purpurea aerial parts and 
root extract (standardized to 10 mg of phenolic 
compounds), E. angustifolia root extract and 
Goldenseal root extract. Prepared in Glycerin and 
water 
Tincture Food supplement 
ECH17 
ECHT 2 mL contain 325 mg of E. purpurea flowers and 
herbs extract and E. angustifolia roots extract 
equivalent to 1470 mg of herbal drug. Prepared in 
Glycerin and water 
Tincture Food supplement 
ECH18 
ECHE 140 mg from fresh E. purpurea root equivalent 
to 838-1177 mg of root (DER: 6-8.4:1) Extraction 
solvent: ethanol 75% 
Capsules THMP 
ECH19 
ECHE 105 mg from fresh E. purpurea root equivalent 
to 630-840 mg of root (DER: 6-8:1) Extraction solvent: 
ethanol 75% 
Tablets THMP 
ECH20 ECHHD 400 mg of E. purpurea aerial parts Capsules Food supplement 
ECH21 ECHE equivalent to 1000 mg of E. purpurea herb Tablets Food supplement 
ECH22 
ECHE 65 mg from E. purpurea root (DER: 4:1) and 
ECHHB 265 mg of E. purpurea aerial parts  
Capsules Food supplement 
ECH23 
ECHE 65 mg from E. purpurea root (DER: 4:1) and 
ECHHB 265 mg of E. purpurea aerial parts  
Capsules Food supplement 
 
Table 3S3 Description of the Black cohosh products analyzed in this work, their pharmaceutical 
dosage form and products type BC: Black cohosh (A. racemosa); BCE: Black cohosh root extract; 
DS: dietary (food) supplement; HDP: herbal drug or herbal preparation; DER: Drug extract ratio. 
Sample 
N° 





BC1 BC 1.25 g of root cut / dosage form Tea bag Finished product, DS 
BC2 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC3 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC4 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC5 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC6 BC 410 mg of root powder / dosage form Capsules Finished product, DS 
BC7 
BC 300 mg of root powder / dosage form. Another 
ingredient: brown rice powder 
Capsules Finished product, DS 
BC8 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC9 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC10 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC11 BC 100 mg of root powder / dosage form Capsules Finished product, DS 
BC12 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC13 BC 370 mg of root powder / dosage form Capsules Finished product, DS 
BC14 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC15 BC 200 mg of root powder / dosage form Capsules Finished product, DS 
BC16 BC 540 mg of root powder / dosage form Capsules Finished product, DS 
BC17 
BC 530 mg of root powder and BCE 20 mg. Extract 
standardized to 2.5% of triterpene glycosides. Another 
ingredient: rice flour 
Capsules Finished product, DS 
BC18 BC root powder and BCE (545 mg) Capsules Finished product, DS 
BC19 
BC 185 mg of root powder and BCE 40 mg. Extract 
standardized to 2.5% of triterpene glycosides 
Capsules Finished product, DS 
BC20 
BC 380 mg of root powder and BCE 80 mg. Extract 
standardized to 2.5% of triterpene glycosides. Other 
ingredients: triglycerides, vitamin E and rosemary oil 
Capsules Finished product, DS 













BC 380 mg of root powder and BCE 80 mg. Extract 
standardized to 2.5% of triterpene glycosides. Other 
ingredients: triglycerides, vitamin E and rosemary oil 
Capsules Finished product, DS 
BC22 BC root powder and BCE (545 mg) Capsules Finished product, DS 
BC23 
BCE 100 mg, standardized to 2.5% of triterpene 
glycosides. Other ingredients: rice flour  
Capsules Finished product, DS 
BC24 
BCE 20 mg, standardized to 2.5% of triterpene 
glycosides, calculated as 26-deoxyactein  
Tablet Finished product, DS 
BC25 
BCE 40 mg, standardized to 2.5% of triterpene 
glycosides. Other ingredients: rice flour 
Capsules Finished product, DS 
BC26 
BCE 40 mg, standardized to 2.5% of triterpene 
glycosides, calculated as 26-deoxyactein  
Capsules Finished product, DS 
BC27 
BCE 40 mg, standardized to 8% of triterpene 
glycosides, calculated as 26-deoxyactein 
Capsules Finished product, DS 
BC28 
BCE 135 mg (DER: 4:1) and BCE 40 mg, 
standardized to 2.5% of triterpene glycosides 
Capsules Finished product, DS 
BC29 
BCE 80 mg, standardized to 2.5% of triterpene 
glycosides. Other ingredients: rice flour 
Capsules Finished product, DS 
BC30 
BCE 80 mg, standardized to 2.5% of triterpene 
glycosides, calculated as 26-deoxyactein 
Tablet Finished product, DS 
BC31 
BCE 40 mg, standardized to 2.5% of triterpene 
glycosides, calculated as 26-deoxyactein 
Capsules Finished product, DS 
BC32 
BCE 250 mg, standardized to 2.5% of triterpene 
glycosides 
Capsules Finished product, DS 
BC33 
BCE 80 mg, standardized to 2.5% of triterpene 
glycosides, calculated as 26-deoxyactein. Other 
ingredients: natural color 
Fluid extract Finished product, DS 
BC34 BC root cut (plant material) ---- HDP 
BC35 BC root cut (plant material) ---- HDP 
BC36 BC root cut (plant material) ---- HDP 
BC37 BC root cut (plant material) ---- HDP 
BC38 BC root cut (plant material) ---- HDP 
BC39 BC root cut (plant material) ---- HDP 
BC40 BC root powder (plant material) ---- HDP 
BC41 BC root whole (plant material) ---- HDP 
BC42 BC root whole (plant material) ---- HDP 
BC43 BC root whole (plant material) ---- HDP 
BC44 BC root whole (plant material) ---- HDP 
BC45 









BC47 BCE powder (DER 4:1) ---- HDP 
BC48 BC root powder (plant material) ---- HDP 
BC49 BC root powder (plant material) ---- HDP 
BC50 BC root powder (plant material) ---- HDP 
BC51 BCE, standardized to 2.5% of triterpene glycosides ---- HDP 
BC52 BCE, standardized to 2.5% of triterpene glycosides ---- HDP 
BC53 BC root powder (plant material) ---- HDP 
BC54 BC root powder (plant material) ---- HDP 
BC55 BC root whole (plant material) ---- HDP 
BC56 BCE powder (DER 10:1) ---- HDP 
BC57 BCE powder (5%) ---- HDP 
BC58 BC root whole (plant material) ---- HDP 
BC59 BC root whole (plant material) ---- HDP 
BC60 BC root whole (plant material) ---- HDP 
 
 






Figure 3S1 HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under UV 254 nm prior to derivatization. Identification method. 
STD: isoferulic acid; RBCR: reference black cohosh root; RBCE: reference black cohosh root 
extract. 
 
Figure 3S2 HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under UV 366 nm prior to derivatization. Identification method. 
STD: isoferulic acid; RBCR: reference black cohosh root; RBCE: reference black cohosh root 
extract. 
 
Figure 3S3  HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under white light after derivatization. Identification method. 
STD: actein and isoferulic acid (increasing RF); RBCR: reference black cohosh root; RBCE: 
reference black cohosh root extract. 






Figure 3S4 HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under UV 366 nm after derivatization with sulfuric acid. 
Identification method. STD: actein and isoferulic acid (increasing RF); RBCR: reference black 
cohosh root; RBCE: reference black cohosh root extract. 
 
Figure 3S5 HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under UV 254 nm prior to derivatization. Test for A. podocarpa; 
RBCR: reference black cohosh root; 10% AP: A. racemosa mixed with 10% of A. podocarpa. 
 
Figure 3S6 HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under UV 366 nm after derivatization with Antimony trichloride 
reagent. Test for A. dahurica. STD: cimifugin; RBCR: reference black cohosh root; 5% AD: A. 
racemosa mixed with 5% of A. dahurica. 






Figure 3S7 HPTLC fingerprint of all black cohosh products (BC1 to BC33) and herbal 
drugs/preparations (BC34 to BC60) under UV 366 nm after derivatization boric acid/oxalic acid 
reagent. Test for A. cimicifuga. STD: cimifugin; RBCR: reference black cohosh root; 5% AD: A. 
racemosa mixed with 5% of A. cimicifuga. 
Calculation of the costs for preparation and analysing the 
samples 
The prices per mL of high-purity solvents (used to prepare the mobile phase and 
extract the samples), of the stationary phases and single use disposable material 
were obtained from Sigma Aldrich and Merck websites: 
https://www.sigmaaldrich.com/switzerland-suisse.html; 
http://www.merckmillipore.com/CH/de; (accessed on 20.12.2019 and 24.01.2020).  
Calculation excludes standards, instruments, glass apparatus, and personal. 
The costs for HPTLC analyses per sample were calculated based on: 
a. The price of the volume of solvent used per plate. 
b. The cost for disposable material such as centrifuge tubes, plastic 
pipettes, and syringe filter. 
c. The price of a single plate. 
d. The cost per derivatization, taking into account the price of solvents and 
reagents needed to prepare 200 mL. The obtained value is divided by 
50 (approximated dipping incidents to consume the 200 mL of reagent). 
Note: This calculation excluded the price per filter paper, which is reusable and it 
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Anàlisi integral de l’empremta dactilar per HPTLC per al control de qualitat de 
drogues vegetals: el cas de l'arrel de Angelica gigas 
 
La qualitat de les drogues vegetals se sol controlar amb diverses proves recomanades en 
una monografia. La cromatografia en capa fina d’alta resolució (HPTLC) és el mètode 
escollit per a la identificació en moltes farmacopees. Si es combina amb un material de 
referència adequat per a la seva comparació, l’HPTLC pot proporcionar informació més 
enllà de la identificació i, per tant, pot simplificar el control de qualitat. 
Aquest article descriu, com a prova de concepte, com es pot aplicar l’HPTLC per a definir 
les especificacions d'un material vegetal de referència i per controlar la qualitat d'una 
droga vegetal segons aquestes especificacions. A partir de múltiples lots d’arrel cultivada 
d’Angelica gigas, es va optimitzar un mètode específic d’HPTLC per a la seva identificació. 
Aquest mètode pot distingir 27 espècies relacionades. També detecta la presència de 
barreges de A. gigas amb dues altres espècies d’Angelica comercialitzades com a "Dang 
gui" i és adequat per a la valoració quantitativa de les mostres mitjançant un test de 
contingut mínim de la suma de decursina i angelat de decursinol. Es proposa el nou 
concepte “anàlisi integral de l’empremta dactilar per HPTLC” (Comprehensive HPTLC 
fingerprinting): les empremtes dactilars (imatges) per HPTLC, que s’utilitzen per a la 
identificació, es converteixen en perfils de pics i les intensitats de zones seleccionades es 
comparen quantitativament amb les zones corresponents del material de referència. 
Després d’un estudi interlaboratori realitzat en tres laboratoris de tres països, el mètode 
es va utilitzar per a avaluar la qualitat d’altres candidats a establir un material de referència 
adequat. En conclusió, aquest cas demostra que una única anàlisi per HPTLC pot 
proporcionar informació sobre la identitat, la puresa i el contingut mínim dels marcadors 
d’una droga vegetal. 
  







Análisis integral de la huella dactilar por HPTLC para el control de calidad de 
drogas vegetales: el caso de la raíz de Angelica gigas 
 
La calidad de las drogas vegetales se suele controlar con varias pruebas recomendadas 
en una monografía. La cromatografía en capa fina de alta resolución (HPTLC) es el 
método elegido para la identificación en muchas farmacopeas. Si se combina con un 
material de referencia adecuado para su comparación, la HPTLC puede proporcionar 
información más allá de la identificación y, por tanto, puede simplificar el control de 
calidad. 
Este artículo describe, como prueba de concepto, como se puede aplicar la HPTLC para 
definir las especificaciones de un material vegetal de referencia y para controlar la calidad 
de una droga vegetal según estas especificaciones. A partir de múltiples lotes de raíz 
cultivada de Angelica gigas, se optimizó un método específico de HPTLC para su 
identificación. Este método puede distinguir 27 especies relacionadas. También detecta 
la presencia de mezclas de A. gigas con dos otras especies de Angelica comercializadas 
como "Dang gui" y es adecuado para la valoración cuantitativa de las muestras mediante 
un test de contenido mínimo de la suma de decursina y angelato de decursinol . Se 
propone el nuevo concepto "análisis integral de la huella dactilar por HPTLC" 
(Comprehensive HPTLC fingerprinting): las huellas dactilares (imágenes) por HPTLC, que 
se utilizan para la identificación, se convierten en perfiles de picos y las intensidades de 
zonas seleccionadas se comparan cuantitativamente con las zonas correspondientes del 
material de referencia. Después de un estudio interlaboratorio realizado en tres 
laboratorios de tres países, el método se utilizó para evaluar la calidad de otros candidatos 
para establecer un material de referencia adecuado. En conclusión, este caso demuestra 
que un único análisis por HPTLC puede proporcionar información sobre la identidad, la 
pureza y el contenido mínimo de los marcadores de una droga vegetal. Después de un 
estudio interlaboratorio realizado en tres laboratorios de tres países, el método se utilizó 
para evaluar la calidad de otros candidatos a establecer un material de referencia 
adecuado. En conclusión, este caso demuestra que un único análisis por HPTLC puede 
proporcionar información sobre la identidad, la pureza y el contenido mínimo de los 
marcadores de una droga vegetal. 
 
  





Comprehensive HPTLC fingerprinting for quality control 















Quality of herbal drugs is usually controlled with several tests recommended in a 
monograph. High-performance thin-layer chromatography (HPTLC) is the method of 
choice for identification in many pharmacopoeias. If combined with a suitable reference 
material for comparison, HPTLC can provide information beyond identification and thus 
may simplify quality control. This paper describes, as a proof of concept, how HPTLC can 
be applied to define specifications for an herbal reference material and to control the 
quality of an herbal drug according to these specifications. Based on multiple batches of 
cultivated Angelica gigas root, a specific HPTLC method for identification was optimized. 
This method can distinguish 27 related species. It also detects the presence of mixtures 
of A. gigas with two other Angelica species traded as “Dang gui” and is suitable for 
quantitative assessment of samples in a test for minimum content of the sum of decursin 
and decursinol angelate. The new concept of “comprehensive HPTLC fingerprinting” is 
proposed: HPTLC fingerprints (images), which are used for identification, are converted 
into peak profiles and the intensities of selected zones are quantitatively compared to the 
corresponding zones of the reference material. Following a collaborative trial involving 
three laboratories in three countries, the method was applied to check the quality of further 
candidates for establishing an appropriate reference material. In conclusion, this case 
demonstrates that a single HPTLC analysis can provide information about identity, purity 
and minimum content of markers of an herbal drug.  
4.2 Introduction 
To describe and assure the quality of herbal drugs, a suite of appropriate tests is recom-
mended by regulatory agencies [1] [2] and organizations [3]. Such tests, as well as specifi-
cations for compliance, are described in pharmacopoeial or other quality monographs. 
They include verification of identity and purity as well as determination of the amount of 





the active substance(s) or marker(s) [4] [5]. To perform all tests, different analytical 
techniques and expertise are needed and together with additional experiments (e.g. test 
for pesticides, mycotoxins, etc.) the overall costs of quality testing can dramatically be 
increased.  
For herbal drugs, identity is still one of the central elements of quality [6]. Identity is 
evaluated primarily based on the morphological characteristics in comparison to a 
descriptive key and/or to an herbal reference material (HRM), representative for the 
species and the corresponding plant part. Identity is also evaluated based on the chemical 
composition, the pattern of which may be compared to that of the HRM [2]. However, 
herbal reference materials could also be used to qualify an herbal drug in a much wider 
sense, since the target material is of “good quality” when, additionally, it meets the purity 
and quantitative specifications of a quality monograph. Such HRM could be the “reference 
material of medicinal plant material (RMPM)” as envisioned and defined by the Forum for 
the Harmonization of Herbal Medicines (FHH) [7].  
The FHH was created with a focus on the harmonization of the approaches to regulation 
and quality of herbal drugs used in and traded among the member countries Australia, 
China, Hong Kong, Japan, Singapore, Republic of Korea, and Vietnam. Other targets in-
clude the establishment of a scientific basis for improvement or development of standards 
in quality, safety, and efficacy of herbal material as well as the establishment of regionally 
applicable RMPM [7]. For establishing their first RMPM, the FHH has selected the root of 
Angelica gigas Nakai. The roots of many Angelica species have a long use as traditional 
medicine [8] [9] [10]. Some are traded in East Asian herbal markets under the same 
common name “Dang gui”: Angelica sinensis (Oliv.) Diels, A. acutiloba (Siebold & Zucc.) 
Kitag., and A. gigas Nakai are most commonly used in China, Japan, the Republic of Korea 
and Vietnam, respectively [11] [12] [13]. They show similar phenotype and organoleptic 
properties, but different chemical composition. Other species from related genera within 
the Apiaceae are also traditionally prescribed for similar purpose.  
In the past years, HPTLC/TLC have been widely adopted by pharmacopoeias around the 
world for the chemical identification of herbal drugs. Acceptance criteria for HRM are either 
given by a results table (European Pharmacopoeia (Ph. Eur.) [14]) or by a paragraph 
describing color and position of zones of the chromatogram [15][16]. More recently images 
of HPTLC/TLC chromatograms have also been published [17] [18] [19] [20] [21] [22] [23]. 
However, HPTLC chromatograms and HPTLC fingerprints carry information beyond 
simple chemical identification.  
The HPTLC fingerprint is the electronic image of the chromatogram. When generated by 
a standardized methodology under use of suitable instruments and software, and qualified 
by a System Suitability Test [14] [15] [16] [24], HPTLC fingerprints can also provide 
quantitative information based on the intensity of zones [25]. Based on the entire 
information from a single HPTLC analysis, the process of quality control could be 
simplified. “Comprehensive HPTLC fingerprinting” might also become a tool for purity 
checks and determination of the minimum content of an herbal drug. Comprehensive 
HPTLC fingerprints derived from an herbal reference material can transfer all relevant 
quality elements of the reference material to the image, which thus could be used 
independently as reference for quality control. 
The goal of this work was to prove this concept for which the terminus “Comprehensive 
HPTLC fingerprinting” is proposed. At the same time, an herbal reference material for the 
root of Angelica gigas Nakai was established by defining the specifications for quality with 
respect to identity, purity, and minimum content. First, a suitable HPTLC method for this 
task was optimized, and an SOP was drafted. The SOP was used as basis for a 
collaborative trial involving three laboratories in three countries to prove the concept. 
Finally, the comprehensive HPTLC fingerprinting, generated in our laboratory, was applied 
for assessment of quality of twenty-four RMPM candidates.  





4.3 Materials and methods 
4.3.1 Plant material and standards  
Powdered root samples of  A. gigas, A. sinensis, A. acutiloba and other 27 related species 
were obtained from the National Institute of Food and Drug Safety Evaluation (NIFDS) – 
Republic of Korea, National Institute of Food and Drug Control (NIFDC) – Peoples 
Republic of China, National Institute of Medicinal Materials (NIMM) - Vietnam, the 
American Herbal Pharmacopoeia (AHP), Freie Universität Berlin (collected and 
authenticated by Prof. Melzig), the European Directorate for the Quality of Medicines 
(EDQM) and from local markets. Additional information about the samples is presented in 
the supplementary information, Tables 3S1 – 3.  
The standards Z-ligustilide (purity ≥ 99%) and nodakenin (purity ≥ 98%) were purchased 
from CromaDex. Ferulic acid (purity ≥ 99%) was purchased from Sigma. Decursinol (purity 
≥ 98%) and 7-demethylsuberosine (purity ≥ 98%) were purchased from ChemFaces. Other 
standards (decursin, purity ≥ 95%, and decursinol angelate, purity ≥ 95%) were isolated 
and supplied by the NIFDS. Imperatorin, isoimperatorin and osthole (purity ≥ 99%) were 
purchased from PhytoLab.  
4.3.2 Reagents 
Toluene (99%), ethyl acetate (99.5%), acetic acid (99.5%) and sulfuric acid (95%) were 
purchased from Acros. Methanol (HPTLC grade) was obtained from Carl Roth GmbH.  
4.3.3 Plant material processing  
Bulk material of A. gigas, A. sinensis, and A. acutiloba was collected by authorities of 
Republic of Korea, Japan and Vietnam, and then processed by washing, drying at 60°C 
for 20-30 min, and further drying in the oven for 7-10 days at 35°C. The roots of each 
sample/batch were milled for 20 seconds to minimize the loss of volatile compounds. 
These materials were provided to the different institutions. 
4.3.4 Preparation of samples and standards solutions 
Test solutions: 1.0 g of the powdered material was suspended in 5 mL of methanol and 
shaken at 3000 rpm for 10 minutes. The suspension was centrifuged at 5000 rpm for 5 
min and the supernatants used. For quantitative evaluation, the A. gigas test solutions 
were diluted 500-fold.  
Standard solutions for system suitability test: 1 mg of imperatorin, osthole, and isoimpera-
torin were dissolved in 1 mL of methanol.  
Decursin standard solutions for the quantitative assessment: five working solutions were 
prepared at concentrations between 8.0 – 40.0 µL/mL.  
4.3.5 High-Performance Thin-Layer Chromatography (HPTLC) 
A CAMAG HPTLC system consisting of Visualizer, Automatic TLC Sampler 4 (ATS4), Au-
tomatic Developing Chamber 2 (ADC2), Scanner 4, Chromatogram Immersion Device III 
and TLC Plate Heater III, and controlled by visionCATS software, was used for the 
analysis. The parameters were chosen based on the USP general chapter <203> [15]: 
Merck HPTLC silica gel F254 plates 20x10 cm (article N° 105642) were utilized as 
stationary phase. Prior to development the plates were conditioned to 33% relative 
humidity and the chamber was saturated for 20 minutes with filter paper and developing 
solvent. The plates were developed up to 70 mm (from the lower edge) and dried for 5 
minutes after development.  
The developing solvent consisted of toluene, ethyl acetate, and acetic acid (90:10:1 v/v/v). 
The volume applied for identity and purity check was 4.0 µL. For the minimum content 
tests (diluted test solutions and standards) the application volume was 2.0 µL. 





4.3.6 Visualization of fingerprints 
Multiple detection modes were employed: UV 254 nm, UV 366 nm, and white light 
(transmission/ reflection) prior to derivatization; UV 366 nm and white light 
(transmission/reflection) after derivatization. For derivatization, plates were dipped (speed: 
3, time: 0) into 10% sulfuric acid in methanol, and then heated at 100°C for 3 min.  
4.3.7 Scanning Densitometry 
Chromatograms were scanned in fluorescence mode at 20 mm/s, with data resolution of 
100 μm/step and slit size of 5 × 0.2 mm at UV 313 nm using a mercury lamp and a 400 
nm cut-off filter K400. 
4.3.8 Converting fingerprints into peak profiles (PPI) and evaluation of data 
The visionCATS software was used to generate peak profiles (PPI) from fingerprints 
(images) by calculating the luminance as L = ( R) + ( G) + ( B) from the average of Red, 
Green, and Blue pixels of each line of the track and then plotting it against the RF values. 
visionCATS was used for all quantitative evaluation. 
4.3.9 Supplementary information 
In the supplementary information the following data are available: 1) Different sources of 
HPTLC/TLC methods for identification of Angelica and related species (Table 4S1); 2) 
Details of samples shown in Figure 4.2 (Table 4S2); 3) Details of samples of A. gigas, A. 
sinensis, and A. acutiloba used in the study (Table 4S3); 4) Content of D+DA of herbal 
reference materials of A. gigas (Table 4S4); and 5) SOP for the collaborative trial. 
4.4 Results and Discussion 
To establish specifications for an herbal drug, the selected sample population has to be 
sufficiently large, properly authenticated, and representative for the desired quality. Thirty-
four samples of A. gigas roots (RMPM 1-10 and AG 1-24) were collected during the 
traditional collection season (October to November). They had been cultivated in 
compliance with Good Agricultural Practices (GAP) in fields in the Gangwon province 
(Republic of Korea). Samples were subjected to botanical and organoleptic identification. 
Those which met the macroscopic and microscopic specification of the Korean 
Pharmacopoeia monograph for Angelica gigas root [26] were further evaluated by DNA 
barcoding and assay in the Herbal Medicine Research Division, National Institute of Food 
and Drug Safety Evaluation, Republic of Korea [11].  
4.4.1 HPTLC fingerprints for identification and evaluation of natural 
variability 
Over the last decades, approximately thirty HPTLC/TLC methods have been published 
that target eight species of Angelica and related genera [12] [26] [27] [28] [29] [30] [31] 
[32] (see Table 4S1, supplementary information). Except for those included in the Ph. Eur., 
the methods are not harmonized and do not provide sufficient information about specific 
chromatographic parameters. Therefore, it was decided to start with “Identification C” of 
the Ph. Eur. monograph on Angelica sinensis root [27], already harmonized with 
monographs for four other related species. Identification C uses standard HPTLC 
methodology as defined in the general chapters of the Ph. Eur. (2.8.25) [14] and the United 
States Pharmacopoeia (USP) (<203>) [15]. The System Suitability Test of the Ph. Eur. 
monographs was modified to the required appearance of the zones corresponding to 
imperatorin, osthole, and isoimperatorin at RF 0.33, 0.38, and 0.44, respectively. 
Furthermore, the exposure time for capturing the image under UV 366 nm was adjusted 
on the track that contains the System Suitability Test [14].  
The method was applied to investigate the natural variability of A. gigas root and to 
establish a “representative” fingerprint comprising most of the chemical characteristics of 





the species. Nineteen samples were analyzed individually and then pooled by mixing 1g 
of each. The pooled sample was homogenized, extracted, and analyzed. Its fingerprint 
(track A) is compared in Figure 4.1 with those of all thirty-four individual samples (tracks 
1-34). While there are slight variations in the individual fingerprints, the pooled sample 
represents an average revealing the typical features of the species.  
 
Figure 4.1 HPTLC fingerprints of 34 samples of A. gigas; UV 254 nm (top) and UV 366 nm prior 
derivatization (bottom); track A: pooled sample of 19 samples on tracks 11-29; tracks 1-10: RMPM 
1-10; tracks 11 – 34: AG 1-24. 
4.4.2 Specificity of the optimized HPTLC method 
Specificity of the Ph. Eur. method was investigated. A series of experiments with a 
modified sample preparation (using methanol instead of heptane) and an additional 
derivatization step with 10% sulfuric acid in methanol, demonstrated that the final method 
is able to generate significantly different fingerprints for the roots of twenty-seven related 
species (Figure 4.2). Several zones between the application position and the zone of 
isoimperatorin (RF 0.44, track 1) can be used to distinguish the species on tracks 2 to 8 
applying different detection modes. The samples on tracks 9 - 13 include Angelica and 
Peucedanum species and show different composition under different detection modes. A. 
gigas (track 12) features a very characteristic and distinctive fingerprint. The samples on 
tracks 14 - 15 (P. alsaticum and A. palustris) show an overall weak fingerprint, both species 
can be distinguished from others under UV 254 nm prior to derivatization and UV 366 nm 
after derivatization. The species on tracks 16 – 29, which contain Z-ligustilide (a blue zone 
at RF 0.58 under UV 366 nm prior to derivatization), can be discriminated by the zones 
between RF 0.2 and 0.55 applying different detection modes. The modified method for 
chemical identification is specific and can detect substitution with other species 
(adulterants).  






Figure 4.2 HPTLC fingerprints of the roots of different species of Apiaceae Family, top to bottom: 
UV 254 nm and UV 366 nm prior derivatization, white light and UV 366 nm after derivatization. 
Track 1: imperatorin, osthole, isoimperatorin and Z-ligustilide (increasing RF); track 2: Peucedanum 
officinale; track 3: Notopterygium franchetii; track 4: Notopterygium incisum; track 5: Angelica 
dahurica var. formosana; track 6: Angelica dahurica; track 7: Peucedanum ostruthium; track 8: 
Angelica grosseserrata; track 9: Angelica decursiva; track 10: Angelica pubescens; track 11: 
Angelica archangelica; track 12: Angelica gigas; track 13: Peucedanum praeruptorum; track 14: 
Peucedanum alsaticum; track 15: Angelica palustris; track 16: Ligusticum mutellina; track 17: 
Ligusticum grayi; track 18: Angelica acutiloba; track 19: Angelica acutiloba var. sugiyamae; track 
20: Ligusticum officinale; track 21: Angelica sinensis; track 22: Ligusticum canbyi; track 23: 
Ligusticum tenuissimum; track 24: Ligusticum jeholense; track 25: Ligusticum sinense; track 26: 
Ligusticum chuanxiong; track 27: Ligusticum porteri; track 28: Levisticum officinale. 
4.4.3 HPTLC fingerprints for determination of purity  
In the next step, a test for purity, this method should be shown to be suitable to detect 
adulterants added to a certain percentage. This involved the assessment of: (1) whether 
the HPTLC fingerprints of the adulterant materials contain zones that can be regarded as 
markers absent in the fingerprint of target material and (2) the detection limit of such 
markers in the fingerprint. 
The two other very common species of Dang gui (A. sinensis and A. acutiloba) were 
chosen as adulterants. Individual pooled samples were created for A. acutiloba from 
twelve samples, for A. sinensis from six samples, and for A. gigas from 10 samples (RMPM 
1-10). The powdered pooled samples of A. gigas were systematically mixed in different 
proportions with either A. sinensis, or A. acutiloba, extracted and analyzed (Figure 4.3). 
Z-ligustilide at RF 0.58 turned out as highly suitable to detect the two adulterants. It 
represents a marker for both A. acutiloba (track 6) and A. sinensis (track 12), but lacks in 
the fingerprint of pure Angelica gigas (tracks 1 and 7). This faint zone was observed when 
only 1% of either A. acutiloba or A. sinensis is mixed with 99% of A. gigas (tracks 2 and 8, 
respectively). 






Figure 4.3 Fingerprints of mixtures: UV 366 nm prior derivatization (enhanced: contrast 1.0; 
normalized over the zone of Z-ligustilide on tracks 5 and 11). Tracks 1 and 7: 100% Angelica gigas 
(AG), track 2: 1% A. acutiloba (AA) and 99% AG, track 3: 5% AA and 95% AG), track 4: 10% AA 
and 90% AG, track 5: 50% AA and 50% AG, track 5: 100% AA, track 8: 1% A. sinensis (AS) and 
99% AG, track 9: 5% AS and 95% AG, track 10: 10% AS and 90% AG, track 11: 50% AS and 50% 
AG, track 12: 100% AS. 
4.4.4 Conversion of electronic images into “peak profile from images” (PPI) 
For a more objective evaluation and comparison of zone intensities for quantitative 
analysis, the HPTLC fingerprints (electronic images, Figure 4.4 A) were converted into 
“peak profiles from images” (PPI). In this process the luminance is calculated from the 
average RGB signals of pixels per line of the track and then plotted as function of the RF 
(Figure 4.4 B). In the peak profile integration ranges were then adjusted to frame the target 
zone Z-ligustilide (Figure 4.4 C). The resulting single peak was rotated 90° so that it is 
seen as a band from its rear end and its height becomes a “bar graph” (Figure 4.4 E). 
 
Figure 4.4 Conversion of electronic images into “peak profiles from images” (PPI); A: Fingerprint 
(image) under UV 366 nm prior to derivatization; B: Fingerprint converted into PPI; C: peak due to 
Z-ligustilide after adjusting the integration range to exclude other peaks; D: isometric view of the 
PPI; E: bar graph representing the peak height due to Z-ligustilide. 
 





In Figure 4.5, the intensities of the Z-ligustilide zones are compared. Admixtures of 5% of 
either species into A. gigas (tracks 3 and 9) are clearly visible in the fingerprint (Figure 
4.3). Thus, this level is proposed as an upper limit for the presence of these two species.  
 
Figure 4.5 Evaluation of PPI derived from Fingerprints in Figure 4.3: detection of mixtures of A. 
gigas with A. acutiloba (red bars) or A. sinensis (blue bars) based on the presence of Z-ligustilide. 
4.4.5 HPTLC fingerprint for minimum content test 
The third part of the study targeted the possibility of determining “minimum content” of 
active or analytical markers as a criterion of quality from the HPTLC fingerprint obtained 
during identification. It was evaluated whether an HPTLC fingerprint of an herbal reference 
material with a known content of markers and a defined minimum content as acceptance 
criterion can be used as a quantitative reference. This could be a simpler and more general 
approach to the assessment of minimum content. Such quantitative evaluation could be 
accomplished during the HPTLC analysis for identification without need for additional work 
or instrumentation.   
For that purpose, several known constituents of A. gigas roots were evaluated with respect 
to their chromatographic behavior, spectral properties, and suitability as positive markers. 
Five of those substances are clearly detectable in the HPTLC fingerprint of the drug 
(Figure 4.6, tracks 1-5) under the conditions of the method for identification. Decursin 
(track 4) and decursinol angelate (DA; track 5) are co-eluting and give the most prominent 
zone of the fingerprint (track 6) with sufficient separation from other zones. The sum of 
decursin plus DA (D+DA) expressed as decursin was selected for assessment of minimum 
content.  
The amount of this sum was determined from peak profiles from scanning densitometry 
(PPSD) in ten herbal reference samples of A. gigas (RMPM 1-10; see Table 4S4). After 
dilution of the test solution for identification at a ratio 1:500, samples fit into a linear calibra-
tion range of 16-80 ng per zone established with a decursin standard. Measurements in 
fluorescent mode at UV 313/>400nm were performed in independent triplicates on three 
HPTLC plates. Results are presented in Table 4.1. The average of D+DA of samples was 
5.55% by PPSD. This value is comparable to 5.9% obtained by HPLC assays of the indivi-
dual compounds [11]. The table compares values from PPSD and PPI. Both 
measurements evaluated peaks areas and heights. For PPI the data was best fitted by a 
polynomial function (Figure 4.7). Good correlation was observed with the results obtained 
by PPSD which were 1.14-fold higher. 





Based on the lowest value for D+DA in the RMPMs, the minimum content expressed as 
decursin was proposed at 3.0% (average between area and height data from PPI). This 
corresponds to 0.012 mg/mL of D+DA equivalent to 0.4 mg/mL of powdered drug extracted 
in methanol.  
 
Figure 4.6 Identification of zones in the fingerprint of Angelica gigas (UV 366 nm prior 
derivatization); track 1: nodakenin; track 2: decursinol; track 3: 7-demethylsuberosine (RF 0.15); 
track 4: decursin; track 5: decursinol angelate; track 6: A. gigas; concentration of reference 
substances: 1 mg/mL in methanol. 
Table 4.1 Average content of D+DA expressed as decursin in ten samples of herbal reference 









Average content of decursin plus DA 
expressed as decursin  5.55% 5.12% 4.74% 4.30% 
Average CV% of the triplicates 4.22% 4.31% 4.87% 4.70% 
Correlation coefficient (R) for plate 1 (samples 
n1) 0.999223
a 0.998699a 0.999004a 0.999183b 
Coefficient of variation of the calibration 
curve for plate 1 2.0232% 2.5136% 2.3615 % 2.0483% 
Correlation coefficient (R) for plate 2 (samples 
n2) 0.993888
a 0.993097 0.998409b 0.998398b 
Coefficient of variation of the calibration 
curve for plate 2 5.7059% 5.9035% 3.0235% 2.9313% 
Correlation coefficient (R) for plate 3 (samples 
n3) 0.998833
a 0.997809a 0.999409b 0.999556b 
Coefficient of variation of the calibration 
curve for plate 3 2.4634% 3.2975% 1.8251% 1.5318% 
a Calculation based on a linear function; b Calculation based on a polynomial function  
 
Figure 4.7 Calibration curves for decursin based on PPI and PPD; Blue dots: sample solutions; 
Green dots: reference solutions. 





4.4.6 The use of RMPM as reference for minimum content test 
To replace the chemical standard, RMPM 4 of A. gigas was prepared to contain 0.012 mg 
of these substances per mL (reference solution used as minimum content (MC)). RMPM 
1-10 were prepared at concentrations of 0.2 g/mL (as for identification test) and diluted 
500-fold (test solutions). Figure 8 compares the test solutions (green bars) with the 
reference solution (red bar). Visually it is difficult to accurately assess from the fingerprint 
if a sample passes or fails the test for minimum content (Figure 4.8 A), but after conversion 
to PPI such determination is quite simple: the content (intensity) of all samples is above 
the limit (Figure 4.8 B). For results with higher accuracy, a single point calibration based 
on peak area or height of D+DA in the reference solution can be used to calculate values 
for the test solutions (Figure 4.8 C and D). Similar results are obtained by PPSD. 
 
Figure 4.8 Test for minimum content of D+DA in A. gigas samples for herbal reference 
material; A: visual comparison of the fingerprints; B: visual evaluation based on PPI; 
Content (%) of D+DA calculated on PPI via height (C) and area (D). MC: minimum 
content/RMPM 4; tracks 1 - 10: A. gigas root RMPM 1-10. 
4.4.7 The collaborative trial 
The above described process of producing an HPTLC fingerprint and rendering it into peak 
profiles which may be integrated for obtaining additional, quantitative information is 
suggested to denominate “Comprehensive HPTLC fingerprinting”. The corresponding 
SOP for Angelica gigas root was drafted. It defines acceptance criteria regarding identity, 
purity, and minimum content with reference to the herbal reference material (see 
supplementary information). This SOP was evaluated in a collaborative trial involving three 
laboratories in three countries, Switzerland, Republic of Korea, and Vietnam. The 
collaborators used identical sets of standards (imperatorin, osthole, isoimperatorin, and 
decursin) and samples (three of A. gigas, RMPM 1, 5 and 10; one sample each of A. 
sinensis and A. acutiloba). Results are presented in Table 4.1.  
The trial evaluated repeatability of the RF of seven zones of the fingerprint. All values were 
within 0.01 RF units, except for Z-ligustilide. According to Reich et al. [6], variability of RF 
in inter-laboratory trials should not exceed 0.07 RF units. All test samples produced 
fingerprints identical to that of A. gigas herbal reference material presented in the SOP. In 
the purity test no lab detected a zone due to Z-ligustilide in the herbal reference samples 
but the zone representing 5% adulteration in the corresponding reference solution made 





from A. acutiloba and A. sinensis. In the test for minimum content, the intensity (peak 
height) of the zone of D+DA in the fingerprint of A. gigas was compared to that of a 
decursin standard solution prepared at a concentration of 0.012 mg/mL. In all laboratories 
all samples passed the limit test for D+DA.  
Table 4.2 Results of the collaborative study performed in three laboratories with three samples of 
herbal reference material of A. gigas roots.  
Qualification of the chromatography/ identity 
Compounds CHb KRc Vietnam ΔRF 
Z-ligustilide 0.58 0.58 0.52 0.06 
Isoimperatorin 0.44 0.44 0.44 0.00 
Osthole 0.38 0.38 0.37 0.01 
Imperatorin 0.33 0.34 0.33 0.01 
Decursin plus DAa 0.27 0.27 0.28 0.01 
7-Demethylsuberosine 0.15 0.16 0.16 0.01 
Decursinol 0.04 0.04 0.04 0.00 
Purity of A. gigas samples 
Presence of Z-ligustilide in 3  
A. gigas samples 
negative negative negative 
Samples not 
adulterated with 
ASd and/or AAe 
Z-ligustilide equivalent to 5% 
adulteration in reference solution 
positive positive positive 
Representation of 
adulteration with 5% 
ASd and AAe is seen
Strength of A. gigas samples 
Content of Decursin plus DAa in 










a Decursinol angelate (DA); b Switzerland (CH); c Republic of Korea (KR); d Angelica sinensis 
(AS); e Angelica acutiloba (AA) 
The new method was applied to twenty-four additional samples of herbal reference 
material of A. gigas (samples AG 1-24). The identification part is included in Figure 4.2 
(tracks 11- 34). All fingerprints are in full agreement with those of RMPM 1-10 (tracks 1-
10). No zone due to Z-ligustilide is seen, indicating the absence of A. acutiloba and/or A. 
sinensis. For visual assessment of minimum content, the PPI of the test solutions were 
compared to that of the reference solution prepared from RMPM 4 containing 3.0% of 
D+DA (Figure 4.9). Nineteen samples (tracks 1-6, 8-10, 12-14, 17-20, 22-24, green bars) 
pass the limit test, one sample (track 15) is in the uncertainty level of ± 5%, and four 
samples (tracks 7, 11, 16 and 21, gray bars) fail the minimum content, and were therefore 
rejected as candidate for herbal reference material. 
 
Figure 4.9 Visual test for minimum content based on PPI; MC: minimum content/RMPM 4; tracks 
1 - 24: A. gigas root herbal reference material (samples AG 1-24). 






In this work the specifications for chemical identity of A. gigas, as well as purity (test for 
adulteration with A. sinensis and A. acutiloba) and minimum amount of D+DA in the roots 
of A. gigas were established based on the data available in the image. The method has 
been successfully evaluated in a collaborative trial involving three laboratories and was 
applied in the analysis of twenty-four commercial samples (samples for herbal reference 
material: AG 1-24).  
To the best of our knowledge, this case study presents a novel, pragmatic, and cost-
efficient approach for establishing and controlling quality of an herbal drug, based on 
“comprehensive HPTLC fingerprinting”. While the fingerprint usually is the electronic ima-
ge of the visual HPTLC chromatogram, the comprehensive fingerprint includes a peak 
profile based on luminance, which can be evaluated quantitatively. A comprehensive 
fingerprint thus contains information about the identity, purity, and minimum content of the 
herbal drug. It represents the quality of an herbal reference material of A. gigas root and 
can be included in an SOP or quality monograph as principal reference for those three 
elements of quality. In the process of establishing further RMPM for herbal drugs, the 
concept of comprehensive HPTLC fingerprinting could be used for creating an HPTLC 
atlas of herbal drug quality for FHH members.  
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4.7 Supplementary information 
Table 4S1 Sources of TLC/HPTLC methods for identification of Angelica and related species 
Species Source TLC / HPTLC identification method and mobile phase 













HPTLC; acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
(ID 1), HPTLC; hexane, ethyl acetate (4:1 v/v) 
(ID 2), HPTLC; toluene, ethyl acetate, formic acid (4:1:0.1 
v/v/v) 
TLC; hexane, ethyl acetate (4:1 v/v) 
(ID 1), HPTLC; hexane, ethyl acetate (5:1 v/v) 
(ID 2), HPTLC; chloroform, ethyl acetate, formic acid 
(10:5:0.5 v/v/v) 
HPTLC; acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
TLC; formic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
TLC; formic acid, ethyl acetate, toluene (1:10:90 v/v/v) 






HPTLC; acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
HPTLC; petroleum ether, ether (3:2 v/v) 
TLC; petroleum ether, ether (3:2 v/v) 
TLC; formic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
TLC; hexane, ethyl acetate (2:1 v/v) 
Angelica 
pubescens 







HPTLC; acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
HPTLC; hexane, toluene, ethyl acetate (2:1:1 v/v/v) 
HPTLC; hexane, toluene, ethyl acetate (2:1:1 v/v/v) 
TLC; petroleum ether, ethyl acetate (7:3 v/v)) 
TLC; hexane, ethyl acetate (4:1 v/v) 
Angelica 
archangelica 
Ph. Eur. [27] 
BP [31] 
HPTLC;  acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
TLC; dichloromethane, toluene (1:1 v/v) 








TLC; petroleum ether, acetone (95:5) 
TLC; toluene, ethyl acetate, formic acid (7:2:0.1 v/v/v) 








TLC; hexane, ethyl acetate (9:1 v/v)  
TLC; hexane, ethyl acetate (9:1 v/v) 
TLC; acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
TLC; hexane, ethyl acetate, methanol (10:2:1 v/v/v) 
Levisticum 
officinale 
Ph. Eur. [27] HPTLC; acetic acid, ethyl acetate, toluene (1:10:90 v/v/v) 
 
Table 4S2 Details of samples shown in Figure 4.2 
Track N° Sample 
1 Imperatorin, osthole, isoimperatorin and Z-ligustilide (increasing RF) 
2 Peucedanum officinale L. c 
3 Notopterygium franchetii  H.Boissieua 
4 Notopterygium incisum K.C.Ting ex H.T.Chang a 
5 Angelica dahurica var. formosana (Boissieu) Yen a 
6 Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav. a 
7 Peucedanum ostruthium (L.) W.D.J.Koch c 
8 Angelica grosseserrata Maxim. a 





Track N° Sample 
9 Angelica decursiva (Miq.) Franch. & Sav. a  
10 Angelica pubescens Maxim. a 
11 Angelica archangelica L. b 
12 Angelica gigas Nakai a 
13 Peucedanum praeruptorum Dunn a 
14 Peucedanum alsaticum L. c 
15 Angelica palustris (Besser) Hoffm.c 
16 Ligusticum mutellina (L.) Crantz c 
17 Ligusticum grayi J.M.Coult. & Rose b 
18 Angelica acutiloba (Siebold & Zucc.) Kitag. a 
19 Angelica acutiloba var sugiyamae Hikino a 
20 Ligusticum officinale (Makino) Kitag. a 
21 Angelica sinensis (Oliv.) Diels a 
22 Ligusticum canbyi J.M. Coult. & Rose b 
23 Ligusticum tenuissimum (Nakai) Kitag. a 
24 Ligusticum jeholense (Nakai & Kitag.) Nakai & Kitag. a 
25 Ligusticum sinense Oliv. a 
26 Ligusticum chuanxiong S.H.Qiu, Y.Q.Zeng, K.Y.Pan, Y.C.Tang & J.M.Xu d 
27 Ligusticum porteri J.M.Coult. & Rose b 
28 Levisticum officinale W.D.J.Koc b 
a) botanical reference material (BRM) provided by the Ministry of Food and Drug Safety (MFDS) – South Korea 
or by the National institute of food and Drug Control (NIFDC) – China; b) BRM provided by the American 
Herbal Pharmacopoeia (AHP) – USA; c) BRM collected and authenticated by Prof. Melzig, Freie Universität 
Berlin; d) provided through the European Directorate for the Quality of Medicines (EDQM) 
Table 4S3 Details of Angelica gigas, Angelica acutiloba and Angelica sinensis samples used in the 







RMPM1 Angelica gigas NIFDS Not available* 
RMPM2 Angelica gigas NIFDS Not available* 
RMPM3 Angelica gigas NIFDS Not available* 
RMPM4 Angelica gigas NIFDS Not available* 
RMPM5 Angelica gigas NIFDS Not available* 
RMPM6 Angelica gigas NIFDS Not available* 
RMPM7 Angelica gigas NIFDS Not available* 
RMPM8 Angelica gigas NIFDS Not available* 
RMPM9 Angelica gigas NIFDS Not available* 
RMPM10 Angelica gigas NIFDS Not available* 
AG1 Angelica gigas  NIFDSa KDNR1404102001 
AG2 Angelica gigas  NIFDSa KDNR1404102002 
AG3 Angelica gigas  NIFDSa KDNR1404102003 
AG4 Angelica gigas  NIFDSa KDNR1404102004 
AG5 Angelica gigas  NIFDSa KDNR1404102005 
AG6 Angelica gigas  NIFDSa KDNR1404102006 
AG7 Angelica gigas  NIFDSa KDNR1404102007 
AG8 Angelica gigas  NIFDSa KDNR1404102008 
AG9 Angelica gigas  NIFDSa KDNR1404102009 
AG10 Angelica gigas  NIFDSa KDNR1404102010 
AG11 Angelica gigas  NIFDSa KDNR1404102011 
AG12 Angelica gigas  NIFDSa KDNR1404102012 
AG13 Angelica gigas  NIFDSa KDNR1404102013 
AG14 Angelica gigas  NIFDSa KDNR1404102014 
AG15 Angelica gigas  NIFDSa KDNR1404102015 











AG16 Angelica gigas  NIFDSa KDNR1404102016 
AG17 Angelica gigas NIFDSa KDNR1404102017 
AG18 Angelica gigas NIFDSa KDNR1404102018 
AG19 Angelica gigas NIFDSa KDNR1404102019 
AG20 Angelica gigas NIFDSa KDNR1404102020 
AG21 Angelica gigas NIFDSa KDNR1404102021 
AG22 Angelica gigas NIFDSa KDNR1404102022 
AG23 Angelica gigas NIFDSa KDNR1404102023 
AG24 Angelica gigas NIFDSa KDNR1404102024 
AA1 Angelica acutiloba NIMMb Ref. H2014V0002 
AA2 Angelica acutiloba Market sample Not available* 
AA3 Angelica acutiloba Market sample Not available* 
AA4 Angelica acutiloba Market sample Not available* 
AA5 Angelica acutiloba NIFDS Not available* 
AA6 Angelica acutiloba NIFDS Not available* 
AA7 Angelica acutiloba NIFDS Not available* 
AA8 Angelica acutiloba NIFDS Not available* 
AA9 Angelica acutiloba NIFDS Not available* 
AA10 Angelica acutiloba NIFDS Not available* 
AA11 Angelica acutiloba NIFDSa KDSR1404212095 
AA12 Angelica acutiloba NIFDS Not available* 
AS1 Angelica sinensis Market sample Not available* 
AS2 Angelica sinensis Market sample Not available* 
AS3 Angelica sinensis Market sample Not available* 
AS4 Angelica sinensis Market sample Not available* 
AS5 Angelica sinensis Market sample Not available* 
AS6 Angelica sinensis Market sample Not available* 
AS1 Angelica sinensis Market sample Not available* 
a) indicates samples deposited at the Herbarium from National Center for Herbal Resources – National 
Institute of Food and Drug Safety Evaluation (NIFDS; Republic of Korea); b) indicates samples provided by 
National Institute of Medicinal Materials (NIMM; Vietnam) * samples were provided with internal reference 
number (column 1) only 
 
Table 4S4 Content of D+DA of herbal reference materials of Angelica gigas RMPMs 
 Average content (n=3) in % based on 
PPSD  
Average content (n=3) in % based 
on PPI  
Samples area height area height 
A. gigas RMPM 1 5.91 ± (0.20%) 5.48 ± (0.20%) 5.37 ± (0.30%) 4.93 ± (0.28%) 
A. gigas RMPM 2 5.41 ± (0.32%) 4.96 ± (0.38%) 4.85 ± (0.43%) 4.42 ± (0.41%) 
A. gigas RMPM 3 7.23 ± (0.35 %) 6.58 ± (0.33%) 6.35 ± (0.41%) 5.61 ± (0.37%) 
A. gigas RMPM 4 3.60 ± (0.14%) 3.24 ± (0.13%) 3.15 ± (0.12%) 2.88± (0.10%) 
A. gigas RMPM 5 4.50 ± (0.14%) 3.87 ± (0.10%) 3.84 ± (0.13%) 3.46 ± (0.10%) 
A. gigas RMPM 6 6.99 ± (0.22%) 5.63 ± (0.14%) 5.85 ± (0.12%) 5.31 ± (0.10%) 
A. gigas RMPM 7 6.49 ± (0.52%) 5.92 ± (0.54%) 5.38 ± (0.52%) 4.87 ± (0.47%) 
A. gigas RMPM 8 4.21 ± (0.06%) 3.76 ± (0.04%) 3.50 ± (0.03%) 3.15 ± (0.02%) 
A. gigas RMPM 9 4.32 ± (0.22%) 3.90 ± (0.15%) 3.57 ± (0.15%) 3.23 ± (0.09%) 
A. gigas RMPM 10 6.81 ± (0.16%) 6.13 ± (0.21%) 5.58 ± (0.20%) 5.03 ± (0.20%) 
 
Method for the identification and assessment of purity and 
strength of Angelica gigas root (SOP) 
1. Preparation of test solutions 





Test solution A: 1.0 g of milled plant material is transferred to a 5 mL volumetric flask. The 
volume is made up to 5 mL with methanol. The mixture is shaken for 10 min and then 
centrifuged. The supernatant is used as Test solution.  
Test solution A1: 1 mL of Test solution A is transferred to a 20 mL volumetric flask and the 
volume is made up to 20 mL with methanol. 1 ml of the diluted solution (1:20) is transferred 
to a 25 mL volumetric flask and the volume is made up to 25 mL with methanol.  
2. Preparation of reference solutions 
Solution for system suitability test (SST): 1 mg each of imperatorin, osthole and 
isoimperatorin are individually dissolved in 1 mL of methanol. 
Reference solution R (identification): a solution of A. gigas roots RMPM is prepared to 
contain 3.0% of decursin plus decursinol angelate as follows (calculate the amount of 





Z = amount of starting material in grams 
𝑌 = percentage of decursin plus decursinol angelate declared in the CoA 
The amount of starting material, calculated in grams (formula above), is transferred to a 5 
mL volumetric flask and volume is made up to 5 mL with methanol. The mixture is shaken 
for 10 min and then centrifuged. The supernatant is used as reference solution. 
Reference solution R1 (limit test): 1 mL of Reference solution R is transferred to a 20 mL 
volumetric flask and the volume is made up to 20 mL with methanol. 1 mL of the diluted 
solution (1:20) is transferred to a volumetric flask and the volume is made up to 25 mL with 
methanol.  
Reference solution R2 (A. sinensis root 100%): 1.0 g of A. sinensis milled plant material is 
transferred to a 5 mL volumetric flask and volume is made up to 5 mL with methanol. The 
mixture is shaken for 10 min and then centrifuged. The supernatant is used as Test 
solution.  
Reference solution R3 (A. sinensis root 5%): 1 mL of reference solution R2 is added to a 
20 mL volumetric flask and the volume is made up to 20 mL with methanol. 
Reference solution R4 (A. acutiloba root 100%): 1.0 g of A. acutiloba milled plant material 
is transferred to a 5 mL volumetric flask and volume is made up to 5 mL with methanol. 
The mixture is shaken for 10 min and then centrifuged. The supernatant is used as Test 
solution.  
Reference solution R5 (A. acutiloba root 5%): 1 mL of reference solution R4 is added to a 
20 mL volumetric flask and the volume is made up to 20 mL with methanol. 
3. Stationary phase 
20x10 cm glass plates HPTLC silica gel 60 F254 (Merck). 
4. Sample application 
4 L of Test solution A, SST and Reference solutions R2-5; and 2 L of Test solution A1 
and Reference solution R1 are applied as 8 mm bands, at least 2 mm apart, 8 mm from 
the lower edge and at least 15 mm from left and right edges of the plate.  
5. Temperature and humidity 
Record temperature and humidity in the laboratory. 
6. Chromatography 





Chamber type:  20x10 cm Twin Trough Chamber 
Configuration:  Place the filter paper into the rear trough of the chamber and 
wet it with 25 mL of developing solvent. Place 10 mL of 
developing solvent in the front trough and close the lid. 
Saturate the chamber for 20 min 
Humidity control:  Condition the plate to 33% rH (saturated MgCl2 solution) 
Developing solvent: Toluene, ethyl acetate, acetic acid (90:10:1 v/v/v),  
Developing distance: 70 mm from lower edge of plate  
Drying:    5 min with cold air  
7. Derivatization  
Derivatization reagent: 10% sulfuric acid in methanol 
Preparation:  Mix 20 mL of sulfuric acid with 180 mL of cold methanol 
Reagent use:  Dip (time: 0; speed: 3) the plate into 10% sulfuric acid 
reagent and heat at 100°C for 3 minutes.  
8. Documentation  
1) Clean plate at UV 254 nm and at white light RT  
2) Developed plate at UV 254 nm 
3) Developed plate at UV 366 nm 
4) Derivatized plate at white light RT 
5) Derivatized plate at UV 366 nm 
 
Evaluation 1 (Identity) 
Detection A: capture images under UV 254 nm and UV 366 nm (normalized on SST) 
Compare results with the images below: 
       UV 254 nm             UV 366 nm 
  
         1       2                 1       2   
System suitability test SST (compare with Track 1):  
Under UV 254 nm quenching zones due to the standards isoimperatorin and imperatorin 
are seen at RF ~ 0.44 and 0.33, respectively. A quenching zone with blue fluorescence 
due to the standard osthole is seen at RF ~ 0.38. 
Under UV 366 nm two greenish blue fluorescent zones due to the standards isoimperatorin 
and imperatorin are seen at RF ~ 0.44 and 0.33, respectively. A blue fluorescent zone due 
to the standard osthole is seen at RF ~ 0.38. 
Acceptance criteria 
Under UV 254 nm the Reference solution R shows one intense quenching/blue 
fluorescence zone at RF ~ 0.27 (decursin plus decursinol angelate) and another quenching 
zone with blue fluorescence at RF ~ 0.15 (7-demethylsuberosine). Other faint quenching 
zones are seen below the position of 7-demethylsuberosine. 
Under UV 366 nm the Reference solution R shows a faint blue fluorescent zone at the 
position of osthole (compare with Track 1). The most prominent zone of the chromatogram 
is due to decursin plus decursinol angelate (a blue fluorescent zone). A blue fluorescent 
Track Sample 
1 SST: isoimperatorin, osthole, imperatorin*   
2 Angelica gigas (Reference solution R) 
* decreasing RF values 





zone due to 7-demethylsuberosine is seen at RF ~ 0.15. Below this position and above the 
application position, several faint, blue fluorescent zones are seen (including the one at RF 
~ 0.03 due to decursinol).  
Additional evaluation 
Compare to the provided images: 
After derivatization, WRT     After derivatization, UV 366 nm 
        
          1        2                      1        2               
Evaluation 2 (Purity) 
Detection B1: capture images under UV 366 nm and normalize on the SST 
Compare results with the images below: 
      
        1      2      3      4      5    
SST Reference solution R2 and R4 (compare with Tracks 1 and 2, respectively):  
Under UV 366 nm a light blue fluorescent zone is seen at RF ~ 0.58 due to Z-ligustilide in 
R2 and R4 (tracks 1 and 2). In the lower half of the chromatogram, a blue fluorescent zone 
at the same RF of decursin plus decursinol angelate and several bluish zones above the 
application position are seen in the Reference solution R4 (A. acutiloba). 
Detection B2: normalize on reference solution R3 or R5 
Compare results with the images below: 
 
        1      2      3      4     5    
Track Sample 
1 SST: isoimperatorin, osthole, imperatorin*   
2 Angelica gigas (Reference solution R) 
* decreasing  RF values 
Track Sample 
1 R2 A. sinensis 100% 
2 R4 A. acutiloba 100% 
3 R3 A. sinensis 5% 
4 R5 A. acutiloba 5% 
5 Angelica gigas (Reference solution R) 
 
Track Sample 
1 R2 A. sinensis 100% 
2 R4 A. acutiloba 100% 
3 R3 A. sinensis 5% 
4 R5 A. acutiloba 5% 
5 Angelica gigas (Reference solution R) 
 





SST Reference solution R3 and R5 (compare with Tracks 3 and 4, respectively):  
Under UV 366 nm a very faint blue fluorescent zone is seen at RF ~ 0.58 due to Z-
ligustilide. 
Acceptance criteria 
No blue fluorescent zone due to Z-ligustilide is seen on Reference solution R (compare 
with track 5).  
Evaluation 3 (Strength/minimum content) 
Detection C1: capture images under UV 366 nm and normalize over Reference solution 
R1 
Compare results with the images below: 
   
        1        2         
SST Reference solution R1 (compare with Track 1):  
Under UV 366 nm a faint blue fluorescent zone is seen in R1 at RF ~ 0.27 in the Reference 
solution R due to decursin plus decursinol angelate.  
Acceptance criteria 
Under UV 366 nm the Test solution A1 (compare with Track 2) shows a faint a blue 
fluorescent zone at RF ~ 0.27 due to decursin plus decursinol angelate. The intensity of 
this zone is not less than that obtained with Reference solution R1 (compare with Track 
1).  
Detection C2: images under UV 366 nm converted into profiles 
Convert electronic images of the fingerprints under UV 366 nm (prior to derivatization) into 
profiles by calculating the luminance as function of RF. Adjust the integration ranges to fit 
the zone due to decursin plus decursinol. Rotate profile 90° so that the peak is seen from 
its front. Compare the height of the peak in the Test solution A1 (track 2, Detection C1) to 
that of the reference solution R1 (track 1, Detection C).  
  
           1                  2         
Track Sample 
1 Reference solution R1 A. gigas RMPM prepared to 
contain 3.0% of decursin plus decursinol angelate  
2 Test solution A1  A. gigas diluted 1:500 
Track Sample 
1 Reference solution R1 A. gigas RMPM prepared to 
contain 3.0% of decursin plus decursinol angelate 
2 Test solution A1  A. gigas diluted 1:500 






The peak height of decursin plus decursinol angelate recorded for Test solution A1 (green 
bar) is equal to or greater than that recorded for Reference solution R1 (red bar).  
Evaluation 4 (Strength/minimum content, Optional) 
Detection D: Densitometry at 330 nm/K > 400  
Scan the tracks corresponding to Test solution A1 (track 2, Detection C1) and Reference 
solution R1 (track 1, Detection C1) from 5.0 mm to 40.0 mm, and record the peak area.  
  
            1                    2         
Acceptance criteria 
The peak area of decursin plus decursinol angelate recorded for Test solution A1 is equal 




1 Reference solution R1 A. gigas RMPM prepared 
to contain 3.0% of decursin plus decursinol 
angelate 







Chapter 5: Comprehensive HPTLC fingerprinting as a tool 
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Anàlisi integral de l’empremta dactilar per HPTLC com a eina per a una anàlisi 
simplificada de la puresa dels productes de ginkgo 
 
Rellevància etnofarmacològica: Els medicaments a base de plantes amb extracte sec 
refinat de fulla de ginkgo (GBE) són un desenvolupament europeu a partir de Ginkgo 
biloba L., espècie utilitzada tradicionalment a l’Àsia Oriental. Avui en dia, els productes de 
ginkgo han augmentat la presència al mercat, principalment com a complements 
alimentosos. La seva adulteració amb rutina i quercetina o extractes vegetals rics en 
aquests compostos és una pràctica habitual. Cal fer assajos que inclouen valoracions i 
detecció d'adulterants, a més d'altres mètodes (per exemple, proves d'identificació). Això 
pot augmentar els costos de l’avaluació de la qualitat dels productes de ginkgo. 
Objectiu de l'estudi: Demostrar que l’anàlisi integral de l’empremta dactilar per HPTLC 
(Comprehensive HPTLC fingerprinting) pot proporcionar informació més enllà de la 
identificació de productes ginkgo, evitant anàlisis cromatogràfiques addicionals per a la 
detecció d'adulteracions. 
Materials i mètodes: La informació continguda en l’empremta dactilar obtinguda per 
l’anàlisi de flavonoides per HPTLC es va utilitzar per a la identificació i per a la detecció 
d’adulterants, així com per verificar els límits de rutina i quercetina, que normalment es 
determinen per HPLC i s’utilitzen per a la detecció d’adulterants. Per a aquest propòsit, es 
van generar perfils de pics a partir d’imatges de cromatograma obtinguts per HPTLC. Els 
mètodes HPLC de la United States Pharmacopea (USP) es van utilitzar per quantificar el 
total de flavonoides i assajar els límits de rutina i quercetina. Les dades HPLC es van 
utilitzar per donar suport a la validesa del mètode HPTLC. Es va desenvolupar un mètode 
HPTLC en fase inversa addicional com a possible mètode de confirmació per a la prova 
de límit de quercetina. 
Resultats: El mètode HPTLC proposat utilitza una seqüència particular de deteccions, 
donant lloc a un nombre d'imatges, que s'interpretaran posteriorment en un determinat 
ordre. És capaç d’identificar productes de ginkgo, de detectar adulterants (rutina, 
quercetina, fruits i botons florals de sòfora, i blat sarraí) i, mitjançant perfils de pics 
generats a partir d’imatges del cromatograma abans i després de la derivatització, 
d’avaluar els límits de la rutina i la quercetina. Quaranta vuit de cinquanta-nou suplements 
dietètics de ginkgo analitzats contenien un o més adulterants. A més, els resultats de les 
assajos límit de rutina i quercetina realitzats per HPTLC i HPLC van coincidir en el 98% 
dels casos. Finalment, per ajudar l’analista a avaluar si les mostres tenen la identitat 
correcta i si contenen o no adulterants, s’inclou un arbre de decisions que mostra la 
seqüència d’interpretació de les empremtes dactilars obtingudes amb les diferents 
deteccions després d’una sola anàlisi per HPTLC. 
Conclusió: Una única anàlisi per HPTLC és capaç de proporcionar informació sobre la 
identitat i la puresa dels productes. Això simplifica el flux de treball analític i redueix el 
nombre d’anàlisis prescrites a la monografia d’extracte sec de ginkgo de la USP. 
 
  







Análisis integral de la huella dactilar por HPTLC como herramienta para un 
análisis simplificado de la pureza de los productos de ginkgo 
 
Relevancia etnofarmacológica: Los medicamentos a base de plantas con extracto seco 
refinado de hoja de ginkgo (GBE) son un desarrollo europeo a partir de Ginkgo biloba L., 
especie utilizada tradicionalmente en Asia Oriental. Hoy en día, los productos de ginkgo 
han aumentado la presencia en el mercado, principalmente como complementos 
alimenticios. Su adulteración con rutina y quercetina o extractos vegetales ricos en estos 
compuestos es una práctica habitual. Es necesario hacer ensayos que incluyen 
valoraciones y detección de adulterantes, además de otros métodos (por ejemplo, 
pruebas de identificación). Esto puede aumentar los costes de la evaluación de la calidad 
de los productos de ginkgo. 
Objetivo del estudio: Demostrar que el análisis integral de la huella dactilar por HPTLC 
(Comprehensive HPTLC fingerprinting) puede proporcionar información más allá de la 
identificación de productos ginkgo, evitando pruebas cromatográficas adicionales para la 
detección de adulteraciones.  
Materiales y métodos: La información contenida en la huella dactilar obtenida por el 
análisis de flavonoides por HPTLC se utilizó para la identificación y para la detección de 
adulterantes, así como para verificar los límites de rutina y quercetina, que normalmente 
se determinan por HPLC y se utilizan para la detección de adulterantes. Para este 
propósito, se generaron perfiles de picos a partir de imágenes de cromatogramas 
obtenidos por HPTLC. Los métodos HPLC de la United States Pharmacopea (USP) se 
utilizaron para cuantificar el total de flavonoides y ensayar los límites de rutina y 
quercetina. Los datos HPLC se utilizaron para apoyar la validez del método HPTLC. Se 
desarrolló un método HPTLC en fase inversa adicional como posible método de 
confirmación para la prueba de límite de quercetina. 
Resultados: El método HPTLC propuesto utiliza una secuencia particular de detecciones, 
dando lugar a un número de imágenes, que se interpretarán posteriormente en un 
determinado orden. Es capaz de identificar productos de ginkgo, de detectar adulterantes 
(rutina, quercetina, frutos y botones florales de sófora, y trigo sarraceno) y, mediante 
perfiles de picos generados a partir de imágenes del cromatograma antes y después de 
la derivatización, de evaluar los límites de la rutina y la quercetina. Cuarenta y ocho de 
cincuenta y nueve suplementos dietéticos de ginkgo analizados contenían uno o más 
adulterantes. Además, los resultados de los ensayos límite de rutina y quercetina 
realizados por HPTLC y HPLC coincidieron en el 98% de los casos. Finalmente, para 
ayudar al analista evaluar si las muestras tienen la identidad correcta y si contienen o no 
adulterantes, se incluye un árbol de decisiones que muestra la secuencia de interpretación 
de las huellas dactilares obtenidas con las diferentes detecciones después de un solo 
análisis por HPTLC. 
Conclusión: Un único análisis por HPTLC es capaz de proporcionar información sobre la 
identidad y la pureza de los productos. Esto simplifica el flujo de trabajo analítico y reduce 
el número de análisis prescritos en la monografía de extracto seco de ginkgo de la USP. 
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Ethnopharmacological relevance: Herbal medicinal products based on ginkgo leaf refined 
dry extract (GBE) are European development from the Eastern Asia traditionally used 
species Ginkgo biloba L. Nowadays, ginkgo products have increased the presence in the 
market, mainly as dietary supplements. Its adulteration with rutin and quercetin or herbal 
extracts rich in these compounds is a common practice. Tests featuring assays and 
detection of adulterants need to be performed on top of other existent methods (e.g. 
identification test). This may increase the costs of evaluating the quality of ginkgo products. 
Aim of the study: To prove that comprehensive HPTLC fingerprinting can provide 
information beyond identification of ginkgo products, avoiding additional chromatographic 
tests for detection of adulterations.  
Materials and methods: The information contained in the fingerprint obtained by HPTLC 
analysis of flavonoids was used for identification and for detection of adulterants, as well 
as to verify the limits of rutin and quercetin, which are normally determined by HPLC and 
used for detection of adulterants. For this purpose, peak profiles were generated from 
HPTLC chromatogram images. USP-HPLC methods were used for quantification of total 
flavonoids and testing the limits of rutin and quercetin. HPLC data were used to support 
the validity of the HPTLC method. An additional reversed phase HPTLC method was 
developed as a possible confirmatory method for the quercetin limit test. 
Results: The proposed HPTLC method uses a particular sequence of detections, resulting 
in a number of images, which are later interpreted in a certain order.  It is able to identify 
ginkgo products, to detect adulterants (rutin, quercetin, sophora fruit and flower bud, and 
buckwheat), and, using peak profiles generated from the chromatogram images prior to 
and after derivatisation, to evaluate the limits of rutin and quercetin. Forty-eight out of fifty-
nine ginkgo dietary supplements analysed contained one or more adulterants. 
Furthermore, results of the HPTLC and HPLC limit tests for rutin and quercetin were in 





agreement in 98% of the cases. Finally, a decision tree showing the sequence of 
interpretation of the fingerprints obtained with the different detections after a single HPTLC 
analysis is included to help the analyst to evaluate whether samples have the correct 
identity and whether they contain or not adulterants. 
Conclusion: A single HPTLC analysis is able to provide information on identity and purity 
of the products. This simplifies the analytical workflow and reduces the number of analyses 
prescribed in the USP powdered ginkgo extract monograph. 
5.2 Introduction 
Ginkgo (Ginkgo biloba L.), considered a sacred tree in the Eastern Asia, is traditionally 
associated with longevity. The earliest known medicinal use of ginkgo dates back to 2800 
BC and it is described for the pseudofruits, which are more frequently used than leaves in 
Eastern Asia. However, based on some not very well documented uses in traditional 
Chinese medicine (TCM), a German company developed a medicinal product from leaves 
for cognitive impairment in dementia. The active ingredient is a ‘special’ extract – extract 
G. biloba (EGb) 761 obtained by a water-acetone extraction and subsequent purification 
(Heinrich, 2010, Drieu and Jaggy, 2000). This ginkgo leaf refined dry extract (GBE), which 
uses 50 kg of leaf to yield 1 kg of extract, is standardized to contain 22-27% of flavonol 
glycosides and 5.4-6.6% of terpene lactones (EDQM, 2018), and it is accepted for the 
improvement of age-associated cognitive impairment and of quality of life in mild dementia 
(European Medicines Agency, 2015). EGB products (with EGb 761 and other similar 
refined extracts), that nowadays are in the market either as medicinal products or as 
dietary supplements, are in high demand. The global trade of gingko leaf extracts has 
registered a consistent growth in the last years. However, to produce such extract, about 
19 steps are involved with costs estimated at $200-250/Kg (Gafner, 2018, Czigle et al., 
2018).  
Because of the complexity and high cost of the manufacturing process, adulteration of 
ginkgo products (GP) has become an important problem in poorly regulated markets. 
Booker et al (2016) evaluated the quality of GP sold as food supplements in the UK, 
revealing that the majority of the samples (32 out of 35) showed a HPTLC fingerprint 
different from that described in the European Pharmacopoeia and US Pharmacopoeia. It 
was hypothesized they were adulterated with rutin, quercetin, and other botanical 
materials. One sample was found to contain only 5-hydroxytryptophan. 
According to Gafner (2018), industry experts agree that adulteration of GP often stems 
from economic considerations. Several publications report the addition of flavonol 
aglycones quercetin and/or kaempferol and/or the flavonol glycoside rutin to ginkgo 
products. Such practice is performed to ensure that those products, containing less 
extract, will have higher levels of total flavonoids after hydrolysis (22-27%) and thus comply 
with the HPLC assay specifications of the Pharmacopoeias (The United States 
Pharmacopoeia (USP), 2016b). The assay is based on the hydrolysis of the glycosides 
and the quantification of the resulting aglycones. Consequently, other botanical material, 
rich in glycosides of the same flavonol aglycones have also been reported as adulterants. 
They are sophora fruit and flower bud (Styphnolobium japonicum (L.) Schott, syn: Sophora 
japonicum L.) and buckwheat herb (Fagopyrum sp Moench) (Avula et al., 2015; Chandra 
et al., 2011; Franz et al., 2011; He and Roller, 2011; Lopez-Gutierrez et al., 2016; Ma et 
al., 2016; Tawab et al., 2010; Wohlmuth et al., 2014; Yang et al., 2016, Gafner, 2018).  
Due to the lack of specificity to detect adulterants of the flavonoid-based assays, several 
publications propose additional methods, using different chromatographic techniques and 
detections (López-Guitiérrez et al., 2016, van Beek and Montoro, 2009). Since 2015, the 
United States Pharmacopoeia (USP) introduced an additional HPLC limit test for rutin and 
quercetin to the ginkgo extract monograph (The United States Pharmacopoeia (USP), 
2016b). As acceptance criteria, the test solution (prior to hydrolysis) should not contain 
more than 4% of rutin and 0.5% of quercetin. As both substances have very different 





polarities, a gradient elution system over 1 hour is needed. To perform all tests for identity, 
purity, and strength according to USP, five different analyses (including HPTLC and HPLC) 
featuring five different sample preparations, to analyse three classes of compounds are 
required. However, if identification is performed by HPTLC based on the “comprehensive 
HPTLC fingerprinting” concept (Frommenwiler et al., 2018), more information can be 
obtained in a single analysis, and so avoid one HPLC test for purity. 
In this paper we aim at further developing and illustrating how HPTLC fingerprints 
generated primarily for identification, can deliver additional information regarding the 
presence of adulterants and specifically on the content of rutin and quercetin in ginkgo 
products. For detection of adulterants, different derivatisation steps and detection modes 
are considered. Additionally, quantitative information of the profiles generated from the 
images are used to verify compliance with the limit test for rutin and quercetin. The 
generated data are compared to those obtained by HPLC. A decision-tree detailing how 
best to perform comprehensive HPTLC fingerprinting for identification and detection of 
adulterations in gingko products is proposed. 
5.3 Experimental 
5.3.1 Samples and reference substances 
Fifty-nine products of Ginkgo, including tablets, capsules, and soft gel capsules (GP1-
PG59), sold as food supplements or medicines were used in the present work. They 
declared to contain either refined extracts (22-27% of flavonol glycosides), extracts with 
either DER 50:1 or no additional information, powdered leaf, extract and leaf, extract and 
rutin, or extract and green buckwheat. A detailed description of the samples is presented 
in the supplementary information, Table 5S1. 
Ginkgo leaf reference extracts (GBE) were obtained from Sigma/HWI (Darmstadt, 
Germany) and Dr. Willmar Schwabe (Karlsruhe, Germany). A sample of ginkgo leaf (GBL) 
was provided by the American Herbal Products Association (AHPA, Silver Spring, MD, 
USA). Botanical reference material of sophora fruit and flower bud were obtained from 
American Herbal Pharmacopoeia (AHP, Scotts Valley, USA). Buckwheat herb (batch 
155239) was obtained from Chrüterhüsli (Basel, Switzerland). The standards genistein 
(99%), quercetin (99.5%) and rutin (91.3%) were obtained from USP (Rockville, USA). 
Kaempferol (97%) was obtained from Sigma (Darmstadt, Germany) and USP. 
Isorhamnetin (99%) from Extrasynthese (Genay, France) and USP. 
5.3.2 Reagents and solvents 
Polyethylene glycol 400 (99.5%), 2-aminoethyldiphenylborinate (96.5%), acetic acid 
(99.5%), toluene (≥99%), acetone (pure), dichloromethane (HPLC grade), sodium acetate 
anhydrous (99.5%) and acetic anhydride (98.5%) were purchased from Merck (Darmstadt, 
Germany). Methanol (HPLC grade) and ortho-phosphoric acid (85%) were purchased from 
Carl Roth GmbH (Karlsruhe, Germany). Acetonitrile (HPLC grade), ethyl acetate (99.5%), 
formic acid (≥98%), tetrahydrofuran (extra pure) and p-anisaldehyde (≥99%) were 
purchased from Acros (New Jersey, USA). Ethanol (99.9%) was purchased from 
Alcosuisse (Bern, Switzerland). Deionized water was generated in-house. For the HPLC 
analysis, methanol, acetonitrile (both HPLC gradient grade) and hydrochloric acid (37%) 
were purchased from Fisher Scientific (Hamptom, USA). Phosphoric acid (≥85%) was 
obtained from Honeywell (New Jersey, USA), and formic acid (98-100%) from Scharlau 
(Barcelona, Spain). 
5.3.3 Instruments 
A CAMAG HPTLC system controlled by visionCATS software and including Visualizer, 
Automatic TLC Sampler 4, Automatic Developing Chamber 2, TLC Plate Heater III and 
Chromatogram Immersion device was used.  





For the HPLC analysis, a Shimadzu instrument of the UFLC series including auto sampler 
SIL-20AC HT, pumps LC-20AD, degasser DGU-20As, column oven CTO-20A, diode array 
detector SPD-M20A, and communication bus module CBM-20A was used. The software 
was LC Solutions (Shimadzu Corporation) version 1.23 SP1. The column used was a 
Phenomenex Gemini® NX C18 (100 Å, 5 μm, 4.6 mm × 250 mm). 
5.3.4 High performance thin layer chromatography (HPTLC) 
HPTLC parameters for plate layout, sample application, conditioning of the plate, plate 
development and visualization were in agreement with the USP general Chapter <203> 
(The United States Pharmacopoeia (USP), 2017). The quality of the chromatography was 
verified based on the position of two or three standards, used as system suitability test 
(SST). The image’s background normalization was adjusted over the SST.  
5.3.4.1 Standard solutions 
Solutions of rutin, chlorogenic acid, and quercetin were prepared at concentration of 0.2 
mg/mL in methanol for the SST. For the limit test of rutin, the standard solution was 
prepared at 0.4 mg/mL of rutin in methanol. For the quercetin limit test based on a 
reference extract (Sigma/HWI GBE was used in this case), the weight of extract was 
adjusted to yield a solution (in methanol) representing 0.5% of quercetin in the extract. For 
the limit test of quercetin on reversed phase, the standard solution was prepared at 0.05 
mg/mL of quercetin in methanol. 
5.3.4.2 Test solutions 
Sample of gingko leaf and products containing leaf were prepared according to the USP 
Ginkgo monograph (The United States Pharmacopoeia (USP), 2016a). Products 
containing ginkgo extract (capsules, soft gel capsules and tablets) were prepared to 
contain 10 mg of extract per mL of methanol, sonicated for 10 minutes at room temperature 
and centrifuged for 5 minutes at 5000 rpm. Products containing leaf plus extract were 
processed as leaf, taking in account the labelled content of extract and the drug-extract 
ratio, which were used to calculate its equivalence as leaf. 
5.3.4.3 Chromatography  
The HPTLC method used for evaluating the samples was based on the USP ginkgo and 
powdered ginkgo extract monographs (The United States Pharmacopoeia (USP), 2016a 
and 2016b). The parameters for application volume, detection and derivatisation methods 
were optimized (see parameters described under HPTLC ID method in Table 5.1). A 
confirmatory additional method for the limit of quercetin was developed using a reversed 
phase plate (parameters are also described in Table 5.1). 
Table 5.1 Parameters for the two HPTLC methods used in the present work. 
Parameters ID method 
Limit of quercetin (reversed 
phase) 
Stationary phase 
20x10cm plates Si 60 F254 (Merck) 
20x10cm plates Si 60 RP-18 W 
(Merck) 
SST 0.2 mg/mL of rutin, quercetin and 
chlorogenic acid 
0.2 mg/mL of rutin and quercetin  
Preparation of 
standards for limit 
test 
0.4 mg/mL (rutin, limit test) 0.05 mg/mL (quercetin, limit test) 
Application volume 3 μL of test and standards solutions 3 μL of test and standards solutions 
Developing solvent  Ethyl acetate, acetic acid, formic 
acid, water (100:11:11:26 V/V/V/V) 
ACNa, THFb and 0.5%H3PO4 
aqueous solution (10:40:50 V/V/V) 
Development 20 min saturation, 10 min 
conditioning at 33% relative 
20 min saturation, 10 min 
conditioning at 33% relative humidity 





humidity (with MgCl2), 70 mm 
distance from lower edge, room 
temperature = 23-27 ⁰C 
(with MgCl2), 70 mm distance from 





UV 254 nm, UV 366 nm Not applicable 
Derivatization 1 Plates were heated at 100 ⁰C for 3 
min and derivatised by dipping 
(speed: 3, time: 0) in NP reagent 
and then in PEG reagent 
Plates were heated at 100 ⁰C for 3 
min and derivatised by dipping 
(speed: 3, time: 0) in NP reagent 
and then in PEG reagent 
Derivatization 2 Plates were heated at 100 ⁰C for 3 
min and derivatised by dipping 
(speed: 3, time: 0) in NP reagent 
Not applicable 
Documentation after 
derivatization 1 or 2 
UV 366 nm UV 366 nm 
Derivatization 3 Plates were dipped (speed: 3, time: 
0) in p-anisaldehyde reagent and 




White light  Not applicable 
aACN: acetonitrile; bTHF: tetrahydrofuran;  
5.3.4.4 Derivatisation reagents 
Natural products reagent (NP) was prepared dissolving 1 g of 2-aminoethyl 
diphenylborinate in 200 mL of ethyl acetate. As a polyethylene glycol reagent (PEG) a 
dissolution of 10 g of polyethylene glycol 400 in 200 mL of dichloromethane was used. 
Finally, the anisaldehyde reagent was obtained dissolving 1 mL of p-anisaldehyde in 200 
mL of a mixture of methanol, acetic acid and sulphuric acid (170:20:10 V/V/V). 
5.3.4.5 Generation of peak profiles from chromatogram images 
Where necessary, the visionCATS software was used to generate peak profiles from 
fingerprints by calculating the luminance as L = (1/3 R)+(1/3 G)+(1/3 B) from the average 
of red (R), green (G), and blue (B) pixels of each line of the track and then plotting it against 
the RF values (Frommenwiler et al., 20118). 
5.3.4.6 Limit tests of rutin and quercetin 
Peak profiles were used for performing the limit tests of rutin and quercetin. Detections 
under UV 254 nm prior to derivatisation (rutin) and under UV 366 nm after derivatisation 
with NP or NP plus PEG (quercetin) were used. Calculations were based on the peak 
heights at the position of rutin or quercetin in the samples and the standard solutions. 
Standard solutions at concentrations corresponding to the maximum limit accepted for 
rutin and quercetin according to USP powdered ginkgo extract monograph were used. 
5.3.4.7 Validation of the limit test of rutin and quercetin using the HPTLC ID method  
The analytical procedure presented in this research has been validated in order to confirm 
its reliability. Linearity was established for rutin, based on the peak area of the peak profile 
under UV 254 nm prior to derivatisation. Six data points in the range of 0.75–1.8 
μg/application with 0.15 and 0.3 μg intervals were used. The correlation coefficient (R2) 
was 0.999050 and the coefficient of variation (CV) was 0.88%. For quercetin, an extract 
was used to build the calibration curve. The peak heights of the peak profile under UV 366 
nm after derivatisation were used. Linearity of the zone at the position of quercetin was 
established using six data points in the range of 0.06– 0.21 μg/application of quercetin with 
0.03 μg intervals, using GB reference extract with known content of quercetin (0.297%). 
The correlation coefficient (R2) was 0.999223 and the coefficient of variation (CV) was 





1.51%. For intraday and interday precision, one GB reference extract was prepared 4 
times (each day), and solutions were analysed twice (2 plates per day). The absolute area 
of the peak at the position of rutin (under UV 254 nm prior after derivatization) and absolute 
height of the peak at the position of quercetin (under UV 366 nm prior to derivatization) in 
GB extract was used for the precision test. The intraday CV% was 2.08 for rutin and 0.89 
for quercetin. The interday CV% was 3.48 for rutin and 2.65 for quercetin. 
5.3.5 High performance liquid chromatography (HPLC) 
The HPLC assay of total flavonoids was performed according to the USP powdered ginkgo 
extract monograph (The United States Pharmacopoeia (USP), 2016b) with all samples 
that declare to contain GBE. Samples that contain leaf were analysed according to its 
specific monograph. For tablets and capsules, an initial weight equivalent to 300 mg of 
extract was used. Additionally, the specific tests (limit of rutin and quercetin) according to 
USP powdered ginkgo extract monograph were applied for products containing refined 
extracts or other extracts. For products containing ginkgo leaf or mixtures of extracts with 
ginkgo leaf, rutin or buckwheat, this limit test was not performed. For tablets and capsules, 
an initial weight equivalent to 100 mg of extract was used. For both, assay and limit tests, 
each sample was prepared and analysed in duplicate.  
5.4 Results and discussion 
In the current study, thirty-five ginkgo products obtained in the UK and twenty-four other 
products from other countries were analysed particularly for their purity. In addition to the 
detection prescribed in the identification section of the monographs, other detections were 
used (UV 254 nm and 366 nm prior to derivatisation). Those multiple images, generated 
during the identification test, are available for each analysis. HPTLC fingerprints and 
results for identity and adulteration of all samples are presented in the supplementary 
information (Figure 5S1-4, Table 5S2). In a first set of experiments, fifty-nine samples of 
ginkgo products were evaluated with the HPTLC ID method. Their fingerprints were 
compared to the description of the monograph and to reference materials of ginkgo leaf 
and extract. Typical fingerprints are shown in Figure 5.1. It was observed that only eleven 
samples were compliant with the monograph description.  
Under UV 254 nm prior to derivatisation (Figure 5.1), several products show intense 
quenching zones at the position of rutin (e.g. GP17), or at RFs 0.12 and/or 0.6 (e.g. GP4). 
The two latter zones are absent in ginkgo. Under UV 366 nm prior to derivatisation (Figure 
5.1), red zones due to chlorophylls are seen in GBL. Additionally, GBL and GBE show a 
blue fluorescent zone at the position of chlorogenic acid, characteristic of ginkgo. Four 
products lacked this zone (e.g. GP4 and GP7) and other four products showed it, but 
fainter than GBL and GBE. Under UV 366 nm after derivatisation 1 (Figure 5.1), twenty 
products showed an intense yellow zone at the position of quercetin (e.g. GP4 and GP5) 
and sometimes faint zones in the rest of the fingerprint (e.g. GP17). 
Eight products lacked zones characteristic of ginkgo and showed mainly a zone due to 
rutin (e.g. GP14). One sample contained only 5-hydroxy tryptophan (GP7) as shown 
previously. One sample (GP3) showed an additional blue zone between RFs 0.6 and 0.7. 
Sixteen samples showed additional green zones between RFs 0.2 and 0.3 (e.g. GP17, 
GP4 and GP3) most of the time combined with high levels of quercetin. Of the five samples 
labelled as containing ginkgo leaf, two yielded fingerprints similar to that of GBE, while 
three corresponded to GBL, but the zones were less pronounced.  
Based on the identification results, it was concluded that many of the analysed products 
seemed to have quality problems, including adulteration. In addition, the intensity of some 
fingerprints was lower than expected. To confirm the hypothesis that some of the products 
had less extract than declared, their total flavonoids content was evaluated. 
 






Figure 5.1 HPTLC fingerprints of reference standards, ginkgo leaf and extract, sophora fruit, 
sophora flower buds, buckwheat herb and different cases of adulterations of ginkgo products under 
different detection modes. Track 1: genistein; SST: system suitability test (rutin, chlorogenic acid, 
and quercetin with increasing RF values); GBE: ginkgo leaf refined dry extract; GBL: ginkgo leaf; 
SJfr: Sophora fruit; SJfl: Sophora flower bud; BWH: Buckwheat herb; GP: ginkgo product. 
5.4.1 HPLC analysis of flavonoids in ginkgo products according to the USP 
The content of flavonol glycosides was determined in fifty-three ginkgo products (GP). Five 
products were not analysed by HPLC due to limited amount of sample available. The per-
centage of flavonoids was calculated from the content of the corresponding aglycones 
obtained after hydrolysis, which are quercetin (Q), kaempferol (K), and isorhamnetin (I). 
Acceptable contents of flavonoids, expressed as flavonol glycosides, were 22.0%-27.0% 
for the extract, and not less than 0.5% for the leaves. Furthermore, the peak area ratios of 
K/Q (required ≥ 0.7) and I/Q (required ≥ 0.1) were calculated for the products containing 
extract, as described in the USP powdered ginkgo extract monograph. Forty-four samples 
that declared to contain extract were also analysed for their content of rutin and quercetin, 
based on the method specified in the USP. Acceptable contents prior to hydrolysis were ≤ 
4% for rutin and ≤ 0.5% for quercetin (see Table 5S3; supplementary information). 
The investigated products fall into five categories according to their claims: refined extracts 
with declaration of total flavonoid content, refined extracts without declaration, mixture of 
extract and additional ingredient, other extracts, and products based on dried leaves.  





Of the thirty-eight products containing refined extract with a declaration of flavonoid 
content, thirty-four were analysed for their flavonol glycosides content. Of those, twenty-
seven contained the amount of flavonol glycosides declared on their labels and twenty-
one complied with the K/Q and I/Q peak ratios. Six products had less than 22% of total 
flavonoids and one had more than 27%. Regarding the rutin and quercetin contents of 
those thirty-four products, four had more than 4% of rutin and twenty-two had more than 
0.5% of quercetin. Thus, GP20, 36-43 and 59 were the only products of this group 
compliant with the USP specifications concerning HPTLC fingerprint, flavonol glycosides 
content by HPLC, K/Q and I/Q ratios and HPLC limit test of rutin and quercetin.  
Eight of the nine products containing refined extract without declaring the flavonoid content 
were analysed. All of them had less than 22.0% of flavonol glycosides by HPLC. Of those, 
two had more than 4% of rutin and five had more than 0.5% of quercetin. 
Of the five products that declared to contain extract mixed with other ingredients, four were 
analysed. They declared to contain either rutin, buckwheat, or ginkgo leaf. The products 
that contained additional rutin or buckwheat had more than 27.0% of flavonol glycosides, 
yet are compliant with their label claims. 
Of the two products containing other type of extracts, both had less than 22.0% of flavonol 
glycosides as determined by HPLC. Finally, all five products declaring to contain ginkgo 
leaf complied with the total flavonoid content for the leaf (NLT than 0.5%).  
In general, most of the products that were compliant with the total flavonoids assay had 
weak fingerprints by HPTLC and/or intense zones at the positions of quercetin or rutin 
and/or additional zones. To properly detect addition of rutin and/or quercetin, a 
supplementary HPLC test is required. Nevertheless, results of the HPTLC ID method 
pointed to quality issues in the same samples as the combined HPLC tests.  
In this context, our goal was to evaluate, whether the HPTLC fingerprint, obtained with the 
ID method, can also be used as tool to determine the purity of ginkgo products by detecting 
the presence of adulterants.  
5.4.2 HPTLC analysis of ginkgo products 
In the next steps of the investigation, first a literature review was performed to identify 
possible adulterants. Then, their HPTLC fingerprints were compared with those of GBL 
and GBE. Thereafter, physical mixtures of GBL and adulterants were analysed. It was 
evaluated whether the HPTLC ID method is capable of distinguishing the adulterants from 
ginkgo and what their respective detection limits were in mixtures. Finally, the HPTLC ID 
method was evaluated for suitability to verify compliance with the USP HPLC limit tests for 
rutin and quercetin. In that step, different detection modes and derivatisation reagents 
were investigated. 
Samples of sophora fruit and flower bud, and buckwheat were individually analysed using 
the HPTLC ID method and their fingerprints were compared to those of GBE extract and 
GBL (Figure 5.1). 
Under UV 366 nm after derivatisation, sophora fruit featured several unique greenish 
zones in the lower half of the chromatogram, a yellow zone at the position of rutin and a 
faint greenish zone at the position of quercetin, kaempferol, and isorhamnetin. The 
fingerprint of sophora flower bud was comparatively rich in rutin and quercetin, and 
contained other flavonoids and phenolic compounds (faint zones). Its fingerprint pattern 
was somewhat similar to that of the GBE. Buckwheat also showed an intense zone at the 
position of rutin and another blue fluorescent zone between RFs 0.4 and 0.5. Other reddish 
and yellowish zones were observed in the upper half of the chromatogram. Other individual 
characteristics were observed under UV 254 nm for each sample.  
For the investigation of admixtures, physical mixtures of 1, 3, 5, 10, 15, and 20% each of 
sophora fruit, sophora flower bud, and buckwheat powdered drugs with 99, 97, 95, 90, 85, 





and 80% of ginkgo leaf were prepared. 
5.4.3 Admixture of buckwheat herb (Fagopyrum sp.) 
To visualise admixtures with buckwheat, different detection modes were evaluated. Under 
UV 366 nm prior to derivatisation (Figure 5S5), a faint reddish zone was seen in the middle 
of the chromatogram in the ginkgo leaf spiked with 15% buckwheat. This zone was absent 
in ginkgo leaf. One sample (GP9), which listed buckwheat as an ingredient, showed similar 
reddish zones. In this respect, the product cannot be considered as adulterated. 
Nevertheless, the same sample was found to contain sophora flower bud.  
5.4.4 Admixture of sophora flower bud 
When sophora flower bud was mixed with ginkgo leaf (Figure 5.2), the amounts of rutin 
and quercetin increased. However, with this method it was not possible to link these higher 
levels of rutin and quercetin to bulk chemicals or an herbal drug. In the absence of specific 
markers to detect the presence of sophora flower bud, alternative derivatisation 3 was 
introduced: following derivatisation with NP reagent and visualising the image under UV 
366 nm, the plate was derivatised with anisaldehyde reagent and documented under white 
light. Because anisaldehyde reagent cannot be used subsequently to PEG reagent (used 
in derivatisation 1 of the ID method), that derivatisation reagent had to be eliminated 
(derivatization 2) (Table 5.1).  
 
Figure 5.2  HPTLC fingerprints of physical mixtures of ginkgo leaf and sophora flower bud, and 
examples of adulterated products. GBL: ginkgo leaf, SJfl: sophora flower bud. Track 1: 100% SJfl, 
track 8: 100% GBL, tracks 2-8: mixtures of SJfl and GBL, tracks 9-10: products adulterated with 
SJfl. 
Detection of flavonoids is not significantly altered by PEG (Figure 5S6). However, 
subsequent use of anisaldehyde instead provided an extra set of data without the need to 
repeat the chromatography.  
The chromatogram of ginkgo leaf spiked with 5% of sophora flower bud showed two purple 
zones above and below the zone due to rutin, combined with an elevated amount of rutin. 
When the ginkgo products were tested with this detection, two samples (GP29 and 17) 
presented a pattern similar to that described above, indicating adulteration with sophora 
flower bud.  





5.4.5 Admixture of sophora fruit 
Avula et al. (2015) and Wohlmuth et al. (2014) stated that genistein is a chara-
cteristic constituent of sophora fruit and can be used as a marker to detect adulteration 
with this drug. However, in the HPTLC ID method genistein migrated close to the solvent 
front and was barely detected after derivatisation under UV 366 nm (Figure 5.1). Under 
UV 254 nm prior to derivatisation, genistein was detectable (Figure 5.1) but co-eluted with 
quercetin.  
In Figure 5.3, the fingerprint of ginkgo leaf containing 1% of sophora fruit after 
derivatisation, showed a green zone between RFs 0.1 and 0.2, which was absent in 100% 
ginkgo leaf. Under UV 254 nm prior to derivatisation one quenching zone between RFs 0.5 
and 0.6 was seen in the sample spiked at 1%. A second zone between RFs 0.1 and 0.2 
was observed in the sample spiked at 3%. The described zones are detected in 17 of the 
59 products. Therefore, these three zones can be used to identify the presence of 1% or 
more of sophora fruit in mixtures with ginkgo leaf.  
 
Figure 5.3 HPTLC fingerprints of the physical mixtures of ginkgo leaf and sophora fruit, and 
examples of adulterated products. Track 1: 100% SJfr, track 8: 100% GBL, tracks 2-8: mixtures of 
SJfr and GBL, tracks 9-25: products adulterated with SJfr. 
5.4.6 Limit test for rutin 
Forty-six products declaring to contain ginkgo extract, were investigated for compliance 
with the USP limit for rutin by the HPTLC ID method using a reference solution containing 
rutin standard at 0.4 mg/mL, equivalent to 4% of the extract weight. Percentage values of 
rutin were calculated. Results are shown in Figure 5.4 and Table 5S2. Eight samples 
(GP14, 17, 23, 26, 32, 45, 49 and 54) exceeded the 4% limit. Of those, samples GP14, 
23, 32, 45 49 and 54 seemed to contain mainly rutin, because they showed only a yellow 
zone at the position of rutin and lacked other zones characteristic of ginkgo. Samples 
GP17 and 26 were found to be adulterated with sophora flower bud and fruit, and 
consequently showed an amount of rutin above the accepted level. One sample that 
contained mainly rutin (GP 30) complied with the limit test and had a low content of flavonol 
glycosides.  
The HPTLC data were compared to those of HPLC. Results were in agreement regarding 
samples passing or failing the limit test. In six samples, the values from HPLC were 
considerably higher than those obtained by HPTLC. This was due to the limited dynamic 
range of the HPTLC detection resulting in saturation. Values below 4% were very similar 





with both methods. Thus, the HPTLC ID method can substitute the HPLC method in the 
limit test for rutin prescribed in the USP powdered ginkgo extract monograph. 
 
 
Figure 5.4 Comparison of the results of the limit test for rutin in relation to the refined extracts 
contained in the products, obtained by the HPTLC ID method and by HPLC. Dashed line: maximum 
content of rutin (4%) according to the USP powdered ginkgo extract monograph. * Not analysed by 
HPLC due to the limited amount of sample. 
5.4.7 Limit test for quercetin 
The compliance to the limit test for quercetin was also investigated in the forty-six products 
using the HPTLC ID method. A ginkgo extract from HWI with known quercetin content was 
prepared to contain 0.5% of quercetin in the solution. This solution representing the 
samples in which quercetin is co-eluting with other zones (Figure 5.1) was used instead 
of a standard solution of quercetin. After conversion of the image under UV 366 nm after 
derivatisation with NP into peak profiles, the height of the yellow/greenish peak at RF 0.9 
(corresponding to Q/K/I and other zones) in the products was compared against that of the 
standard. Results are shown in Figure 5.5. 
Of the investigated products, only eighteen complied with the limit test for quercetin. Of 
those, seven contained mainly rutin (GP 14, 23, 30, 32, 45, 49 and 54) and one was 
adulterated with sophora fruit (GP26). Only ten had a fingerprint similar to GBE (GP 20, 
36-43 and 59) (Figures 5S1 and 5S2). This result was in agreement with the HPLC limit 
test for quercetin (Figure 5.5). One product (GP54), which was found to be compliant after 
HPTLC analysis, was, however, found to contain more than 0.5% of quercetin when 
analysed by HPLC. Nevertheless, this sample was not compliant with the rutin limit test, 
and would thus fail in quality control. 
An additional reversed phase HPTLC method (Table 5.1), which improves the separation 
of quercetin from the other two aglycones, was used for confirmation of results of the limit 
test for quercetin in all samples (Figure 5S7). Peak profiles were generated from images 
under UV 366 nm obtained after derivatisation with NP and PEG reagents. The quercetin 
percentages were determined against a quercetin standard solution equivalent to 0.5% of 
the extract weight (Figure 5.6 and Table 5S2). Results were in accordance to those 
obtained by HPLC. 
The data using HPLC and HPTLC ID methods for the quercetin limit were comparable in 
98% of the cases, and when combined with the other data, the HPTLC results lead to the 
same conclusion as those obtained by HPLC. Thus, the HPTLC ID method can be used 
instead of the USP HPLC method for determining the limit of quercetin. Samples with 
borderline results by HPTLC may be evaluated with other methodologies (HPLC or 
reversed phase HPTLC) for confirmation.  






Figure 5.5 Comparison of the quercetin zone intensity, expressed in AU, of forty-six ginkgo 
products containing refined extract with GBE representing 0.5% of quercetin.  
 
Figure 5.6 Comparison of the results of the limit test for quercetin in relation to the refined extracts 
contained in the products, obtained by HPTLC reversed phase method and by HPLC. Dashed line: 
maximum content of quercetin (0.5%) according to the USP powdered ginkgo extract monograph. 
*Not analysed by HPLC due to the limited amount of sample. 
5.4.8 HPTLC decision tree 
For better understanding of the significance of the proposed HPTLC method for the routine 
quality control of ginkgo products a decision tree has been designed (Figure 5.7). It shows 
the sequence of interpretation of the fingerprints obtained with the different detections after 
a single HPTLC analysis. Thus, this decision tree can help the analyst to evaluate whether 
samples have the correct identity and whether they contain or not adulterants. 






Figure 5.7 Decision-tree about how to best perform comprehensive HPTLC fingerprinting for 
identification and detection of adulterations in ginkgo products.  
5.5 Conclusion 
This work provides a new pragmatic and cost-efficient approach to the quality control of 
ginkgo products, based on the “comprehensive HPTLC fingerprinting” concept. A single 
HPTLC analysis, carried out during identification, can also be used to detect adulteration 
with sophora fruit, sophora flower bud, buckwheat herb, quercetin, or rutin. Peak profiles 
generated from the images can be used to perform a limit test for quercetin and rutin 
without the need of an additional analysis if reference standards are applied at suitable 
levels. In this case HPTLC and HPLC data lead to the same conclusion. However, the 
HPTLC method cannot be considered valid for rutin or quercetin quantification purposes 
out of the limit test, which is only aimed to give a pass/fail decision. 
Only eleven of the investigated fifty-nine GB products comply with specifications of the 
USP for identity, limits on rutin and quercetin, and content of total flavonoids. To the best 
of our knowledge, this is the largest study performed on commercial ginkgo products. Such 
a large percentage of poor quality and clearly adulterated products calls for quality control 
measures at earlier stages and throughout the value chains from the raw material to 





finished products (Booker and Heinrich 2016). For legitimate companies wanting to 
produce good quality products, HPTLC is able to provide important information concerning 
raw material acquisition, product development, the control of intermediate processing 
steps and final product compliance. However, much of the poor quality appears to be either 
deliberate (such as in the case of adulteration) or arising through an insufficient 
understanding of the manufacturing processes. In this context HPTLC can be a valuable 
tool used to highlight poor practice within the industry, provide evidence to regulatory 
bodies and ultimately to disseminate a greater awareness of product differences to the 
general public.   
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5.7 Supplementary Information 
Table 5S1 Description of the products analysed in this work, their dosage form and country of origin. 










GBE 120 mg equivalent to 6000 mg of leaf. Standardised to contain 24% of 
flavone glycosides (28.8 mg) and 6% of terpene lactones (7.2 mg) 
Tablet UK 
GP2 
GBE 120 mg equivalent to 6000 mg of leaf, 24% of flavone glycosides and 
6% of terpene lactones 
Tablet UK 
GP3 GBE 5 mg (DER 50:1) and 250 mg of Ginkgo biloba leaf Tablet UK 
GP4 
GBE 120 mg. Standardised to contain 24% of flavone glycosides (28.8 mg) 
and 6% of ginkgolides plus bilobalide (7.2 mg) 
Tablet UK 
GP5 GBE, equivalent to 6000 mg of dried leaf. Contain 24% of flavone glycosides Tablet UK 
GP6 




GBE 600 mg, equivalent to 30.000 mg of leaf. Contain 24% of flavone 
glycosides (114 mg) and 6% of terpene lactones (36 mg).  
Capsule UK 
GP8 




GBE 100 mg. Contain 23 mg of flavone glycosides, 6 mg of terpene 
lactones, 300 mg of green buckwheat and 10 mg of Vitamin E 
Tablet UK 
GP10 GBE 120 mg (DER 50:1), providing 6000 mg Tablet UK 
GP11 
GBE 120 mg (DER 50:1) equivalent to 6000 mg of herb powder, providing 
28.8 mg of flavone glycosides and 7.2 mg of terpene lactones 
Tablet UK 
GP12 
GBE 60 mg. Standardized to contain 14.3 mg of flavone glycosides and 3.6 
mg of terpene lactones 
Capsule UK 
GP13 GBE 120 mg (DER 50:1), providing 6000 mg Tablet UK 
GP14 
GBE 60 mg (DER 50:1), equivalent to 3000 mg of leaf. Contain 24% of 
flavone glycosides and 6% of terpene lactones 
Tablet UK 
GP15 GBE 120 mg (DER 50:1), providing 6000 mg Tablet UK 
GP16 GBE 120 mg (DER 50:1), providing 6000 mg Tablet UK 
GP17 
GBE 100 mg, equivalent to 5000 mg Gingko biloba. Containing 24 mg of 
flavone glycosides and 6 mg of terpene lactones 
Tablet UK 
GP18 GBE 120 mg (DER 50:1), equivalent to 6000 mg Tablet UK 
GP19 GBE 120 mg (DER 50:1) equivalent to 6000 mg of whole dried leaf Tablet UK 
GP20 




GBE 120 mg (DER 50:1), equivalent to 6000 mg of leaf. Contain 28.8 mg of 
flavone glycosides and 7.2 mg of terpene lactones  
Tablet UK 
GP22 
GBE 120 mg (DER 50:1), equivalent to 6000 mg of leaf. Contain 28.8 mg of 
flavone glycosides and 7.2 mg of ginkgolides A B & C and bilobalide 
Tablet UK 
GP23 
GBE 120 mg from leaf. Standardized to contain 24% of flavone glycosides 
(28.8 mg) and 6% of terpene lactones (7.2 mg) 
Capsule UK 
GP24 
GBE 60 mg from leaf. Standardized to contain 24% of flavone glycosides 




GBE 8 mg, equivalent to 400 mg of herb powder. Contain 24% of flavone 
glycosides and 6% of terpene lactones 
Capsule New 
Zealand 
GP26 GBE 120 mg (DER 50:1) equivalent to 6000 mg of whole herb Capsule UK 
GP27 
GBE 60 mg from leaf. Contain 24% of flavone glycosides (14.4 mg) and 30 
mg of Ginkgo biloba leaf powder  
Capsule
USA 
GP28 Ginkgo biloba leaf powder 130 mg Capsule UK 
GP29 
GBE 120 mg, equivalent to 6000 mg of herb powder. Contain 24% of flavone 
glycosides and 6-7% of ginkgolides A B & C and bilobalide and 50 mg of 
rutin 
Capsule UK 












GP30 GBE 200 mg (DER 50:1), equivalent to 10.000 mg of herb powder.  Capsule UK 
GP31 
GBE 100 mg (DER 50:1), equivalent to 5000 mg of Ginkgo biloba powder. 




GP32 GBE 120 mg, equivalent to 6000 mg of whole Ginkgo biloba. Tablet Netherlands 
GP33 GE 90 mg (DER 3-5:1) prepared from fresh leaf Tablet Switzerland 
GP34 Ginkgo biloba leaf powder 180 mg Capsule UK 
GP35 
GBE 120 mg. Contain 24% of flavone glycosides (28.8 mg) and 6% of 
terpene lactones (7.2 mg) 
Capsule USA 
GP36 
GBE 80 mg. Contain 17.6-21.6 mg of flavone glycosides and 4.0- 5.6 mg of 
terpene lactones.  
Tablet Switzerland 
GP37 
Quantified and refined GBE 120 mg from leaf (DER 35-67:1). Contain 26.4-
32.4 mg of flavonoid glycosides, 3.12-3.84 mg of bilobalide, 3.36-4.08 mg of 
ginkgolides A, B & C 
Tablet Switzerland 
GP38 
Quantified and refined GBE 120 mg (DER 35-67:1). Contain 26.4-32.4 mg 
of flavonoid glycosides, 3.12-3.84 mg of bilobalide, 3.36-4.08 mg of 
ginkgolides A, B, C and NMT 5 ppm of ginkgolic acid  
Tablet Switzerland 
GP39 
Quantified and refined GBE 120 mg (DER 35-67:1). Contain 26.4-32.4 mg 
of flavonoid glycosides and 6.48-7.92 mg terpene lactones 
Tablet Switzerland 
GP40 
GBE 120 mg from leaf (DER 35-67:1). Contain 26.4-32.4 mg of flavonoid 
glycosides, 6.0-8.4 mg of terpene lactones, of which 3.12-3.84 mg of 
bilobalide, 3.36-4.08 mg of ginkgolides A, B & C 
Tablet Germany 
GP41 
GBE 120 mg from leaf (DER 35-67:1). Contain 26.4-32.4 mg of flavonoid 
glycosides, 6.0-8.4 mg of terpene lactones, of which 3.12-3.84 mg of 
bilobalide, 3.36-4.08 mg of ginkgolides A, B & C 
Tablet Germany 
GP42 
GBE 120 mg from leaf (DER 35-67:1; EGb 761). Contain 26.4-32.4 mg of 
flavonoid glycosides, 6.0-8.4 mg of terpene lactones, of which 3.12-3.84 mg 
of bilobalide, 3.36-4.08 mg of ginkgolides A, B and C  
Tablet Germany 
GP43 
GBE 120 mg from leaf (DER 35-67:1). Contain 22-27% of flavonoid 
glycosides, 2.8-3.4% of ginkgolides A, B & C, 2.6-3.2% of bilobalide and 
NMT 5ppm of ginkgolic acids  
Capsule Germany 
GP44 




Standardized GBE (120 mg). Contain NLT 24% of flavonol glycosides and 
6% of terpene lactones.  
Capsule Serbian 
GP46 Ginkgo biloba leaf 330 mg Tablet Spain 
GP47 Ginkgo biloba leaf 180 mg  Tablet Spain 
GP48 
GBE 40 mg (40-50:1). Contain 8.8-10.8 mg of flavone glycosides, 1.12-1.36 
mg of Ginkgolide A, B & C, and 1.04-1.28 mg of bilobalide 
Tablet Croatia 
GP49 
GBE 120 mg. Contain 24% of flavone glycosides (28.8 mg) and 6% terpene 
lactone (7.2 mg).  
Capsule Netherlands 
GP50 
GBE 410 mg and leaf (amount not informed). Contain 24% of flavone 
glycosides.  
Capsule Italy 












GP54 GBE 80 mg. Contain 19.2 mg of flavone glycosides Capsule Colombia 
GP55 GE 50 mg, equivalent to 500 mg of GBL Tablet Spain 
GP56 
Ginkgo biloba leaf, equivalent to 500 mg (200 mg of leaf and 40 mg of extract 
7.5:1) 
Tablet Spain 
GP57 GBE 120 mg. Contain 24% of flavone glycosides (28 mg) Capsule USA 
GP58 GBE 60 mg. Contain 24% of flavone glycosides (14.4 mg) Tablet USA 
GP59 GBE 120 mg from leaf. Contain 24% of flavone glycosides (28.8 mg) Capsule USA 






Figure 5S1 HPTLC fingerprints of all ginkgo products under UV 254 nm prior to derivatization. SST: 
system suitability test (rutin, chlorogenic acid, and quercetin, increasing RF values). 
 
Figure 5S2 HPTLC fingerprints of all ginkgo products under UV 366 nm prior to derivatization. SST: 
system suitability test (rutin, chlorogenic acid, and quercetin, increasing RF values). 
 
Figure 5S3 HPTLC fingerprints of all ginkgo products under UV 366 nm after derivatisation 2 (NP 
reagent). SST: system suitability test (rutin, chlorogenic acid, and quercetin, increasing RF values). 






Figure 5S4 HPTLC fingerprints of all ginkgo products under UV 366 nm after derivatisation 1. SST: 
system suitability test (rutin, chlorogenic acid, and quercetin, increasing RF values). 
Table 5S2 Table of results obtained by HPTLC regarding identity, purity, and percentages of rutin 
and quercetin, for all products. Products similar to that of reference ginkgo leaf or extract are 
indicated with green squares, and not similar with red circles. GBE: Refined ginkgo extract; GL: 
Ginkgo leaf (GBL); SJfr: Sophora fruit; SJfl: Sophora flower bud; BWH: Buckwheat herb; 5-HTTP: 
































GP1 ● x     0.69 x 3.74 
GP2 ● x     1.92 x 3.11 
GP3a ● x     n.a.  n.a. 
GP4 ● x     1.95 x 3.80 
GP5 ●      1.35 x 3.16 
GP6 ●      1.72 x 2.24 
GP7 ●    x  n.a.  n.a. 
GP8 ●      0.94 x 2.88 
GP9b ● x  x   n.a. x n.a. 
GP10 ● x     0.42 x 2.50 
GP11 ●      1.49 x 1.99 
GP12 ●      1.46 x 3.52 
GP13 ● x     1.31 x 2.53 
GP14 ●     x 6.61  0.24 
GP15 ● x     1.10 x 2.89 
GP16 ●      0.45 x 2.55 
GP17 ●  x   x 6.62 x 1.07 
GP18 ● x     2.54 x 1.68 
GP19 ●      0.43 x 2.89 
GP20 ■      2.20  0.16 
GP21 ●      1.18 x 2.85 
GP22 ● x     1.73 x 2.93 
GP23 ●     x 6.45  0.29 
GP24 ● x     1.22 x 2.14 
GP25 ●      2.86 x 1.80 




































GP26 ● x     5.47  0.35 
GP27a ●      n.a. x n.a. 
GP28c ●      n.a. x n.a. 
GP29d ●  x   x n.a. x n.a. 
GP30 ●     Only rutin 1.75  0.00 
GP31 ●      1.74 x 2.79 
GP32 ●     x 6.51  0.27 
GP33e ■      1.71  0.20 
GP34c ●      n.a. x n.a. 
GP35 ●      1.41 x 2.79 
GP36 ■      2.84  0.09 
GP37 ■      1.96  0.05 
GP38 ■      2.11  0.04 
GP39 ■      2.63  0.12 
GP40 ■      2.79  0.31 
GP41 ■      2.73  0.16 
GP42 ■      2.89  0.29 
GP43 ■      1.93  0.09 
GP44 ● x     1.37 x 2.60 
GP45 ●     x 6.91  0.01 
GP46c ●      n.a.  n.a. 
GP47c ●      n.a.  n.a. 
GP48 ●      1.85 x 2.04 
GP49 ●     x 6.95  0.50 
GP50a ●      n.a. x n.a. 
GP51 ● x     1.78 x 2.10 
GP52 ●      0.49 x 2.32 
GP53 ● x     2.73 x 2.05 
GP54 ●     x 6.23  0.66 
GP55e ● x     1.66 x 4.44 
GP56c ●      n.a.  n.a. 
GP57 ●      2.82 x 2.15 
GP58 ●      2.47 x 2.35 
GP59 ■      2.38  0.39 
Total 11 16 2 1 1 9 --- 35 --- 
a Products that declare to contain mixture of refined ginkgo extract and ginkgo leaf; b Products that declare to 
contain mixture of refined ginkgo extract and green buckwheat; c Products that declare to contain ginkgo leaf; 
d Products that declare to contain mixture of refined ginkgo extract and rutin; e Products that declare to contain 











Table 5S3 HPLC results of the assay of total flavonoids, the peak ratios kaempferol/quercetin (K/Q) 
and isorhamnetin/quercetin (I/Q), and the limit tests for ruitn and quercetin. Samples marked in red 
show one or more results not compliant with the USP monograph. Samples marked in green are 
compliant with the USP monograph for the analyses performed. Samples in which conformity to the 
monograph is not applicable are marked in black. n.a.: not applicable. 






Peak area ratio 
K/Q 
(≥ 0.7)b 







GP1 24.6 0.3 0.1 0.6 8.13 
GP2 22.3 0.9 0.2 1.6 3.18 
GP4 25.9 1.1 0.1 1.3 4.08 
GP5 24.9 0.6 0.2 1.0 5.16 
GP6 16.0 0.9 0.2 1.2 2.60 
GP7 Not analysed Not analysed Not analysed Not analysed Not analysed 
GP8 22.3 0.8 0.1 0.4 5.75 
GP11 17.8 0.4 0.1 0.8 2.05 
GP12 24.8 0.3 0.1 0.4 3.33 
GP14 Not analysed Not analysed Not analysed Not analysed Not analysed 
GP17 Not analysed Not analysed Not analysed Not analysed Not analysed 
GP20 23.2 0.9 0.1 2.5 0.12 
GP21 25.6 0.9 0.1 0.6 4.70 
GP22 25.2 0.9 0.1 1.4 4.15 
GP23 10.0 0.04 0.02 23.8 0.33 
GP24 22.0 1.0 0.2 1.1 2.72 
GP25 Not analysed Not analysed Not analysed Not analysed Not analysed 
GP31 21.2 0.8 0.2 0.7 2.24 
GP35 25.9 0.8 0.2 0.9 4.37 
GP 36 23.1 1.0 0.3 2.3 0.18 
GP 37 23.5 1.2 0.4 2.0 0.18 
GP 38 22.2 1.5 0.4 1.8 0.18 
GP 39 22.2 1.3 0.5 2.4 0.20 
GP 40 23.1 1.0 0.3 2.3 0.34 
GP 41 23.0 1.0 0.3 2.3 0.24 
GP 42 24.4 1.0 0.3 2.5 0.34 
GP 43 23.0 1.6 0.3 1.4 0.22 
GP 44 28.8 0.9 0.1 1.1 3.62 
GP 45 27.0 0.0 0.0 23.2 0.02 
GP 48 26.3 0.8 0.2 1.2 3.13 
GP 49 26.9 0.0 0.0 20.6 0.47 
GP 51 17.3 1.4 0.1 0.8 1.69 
GP 52 19.3 0.8 0.1 0.1 1.53 
GP 53 27.0 1.1 0.1 2.1 2.36 
GP 54 15.4 0.0 0.0 14.5 0.73 
GP 57 25.6 1.0 0.1 2.5 3.11 
GP 58 26.4 1.0 0.1 2.0 3.61 
GP 59 26.9 1.1 0.4 2.5 0.38 











Peak area ratio 
K/Q (≥ 0.7)b 
Peak area ratio 





GP10 12.4 0.3 0.1 0.2 3.01 
GP13 13.3 0.3 0.1 0.8 3.05 
GP15 11.4 0.8 0.1 0.5 1.93 
GP16 10.0 0.3 0.1 0.2 3.24 
GP18 Not analysed Not analysed Not analysed Not analysed Not analysed 
GP19 14.1 0.3 0.1 0.2 3.92 
GP26 16.3 0.5 0.1 13.0 0.39 
GP30 0.1 0.8 0.1 0.7 0.01 
GP32 19.3 0.02 0.01 21.0 0.39 







Peak area ratio 
K/Q 
(requirement n.a.) 










GP33 2.9 1.4 0.4 0.2 0.00 
GP55 16.3 0.4 0.1 0.5 3.44 







Peak area ratio 
K/Q 
(requirement n.a.) 










GP29 37.3 0.2 0.1 n.a. n.a. 







Peak area ratio 
K/Q 
(requirement n.a.) 










GP9 8.2 0.2 0.04 n.a. n.a. 
Products that declare to contain mixture of ginkgo refined extract (declaring 22-27% of 







Peak area ratio 
K/Q 
(requirement n.a.) 










GP3 15.1 0.8 0.1 n.a. n.a. 
GP27 22.3 1.0 0.1 n.a. n.a. 
GP50 Not analysed Not analysed Not analysed Not analysed Not analysed 






Peak area ratio 
K/Q 
(requirement n.a.) 










GP28 0.8 n.a. n.a. n.a. n.a. 
GP34 0.6 n.a. n.a. n.a. n.a. 
GP46 0.5 n.a. n.a. n.a. n.a. 





GP47 0.9 n.a. n.a. n.a. n.a. 
GP56 0.5 n.a. n.a. n.a. n.a. 
a Results expressed in relation to the extract contained in the product. b Requirements of the USP monograph 
on Powdered Ginkgo Extract. c These extracts did not declare any content of flavonoids but a DER of 50:1, 
typical of the GBE. For this reason, were considered as GBE and thus, compliance to the requirements 
described in the USP monograph on Powdered Ginkgo Extract was assessed. d Results expressed in relation 
to the sum of the declared amounts of GBE and rutin. e Results expressed in relation to the sum of the 
declared amounts of GBE and green buckwheat. f Results expressed in relation to GBE equivalent, sum of 
the amounts of GBE and GBE equivalent to ginkgo leaf (calculated from a DER 50:1). g Results expressed 




Figure 5S5 HPTLC fingerprints of the physical mixtures of ginkgo leaf and buckwheat herb, and 
examples of adulterated product (GP9). BWH: buckwheat herb, GBL: ginkgo leaf. Track 1: 100% 
BWH, track 8: 100% GBL, tracks 2-8: mixtures of BWH and GBL, track 9: product containing BWH. 
 
Figure 5S6 Fingerprints of GBL (track 1) and GBE (track 2) under UV 366 nm after derivatization 
with NP (left) and NP + PEG (right). 
 






Figure 5S7 HPTLC fingerprints of forty-eight ginkgo products analysed with the reverse-phase 
HPTLC method under UV 366 nm after derivatisation 1. SST: system suitability test (quercetin and 








Chapter 6: An alternative and simplified approach to 
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Un enfocament alternatiu i simplificat per a la identificació i la assaig de contingut 
mínim en drogues vegetals emprades en medicina tradicional xinesa (TCM) 
 
Seguint una decisió de la Comissió de la Farmacopea Europea (Ph. Eur.), el grup de 
treball sobre drogues vegetals emprades en TCM va iniciar una fase pilot per examinar la 
idoneïtat de l’assaig de contingut mínim per HPTLC per reemplaçar la valoració clàssica 
en monografies TCM. Aquest plantejament es va avaluar amb dos drogues vegetals de la 
TCM: els bulbs Fritillaria thunbergii (FTB) i el rizoma de coridalis (CYR). 
En primer lloc, es van optimitzar els mètodes HPTLC existents per a les dues drogues 
vegetals. Els nous mètodes es van aplicar a l'avaluació de múltiples mostres i a 
l’establiment de criteris d'acceptació per a la identificació, seguint el capítol general 2.8.25 
de la Ph. Eur.. A continuació, es van desenvolupar i validar els assajos de contingut mínim 
de marcadors. per HPTLC. En aquest assaig, es compara la intensitat de la zona del 
marcador a l’empremta dactilar de la mostra amb la zona corresponent de la solució de 
referència, que té una concentració que dóna una intensitat equivalent al criteri 
d’acceptació. Aquesta prova dóna un resultat de passa o falla per a cada mostra, en lloc 
d’un contingut, i es pot realitzar visualment (amb les imatges) o mitjançant programari 
(utilitzant perfils de pics generats a partir d’imatges, PPI). 
Es va avaluar la reproductibilitat dels mètodes HPTLC en estudis interlaboratori en els que 
participaren sis laboratoris. En resum, els resultats de FTB de cinc laboratoris estaven 
d'acord. El laboratori restant no va passar la identificació de les mostres. Per a CYR, tots 
els laboratoris van presentar els mateixos resultats per a la seva identificació. A la prova 
de contingut mínim, una mostra que es trobava a la zona límit va passar a 4 laboratoris i 
va fallar en dos. Tots els laboratoris van arribar a conclusions similars per a les altres set 
mostres. 
Els mètodes HPTLC proposats ofereixen un enfocament simplificat per avaluar la identitat 
i el contingut mínim de drogues vegetals de la TCM en una única anàlisi. 
 
  







Un enfoque alternativo y simplificado para la identificación y el ensayo de 
contenido mínimo en drogas vegetales utilizadas en medicina tradicional china 
(TCM) 
 
Siguiendo una decisión de la Comisión de la Farmacopea Europea (Ph. Eur.), El grupo de 
trabajo sobre drogas vegetales empleadas en TCM inició una fase piloto para examinar 
la idoneidad del ensayo de contenido mínimo por HPTLC para reemplazar la valoración 
clásica en monografías TCM. Este planteamiento se evaluó con dos drogas vegetales de 
la TCM: los bulbos Fritillaria thunbergii (FTB) y el rizoma de coridalis (CYR). 
En primer lugar, se optimizaron los métodos HPTLC existentes para ambas drogas 
vegetales. Los nuevos métodos se aplicaron a la evaluación de múltiples muestras y al 
establecimiento de criterios de aceptación para la identificación, siguiendo el capítulo 
general 2.8.25 de la Ph. Eur. A continuación, se desarrollaron y validaron los ensayos de 
contenido mínimo de marcadores por HPTLC. En este ensayo, se compara la intensidad 
de la zona del marcador a la huella dactilar de la muestra con la zona correspondiente de 
la solución de referencia, que tiene una concentración que da una intensidad equivalente 
al criterio de aceptación. Esta prueba da un resultado de pasa o falla para cada muestra, 
en lugar de un contenido, y se puede realizar visualmente (con las imágenes) o mediante 
software (utilizando perfiles de picos generados a partir de imágenes, PPI). 
Se evaluó la reproducibilidad de los métodos HPTLC en estudios interlaboratorio en los 
que participaron seis laboratorios. En resumen, los resultados de FTB de cinco 
laboratorios estaban de acuerdo. El laboratorio restante no pasó la identificación de las 
muestras. Para CYR, todos los laboratorios presentaron los mismos resultados para su 
identificación. En la prueba de contenido mínimo, una muestra que se encontraba en la 
zona límite pasó a 4 laboratorios y falló en dos. Todos los laboratorios llegaron a 
conclusiones similares para las otras siete muestras. 
Los métodos HPTLC propuestos ofrecen un enfoque simplificado para evaluar la identidad 
y el contenido mínimo de drogas vegetales de la TCM en un único análisis. 
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6.1 Abstract 
Following a decision of the European Pharmacopoeia Commission, the TCM working party 
started a pilot phase to examine the suitability of HPTLC minimum content test for 
replacing the classical assay in TCM monographs. This approach was evaluated with two 
TCM herbal drugs: Fritillaria thunbergii bulbs (FTB) and Corydalis rhizome (CYR). 
Firstly, the existing HPTLC methods were optimized for both drugs. The new methods 
were applied to the evaluation of multiple samples, and acceptance criteria for the 
identification, following Ph. Eur. chapter 2.8.25, were set. Then, the HPTLC tests for 
minimum content of markers were developed and validated. In this test, the intensity of the 
zone of the marker in the fingerprint of the sample is compared to the corresponding in the 
reference solution, which has a concentration giving an intensity equivalent to the 
acceptance criterion. This test gives a pass or fail result rather than a content and can be 
performed visually (on the images) or by software (using peak profiles from images, PPI). 
Reproducibility of the HPTLC methods was evaluated in a collaborative trial including six 
laboratories. In summary, results for FTB from five laboratories were in agreement. The 
remaining laboratory did not pass the identification of the samples. For CYR, all 
laboratories presented the same results for identification. In the test for minimum content, 
one borderline sample passed in 4 laboratories and failed in two. All laboratories reached 
similar conclusions for the other seven samples. 
The HPTLC methods proposed offer a simplified approach to evaluating identity and mini-
mum content of TCM drugs in a single analysis.  
6.2 Introduction 
The European Pharmacopoeia plays an important role in the global quality control of 
herbal drugs. The 10th Edition (including supplement 10.2) contains 346 monographs of 
herbal drugs and herbal drug preparations [1]. Of these, 73 are devoted to the quality of 
TCMs (Traditional Chinese Medicines) drugs. In order to evaluate the quality of herbal drugs 
and preparations, monographs contain a suite of tests, used for the identification of the 
herbal drug or preparation, detection of impurities, and content of a constituent or a group 
of constituents.  
The constituents used for quality control of herbal drugs are classified in three categories: 
compounds with known therapeutic activity, active markers and analytical markers. The 





two first groups have an accepted responsibility or contribution to the clinical efficacy of 
the herbal drug. Quantification of these constituents is considered relevant in the 
assessment of the quality of the herbal drugs. Nevertheless, in most herbal drugs, due to 
the limited knowledge on the responsibility of their constituents on its clinical efficacy, a 
constituent or a group of constituents are used as analytical marker(s). The quantification 
of an analytical marker can help in the control of the manufacturing process of an herbal 
drug and the resulting medicinal product. Nevertheless, in many cases, the determined 
content of analytical marker(s) is not indicative of the suitability of the herbal drug for the 
intended use and does neither guarantee the quality nor the stability of the drug. Still, the 
usual practice is, that wherever possible, an assay shall be described in monographs on 
herbal drugs and preparations and this assay is very often based on chromatographic 
methods, like LC or GC using reference standards with assigned content.  
Usually, one analytical marker is determined quantitatively in these assays and the 
Definition section of the monograph describes a minimum content. However, as an 
analytical marker is not responsible of the therapeutic activity, there is an ongoing 
discussion amongst experts whether less sophisticated methods could not fulfil the same 
requirements concerning quality control and simultaneously enable the control of several 
markers and therefore provide a more holistic approach. This concept has already 
described in the literature as “comprehensive HPTLC fingerprinting” [2][3] and has the 
advantage that identification test and determination of analytical marker(s) can be 
performed within one test.  Furthermore, with the modernization of the monographs in the 
Ph. Eur., the new HPTLC 2.8.25 acknowledges the quantitative aspects of the HPTLC 
image with the inclusion of intensity markers.  
Following a decision of the European Pharmacopoeia Commission at its 157th session in 
November 2016, the TCM working party started a pilot phase to examine the suitability of 
a semi-quantitative HPTLC approach to replace the classical assay in those monographs 
on TCMs (Traditional Chinese Medicines) which are not covered by a marketing 
authorisation in Europe. The idea was to offer a simpler test for minimum content that can 
be performed in parallel with identification. This approach was tested in two case studies, 
chosen by the experts of the TCM working party: Fritillaria thunbergii bulbs (FTB) and 
Corydalis rhizome (CYR).  
The results of the pilot phase are described in this paper.  
6.3 Materials and Methods 
6.3.1 Samples, reagents and instruments 
Papaverine hydrochloride (95% pure), yohimbine hydrochloride (95% pure), peimine (95% 
pure), peiminine (95% pure), isofraxidin (95% pure), scopoletin (95% pure), corydaline 
(95% pure), tetrahydropalmatine (95% pure), and all samples of Fritillaria thunbergii bulbs 
and Corydalis rhizome were provided by the European Directorate for the Quality of 
Medicines (EDQM) (Strasbourg, France). Other standards listed in the supplementary 
information were obtained from Sigma Aldrich.   
HPTLC instruments from CAMAG (Muttenz, Switzerland) were used, including: Automatic 
TLC Sampler (ATS 4), Automatic Development Chamber (ADC 2) with humidity control, 
Plate Heater 3, TLC Visualizer 2, and Immersion Device 3. These instruments were also 
used by the laboratories participating in the collaborative trial, whenever available. 
Solvents (≥95% pure) and reagents were purchased from Roth (Karlsruhe, Germany), 
Acros (Gent, Belgium), Fisher Scientific (Hampton, United States), and Merck (Darmstadt, 
Germany). Silica gel 60 F254 HPTLC glass plates (20 x 10 cm) were manufactured by Merck 
(Darmstadt, Germany). 





6.3.2 Sample preparation 
6.3.2.1 Fritillaria thunbergii bulb 
In a closed centrifuge tube, 0.5 g of the powdered herbal drug were macerated for 30 
minutes with 2.5 mL of concentrated ammonia (min 30%). Then 12.5 mL of methanol were 
added, the tube was closed again, and the mixture was shaken for 20 minutes at 300 rpm. 
Then, following centrifugation for 5 minutes, the supernatant was used as test solution. 
6.3.2.2 Corydalis rhizome 
In a closed centrifuge tube, 0.5 g of the powdered herbal drug were sonicated for 15 
minutes with 10 mL of 50% aqueous ethanol. Then, following centrifugation for 5 minutes, 
1.0 mL of the clear supernatant was transferred into a 10 mL volumetric flask and diluted 
to 10 mL with 50% aqueous ethanol. 
6.3.3 High-Performance Thin-Layer Chromatography (HPTLC) 
General HPTLC parameters for plate layout, sample application, conditioning of the plate, 
plate development, and visualization were in agreement with the Ph. Eur. general chapter 
2.8.25 [4]. The specific parameters are described in Table 6.1 and Table 6.2.  
Table 6.1 Parameters for HPTLC analysis of Fritillaria thunbergii bulb. 
Stationary phase 20x10 cm glass plates silica gel 60 F254 (2-10 µm) (Merck) 
Ref. solution a Papaverine at 0.5 mg/mL in methanol 
Ref. solution b Yohimbine at 0.1 mg/mL in methanol 
Ref. solution c Peimine at 40 µg/mL in methanol 
Ref. solution d Peiminine at 40 µg/mL in methanol 
Ref. solution e Peimine at 10 µg/mL in methanol 
Ref. solution f Peiminine at 10 µg/mL in methanol 
Ref. solution g Peimine at 20 µg/mL in methanol 
Ref. solution h Peiminine at 6.7 µg/mL in methanol 
Application  5 μL of test and reference solutions, quantitative mode 
Developing solvent Toluene, acetone, diethylamine (9:9:1.2, v/v/v) 
Development 
Unsaturated chamber (deviating from HPTLC standard conditions), 10 
min conditioning at 33% relative humidity (with MgCl2), to 70 mm from 
the lower edge of plate, room temperature (22 ± 5⁰C)  
Documentation prior 
to derivatization 
UV 254 nm, UV 366 nm, and white light 
Derivatization reagent 
10% sulfuric acid in methanol: to 180 mL of cold methanol, 20 
mL of sulfuric acid were added. The mixture was allowed to cool 
to room temperature before use. 
Derivatization 
Plates were dipped (speed: 1, dwell time: 0) into the derivatization 
reagent, dried for 1 min in a stream of cold air and then heated at 120 
⁰C for 5 min 
Documentation  
Images were recorded immediately after derivatization, under UV 366 
nm and white light 
Table 6.2 Parameters for HPTLC analysis of Corydalis rhizome. 
Stationary phase 20x10 cm glass plates silica gel 60 F254 (2-10 µm) (Merck) 
Ref. solution a Isofraxidin at 0.5 mg/mL in methanol 
Ref. solution b Scopoletin at 0.5 mg/mL in methanol 
Ref. solution c Corydaline at 12.5 µg/mL in methanol 





Ref. solution d Tetrahydropalmatine at 12.5 µg/mL in methanol 
Ref. solution e Corydaline at 3.125 µg/mL in methanol 
Ref. solution f Tetrahydropalmatine at 3.125 µg/mL in methanol 
Ref. solution g Corydaline at 2 µg/mL in methanol  
Ref. solution h Tetrahydropalmatine at 3 µg/mL in methanol  
Application  2 μL of test and reference solutions, quantitative mode 
Developing solvent Toluene, anhydrous ter-butyl methyl ether, isopropanol (8:2:0.2, v/v/v) 
Development 
Unsaturated chamber (deviating from HPTLC standard conditions), 10 
min conditioning at 33% relative humidity (with MgCl2), to 70 mm from 
the lower edge of plate, room temperature (22 ± 5⁰C)  
Documentation prior 
to derivatization 
UV 254 nm, UV 366 nm, and white light 
Derivatization reagent 
Iodine vapor: a glass chamber was saturated for 30 minutes with 1 g of 
iodine, spread evenly. 
Derivatization 
The plate was exposed to iodine vapor for 3 minutes. The excess of 
iodine absorbed on the plate is removed in a stream of cold air for 10 
minutes. 
Documentation  
Images were taken immediately after derivatization, under UV 366 nm 
and white light 
 
6.3.4 Generation of peak profiles from images (PPI) 
The visionCATS software (CAMAG, Switzerland) was used to generate peak profiles from 
images (fingerprints) by calculating the luminance L = (1/3 R)+(1/3 G)+(1/3 B) from the 
averaged signals of the red (R), green (G) and blue (B) channels of each pixel line of the 
track. L in fluorescence mode, respectively L-1 in absorption mode, is plotted as a function 
of the RF value [5]. 
6.4 Results and discussion  
This work presents two case studies of an alternative method combining identification and 
test for minimum content, that were proposed for pilot studies of the Ph. Eur.: 
 Fritillaria thunbergii bulb (FTB) 
 Corydalis rhizome (CYR) 
6.4.1 Fritillaria thunbergii bulb (FTB)  
The dried bulb of Fritillaria thunbergii Miq. (FTB) is used in traditional Chinese medicine 
(TCM) for treating cough and airway inflammatory diseases [6]. According to Li et al. [7], 
the alkaloids peimine (verticine) and peiminine (verticinone) are the major constituents of 
fritillaria and primarily responsible for the activity of the drug. Therefore, identification C of 
the first draft monograph elaborated by the TCM WP of the European Pharmacopoeia 
(confidential document) is using alkaloids as markers, and in the monograph for Fritillariae 
Thunbergii Bulbus of the Chinese Pharmacopoeia [8] an assay for peimine and peiminine 
is prescribed. Before starting the work presented here, sample preparation and HPTLC 
method of the first draft for Ph. Eur. were optimized to improve repeatability (data not 
shown). 
6.4.1.1 Identification, intensity marker, system suitability test (SST) and specificity 
of the method  
The optimized method, as described in the experimental section, was used to evaluate 
twenty-four samples of FTB. Fingerprints are shown in Figure 6S1 of the supplementary 
information. Figure 6.1 shows the chromatograms of the reference solutions (tracks A to 
D) and, as test solution, an average fingerprint generated through electronic merging of 





the individual fingerprints of all FTB samples (track 1). The eight main zones of the test 
solution are labeled alphabetically on the chromatogram and described in a table as 
acceptance criteria for identification. Under UV 366 nm after derivatization a sample 
should contain a blue fluorescent zone at the position of peiminine [e], a blue fluorescent 
zone [f], a blue fluorescent zone [g], barely separated from a faint green fluorescent zone 
[h], a greenish fluorescent zone at the position of peimine [j], one blue zone [k] and a faint 
blue zone [l]. 
6.4.1.2 Intensity marker  
In order to improve the description of the intensity of the zones in the chromatogram, the 
concept of intensity markers adopted in the HPTLC general chapter 2.8.25 [4] was 
followed. According to this chapter, solutions of one or two substances are prepared in two 
concentrations. One that resembles the intensity of the main zone(s) in the fingerprint of 
the test solution (R) and another solution with the same standards diluted 4-fold (R/4). To 
describe the intensity of the zones in the fingerprints, their intensities are visually 
compared with the intensity of the zones in solutions (R) and (R/4). Zones that are more 
intense than the solution (R) are described as intense zone, while those of similar intensity 
are described as (equivalent) zones. Zones that show intensity between solutions (R) and 
(R/4) are referred to as faint, and those less intense than solution (R/4) are very faint.  
 
Figure 6.1 HPTLC chromatograms and table description for visual identification and test for the 
minimum content of peimine and peiminine in Fritillaria thunbergii bulb (FTB). Track A: SST; Tracks 
B to D: reference solutions. Track 1: FTB test solution (average fingerprint). Tracks B to D and 1 
normalized over peiminine in track B. Intensity markers: peimine for zones [i] and [h], peiminine for 
all the other zones. 





In the case of FTB, the reference solutions of peimine and peiminine were used as intensity 
markers. First, they were prepared at ten different concentrations, between 500 µg/mL and 
10 µg/mL (Figure 6S2). The solutions at a concentration of 40 µg/mL were suitable as first 
intensity markers (reference solutions c and d) and their 4-fold dilutions (10 µg/mL) as 
diluted intensity markers (reference solutions e and f) (Figure 6.1). Peimine is used as 
intensity marker for the corresponding zone [j] and zone [h], and peiminine for all the other 
zones. 
A more objective description of the intensity is possible using the peak profiles from images 
(PPI). In this approach, the height of the peaks can be directly compared using suitable 
software. An example is shown in Figure 6.2 for the fingerprint of one FTB sample. Peaks 
[j] and [h] are compared to peimine as intensity marker [d] and would be described as faint. 
The other peaks are compared to peiminine as intensity marker [c], and, consequently, 
peaks corresponding to the zones [f], [g] and [k] would be described as intense zones, 
whereas peaks [e] and [l] as faint zones. 
 
Figure 6.2 Chromatograms and PPI of reference and test solutions. Peimine (zone [d]) and 
peiminine (zone [c]) are used as intensity markers for zones [i] and [h] and all the other zones, 
respectively.  
6.4.1.3 System Suitability Test (SST) 
Besides intensity markers, the HPTLC general chapter 2.8.25 [4] also requires the use of 
a system suitability test (SST) to evaluate the quality of the chromatography. According to 
this chapter, the SST consists of two substances on the same track, which, after chroma-
tography, are barely separable. Different separation pattern can indicate problems in the 
chromatography. For FTB, twenty-eight standards were tested (Figure 6S3). Only twelve 
alkaloids migrated between RF 0.2 and 0.8. Those that showed similar RF were then com-
bined. While no suitable combination was obtained after derivatization, three of them were 
proposed for evaluation prior to derivatization under UV 254 and 366 nm (Figure 6.3). 
Quinine and boldine showed good separation, but after derivatization, the intensity of the 
zone due to quinine interferes with the detection of other zones on the plate. The 
combination of brucine and theobromine was tested in a collaborative trial, including six 
laboratories, and some participants had difficulties with completely dissolving 
theobromine, which affected the detectability of this standard. Therefore, papaverine and 
yohimbine were finally selected as SST. Detection at UV 366 nm was chosen for its higher 
sensitivity, particularly for yohimbine. The concentration of the standards was adjusted to 
0.5 mg/mL for papaverine and 0.1 mg/mL for yohimbine as shown in Figure 6.1. 






Figure 6.3 Images of the possible SST, under UV 254 and 366 nm prior to derivatization 
6.4.1.4 Development of the test for minimum content based on PPI 
For FTB, the HPTLC test for minimum content was developed on the basis of the HPLC 
assay of the Chinese pharmacopoeia [8]. In the first part of the HPTLC investigation, 
peimine and peiminine were quantified in 9 authenticated samples (FTB1-9). The minimum 
content of both markers was established. Then, the optimized HPTLC method was 
validated with a new set of samples (FTB 10-24), and results were compared to data 
obtained by HPLC. 
Establishing minimum content of peimine and peiminine 
The contents of peimine and peiminine were established prior to method optimization, 
using the HPTLC method of the draft monograph (confidential document) and diluted test 
solutions, prepared according to method 2 described in Table 6S1. A calibration curve 
using peak areas from PPI for peimine was used to calculate both peimine and peiminine 
in samples FTB1-9. First, the linear working range was evaluated. Linearity was achieved 
with five concentration levels ranging from 2 to 8 µg/mL (4-16 ng/application). To fit the 
test solutions into the linear working range, they were further diluted 4-fold   
The content of peimine in samples FTB1-9 varied between 0.01% and 0.11% (0.06% on 
average), with 77% of the samples having a content ≥0.06%. The content of peiminine in 
these samples varied between 0.01% and 0.05% (0.02% on average), 89% of the samples 
showing a percentage ≥0.02%. Result are shown in Table 6S2. Based on these results it 
was agreed to propose 0.06% and 0.02% as minimum contents for peimine and peiminine, 
respectively. These limits include 56% of the samples analyzed.  
Validation of the HPTLC method in comparison to HPLC assay  
For validating the new HPTLC method against the existing HPLC assay method 
elaborated and validated by the experts of the TCM WP of the European Pharmacopoeia 
(confidential document), the content of peimine and peiminine was assessed in fifteen new 
samples (FTB10-24). To improve accuracy of the HPTLC determination, a separate 
calibration curve for peiminine, ranging from 2-10 µg/mL (4-20 ng/application), was 
prepared (Figure 6S4), whereas for peimine, the calibration curve described in previous 
section was used. The sample preparation for HPLC is described in Table 6S1 (method 
1). For HPTLC, the same sample preparation was used, but with an additional 25-fold 
dilution in order to fit in the linear range. Quantifications were performed in the PPI by peak 
area for peimine and peak height for peiminine, due to a lack of baseline separation from 
the neighboring peak. HPTLC results were compared to HPLC data provided by an expert 





of the TCM WP (confidential document). 
In Figure 6.4, HPTLC results are, on average, 1.1 and 1.5-fold greater than those of HPLC 
for peimine and peiminine, respectively. Nevertheless, both techniques lead to same con-
clusion of the test for minimum content for peimine (thirteen samples passed) and 
peiminine (all samples passed). 
 
Figure 6.4 Comparison of the contents of peimine and peiminine by HPTLC and HPLC. Black lines: 
minimum content of peimine (0.06%) and peiminine (0.02%). 
6.4.1.5 Collaborative trial: organization  
The reproducibility of the new HPTLC method was evaluated in a collaborative trial 
involving six laboratories using a common set of six samples (FTB 25-30) and reference 
solutions. Reference (a) to (f) and test solutions for identification were prepared according 
to the experimental section. Brucine and theobromine were used as SST. 
The test for minimum content was performed visually and by PPI using single levels of 
peimine and peiminine equivalent to 0.06% respectively 0.02% in the herbal drug 
(reference solutions (g) and (h).  
The test performed by PPI (software) involved an additional set of test and reference solu-
tions at a 4-fold dilution ensuring determination within the linear range. Due to the low 
intensity of its zones this set is not suitable for visual evaluation. 
The participating laboratories evaluated whether the SST, intensity markers and samples 
met the acceptance criteria below:  
 Evaluation 1, SST: The quenching zones due to theobromine [a] and brucine [b] are 


























































 Evaluation 1, intensity markers: A blue zone due to peiminine [c] and a greenish zone 
due to peimine [d] are seen at RF ~ 0.59 and 0.34, respectively. The ∆RF between 
experimental and theoretical RF should not be greater than 0.05. 
 Evaluation 2, identification: Fingerprints of test solution should contain zones [e] to [k], 
with colors and intensities similar to those described in the table of Figure 6.2. Refe-
rence solutions (c) to (f) are used. 
 Evaluation 3, minimum content (visual evaluation): under UV 366 nm after derivatiza-
tion, the intensity of the zones due to peimine and peiminine in the fingerprint of test 
solution is not less than that obtained with reference solutions g and h, respectively. 
 Evaluation 4, minimum content (PPI): In the PPI of the image under UV 366 nm after 
derivatization (non-diluted and diluted), peak heights of peimine and peiminine 
recorded for the test solutions are equal to or greater than those recorded for 
reference solutions. 
6.4.1.6 Collaborative trial: results  
Results of the collaborative trial are presented in Table 6S3 and Figure 6.5. The first SST 
(brucine and theobromine) passed in four laboratories but problems with solubility and 
detection of theobromine were observed. This could be the reason for observing only one 
zone in two laboratories, causing the SST to fail. Therefore, the new SST-2 (yohimbine 
and papaverine) was proposed, positively tested in several laboratories, and implemented 
in the method proposed for the monograph. Results of all laboratories were compliant 
regarding the position of the intensity markers, except for one that showed ΔRF greater 
than 0.05 for peimine. 
 
Figure 6.5 Results of the collaborative trial for FTB with 6 participant laboratories.  
For the identification (evaluation 2), all laboratories reported the seven zones with colors 
matching those of the description table. One Laboratory (4) obtained overall faint finger-
prints. The reason for that is not clear. Because all samples failed the ID test, the results 
of the test for minimum content from Laboratory 4 were not considered.  
In the visual test for minimum content (evaluation 3), five laboratories passed samples 
FTB 25 and 27-29. Samples FTB 26 and 30 showed lower content of peimine. The same 
result was observed in the test for minimum content based on evaluation of the PPI 
performed by three participants. Because results were similar, the experts of the TCM 





Working Party adopted the non-diluted set for this test.  
In summary, five laboratories came to uniform pass/fail decisions, which were in line with 
those based on the HPLC assay. Based on this study, the draft monograph under elabora-
tion was updated and the final version published in Pharmeuropa. 
6.4.2 Corydalis rhizome (CYR) 
The dried rhizome of Corydalis yanhusuo (Y.H.Chou & Chun C.Hsu) W.T.Wang ex Z.Y.Su 
& C.Y.Wu (CYR) has been used traditionally to promote blood circulation and as analgesic. 
CYR contains isoquinoline alkaloids, such as tetrahydropalmatine (THP), corydaline, 
isocorypalmine, stylopine, columbamine, coptsin, and others. Some studies demonstrated 
a relation between I-THP and the analgesic effect [9]. Due to its importance for the 
biological effect of the herbal drug, chemical identification and assay of analytical markers 
in the current Ph. Eur. monograph 2976 [10] focus on the isoquinoline alkaloids profile. 
Before starting the work described here, the sample preparation and HPTLC method were 
optimized to improve repeatability (data not shown). 
6.4.2.1 Identification of multiple samples, SST and intensity marker 
The optimized method was used to evaluate thirty-five samples of corydalis (CYR1-35, 
Figure 6S5). Figure 6.6 shows the chromatograms of the reference solutions (tracks A to 
D) and an average fingerprint generated through electronic merging of the individual 
fingerprints of all CYR samples (track 1). The four main zones observed in the test 
solutions are labeled alphabetically and described in a table as acceptance criteria for 
identification. Under UV 366 nm after derivatization, the test solution shows a faint to 
equivalent green fluorescent zone [e], a faint to equivalent blue fluorescent zone [f], a very 
faint green fluorescent zone [g], a faint to equivalent green fluorescent zone [h], and an 
intense fluorescent green zone at the application position [j]. 
 
Figure 6.6 HPTLC chromatogram and acceptance criteria for visual identification and test for mini-
mum content of corydaline and tetrahydropalmatine (THP) in corydalis rhizome (CYR). Track A: 





SST; Tracks B to D: reference solutions. Track 1: CYR test solution (average fingerprint). Tracks 
B-D and 1 are normalized over track B. Intensity markers: corydaline for zone [f], THP for all the 
other zones.  
6.4.2.2 SST and Intensity markers  
For selecting a SST for CYR, twenty one substances were tested with the mobile phase 
described in the experimental section (Figure 6S6). Mainly the coumarins and few 
alkaloids migrated between RF 0.1 and 0.3. The most suitable combination was isofraxidin 
and scopoletin detected under UV 366 nm after derivatization. Concentrations were 
adjusted to 0.5 mg/mL (Reference solutions (a) and (b), track A, Figure 6.6).  
For setting intensity markers, the same process as for FTB was followed. Reference solu-
tions of tetrahydropalmatine and corydaline at 12.5 µg/mL were used as reference 
solutions (c) and (d). Those solutions were diluted 4-fold to yield a concentration of 3.125 
µg/mL for reference solutions (e) and (f). 
6.4.2.3 Development of the test for minimum content based on PPI 
The HPTLC test for the minimum content of CYR was developed based on the existing 
method from the Ph. Eur. [10], in which the contents of corydaline and THP are quantified 
by HPLC and combined. With HPTLC, minimum contents for each marker were 
individually established. As in the case of FTB, first, the contents were assessed in 2 
authenticated samples (CYR1 and 2), and a minimum content was agreed upon. In the 
second part, the linear working ranges for both substances were investigated. The 
concentration of test solutions was adjusted to the linear range of both standards.  
Establishing minimum content of corydaline and THP 
The minimum content of corydaline and THP were established prior to method 
optimization, using the HPTLC method of the current monograph on Corydalis rhizome 
[10]. The concentration of all solutions was 10-fold higher. This part of the work was 
performed by the EDQM laboratory. First, the contents of both markers were quantified in 
samples CYR1 and 2, prepared in triplicate, and using calibration curves with five levels 
of concentration. The calibration data were obtained from PPI under UV 366 nm after 
derivatization. The amounts of corydaline were 0.04% and 0.09%, and THP were 0.06% 
and 0.08% in samples CYR 1 and 2, respectively. For the minimum content, it was agreed 
to use the lowest content of corydaline and THP of these two samples: 0.04% and 0.06%, 
respectively.  
Establishing a linear working range for test solutions 
In order to achieve a more accurate quantification by single level calibration, used in the 
test for minimum content, the linear working range for corydaline and THP in the test 
solutions was evaluated. For that, the optimized HPTLC method was used. Calculations 
were based on peaks areas from PPI under UV 366 nm after derivatization. Linearity was 
achieved for five concentration levels ranging from 1 to 10 µg/mL (2-20 ng/application), for 
both markers. Fitting the test solutions in the linear working range required a 10-fold 
dilution of the test solution described current monograph (to a concentration equivalent to 
5 mg/mL of the herbal drug). Calibration curves are shown in Figure 6S7. 
6.4.2.4 Collaborative trial: organization and results 
As in the case of FTB, a collaborative trial was performed by six laboratories. For that, 
eight samples of corydalis (CYR36-43), chemical compounds for reference solutions and 
a SOP were distributed to the participants.  
The following acceptance criteria were used to pass/fail samples and reference solutions: 





 Evaluation 1, SST: Two blue fluorescent zones due to the standards scopoletin [a] 
and isofraxidin [b] are barely separable and are seen at RF ~ 0.16 and 0.14, 
respectively.  
 Evaluation 1, intensity markers: A blue zone due to corydaline [c] and a green zone 
due to THP [d] are seen at RF ~ 0.40 and 0.16, respectively in the tracks corresponding 
to the reference solutions (c)+(d) and (e)+(f). The ∆RF between experimental and 
theoretical RF should not be greater than 0.05. 
 Evaluation 2, identification: The fingerprint of the test solution should contain zones 
[e] to [j], with color and intensities similar to these described in the table of Figure 6.6. 
Reference solutions c-f are used. 
 Evaluation 3, minimum content (visual evaluation): The intensity of the zones due to 
corydaline and THP in the fingerprint of the test solution is not less than that obtained 
with reference solutions (g) and (h), respectively. 
 Evaluation 4, minimum content (PPI evaluation): The PPI of the image under UV 366 
nm after derivatization was used. The peak heights of corydaline and THP, recorded 
for the test solution, are equal to or greater than those recorded for reference solutions 
(g) and (h). 
The results of the collaborative trial are presented in Table 6S4 and Figure 6.7. The RF 
values for the SST and intensity markers were compliant with the acceptance criteria in all 
laboratories (evaluation 1). All eight samples were compliant with the table description, 
regarding the number of zones, their colors, and intensities (evaluation 2). 
For the test of minimum content based on the visual evaluation (evaluation 3), all six labo-
ratories passed samples CYR38-43 and failed sample CYR 36. Two laboratories failed 
sample CYR37 due to the low intensity of THP (laboratory 2) or both markers (laboratory 
1). All other participants considered this sample passing. The same pattern was observed 
for the test for minimum content based on PPI (evaluation 4): laboratories 1 and 2 found 
sample CYR37 having a lower content of THP. All other samples had similar results as 
evaluation 3.  
 
Figure 6.7 Results of the collaborative trial for CYR with 6 participant laboratories.  
In general, all laboratories participating in the trial came to uniform pass/fail decision for 
seven out of the eight samples in all evaluations. Discrepancies were observed only for 





CYR37 showing a borderline situation, particularly for THP. In this case, it is recommended 
to repeat the test two times to confirm the results.  
These samples were also assayed by HPLC. The results of the collaborative trial showed 
that there was good agreement between results obtained by HPTLC and HPLC with the 
exception of one sample (CYR37) whose THP content failed by HPTLC in two labs and 
passed by LC. This might be explained by the fact that the content of the marker in the 
sample was borderline. 
6.5  Discussion  
During the initial evaluations, several reproducibility problems were encountered for the 
existing (HP)TLC methods from pharmacopoeias. This is because most of the (HP)TLC 
methods have never been optimized and validated for achieving reproducible quantitative 
results in different laboratories. Therefore, new HPTLC methods were established based 
on the investigation and optimization of different parameters, standardization and 
validation of the methodologies. After this step, multiple samples were evaluated with the 
optimized methods and acceptance criteria for the identification were set. Reference 
solutions, used as SST and intensity markers, were established following chapter 2.8.25.  
This work shows how to use PPI for the analysis and description of the intensities of the 
zones in the identification of herbal drugs. For that, the intensity (height) of the peaks in 
the reference solutions (undiluted and 4-fold diluted) and the test solutions are compared, 
providing a more objective way of evaluation than visual observation.  
The innovative part of this work demonstrated how the HPTLC method for identification 
can be used for the test for minimum content of markers in the herbal drugs. First, the 
actual contents of the markers were quantitatively determined in samples against a five-
level calibration curve. Then the minimum content for each substance was established 
based on the outcome of this test. For simplicity of routine use, the HPTLC test for 
minimum content features only one reference solution, prepared at a concentration within 
the linear range and equivalent to the minimum content in the sample. This approach is 
suitable for software evaluation through PPI, as well as for visual evaluation.  
The reproducibility of the HPTLC methods for the test for minimum content were evaluated 
and found to be suitable in collaborative trials.  
An interim report was presented to the Commission on its 159th session and the 
Commission encouraged the TCM WP to continue the work. Finally, the Commission 
accepted the results of the pilot phase unanimously at the 163th session in March 2019. 
6.6 Conclusion 
The presented HPTLC methods offer a simplified and alternative approach to verifying the 
quality of two TCM drugs, by eliminating the need for an HPLC based assay. The new 
HPTLC methods combine identification and test for minimum content in a single analysis. 
The methods proposed to the European Pharmacopoeia are suitable for any type of labo-
ratory: those that perform manual HPTLC and laboratories equipped with HPTLC instru-
ments and software. This gives laboratories with low budget a better chance to be 
compliant with the pharmacopoeia. After the introduction of the intensity marker to 
describe the intensity of fingerprints, the (visual) assessment of the minimum content of a 
single marker against a chemical reference represents an essential step towards a 
comprehensive use of the HPTLC fingerprints. Further studies will show if this concept can 
be extended to a multi-marker analysis that enables a more holistic approach for the quality 
control of herbal drugs. 
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6.8 Supplementary information 
 
6.8.1 Fritillaria thunbergii bulb 
 
Figure 6S1 Fingerprints of all Fritillaria thunbergii bulb (FTB) evaluated samples (FTB1-24) under 
UV 366 nm after derivatization. Track 1- Electronically merged image of all fingerprints. 
 
 
Figure 6S2 Fingerprints of peimine (green zone at RF 0.34) and peiminine (blue zone at RF 0.60), 
prepared at 10 different concentrations (tracks 1-10) and an electronically merged image of all FTB 
fingerprints, under UV 366 nm after derivatization. 






Figure 6S3 Fingerprints of the reference solutions at 1 mg/mL from secondary metabolites of 
different classes (e.g. flavonoids, saponins, sugars and alkaloids), analyzed for the selection of a 
system suitability test (SST) for Fritillaria thunbergii bulb HPTLC method. 
Table 6S1 Description of the sample preparation methods tested with pooled sample of Fritillaria 
thunbergii bulb. 




In a 250 mL round bottom flask, 1.0 g of the powdered herbal drug were 
macerated for 30 minutes with 2 mL of concentrated ammonia (25-35%). Then, 
20 mL of a mixture of dichloromethane and methanol (4:1) were accurately 
added, and the mixture was heated under reflux on a water bath at 60°C for 45 
minutes. After cooling, the mixture was filtered over sodium sulfate into a 20 ml 
volumetric flask. The round bottom flask was rinsed twice, transferred to the 
volumetric flask and the volume was filled up with solvent mixture to the mark. 
Ten mL of the filtrate was evaporated to dryness and the residue was dissolved 




In a stopped centrifuge tube, 0.5 g of the powdered herbal drug were macerated 
for 30 minutes with 2.5 mL of concentrated ammonia (25-35%). Then, 12.5 mL 
of a mixture of dichloromethane and methanol (1:1) were added, the tube was 
again stopped, and the mixture was sonicated for 10 minutes. The test solution 
was centrifuged, and supernatant was used. For quantification, 1 mL of the 




In a stopped centrifuge tube, 0.5 g of the powdered herbal drug were macerated 
for 30 minutes with 2.5 mL of concentrated ammonia (25-35%). Then, 12.5 mL 
of methanol were added the tube was again stopped, and the mixture was 
shaking for 20 minutes. The test solution was centrifuged, and supernatant was 
used. For quantification, 1 mL of the supernatant was diluted with 3 mL of 










In a stopped centrifuge tube, 0.5 g of the powdered herbal drug were macerated 
for 30 minutes with 0.5 mL of concentrated ammonia (25-35%).  Then, 2.5 mL 
of a mixture of dichloromethane and methanol (1:1) were added, the tube was 
again stopped, and the mixture was sonicated for 10 minutes. The test solution 
was centrifuged, and supernatant was used. 
 
 
Figure 6S4 Calibration curves of peimine and peiminine. Detection mode: UV 366 nm after 
derivatization. 
Table 6S2 Contents of peimine and peimine in Fritillaria thunbergii bulb samples (FTB1-9), 
calculated with the original HPTLC method. Detection mode: UV 366 nm after derivatization.  
Sample Peimine UV 366 nm (PPI) % 
Peimine UV 366 nm (PPI) 
% 
FBT1 0.08 0.02 
FBT2 0.10 0.03 
FBT3 0.07 0.02 
FBT4 0.08 0.02 
FBT5 0.07 0.01 
FBT6 0.01 0.05 
FBT7 0.08 0.02 
FBT8 0.01 0.02 
FBT9 0.03 0.04 
Agreed minimum content  0.06 0.02 





Table 6S3 Summary of the results of the collaborative trial for Fritillaria thunbergii bulb HPTLC 
method, among six laboratories. 
Laboratories 1  2  3  4 5  6  
Evaluation 1: SST and intensity markers  
SST 









Ref. solution b 
(brucine) 







Ref. solution a 
(papaverine) 
Pass n.a. n.a. n.a. Pass n.a. 
Ref. solution b 
(yohimbine) 
Pass n.a. n.a. n.a. Pass n.a. 
IMa 
 
Ref. solution c 
and e (peimine) 
Fail (deviant 
RF values) Pass Pass Pass Pass Pass 
Ref. solution    d 
and f (peiminine) 
Fail (deviant 
RF values) 
Pass Pass Pass Pass Pass 
Evaluation 2: Identity  
























Evaluation 3: Minimum content, visual evaluation  













FTB 27 Pass Pass Pass n.a. Pass Pass 
FTB 28 Pass Pass Pass n.a. Pass Pass 













Evaluation 4: Minimum content, PPI (non-diluted test and reference solutions) 
FTB 25 n.a. Pass Pass n.a. Pass n.a. 









FTB 27 n.a. Pass Pass n.a. Pass n.a. 
FTB 28 n.a. Pass Pass n.a. Pass n.a. 
FTB 29 n.a. Pass Pass n.a. Pass n.a. 









Evaluation 4: Minimum content, PPI (diluted test and reference solutions) 
FTB 25 n.a. Pass Pass n.a. Pass n.a. 









FTB 27 n.a. Pass Pass n.a. Pass n.a. 
FTB 28 n.a. Pass Pass n.a. Pass n.a. 
FTB 29 n.a. Pass Pass n.a. Pass n.a. 









a Intensity marker; 





6.8.2 Corydalis rhizome 
 
Figure 6S5 Fingerprints of all Corydalis rhizome (CYR) evaluated samples (CYR1-35) under UV 
366 nm after derivatization. Track 1: Electronically merged image of all fingerprints. 
 
Figure 6S6 Fingerprints of the reference solutions at 1 mg/mL from secondary metabolites of 
different classes (e.g. coumarins, alkaloids, hydroxycinnamic acids and flavonoids), analyzed for 
the selection of the system suitability test (SST) for the Corydalis rhizome HPTLC method. 






Figure 6S7 Calibration curves of tetrahydropalmatine and corydaline. Detection mode: UV 366 nm 
after derivatization. 
 
Table 6S4 Summary of the results of the collaborative trial for Corydalis rhizome (CYR) HPTLC 
method, among six laboratories 
Laboratories 1  2  3  4 5  6  









Pass Pass Pass Pass Pass Pass 
IMa 
 
Ref. solution  
c and e 
(corydaline) 
Pass Pass Pass Pass Pass Pass 
Ref. solution 
d and f (THP) 
Pass Pass Pass Pass Pass Pass 
Evaluation 2: Identity  
CYR36 Pass Pass Pass Pass Pass Pass 
CYR37 Pass Pass Pass Pass Pass Pass 
CYR38 Pass Pass Pass Pass Pass Pass 
CYR39 Pass Pass Pass Pass Pass Pass 
CYR40 Pass Pass Pass Pass Pass Pass 
CYR41 Pass Pass Pass Pass Pass Pass 
CYR42 Pass Pass Pass Pass Pass Pass 
CYR43 Pass Pass Pass Pass Pass Pass 





























Fail (THP) Pass Pass Pass Pass 
CYR38 Pass Pass Pass Pass Pass Pass 
CYR39 Pass Pass Pass Pass Pass Pass 
CYR40 Pass Pass Pass Pass Pass Pass 
CYR41 Pass Pass Pass Pass Pass Pass 
CYR42 Pass Pass Pass Pass Pass Pass 
CYR43 Pass Pass Pass Pass Pass Pass 




















CYR37 Fail (THP) Fail (THP) Pass Pass Pass Pass 
CYR38 Pass Pass Pass Pass Pass Pass 
CYR39 Pass Pass Pass Pass Pass Pass 
CYR40 Pass Pass Pass Pass Pass Pass 
CYR41 Pass Pass Pass Pass Pass Pass 
CYR42 Pass Pass Pass Pass Pass Pass 
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Anàlisi integral de l’empremta dactilar per HPTLC: un nou enfocament econòmic 
per avaluar la qualitat del carpòfor de Ganoderma lucidum 
L’avaluació de qualitat dels medicaments a base de plantes requereix l’avaluació de la 
identitat i les possibles adulteracions, així com la determinació del contingut de principis 
actius o marcadors. Per això, normalment, a les monografies de Farmacopea, es 
prescriuen diferents mètodes que utilitzen diferents tècniques cromatogràfiques. 
L’objectiu d’aquest treball és proposar un nou mètode d’avaluació, basat en l’anàlisi 
integral de l’empremta dactilar per HPTLC (Comprehensive HPTLC fingerprinting): una 
única anàlisi per HPTLC, que combina la identificació del carpòfor de Ganoderma lucidum 
amb un assaig d’adulteració i la determinació quantitativa del contingut d’àcids triterpènics 
totals. 
Els paràmetres del mètode per HPTLC es van optimitzar per a obtenir senzillesa i 
robustesa. A continuació, es van avaluar una cinquantena de mostres de carpòfor de G. 
lucidum, així com mostres de possibles espècies adulterants, que demostren 
l’especificitat del mètode per a l’espècie objectiu. Els àcids triterpènics es van analitzar 
integrant els pics d’àcids ganodèrics a l’empremta dactilar, sumant les seves àrees i 
quantificant-los enfront d’un punt de calibració d’un sol nivell d’àcid ganodèric A. 
El mètode HPTLC presentat ofereix una alternativa econòmica però poderosa a l’actual 
monografia USP sobre el carpòfor de G. lucidum. Combina la identificació i la valoració 
quantitativa en un assaig de baix cost, eliminant la valoració d’àcids triterpènics totals per 
UHPLC. D’aquesta manera es pot descriure de forma exhaustiva la qualitat de les 
mostres. 
Resumen 
Análisis integral de la huella dactilar por HPTLC: un nuevo enfoque económico 
para evaluar la calidad del carpóforo de Ganoderma lucidum 
La evaluación de calidad de los medicamentos a base de plantas requiere la evaluación 
de la identidad y las posibles adulteraciones, así como la determinación del contenido de 
principios activos o marcadores. Por eso, normalmente, en las monografías de 
Farmacopea, se prescriben diferentes métodos que utilizan diferentes técnicas 
cromatográficas.El objetivo de este trabajo es proponer un nuevo método de evaluación, 
basado en elanálisis integral de la huella dactilar por HPTLC (Comprehensive HPTLC 
fingerprinting): un único análisis por HPTLC, que combina la identificación del carpóforo 
de Ganoderma lucidum con un ensayo de adulteración y la determinación cuantitativa del 
contenido de ácidos triterpénicos totales. 
Los parámetros del método por HPTLC se optimizaron para obtener sencillez y robustez. 
A continuación, se evaluaron una cincuentena de muestras de carpóforo de G. lucidum, 
así como muestras de posibles especies adulterantes, que demuestran la especificidad 
del método para la especie objetivo. Los ácidos triterpénicos se analizaron integrando los 
picos de ácidos ganodéricos en la huella dactilar, sumando sus áreas y cuantificándolos 
frente a un punto de calibración de un solo nivel de ácido ganodérico A. 
El método HPTLC presentado ofrece una alternativa económica pero poderosa a la actual 
monografía USP sobre el carpóforo de G. lucidum. Combina la identificación y la 
valoración cuantitativa en un ensayo de bajo coste, eliminando la valoración de ácidos 
triterpénicos totales por UHPLC. De esta manera se puede describir de forma exhaustiva 
la calidad de las muestras.  
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Quality evaluation of herbal drugs requires the assessment of identity and possible 
adulterations, as well as the determination of the content of active principles or markers. 
For that, normally, different methods, using different chromatographic techniques are 
prescribed in the Pharmacopoeia monographs. The goal of this work is to propose a new 
method for evaluation, based on “comprehensive HPTLC fingerprinting”. A single HPTLC 
analysis, which combines identification of Ganoderma lucidum fruiting body with a test for 
adulteration and quantitative determination of the content of total triterpene acids. 
Parameters of the HPTLC method were optimized for simplicity, and robustness. Then, 
fifty samples of G. lucidum fruiting body, plus samples of possible adulterating species 
were evaluated, proving specificity of the method for the targeted species. Triterpene acids 
were assayed by integrating the peaks of ganoderic acids in the fingerprint, summing their 
areas, and quantifying them against a single level calibration point of ganoderic acid A.  
The presented HPTLC method offers an economic yet powerful alternative to the current 
USP monograph on G. lucidum fruiting body. It combines identification and quantitative 
assessment in a single, low-cost test, eliminating the UHPLC assay of total triterpene 
acids. This way the samples’ quality can be comprehensively described. 
7.2 Introduction approach 
The quality of herbal supplements is evaluated based on Current Good Manufacturing 
Practice (cGMP). As for herbal medicines, manufacturers are required to assess the 
identity, purity, and content of their ingredients and products, among other parameters. 
Scientifically valid methods and acceptance criteria are required [1][2][3]. Pharmacopoeias 
and other compendia offer ready-to-use specifications (methods and acceptance criteria) 
for quality control of herbal drugs, preparations and products [4][5], which may fulfil the 
requirements of cGMP even if the monograph describes materials regulated in different 
categories. 
While the quality control for synthetic drug substances is simple and straightforward, this 
process can be more complex for herbal drugs and preparations. For the first ones, the 
active molecule and the impurities are monitored to establish identity, purity, and content, 
normally based on a single analysis (e.g. HPLC). Herbal drugs and preparations often 
contain a complex mixture of dozens of substances and there is a limited knowledge of 
their active constituents [6]. Therefore, testing and assuring the quality of herbals becomes 
a much more complex and difficult task, which may require a larger number of substances 





to be monitored and tests to be included.  
In monographs, pharmacopoeias prescribe a suite of tests for identity, purity, and content 
of one or more constituents. In most of the cases, TLC or HPTLC is used for the chemical 
identification and detection of adulterants while the assay of constituents with known thera-
peutic activity, active markers or analytical markers is mainly performed by HPLC or GC 
[6]. The marker concept is suitable only for herbals of which the therapeutically active 
constituents are not known. In this case the entire herbal ingredient is considered to 
provide the health benefit. Markers can be a single constituent or a group of them. 
Aiming at describing the quality of herbal supplements, USP developed a monograph for 
Reishi mushroom, Ganoderma lucidum (Curtis) P. Karst fruiting body GLFB [7]. This 
herbal drug is used in the Traditional Medicine of China and other Asian countries. It 
contains polysaccharides, triterpenoids, sterols, and fatty acids. The pharmacological 
properties of GLFB have been associated with the triterpenoids [8]. Therefore, USP 
monograph includes assays of a number of triterpene acids (ganoderic and ganoderenic 
acids) by UHPLC in addition to other quality tests. The assay method offers a more holistic 
approach than the single analytical marker quantification, but is challenging due to the 
required unusually long UHPLC column and the resulting need for a strong pump and a 
gradient run of 1 hour per sample. 
Since the introduction of standardized HPTLC into the pharmacopoeias (e.g. general 
HPTLC chapters USP <203> in 2015 [9] and Ph. Eur. 2.8.25 in 2017 [10]), it is possible to 
reproducibly generate HPTLC fingerprints for identification of herbals. Those fingerprints 
are static two-dimensional arrays of separated compounds on HPTLC plates. The concept 
of “comprehensive HPTLC fingerprinting” [11] combines visual image data and quantitative 
information from peak profiles generated from images (PPI). “Comprehensive HPTLC fin-
gerprinting” can be seen as a multidimensional evaluation of quality of an ingredient based 
on qualitative and quantitative data obtained during identification, thus by eliminating a 
separate experiment for the assay reducing the overall cost of analysis. 
The goal of this work was to elaborate an example of how HPTLC can be used as a rapid 
and cost-efficient tool for comprehensive description of quality. A single HPTLC analysis, 
which combines identification of GLFB with a test for adulteration and determination of the 
content of total triterpene acids expressed as ganoderic acid A is proposed. 
7.3 Materials and methods 
7.3.1 Samples, standards, instruments, solvents and reagents 
Fifty samples of GLFB (whole, powdered, chopped) where acquired from or provided by 
different companies and institutions from USA, France, Switzerland and Canada. For addi-
tional information, see Table 7S1 in the supplementary information. Standards of 
ganoderic acid A, B, C2, D, and G were purchased from ChemFaces (Hubei – People’s 
Republic of China). Ganoderma lucidum fruiting body reference extract (lot: #F012B0) and 
ergosterol were provided by USP (Rockville, MD, USA).   
HPTLC equipment from CAMAG (Muttenz, Switzerland) was used, including: Automatic 
TLC Sampler (ATS 4), Automatic Development Chamber (ADC 2) with humidity control, 
Scanner 4, Plate Heater 3, TLC Visualizer 2, and Immersion Device 3. The solvents and 
reagents were purchased from Sigma-Aldrich (Buchs, Switzerland), Roth (Karlsruhe, 
Germany), Acros (Gent, Belgium) and Merck (Darmstadt, Germany). Silica gel 60 F254 
HPTLC glass plates (20 x 10 cm) were manufactured by Merck (Darmstadt, Germany). 
7.3.2 Sample preparation for identification and quantitative tests 
Samples of GLFB were milled for one minute at 1900 rpm in a grind system (Tube Mill 
control, IKA, Switzerland). Then, 400 mg of the powder were accurately weighed into cen-
trifuge tubes and 5.0 mL of absolute ethanol were added. The mixture was shaken for 15 





minutes at 3000 rpm on an Orbital Shaking Platform POS-300 (Grant-Bio, UK). After cen-
trifugation for five minutes, the supernatant was used as test solution. 
7.3.3 Standards preparation 
3 mg of ganoderic acid A were accurately weighed and dissolved in 3.0 mL of methanol. 
The resulting stock solution was diluted with methanol to different concentrations in a 
range from 0.04 to 0.60 mg/mL. Other standards were prepared at 1 mg/mL in methanol. 
For single level calibration 5 µL of standard solution at 0.1 mg/mL were used. 
7.3.4 High performance thin layer chromatography (HPTLC) 
General HPTLC parameters for plate layout, sample application, conditioning of the plate, 
plate development and visualization were in agreement with the USP general Chapter 
<203> [9]. The background of the images obtained in fluorescence mode was normalized 
on the ganoderic acid A standard track. The optimized parameters are described in Table 
7.1. 
Table 7.1 Parameters for the HPTLC methods used in the present work. 
Stationary phase 20x10 cm plates Si 60 F254 (Merck) 
Concentration of stan-
dard 
0.1 mg/mL (ganoderic acid A, content test) 
Application  5 μL of test and standards solutions, quantitative mode 
Developing solvent Toluene, tetrahydrofuran, acetic acid (70:30:1 v/v/v) 
Development 
Unsaturated chamber, 10 min conditioning at 33% relative humidity 
(with MgCl2), 70 mm distance from lower edge, room temperature = 
22 ± 5⁰C  
Documentation prior to 
derivatization 
UV 254 nm, UV 366 nm and white light 
Peak Profiles from Sca-
nning densitometry 
(PPSD) 
Densitometric analysis for quantification is performed before 
derivatization in absorbance mode at 260 nm, using deuterium 
lamp, slit dimension 5.0 x 0.2 mm, scanning speed 20 mm/s. 
UV spectra 
UV spectra of samples and standards were recorded before 
derivatization in absorbance, between the wavelengths 200 and 
400 nm, using a deuterium lamp, slit dimension 8.0 x 0.4 mm, 
scanning speed 10 mm/s 
Derivatization reagent 
10% sulfuric acid in methanol. To 180 mL of cold methanol, 20 mL 
of sulfuric acid are added. The mixture is allowed to cool to room 
temperature before use. 
Derivatization 
Plates were dipped (speed: 1, time: 0) into the derivatization 
reagent, dried for 1 min in a stream of cold air and then heated at 
100 ⁰C for 3 min 
Documentation  
Images are taken 12 minutes after derivatization, under UV 366 
nm and white light 
  
7.3.5 Generation of peak profiles from images (PPI) 
The visionCATS software (CAMAG, Switzerland) was used to generate peak profiles from 
images (fingerprints) by calculating the luminance L = (1/3 R)+(1/3 G)+(1/3 B) from the red 
(R), green (G) and blue (B) channel for each pixel line of the track. L in fluorescence mode, 
respectively 1-L in absorption mode, is plotted as a function of the RF value [11]. 
7.3.6 Repeatability of quantitation 
Six individual solutions of sample GL20 were prepared according to the method described 
above. The areas of PPI and PPSD between RF 0.1 and 0.5 were added and the coefficient 
of variation (CV) of the total content of triterpene acids was calculated against a single 





level of ganoderic acid A. 
7.4 Results and discussion 
Starting point of the work was an evaluation of monographs for GLFB from the Hong Kong 
Chinese Materia Medica Standards (HKCMMS) [12], the United States Pharmacopoeia 
(USP) [7], and the Pharmacopoeia of the People’s Republic of China (PPRC) [13].  
Beside other tests, these monographs include mainly identification by macroscopy, 
microscopy, TLC or HPTLC, and HPLC, focusing on the detection of the triterpene acids. 
For the quantitative analysis, the PPRC prescribes an unspecific assay of 
polysaccharides, triterpenes and sterols by spectrophotometry. Only the USP monographs 
include a minimum content test by UHPLC, which sums up peaks of 10 different triterpene 
acids and expresses them as ganoderic acid A.  
The HPTLC method from USP (which is also included in the American Herbal 
Pharmacopoeia [14] and the method collection of the HPTLC Association [15]) is suitable 
for identification of Ganoderma lucidum fruiting body. However, with respect to separation 
of ganoderic acids the method published by Xie and Yun [14] gives superior results.  
The selectivity of these two methods as well as the results of the USP UHPLC assay were 
included as benchmarks for the development of a new approach combining identification 
of the herbal drug with quantification of its minimum content on triterpene acids, based on 
the concept of “HPTLC comprehensive fingerprinting” [11]. 
7.4.1 Optimization of the HPTLC parameters 
Changing the mobile phase of the USP HPTLC method (toluene, ethyl formate, formic acid 
25:25:1 v/v/v) [7] (Figure 7.1 A) to toluene, tetrahydrofuran, acetic acid (70:30:1 v/v/v) 
afforded superior separation of triterpene acids and thus improved the quantification of 
these compounds (Figure 7.1 C). In comparison to the gradient elution method of Xie and 
Yun [16] (Figure 7.1 B), the achieved resolution is comparable, but due to the use of 
standard HPTLC equipment the method is technically much simpler and thus easier to 
reproduce.  
 
Figure 7.1 Fingerprints of USP G. lucidum reference extract, developed with USP [7] (A) and Xie 
and Yun [129] (B) methods, and the new mobile phase (C). Images under UV 254 nm prior to 
derivatization (Track 1) and UV 366 nm after derivatization (track 2). Zones within the orange 
bounds are due to triterpene acids.  





7.4.2 Extraction method  
With the goal of selecting a simple, rapid, and robust quantitative extraction method that 
can be compared to the 45 min extraction under reflux used in the USP assay of triterpene 
acids in GLFB [7], 5 procedures were evaluated. Aliquotes of the same samples were 
extracted by shaking or sonication for different times in duplicate keeping the extraction 
ratio at 80 mg of powdered drug per 1 mL of ethanol (see supplementary information, 
Table 7S2, for description of the sample preparation methods). After chromatography the 
efficiency of extraction was evaluated based on the comparison of the intensity of the 
peaks between RF 0.1 and 0.5 of the PPI under UV 254 nm prior to derivatization. Results 
were similar for all methods (see supplementary information, Figure 7S1). Fifteen minutes 
shaking at room temperature (22±5°C) was chosen as final extraction for its simplicity and 
low susceptibility to temperature change (e.g., increase of temperature in the ultrasonic 
bath during sonication).  
7.4.3 Derivatization procedure 
Derivatization with sulfuric acid reagent is an important step for proper identification of 
GLFB. As shown in Figure 7.2, some nonpolar substances in the upper RF range can only 
be seen after derivatization. Most of the triterpene acids (between RF 0.1 and 0.5) develop 
colored zones that are more intense than prior to derivatization. This facilitates visual 
evaluation of the samples. It was observed during evaluation of extraction, that the color 
of the zone due to the ganoderic acid A standard after derivatization varied between the 
analyses, indicating instability during and after this step. Therefore, the influence of the 
following parameters on the color of the zones were investigated: 1) preparation of sulfuric 
acid reagent in methanol versus ethanol; 2) stability of the color and intensity of the zones 
after derivatization with time. 
 
Figure 7.2 HPTLC of ergosterol, ganoderic acids D, B, A. G and C2 (prepared at 1 mg/mL) and 2 
samples of G. lucidum fruiting body (GL13 and GL12, respectively) under UV 254 nm prior to deriva-
tization (left) and UV 366 nm after derivatization (right). Standards on tracks 1, 3 and 6 show more 
than one zone due to impurities. 
In the first experiment post-derivatization stability of the fingerprint was evaluated on plates 
derivatized with 10% sulfuric acid in methanol and ethanol, respectively. The developed 
plates were dipped into freshly prepared reagent, dried for 1 minute at room temperature 
and then heated at 100°C for 3 minutes. After derivatization, images were recorded at 3, 
6, 9, 12, 15, 18, 21 and 60 minutes. It was found that with time methanolic sulfuric acid 
yields less change in color than ethanolic sulfuric acid. Stability was reached nine minutes 
after derivatization. At this point in time the intensity of the zones changed only marginally 
(supplementary information, Figures 7S2, 7S3, 7S4).  
7.4.4 Choice of the detection modes for quantitative assessments 
As observed in Figure 7.2, ganoderic acids D, B, A, G and C2 are detected as standards 





and in the samples prior to and after derivatization. Other zones between 0.1 and 0.5 were 
not identified due to the lack of standards. Nevertheless, their UV spectra in a pooled 
sample were recorded and compared with those of ganoderic acids. The similarity of the 
UV spectra and RF values suggests that these zones are due to ganoderic acids, and thus 
will be used for quantification of total triterpene acids (see supplementary information, 
Figures 7S5 and 7S6)  
Selection of the most suitable PPI for quantification was based on the response of 
ganoderic acid A at 0.25 mg/mL, applied at four different positions on the plate. After 
chromatography, the (CV) for the corresponding peak areas was calculated. CV was low 
prior to derivatization (1.2%), while after derivatization it reached 12.3%. Therefore, the 
PPI prior to derivatization are used for quantitation, while the images after derivatization 
(under UV 366 nm) are used for identification. 
Quantitation based on PPI was compared to peak profiles from scanning densitometry 
(PPDS) at 260 nm, selected for detection based on the absorption maximum of the 
ganoderic acids (Figure 7S5, supplementary information).  
7.4.5 Evaluation of samples with optimized HPTLC method  
Fifty samples of GLFB were analyzed with the optimized HPTLC method. Their fingerprints 
were compared to that of a USP reference extract prepared at 10 mg/mL. Results are 
presented in Figure 7.3.  
 
Figure 7.3 Fingerprints of fifty samples of Ganoderma lucidum fruiting body (GL) and the USP 
extract (GLe) under UV 366 nm after derivatization.  
Half of the samples (GL2-27) show fingerprints similar to that of the USP reference extract 
(GLe). Four of them show very faint or no zones in the upper third of the chromatogram, 
such as ergosterol (GL9, 25-27). Two samples (GL1-2) present additional yellow zones in 
the lower third of the chromatogram. Sample GL1 presents different proportions of the 
triterpene acids, compared to the reference extract. Samples GL28-50 lack either one or 
more yellow zone(s) due to triterpene acids, a zone at the position of ganoderic acid A or 
all of them (only triterpenes in the upper part of the chromatogram and some other faint 
zones are present). Therefore, samples GL2-8, 10-24 were considered compliant with the 
USP specifications (fingerprint similar to that of the reference extract). Samples GL1, 9, 
25-27 were considered of questionable quality and GL 28-50 were considered not 
compliant with USP specifications because they lack zones of triterpene acids.  





7.4.6 Specificity of the optimized HPTLC method 
The specificity of the proposed method was evaluated based on its capacity to distinguish 
fruiting bodies of Ganoderma lucidum from fruiting bodies of other mushrooms. None of 
the 13 species shown in Figure 7.4 show quenching zones or yellow and green zones due 
to triterpene acids prior to (A) and after derivatization (D), respectively. Instead, they 
feature zones in the upper third of the chromatogram or at the application position, which 
might be used to detect their presence in mixtures with G. lucidum. The optimized method 
proved to be specific for GLBF.  
 
Figure 7.4 Fingerprints of fruiting bodies of Ganoderma lucidum and other mushroom species 
under UV 254 nm (A; enhanced, contrast 4.0) and 366 nm (B) prior to derivatization, and white light 
(C) and UV 366 nm (D) after derivatization. Tracks 1: fruiting body samples of G. lucidum (GL), 2: 
G. applanatum (GA), 3: G. sinensis (GS), 4: Inonotus obliquus (IO), 5: Hericium erinaceus (HE), 6: 
Grifola frondosa (GF), 7: Fomes fomentarius (FF), 8: Coprinus comatus (CC), 9: Cordyceps 
sinensis (CS), 10: Agaricus blazei (AB) 11: Lentinus edodes (LE), 12: Phellinus linteus (PL), 13: 
Pleurotus spp. (PS), 14: Tremella fuciformis (TF).  
7.4.7 Quantitative assessment 
Like the UHPLC assay of ganoderic acids of the USP monograph, HPTLC can determine 
a sum of peaks (total triterpene acids) in the chromatogram (PPI), calculated as ganoderic 
acid A. In the proposed method, triterpene acids migrate to positions between RF 0.1 and 
0.5 (Figure 7.2).  
7.4.7.1 Linear range of ganoderic acid A 
The linear range of ganoderic acid A was determined from PPI under UV 254 nm and 
PPSD at UV 260 nm based on a dilution series prepared at concentrations between 0.02 
and 0.15 mg/mL (100-750 ng/zone), with increments of 0.01 mg/mL per level. The linear 
range of ganoderic acid A under both detections was between 0.04 - 0.10 mg/mL (200-
500 ng/zone). The calibration curves are shown in the supplementary information, Figure 
7S7.  
7.4.7.2 Determination of ganoderic acid A in the USP reference extract by 
multilevel calibration 
To prove that the HPTLC method yields results comparable to that of the UHPLC method, 
the content of ganoderic acid A was quantified in the USP reference extract and compared 
to the value specified in the certificate of analysis. For that, a five level calibration curve of 
ganoderic acid A, ranging from 200 to 500 ng/application was used. Results obtained with 
HPTLC method were 1.0% (PPI) and 1.0% (PPSD), were close to the declared content of 
0.9%. 





7.4.7.3 Linear range of triterpene acids in G. lucidum fruiting body 
The linear range for each of the main peaks between RF 0.1 and 0.5 in GLFB was deter-
mined, in order to find a suitable concentration of the test solution for quantification. The 
goal was to obtain a fingerprint in which all the main peaks are within linear range, and 
their sum can be calculated against a single level calibration. First, samples available in 
large quantities with fingerprints similar to that of the USP reference extract (GL9, 13, 14, 
16, 19, 20, and 23) were pooled to create an average sample. The pooled sample was 
prepared at 80 mg/mL with the optimized extraction method. Fifteen dilutions were 
prepared from this stock solution, at concentrations between 6 and 80 mg/mL. Each of the 
seven peaks within the selected RF range (Figure 7.5) was integrated manually using the 
perpendicular drop method. The baseline correction was done automatically by the 
software between RF 0.1 and 0.5 (Figure 7.5). Calibration curves were built for each zone 
by plotting the area of the corresponding peak against the concentration of the test 
solution. Linearity was calculated for each peak and is shown in Table 7S3 (supplementary 
information). The test solution at concentration of 80 mg/mL used for identification is within 
the linear range. Therefore, the same test solution can be used for identification and 
quantification.  
 
Figure 7.5 Illustration of the peaks evaluated for linearity and quantification of G. lucidum samples. 
Profile under UV 254 nm (enhanced image, contrast 2.1), PPI and PPSD of the pooled sample.  
7.4.7.4 Quantification of triterpene acids 
According to the USP monograph, GLFB should contain not less than 0.3% (weight 
percent) of total triterpenoic acids, calculated as a sum of ganoderic acids A, B, D2, D, F, 
G and H and ganoderenic acids B, C and D [7]. The same acceptance criterion was 
implemented for quantitative HPTLC.  





Good correlation is observed between PPI and PPSD at 260 nm, which was recorded for 
comparison (Table 7.2). 
Of the fifty samples, twenty-eight (GL1-7, 9-25, 28-30 and 44) show a content of triterpene 
acids equal to or higher than 0.3%. Of these, twenty-one (GL2-7, 10-24) show a fingerprint 
similar to that of USP reference extract (Figure 7.2). Samples GL1, 9 and 25 show ques-
tionable fingerprints during identification. Even though samples GL 28-30 and 40 pass the 
assay, they lack yellow zones due to triterpene acids in the identity test. Three samples 
(GL 32, 38-39) have borderline content (between 0.27% - 0.29%) in one or both detections, 
but their identity is not matching the USP reference extract. Of the nineteen samples that 
have less than 0.27% of triterpene acids in one or both detections, one (GL8) shows a 
fingerprint similar to that of the USP reference extract, two are questionable samples 
(GL26 and 27), and sixteen (GL31, 33-37, 40-43, 45-50) lack one or more triterpene acids 
zones. 
Based on the USP acceptances criteria for the assay and identity test, twenty-one samples 
(02-07, 10-24) are considered compliant. All other samples fail one or both tests.  
Table 7.2  Results of quantification of 50 samples of GLFB 
Sample 




Total amount of triterpene 
acids (%) 
 254 nm (PPI) 260 nm (PPSD)   254 nm (PPI) 260 nm (PPSD) 
GL1 0.40 0.39  GL26 0.24 0.23 
GL2 0.48 0.51  GL27 0.23 0.24 
GL3 0.64 0.63  GL28 0.45 0.51 
GL4 0.38 0.36  GL29 0.47 0.48 
GL5 0.30 0.32  GL30 0.39 0.37 
GL6 0.42 0.41  GL31 0.22 0.20 
GL7 0.48 0.53  GL32 0.27 0.31 
GL8 0.25 0.23  GL33 0.18 0.20 
GL9 0.36 0.39  GL34 0.09 0.12 
GL10 0.61 0.59  GL35 0.08 0.08 
GL11 0.46 0.43  GL36 0.11 0.10 
GL12 0.40 0.38  GL37 0.09 0.08 
GL13 0.51 0.54  GL38 0.28 0.29 
GL14 0.38 0.44  GL39 0.25 0.27 
GL15 0.35 0.32  GL40 0.23 0.19 
GL16 0.52 0.56  GL41 0.21 0.19 
GL17 0.35 0.34  GL42 0.22 0.22 
GL18 0.32 0.32  GL43 0.15 0.15 
GL19 0.35 0.39  GL44 0.58 0.62 
GL20 0.43 0.50  GL45 0.20 0.23 
GL21 0.30 0.32  GL46 0.25 0.24 
GL22 0.50 0.48  GL47 0.12 0.09 
GL23 0.31 0.33  GL48 0.10 0.06 
GL24 0.58 0.62  GL49 0.14 0.15 
GL25 0.59 0.62  GL50 0.05 0.07 
7.4.7.5 Repeatability of the quantification method 
The repeatability of the chromatographic quantification of triterpene acids was evaluated 
in a single sample (n=6). It shows a CV of 1.2% for PPI and 3.1% from PPSD. 





7.4.8 Setting new acceptances criteria for identity and minimum content 
The development of a new method requires the establishment of new acceptance criteria. 
This is because the sequence of zones evaluated for identification has changed (Figure 
7.1). A new description of the HPTLC fingerprint is proposed in Figure 7.6, based on an 
image (GLm) that was generated by electronically merging all passing samples (GL2-8, 
GL10-24). Other faint zones not described may be present. Passing samples should 
contain at least the zones (c) to (h).  
For the assay, the quantification data of samples that pass the identification test (GL2-8 
and 10-24) were considered. Based on the lowest value for total triterpene acids in the PPI 
of these samples, the minimum content expressed as ganoderic acid A is proposed at 
0.25%. 
 
Figure 7.6 Fingerprints of G. lucidum pooled sample (GLm) and USP G. lucidum extract (GLe) 
under UV 366 nm after derivatization, and their description in the format of a table.  
7.4.9 Economic aspects of the proposed method 
The proposed HPTLC method is an economic alternative for evaluation of the quality of 
GLFB. It allows identification, purity testing and quantification of triterpene acids, all in one 
analysis, and thus reduces the number of tests to be performed (e.g. UHPLC assay). The 
economic aspects of the new method in comparison to the approach of the USP 
monograph (HPTLC for identification and UHPLC for the assay of total triterpene acids) 
are presented in  
Table 7.3. Costs of the analysis, volume of solvent and time were calculated for 1-13 
samples (the capacity of each HPTLC plate plus one standard and one track for the refe-
rence extract). The total analysis cost and time per sample for the new HPTLC method 
were calculated based on the added costs/time of preparation and analysis of one sample. 
For the USP methods (HPTLC and UHPLC), the costs/time for sample preparation and 
analysis of one sample were combined. For the UHPLC method, cost/time of an additional 
run for one standard solution was added to the calculation. Details of all calculation are 
described in supplementary information.  
Also, the proposed sample preparation method is faster, less expensive and uses less 
solvent than those of USP HPTLC and UHPLC. Furthermore, the new HPTLC method is 
more than 1.5 times shorter, uses 8 times less solvent, and costs about 75% of the UHPLC 
analysis of 1 sample. For the same kind of information to be obtained, the costs of the 
USP HPTLC and UHPLC methods need to be combined. While for the HPTLC methods, 





the fixed cost of the analysis remains the same for one to thirteen samples, for the UHPLC 
method the costs per sample are additive.  
Table 7.3 Comparison of different economic aspects and time consumption of the new HPTLC 
method with the methods of USP (HPTLC and UHPLC) 
 New HPTLC 
method 
USP – HPTLC 
ID method  
USP – UHPLC 
method 
Sample preparation time (approxi-
mately) per sample 
23 minutesa 35 minutesa 
> 60 minutesb (ex-
cluding SPE) 
Volume of solvent (sample prepa-
ration) per sample 
5 mL 52 mL 
120 mL (excluding 
SPE) 
Approximate cost for preparation 
of one sample 
1.0 CHF 4.70 CHF 
11.90 CHF (ex-
cluding SPE) 
Number of samples and reference 
solutions analyzed per run 
13 samples + 2 
references  
13 samples + 2 
reference 
1 sample or refe-
rence 
Analysis time for 1-13 runs (equi-
valent to one plate) 
90 min 82 min 
(58 to 754) + 58 
min 
Approximate cost for the analysis 
of 1-13 samples (equivalent to 
one plate) 
26.10 CHF 33.60 CHF 
(12.00 to 156.00) 
+ 12.00 CHF 
Volume of solvent used for the 
analysis of 1-13 samples, plus re-
ference extract and substance 
20 mL 50 mL 
(23.2 to 301.6) + 
23.2 mL 
Total analysis costs of one 
sample 
27.10 CHF 74.20 CHF 
Total analysis costs per 13 samples 39.10 CHFa 417.40 CHFa,b 
Total analysis time per sample 113 minc 293 mind 
Total analysis time per 13 samples 113 minc 1349 mind 
a Samples prepared in parallel; b 2 samples prepared in parallel; cost and analysis time for the new 
HPTLC methodc, and for the USP HPTLC and UHPLC methods combinedd. Swiss Francs (CHF). 
7.4.10 The future 
The use of pattern recognition tools can facilitate the routine quality control analysis of 
herbals and transfer the knowledge of experts into machines. By using existing 
descriptions of the HPTLC fingerprints, e.g. those in the style of the European 
Pharmacopoeia, which are similar to that in Figure 7.6, it is possible to automate the 
identification of samples. For example: a prototype functionality of the visionCATS 
software, used for identification of GLFB, allows entering peak information such as RF, 
acceptable ∆RF, color appearance value (Hue), variation in color appearance (∆Hue) and 
intensity. In this experiment, the USP reference extract was used as reference for the 
pattern. The peaks (c) to (h) were included in the acceptance criteria. The parameters for 
each peak are described in Table 7.4. Based on the information given to the software, all 
samples that passed or failed the visual evaluation also passed or failed the software 
evaluation. One exception is sample GL20, in which the zone (c) presents different color 
than ergosterol and was rejected by the software. Visual and software interpretations were 
very similar for zones present or absent (see Table 7S4 in supplementary information).   
Table 7.4 Values of RF, colors and intensity used for pattern recognition for each peak.  
Peaks from  




(c) 0.59 0.03 0.585 0.05 0.05 
UV 366 nm 
after 
derivatization 
(d) 0.35 0.02 0.560 0.12 0.05 
(e) 0.30 0.02 0.400 0.20 0.05 
(f) 0.25 0.02 0.400 0.20 0.05 
(g) 0.19 0.02 0.576 0.20 0.05 
(h) 0.15 0.02 0.400 0.20 0.05 





In addition, it is possible to describe the quality of an herbal more holistically, taking into 
account its entire fingerprint. In this type of assessment, the presence or absence of peaks 
in the chromatogram and their intensities are compared to the specifications, which are 
displayed in the shape of a “window” (e.g. Figure 7.7, dotted grey lines).  
 
Figure 7.7 Acceptance window model to evaluate quality of Ganoderma lucidum fruiting body. A: 
Example of GIe – passes test. B: two examples that fail tests (GL1 and 39). Arrows indicate zones 
of profiles that are out of the acceptance criteria. PPI from image after derivatization under UV 366 
nm. 
Such evaluation can be done using a suitable software (e.g. Microsoft Excel) and the RF 
and intensity in arbitrary units (a.u.) values from the PPI. To set the acceptance criteria, 
the passing samples (GL2-8, 10-24) are used as references. The lowest and the highest 
intensity values for each RF among these samples are used to create the lower and upper 
limits of the “acceptance window”. The acceptance criteria were defined so that 95% of 





the whole profile is within that “window” to be immune to slight RF shifts and very intense 
signals at the application position. In order to define the acceptance range every profile 
has to be normalized to its surface to emphasize the shape of the profile. Additionally, this 
normalization avoids that the range between lower and upper limit depends on 
concentrated or faint signals, which limits the specificity of the “acceptance window”. A 
profile of an unknown sample has to be normalized prior to evaluation. An average PPI 
was created based on these twenty-two samples (black line, Figure 7.7). 
The new model was tested with the 50 samples and USP reference extract. The passing 
samples and the USP reference extract were within the acceptance window (e.g. GLe, 
green profile Figure 7.7 A). All the samples that have failed the visual and peak evaluation 
in the previous section (GL1, 8, 25-50) showed zone(s) above and/or below the 
acceptance range, as observed in the examples of Figure 7.7 B (orange and blue profiles). 
Sample GL1 (orange profile) shows additional zones (orange arrows), absent in the 
reference fingerprints of GLFB. Sample GL39 (blue profile) shows no zone at the position 
of ganoderic acid A (RF 0.19) and at RF 0.30, and a zone at RF 0.80 more intense than this 
of the acceptance range. A good correlation between the visual evaluation and the window 
model was observed.  
7.5 Conclusion 
The presented HPTLC method offers a simplified yet comprehensive assessment of 
quality of Ganoderma lucidum fruiting body. On the same plate and in one analysis, using 
the same reference substances as the USP monograph (USP ganoderic acid A and 
Ganoderma lucidum powdered dry extract RS), a sample can be identified, the presence 
of confounding species can be excluded and the minimum content of triterpene acids 
expressed as ganoderic acid A can be established. Applying standard HPTLC conditions 
and analyzing 13 samples per plate, analysis time is 113 min (for 1-13 samples, including 
sample preparation) and cost for chromatography per sample is 27.10 CHF. Further 
validation of the quantitative method under routine conditions is pending.  
Disclosure statement 
The authors declare that they have no competing interests 
7.6 References 
[1] He, T.-T.; Ung, C. O. L.; Hu, H.; Wang, Y.-T. Good manufacturing practice (GMP) regulation of 
herbal medicine in comparative research: China GMP, cGMP, WHO-GMP, PIC/S and EU-GMP. 
Eur. J. Integr. Med. 2015, 1, 55–66. 
[2] Cavaliere, M. and Blumenthal, M. Review of FDA’s Final GMPs for Dietary Supplements. 
HerbalGram. 2007, 76, 58–61. 
[3] World Health Organization (WHO). WHO guidelines on good manufacturing practices (GMP) for 
herbal medicines; WHO Library Cataloguing in Publication Data: Geneva, 2007. 
[4] Keitel, S. Inside EDQM: The Role of the Pharmacopeia in a Globalized World. Pharmtech. 2010, 
34, 4. 
[5] World Health Organization (WHO). Review of world Pharmacopoeias. In International Meeting 
of World Pharmacopoeias, Geneva, March 01-03.2012. 
[6] Folcarà, S. C. Medicamentod a Base de Plantas: el Reto de la Calidad y la Framacopea como 
Hierramenta para Alcanzarla. Revista de Fitoterapia. 2013, 13, 2, 101–122. 
[7] Monographs for Ganoderma lucidum Fruiting Body and Ganoderma lucidum Fruiting Body 
Powder. In The United States Pharmacopoeia (USP) 41–NF36. United States Pharmacopeial: 
Rockville, USA, 2018, pp. 4629–4635. 
[8] Ahmad, M. F. Ganoderma lucidum: Persuasive biologically active constituents and their health 
endorsement. Biomedicine and Pharmacotherapy. 2018, 107, 507–519. 
[9] Chapter 203: High-Performance Thin-Layer Chromatography procedure for identification of 





articles of botanical origin. In United States Pharmacopoeial Convention 40–NF35. United 
States Pharmacopeial: Rockville, USA, 2017, pp. 258–260. 
[10] European Directorate for the Quality of Medicines and Healthcare (EDQM). Chapter 2.8.25: 
High-performance thin-layer Chromatography of herbal drugs and herbal preparations. In 
European Pharmacopoeia, 9.0. European Pharmacopoeia: Strassbourg, France, 2017, pp. 
295–296. 
[11] Frommenwiler, D. A.; Kim, J.; Yook, C.-S.; Tran, T. T. T.; Cañigueral, S.; Reich, E. 
Comprehensive HPTLC Fingerprinting for Quality Control of an Herbal Drug – The Case of 
Angelica gigas Root. Planta Medica, 2018, 84, 6-07, 465-474. doi: 10.1055/a-0575-4425. 
[12] Chinese Medicine Regulatory Office. Ganoderma. In Hong Kong Chinese Materia Medica 
Standards, Vol. 9; Chinese Medicine Division, Department of Health Government of the Hong 
Kong Special Administrative Region: Wanchai, Hong Kong, 2005, pp. 99–123. 
[13] Chinese Pharmacopoeia Commission. Monograph for Ganoderma (Lingzhi). In 
Pharmacopoeia of the people’s Republic of China. The Stationery Office: Beijing, China, 2015, 
pp. 205–206. 
[14] Upton, R.; Graff, A.; Länger, R.; Sudberg, S.; Sudberg, E.; Williamson, E.; Reich, E.; Bieber, 
A.; Mattioda, J.; Mutch, J.; Chen, J. Reishi Mushroom (Ganoderma lucidum),” in American 
Herbal Pharmacopoeia (AH) and Therapeurical Compendium, R. Upton and C. Petrone, Eds. 
Scotts Valley: The American Herbal Pharmacopoeia, 2000, pp. 1–24. 
[15] The International Association for the Advancement of High Performance Thin Layer 
Chromatography (HPTLC Association). Ganoderma lucidum - fruiting body. https://www.hptlc-
association.org/methods/methods.cfm (accessed Nov 15, 2019). 
[16] Xie P.; Yun, Y. Chromatographic fingerprints for the detailed illustration of the quality of herbal 
medicines; Fujian Science and Technology Press: Beijing/China, 2010 
 





7.7 Supplementary information 
Table 7S1 Description of investigated samples. 
Sample CAMAG Batch Description County  
GL1 S16791 Ganoderma lucidum fruiting body US 
GL2 S13014 Ganoderma spp. Unknown 
GL3 S16790 Ganoderma lucidum fruiting body US 
GL4 S17874 Reishi mushroom - Stem, pores pileal layer Canada 
GL5 S16484 Ganoderma lucidum fruiting body Unknown 
GL6 S18406 Ganoderma lucidum fruiting body US 
GL7 S18405 Ganoderma lucidum fruiting body Unknown 
GL8 S18403 Ganoderma lucidum fruiting body US 
GL9 S12211 Ganoderma lucidum fruiting body US 
GL10 S16726 Ganoderma lucidum fruiting body powder Germany 
GL11 S12215 Ganoderma spp. US 
GL12 S12018 Ganoderma lucidum fruiting body powder China 
GL13 S12016 Ganoderma lucidum fruiting body powder China 
GL14 S2351 G. lucidum fruiting body cultivated on Duan wood Unknown 
GL15 S16485 Ganoderma lucidum fruiting body Unknown 
GL16 S12014 Ganoderma lucidum fruiting body powder China 
GL17 S12214 Ganoderma spp. US 
GL18 S12015 Ganoderma lucidum fruiting body powder China 
GL19 S16725 Ganoderma lucidum fruiting body powder Germany 
GL20 S12020 Ganoderma lucidum fruiting body powder US 
GL21 S16663 Ganoderma lucidum fruiting body Canada 
GL22 S15945 Ganoderma lucidum fruiting body France 
GL23 S17873 Reishi mushroom - Stem, pores pileal layer Canada 
GL24 S16594 Ganoderma lucidum fruiting body  China 
GL25 S16592 Ganoderma lucidum fruiting body  China 
GL26 S16589 Ganoderma lucidum fruiting body  China 
GL27 S16595 Ganoderma lucidum fruiting body  China 
GL28 S12024 Ganoderma lucidum fruiting body powder US 
GL29 S2353 Ganoderma lucidum fruiting body  Unknown 
GL30 S12017 Ganoderma lucidum fruiting body powder China 
GL31 S2347 Ganoderma lucidum fruiting body  Unknown 
GL32 S17872 Reishi mushroom - Stem, pores pileal layer Canada 
GL33 S16662 Ganoderma lucidum fruiting body Canada 
GL34 S16680 Ganoderma lucidum fruiting body  Germany 
GL35 S16817 Ganoderma spp. fruiting body ROK 
GL36 S16795 Ganoderma lucidum fruiting body US 
GL37 S16799 Ganoderma lucidum fruiting body US 
GL38 S12026 Ganoderma lucidum fruiting body powder US 
GL39 S16794 Ganoderma lucidum fruiting body powder US 
GL40 S16793 Ganoderma lucidum fruiting body powder US 
GL41 S16798 Ganoderma lucidum fruiting body powder US 
GL42 S16792 Ganoderma lucidum fruiting body, whole US 
GL43 S16797 Ganoderma lucidum fruiting body US 
GL44 S16789 Ganoderma lucidum fruiting body (antler form) US 
GL45 S2357 G. lucidum fruiting body cultivated on Duan wood Unknown 
GL46 S12027 Ganoderma lucidum fruiting body powder US 
GL47 S18404 Ganoderma lucidum fruiting body powder Unknown 
GL48 S2355 Ganoderma lucidum fruiting body powder Unknown 
GL49 S1202S2 Ganoderma lucidum fruiting body powder US 
GL 50 S12025 Ganoderma lucidum fruiting body powder US 
GLe S18403 
G. lucidum fruiting body reference extract (USP) Lot 
#F012B0 
US 
Gle1 R11732 G. lucidum fruiting body extract (USP), Lot #B120665 US 
Gle2 S17878 G. lucidum mushroom extract Canada 





Sample CAMAG Batch Description County  
Gle3 S18014 G. spp entire mushroom extract Canada 
Gle4 S17879 G. lucidum mushroom extract Canada 
GLe5 S17877 G. lucidum mushroom extract Canada 
GLe6 S17876 G. lucidum mushroom extract Canada 
GLe7 S16756 G. lucidum mushroom extract US 
GLe8 S16737 G. lucidum mushroom extract Germany 
GLe9 S17881 G. lucidum mushroom extract Canada 
GA S12028 Ganoderma applanatum fruiting Body wildcrafted  US 
GS S16815 Ganoderma sinensis reference extract US 
IO S16828 Inonotus obliquus fruiting body US 
HE S16685 Hericium erinceus fruiting body Germany 
GF S16643 Grifola frondosa fruitning body US 
FF S16687 Fomes fomentarius fruiting body powder Germany 
CC S16675 Coprinus comatus fruiting body Germany 
CS S16681 Cordyceps sinensis fruiting body Germany 
AB S16674 Agaricus balzei fruiting body Germany 
LE S16676 Lentinus edodes fruiting body Germany 
PL S16678 
Phellinus linteus (maybe F. fomentarius) fruiting 
body 
Germany 
PS S16686 Pleurotus spp. fruiting body powder Germany 
TF S16683 Tremella fuciformis fruiting body Germany 
 
Table 7S2 Description of the six tested extraction methods. 
Method 
description 
400.0 mg of powdered G. lucidum fruiting body were mixed with 5.0 mL of 
solvent and then prepared according to the method. After centrifugation, the 





USP reflux 3 and 4 Solvent: ethanol; method: sonicated for 30 minutes at 60°C  
Sonication 
15 minutes 
5 and 6 Solvent: ethanol; method: sonicated for 15 minutes  
Sonication 
30 minutes 
7 and 8 Solvent: ethanol; method: sonicated for 30 minutes 
Shaking  
15 minutes 
9 and 10 Solvent: ethanol; method: shaken for 15 minutes  
Shaking 
30 minutes 
11 and 12 Solvent: ethanol; method: shaken for 30 minutes  
Sonication 30 
min, 60°C 
13 and 14 Solvent: ethanol; method: sonicated for 30 minutes at 60°C 
 
Table 7S3 Concentration ranges of GLFB pooled test solution in which the relevant peaks are within 




UV 254 nm (PPI) UV 260 nm (PPSD) 
Concentration 
of test solution 
in mg/mL 
Amount of sample 
on the plate in µg 
(absolute) 
Concentration 
of test solution 
in mg/mL 
Amount of sample 
on the plate in µg 
(absolute) 
1 25-80 125-400 15-80 75-400 
2 25-80 125-400 20-80 100-400 
3 15-80 75-400 20-80 100-400 
4 15-80 75-400 15-80 75-400 





5 15-80 75-400 20-80 100-400 
6 15-80 75-400 20-80 100-400 
7 25-80 125-400 20-80 100-400 
 
Table 7S4 Assessment of the identity of G. lucidum by a pattern recognition software, based on the 
presence of six zones in the fingerprint after derivatization under UV 366 nm.  
Sample CAMAG Batch Pass/fail (c) (d) (e) (f) (g) (h) 
GL1 S16791        
GL2 S13014        
GL3 S16790        
GL4 S17874        
GL5 S16484        
GL6 S18406        
GL7 S18405        
GL8 S18403        
GL9 S12211        
GL10 S16726        
GL11 S12215        
GL12 S12018        
GL13 S12016        
GL14 S2351        
GL15 S16485        
GL 16 S12014        
GL 17 S12214        
GL 18 S12015        
GL 19 S16725        
GL 20 S12020        
GL 21 S16663        
GL 22 S15945        
GL 23 S17873        
GL 24 S16594        
GL 25 S16592        
GL 26 S16589        
GL 27 S16595        
GL 28 S12024        
GL 29 S2353        
GL 30 S12017        
GL 31 S2347        
GL 32 S17872        
GL 33 S16662        
GL 34 S16680        
GL 35 S16817        
GL 36 S16795        
GL 37 S16799        
GL 38 S12026        
GL 39 S16794        
GL 40 S16793        
GL 41 S16798        
GL 42 S16792        
GL 43 S16797        
GL 44 S16789        
GL 45 S2357        
GL 46 S12027        
GL 47 S18404        
GL 48 S2355        
GL 49 S1202S2        





Sample CAMAG Batch Pass/fail (c) (d) (e) (f) (g) (h) 
GL 50 S12025        





Figure 7S1 Comparison of the intensity of the main peaks between RF 0.1 and 0.5 of sample GL33, 
























Figure 7S2 Image of the plate derivatized with 10% sulfuric acid in ethanol, taken at different times. 
Track 1: ganoderic acid A 0.5 mg/mL; track 2: GL7; track 3: USP G. lucidum extract (GLe1); track 
4: G. lucidum USP reference extract (GLe); track 5: G. lucidum USP reference extract (1 µL 
application volume); tracks 6-13: G. lucidum extract samples GLe2-9, respectively.  
 
  









Figure 7S3 Images of the plate derivatized with 10% sulfuric acid in methanol, taken at different 
times. Track 1: ganoderic acid A 0.5 mg/mL; track 2: GL7; track 3: USP G. lucidum extract (GLe1); 
track 4: G. lucidum USP reference extract (GLe); track 5: G. lucidum USP reference extract (1 µL 
application volume); tracks 6-13: G. lucidum extract samples GLe2-9, respectively.  






Figure 7S4 Profiles of G. lucidum fruiting body USP reference extract (R11732), recorded between 
3 and 18 minutes after derivatization. 
  
Figure 7S5 UV spectra (overlaid) of ganoderic acids A, B, D, G, C2 prior to derivatization 
(absorption mode).  
 
Figure 7S6 UV spectra (overlaid) of eight peaks between RF 0.1 and 0.5 and ergosterol, prior to 
derivatization (absorption mode) in the pooled sample.  
 






Figure 7S7 Calibration curve for Ganoderic acid A in the range 0.04 to 0.1 mg/mL. Left image: PPI 
at UV 254 nm prior to derivatization; right image: PPSD at UV 260 nm prior to derivatization. 
Calculation of the costs and time for preparation and analysing the samples 
The prices per mL of high-purity solvent (used to prepare the mobile phase and samples), 
of the stationary phases and single use disposable material were obtained from Sigma 
Aldrich, Merck and Alcosuisse websites: https://www.sigmaaldrich.com /switzerland-
suisse.html; http://www. merckmillipore.com/CH/de; and https://www.alcosuisse.ch/ 
(accessed on 20.12.2019).  
Calculation excludes instruments, glass apparatus, personal and solid phase extraction 
SPE (in the case of UHPLC analysis). 
a. Preparation cost per sample: the prices per mL of solvent used in each method and 
single use disposable material such as centrifuge tubes, plastic pipettes, and syringe 
filter, were used for calculation. 
b. Preparation time per sample: This calculation was done mainly based on the 
extraction time and other steps (such as centrifugation or filtration and precise 
weighing). Milling time was excluded from calculation.  
c. Analysis cost for 1-13 samples: The costs for HPTLC analyses were calculated 
based on the volume of solvent used per plate and the price of a single plate. This 
calculation excluded the price per filter paper because it is not predictable how 
many times a single sheet can be used for the USP HPTLC method.  The costs for 
UHPLC analyses were calculated for 1-13 samples, based on the volume of solvent 
used per run (including equilibration and cleaning steps) plus one run for the 
standard solution and the cost of a UHPLC column shared by 1000 runs.  
d. Analysis time per sample: For the HPTLC methods, the time spent in each step 
was used for the calculation (e.g. application, development, documentations, 
derivatization). For the UHPLC analysis, this calculation was done based on the 
gradient time plus 10 minutes for equilibration before the first run. 





e. Total analysis cost/time per sample: The total cost/time for the new HPTLC 
analyses was calculated based on the cost/time for preparation of one sample, plus 
the analysis cost/time one plate (with capacity for 1-13 samples). The cost/time for 
the USP analysis (combined HPTLC plus UHPLC) was calculated based on the 
added cost/time for preparation of one sample with both methods, plus the added 
cost/time for the HPTLC analysis of 13 samples and UHPLC analysis of 1 sample 
plus 1 standard solution. 
f. Total analysis cost/time per 13 samples: The cost/time for the new HPTLC 
analyses was calculated based on the cost/time for preparation of one sample 
multiplied by 13, plus the analysis cost/time for one plate. The cost for the USP 
analysis (combined HPTLC plus UHPLC) was calculated based on the added cost 
for preparation of one sample with both methods multiplied by 13, plus the added 
cost for the analysis of 13 samples with both methods. For the UHPLC method the 
cost of one run (for the standard solution) was added. The total analysis time for 
the USP method was calculated based on the sample preparation time of one 
sample (13 samples were prepared in parallel) for the HPTLC method, plus the 
preparation time of 7 samples (2 samples were prepared in parallel) for the UHPLC 
method, plus the analysis time for the 13 samples with each method, and plus the 


































8.1.1 The evolution of HPTLC in the context of the Pharmacopoeias 
Quality control of herbal drugs has its roots in botanical morphology and organoleptic 
testing. One of the first chemical methods used in the quality control of herbal drugs were 
tests for the detection of functional groups by color reaction [4]. Around the year 1950, 
thin-layer chromatography (TLC) has started to become a popular technique [130]. 
Therefore, in subsequent years, TLC was the first chromatographic method adopted by 
most pharmacopoeias as an identification method of herbal drugs, in combination with 
morphological analysis [6]. Over many years, the identification by TLC in the phar-
macopoeias was mainly focused on the evaluation of few (1-3) specific markers (e.g., 
echinacoside in Echinacea sp.) rather than the evaluation of the entire fingerprint. 
The first edition of the European Pharmacopoeia (Ph. Eur.), published in 1969, includes a 
general chapter for TLC, in which few parameters are described (e.g., manual preparation 
of plates, application of the samples and the type of chamber used) [131]. The lack of 
description, validation, and standardization of the parameters led to a lack of reproducibility 
of the TLC methods.  
In 1989, a new TLC chapter (V.6.20.2) was published in the 13th fascicle of the 2nd edition 
of the Ph.Eur. [132], that in the Ph. Eur. 3.0 became the chapter (2.2.27), with no 
modification [133]. It comprised a more detailed description of the chromatographic (TLC) 
process and the type of instrumentation used. This chapter introduced many options to the 
analyst: use of prefabricated plates, spot or band application with different sizes, regular, 
two-dimensional or horizontal development, use of flat bottom or twin-through chambers, 
and so forth. However, there was still no consensus on a standard methodology to be 
applied. Furthermore, the identification was still performed by comparing the spots 
obtained in the chromatogram of the test solution with those of the chemical reference 
substances.  
In 1994, with the approval of the Dietary Supplement Health and Education Act (DSHEA) 
in the US legislation, some awareness regarding the need for a more comprehensive 
identification of herbal dietary supplements had been raised in the herbal industry. 
According to this legislation, manufactures should produce dietary supplements under 
good manufacturing practice and should perform proper identification of their material 
[134]. Following this policy, the way that TLC was performed for the quality control of 
herbals underwent a modernization. The American Herbal Pharmacopoeia (AHP) was the 
first compendium to modernize TLC methods for identification. Starting with the 
monograph on hawthorn leaf with flower, published in 1999, it included images of the 
HPLTC chromatograms under multiple detections and described more precisely the 
HPTLC parameters [135]. It was also the first to mention the term “HPTLC fingerprint” 
reference. 
Given the need for standardization and modernization of the TLC methodology in the ana-
lysis of herbal drugs, two important papers were published in the year 2003. First, in their 
article published in Pharmeuropa [136], Reich et al. pointed out the need for some 
improvements in the general TLC method description of the Ph. Eur., focusing on the 
standardization of the experimental details. The authors view High-Performance TLC 
(HPTLC) as the miniaturization of TLC, with a special stationary phase consisting of fine 
particles and customized parameters. Second, Koll et al. [137] published in the Journal of 
AOAC the outcome of her thesis: a pioneer work about the validation of HPTLC methods 
for identification of herbal drugs, using standardized HPTLC methodology. These papers 
became the basis for the modernization of chapter 2.2.27 in the 5th edition of the Ph. Eur. 
(2005) [138], in which HPTLC was mentioned for the first time in this pharmacopoeia and 
for the upcoming new HPTLC concept. In this chapter, some parameters, such as pre-
treatment of the plate and sample application, were amended. Other parameters, such as 





documentation and quantitative TLC, were introduced. The 5th edition also included the 
first monographs using TLC and HPTLC, with differential parameters of the latter written 
in brackets.  
In parallel, the United States Pharmacopoeia (USP) general chapter <621> Chromato-
graphy [139] was revised and harmonized with Ph. Eur. 2.2.27. 
In the following years, other publications dealt with the topic of standardization and 
validation of HPTLC methods (e.g., [123] and [140]). During that time, the term High-
performance TLC (HPTLC) was widely used in the scientific community and literature. 
However, there was still no official definition of or agreement on the HPTLC concept.  
In 2009, for the first time, an official yet non-binding compendium (Dietary Supplement 
Compendium of the USP [141]) published color images of HPTLC and TLC fingerprints of 
herbal dietary supplements. That marked a new possibility: evaluating the identity of herbs 
by comparing the fingerprints of the tested samples with reference images. Meanwhile, 
the parameters for the description of the TLC and HPTLC chromatograms in the leading 
pharmacopoeias have changed to be more comprehensive. 
HPTLC and TLC co-exist in some monographs of the Ph. Eur. until today, yet the official 
transition from TLC to HPTLC began in December of 2015 with the United State 
Pharmacopoeia chapter <203> [142] coming into effect followed by the Ph. Eur. chapter 
2.8.25 [143] in January of 2017. Both chapters are based on the standard operating 
procedure for HPTLC published in 2012 by the International Association for the 
Advancement of HPTLC [144]. In these chapters, the concept of HPTLC is made official, 
representing a milestone in the field of quality control of herbals as all the HPTLC 
parameters are well defined and optimized for practicality. 
On this basis, this thesis aims to explore the capabilities of standardized HPTLC in the 
quality control of herbal drugs, preparations, and products. The hypothesis was that if 
HPTLC is used to its full potential during identification of herbals, additional information 
about the purity and content of the analyzed sample can be obtained in a single analysis. 
Certain tests could be eliminated and, consequently, the quality control could be performed 
in a simpler and more cost-efficient way. 
Because quality control is related to regulation, capabilities of analytical techniques, and 
their routine feasibility, these topics were reviewed before presenting the new findings. 
The goal of this literature review was to understand how different regulations tackle these 
quality requirements in two different regions of the world. Secondly, it was aimed to 
understand the concepts and requirements of the quality of herbals and to compare 
different techniques used for its quality control.  
8.1.2 The regulatory environment concerning the quality of herbals 
Besides natural and processing factors that can directly affect the quality of herbal drugs, 
preparations, and products, several authors (e.g., [20] and [19]) have stated that different 
regulatory frameworks can also impact the quality of herbals. The regulation of herbals 
exists to protect the consumer and to ensure good quality, safe, and efficacious material. 
It could mean that a less stringent regulatory framework may be expected to result in 
products of lower quality.  
Herbal products do not fit a single specific regulatory category in any country/region. De-
pending on their intended use, preparations, dosages and dosage forms, herbal products 
can fall into five main groups: medicinal products, medical devices, cosmetics, food 
supplements, and food. In this discussion, the emphasis is given to “medicines” and “food 
supplements”.  
In the regulatory category “medicinal product”, the herbals need to undergo a strict assess-
ment of quality, safety, and efficacy before their marketing. Herbal medicinal products are 
allowed to make therapeutic claims. Depending on the substance, indication, and intended 





claim, different levels of evidence are required for efficacy. In some regulation subclasses 
(e.g., well-established medicinal use medicines –WEU– in EU), the therapeutic effects can 
be supported with scientific literature. A combination system (new trials plus scientific 
publications) can also be used. In the Traditional Herbal Medicinal Products (THMP) 
subclass, the therapeutic effects are proven based on long-standing traditional use 
(described in bibliographical or expert evidence) for minor indications. Regarding quality, 
requirements are the same for all types of medicines. The monographs from official 
pharmacopoeias are mandatory for testing the quality of herbal medicinal products. If no 
monograph is available, manufacturers need to develop their own methods, set 
specifications, and prove the quality, including the production under GACP, GSP, and 
GMP of their product [31] [30].  
In many countries, food and food supplements are regulated under the same law, as in 
the case of the EU. The food supplement category generally does not allow claims 
concerning treatment or cure of diseases, but only nutrition (e.g., “low fat”, “low sugar”, 
etc.) or limited health claims (e.g., reduction of gastrointestinal discomfort, designated to 
healthy consumers to maintain their health). Food supplement regulation is less stringent 
than that of the medicinal products category. Quality (and in some cases, the safety) of 
the product may be tested, depending on the jurisdiction. Efficacy assessment is generally 
not required. Usually, products are exempted from marketing approval, if they have been 
already commercialized before a specific period. This is because they are generally 
considered as safe based on a history of use. On the other hand, novel food (products 
marketed after this specific date) should undergo an assessment to prove safety and 
quality. Unlike for medicinal products, there exist no compulsory guidelines for quality 
control of food supplements in many countries/regions [20] [24]. 
By comparing the requirements of these two categories, it was observed that the medicinal 
products have the most stringent criteria concerning quality, safety, efficacy over the milder 
criteria for food supplements, resulting in the production of higher quality herbal products. 
This situation often leads to very relevant differences in the quality of the marketed 
products of the two categories, in particular with respect to adulteration frequently being 
detected in food supplements. 
8.1.3 The quality control of herbals and the state of the art of analytical tech-
nology  
Quality control is the process designated to demonstrate compliance with the 
specifications and to detect quality problems in a product [145]. Performing quality control 
of herbals is particularly challenging. Several aspects, such as environment and genetic 
factors, natural variation, presence of contaminants, adulterants, misidentification, and 
others, can compromise the quality of the herbal drug, leading to low-quality preparations 
and products. For ensuring good quality herbals, it is necessary to enforce the adoption of 
GACP, GMP, GSP, the standardization and validation of processes, and the establishment 
of quality specifications [12].  
Pharmacopoeias and non-official compendia are crucial instruments for the quality control 
of herbals. They provide the specifications that include the test methods and criteria of 
acceptance for individual herbal drugs and preparations, in the form of monographs [13] 
[146]. During these evaluations, different techniques are recommended, targeting aspects 
of identity, purity, and content. Among them are the morphoanatomical, genomic, 
spectroscopic, and chromatographic techniques.    
Morphoanatomical identification of herbal products through macroscopical, microscopical, 
and organoleptic analysis are low-cost methods, that, in some cases, are also suitable for 
purity testing. Its applicability has some limitations in the case of powdered herbal drugs 
and is not suitable for extracts and other herbal preparations [69] [71].  
Genomic techniques, such as DNA barcoding, represent a powerful and sensitive method 





for identification and test for contaminants with multiple other species, which is 
independent of seasonal variation and age of the plant. However, it is an expensive 
method, requires solid knowledge of the DNA barcode of the species. It is not 
recommended for the identification of highly processed material (e.g., extracts), and can 
neither distinguish between different plant parts of the same species, nor detect 
adulteration with chemicals [72].  
Spectroscopic techniques, such as NIR and UV/VIS spectroscopy, represent low to 
medium cost methods that are simple, rapid, flexible, easy to use, and require little to no 
sample preparation. They produce qualitative and quantitative results and have 
applications for identification, tests for purity, and assays. Shortcomings are: low sensitivity 
and the need for a large number of samples to calibrate the instrument for automatic 
identification routines (NIR) [81]; the detection of substances is limited to the presence of 
chromophoric groups, and the applicability for identification is limited (UV) [6]. NMR is a 
non-destructive, reproducible, and robust technique that does not require complicated 
sample preparation, that can be used without separation techniques, and can perform 
quantification. It is the most universal detection. Limitations are the cost for instruments, 
consumables, and maintenance, as well as low sensitivity. Interpretation of data from 
complex samples (e.g., herbals) may require chemometric methods [7] [93]. 
Chromatographic techniques, such as GC, HPLC (coupled with different detectors), and 
(HP)TLC, are widely used in the monographs for identification, tests for purity, and assay. 
Their greatest advantage is the possibility of separating complex mixtures [106]. While GC 
is a robust technique, has high separation efficiency, and can provide sensitive detection 
of compounds, its applicability is limited to the detection of volatile substances (e.g., 
analysis of essential oils) [112]. HPLC is a well-established, fully automated technique with 
vast literature available in the field of herbals, and it is suitable for analyzing a wide range 
of constituent classes [118]. Nevertheless, it has medium to high instrumentation costs, 
uses large volumes of solvent, samples may require additional clean-up steps, and the 
most common detectors are not universal [119] [147]. In monographs, HPTLC is used 
mainly for identification and purity testing, and in some rare cases, for quantification. It 
usually does not require cumbersome sample preparation, consumes little solvents, and 
allows multiple detections in a single analysis through chemical derivatization [122]. 
Limitations are lower resolution and separation capability, sensitivity, precision and 
linearity range, and variations in the selectivity between the plates from different 
manufacturers [148].  
In conclusion, there exists no absolute method capable of evaluating all quality parameters 
for herbals. Instead, a combination of methods is often applied. It is also important to con-
sider that: (1) the chemical composition of an herbal is responsible for its pharmacological 
activity and its safety, and thus the focus of the quality control and assurance should rely 
primarily on chemical characteristics of the herbal; (2) a large number of tests are 
prescribed to describe the quality of the material, increasing the associated cost. Instead, 
the exploitation of one technique for its entire potential could help to reduce the number of 
analyses and cost. In this context, HPTLC is a simple, visual, and pragmatic technique 
capable of delivering reliable and reproducible results based on standardized 
methodology, improved software, and instrumentation.  
8.2 The new findings 
As shown in section 8.1.1, TLC has officially been part of the quality control of herbals for 
at least 70 years. Advances and standardization of the technique and new regulation of 
herbals have improved the way herbals are identified and controlled. Methods described 
in the pharmacopoeia are now reproducible and allow the use of HPTLC for more than just 
identification. The next subsections will discuss the contribution of this work to the 
advances in the field of quality control of herbals, after the publication of chapters USP 
<203> and Ph. Eur. 2.8.25. For that, five studies were performed. They are discussed in 





sections 8.2.1 to 8.2.5. 
8.2.1 HPTLC as a tool for assessing the market situation concerning the 
quality of herbals 
As mentioned in section 8.1.2, herbal products regulated in different categories could be 
of different quality. This fact has been demonstrated by the increasing number of reports 
on low quality herbal products. These reports are related mainly to accidental and 
intentional adulterations with chemical substances, plant parts, or extracts, for example 
(as discussed in [72], [149], and many other publications).  
Because quality assessment starts with suitable identification of the herbal ingredient, se-
veral problems can already be detected during this step. HPTLC, as recommended for 
assessing the identity of herbals can also deliver valuable data describing their quality. 
When applying the new chapter Ph. Eur. 8.2.25., the entire fingerprint can be used for the 
evaluation rather than only a few zones, and detecting the presence or absence of certain 
zones may indicate quality problems [122].  
This approach is the first step towards better exploiting HPTLC data. It was used in the 
three case studies described in chapter 3. Their objectives were: (1) to assess the quality 
of different herbal drugs, preparations, and products, as a function of their regulation 
category; and (2) to show the usefulness of HPTLC, as described in chapters USP <203> 
and Ph. Eur. 2.8.25, as a tool for detecting quality problems, mainly adulterations (other 
plants, extracts, synthetic drugs, or other molecules). 
For that, the following herbals were chosen according to their market importance and the 
availability of HPTLC methods for identification ([150] [151] [152]): milk thistle fruits 
(Silybum marianum (L.) Gaertn.), coneflower (root and herb of Echinacea purpurea (L.) 
Moench and roots of E. angustifolia DC. and E. pallida Nutt.) and black cohosh root 
(Actaea racemosa L.). For the two first cases, products regulated as traditional herbal 
medicinal products (THMP) and food supplements (FS) were purchased in the UK market. 
For black cohosh, products regulated as dietary (food) supplement (FS) and black cohosh 
preparations (used as ingredients of the finished products) were purchased in the US 
market. The HPTLC methods used in this work were adapted from the Ph. Eur.  
The most significant deviation from the original methods was the inclusion of the evaluation 
and interpretation of the entire fingerprint (beyond what is prescribed in the Ph. Eur. mono-
graphs). Additional detection modes on the same plate, give access to confirming and 
complementary information without additional analytical efforts. Examples are shown in.  
In the case of purple coneflower herb, the phenolic fingerprint contained a red zone due 
to chlorophylls. The absence of this zone in the profile of one product, labeled as tincture 
of E. purpurea herb, led to the conclusion that the declared aerial parts were absent (e.g., 
Figure 8.1, red arrow, tracks 3). For milk thistle, five samples showed a yellow zone under 
UV 366 nm before derivatization, not observed in the characteristic fingerprint of the herbal 
drug (e.g., Figure 8.1, yellow arrows, tracks 6-7). The origin of this zone is not clear, and 
it could indicate a quality issue of the products, unrelated to excipients. As in the case of 
coneflower, the detection of a red zone due to chlorophyll (e.g., tracks 6-7, orange arrow, 
Figure 8.1) helped to confirm the presence of aerial parts, from both milk thistle and other 
herbal products, in eight MT products. The distinction between the fingerprints of fruit and 
fruit extract of milk thistle was made possible by the detection of a blue zone at RF 0.13 
before and after derivatization, that was present in the fruit and absent in the extract (e.g., 
Figure 8.1, blue arrows, tracks 4-5). In the case of black cohosh, the goal was to assess 
the market situation concerning possible adulterations with Chinese Actaea species and 
deviations from the fingerprint described in the Ph. Eur. monographs. 
A general conclusion regarding the quality of the samples and their regulatory 
classification is shown in Table 8.1. The three case studies showed that (1) the products 
regulated as THMP had a consistent and homogenous fingerprint, in accordance to 





botanical reference material and authentic samples; (2) Only products classified as food 
supplements or herbal preparations (powdered herbal drug, extracts) showed quality 
problems. Those were: lack of characteristic zone(s), overall faint fingerprint, no zone 
characteristic of the declared herbal drug, or the presence of zones characteristic of 
adulterants. They accounted for 52.4% of the milk thistle FS, 33.3% of the coneflower FS, 
45.5% of the black cohosh FS and 66.6% of black cohosh preparations.  
 
Figure 8.1 How additional detection modes and evaluation of the entire fingerprint can help 
detecting quality problems: Fingerprints of coneflower and milk thistle under UV 366 nm prior to 
(left) and after derivatization (right). Blue arrows indicate the presence of a zone characteristic of 
milk thistle fruit, absent in the extract. Yellow arrows indicate the presence of an additional zone, 
not characteristic of Milk thistle fruit and present in the products. Red and orange arrows indicate 
the red zone due to chlorophylls, characteristic of purple coneflower aerial parts and milk thistle 
aerial parts, respectively. 
Table 8.1 Classification of the samples as having good or questionable quality, grouped according 
to their regulatory status. Percentages are given in relation to the total number of samples of each 
category and the absolute number of samples in parenthesis. 
 Milk thistle 
fruit 
Coneflower Black cohosh 
Traditional Herbal Medicinal Products (THMP) 
Good quality samples 100% (10) 100% (11) ─ 
Questionable quality 0% (0) 0% (0) ─ 
Food supplements (FS) 
Good quality samples 47.6% (10) 75% (9) 54.5% (18) 
Questionable quality 52.4% (11) 25% (3) 45.5% (15) 
Herbal drugs / herbal preparations  
Good quality samples ─ ─ 33.3% (9) 
Questionable quality ─ ─ 66.6% (18) 
If herbal medicines do not meet the acceptance criteria of the pharmacopoeial monograph, 
these are considered to be adulterated. On the other hand, food supplements that show 
fingerprint deviating from that of the monograph, but do not claim compliance with it, may 
not be considered adulterated, unless other undeclared constituents are detected. 
In this study it was observed a significant number of food supplements did not comply with 
their labels claim. These findings confirm that less stringent regulation can negatively 
affect the quality of herbal products, compromising their safety and efficacy, and 
misleading the consumers. The great advantage of HPTLC in this context is that using 





existing optimized and standardized HPTLC methods, and evaluating the entire fingerprint 
under several detections, a range of quality problems was quickly detected.  
A manuscript was submitted to Journal of AOAC international: D. A. Frommenwiler, E. 
Reich, M. H. M. Sharaf, S. Cañigueral and C. J. Etheridge. Investigation of market herbal 
products regulated under different categories: how can HPTLC help to detect quality 
problems? The manuscript is shown in chapter 3. 
8.2.2 The development of the comprehensive HPTLC fingerprinting concept 
and its application to Angelica gigas Nakai root  
Section 8.2.1 have shown the advantages of exploiting all qualitative information given in 
an HPTLC analysis using the entire fingerprint and several modes of detection. In the 
following sections, the quantitative features carried by the HPTLC chromatogram will be 
explored.  
Quantitative TLC analysis started to become popular in the mid-1960s when the first instru-
ments for scanning densitometry were commercialized. Since that time, it is still predomi-
nantly performed using slit-scanning densitometers [153]. In 1989, quantitative TLC was 
acknowledged for the first time in the Ph. Eur., when a section “quantitative 
measurements” was added to the new thin-layer chromatography chapter V.6.20.2 [132] 
(that later became 2.2.27). Nevertheless, no monograph includes quantification by HPTLC 
or TLC. One of the possible reasons is that scanning densitometers are expensive and not 
considered to be standard laboratory equipment. However, this instrument is still essential 
for development and validation of quantitative HPTLC methods. 
At the end of the 20th century, with the onset of the digital age and the introduction of 
digital cameras, it became possible to carry out a quantitative evaluation based on 
electronic images. This had been initially applied to electrophoresis and then to TLC 
analysis [154]. The new quantitative approach was attractive due to its low cost and 
convenience. With the evolution of software for image analysis, quantitative aspects of the 
HPTLC fingerprint became objectively accessible. According to Sherma and Rabel [153], 
a range of software is available for such analysis, for example, Microsoft Paint, Sorbfil TLC 
Videodensitometer, UN-SCAN-IT, JustTLC, ImageJ, TLSee, The Gimp, VideoScan, and 
visionCATS. 
Unlike in scanning densitometry, that measures the absorbance or fluorescence of a zone, 
using a single wavelength per scan, in image analysis, the pixels of three channels (red 
(R), green (G), and blue (B)) are assessed. To create the core data for HPTLC image 
analysis, the average luminance may be calculated as L = (1/3 R) + (1/3 G) + (1/3 B) from 
the RGB channels for each pixel line of a track. Then, L is plotted as a function of the RF 
value. The resulting profile of a fingerprint is called “peak profile from image” (PPI). L, as 
described, is used for images taken at UV 366 nm, and for images taken at daylight or UV 
254 nm, 1-L is used. 
Because the luminance formula weighs the RGB channels equally, the relative intensities 
of zones seen in the image of the fingerprint may not be equivalent to the peak heights 
observed in the PPI. Furthermore, the color impression is lost during this conversion. Con-
sequently, for a comprehensive evaluation of the fingerprint, the PPI needs to be analyzed 
together with the corresponding image. This led to the development of the “comprehensive 
HPTLC fingerprinting”: tests for identity, purity, and content can be performed in a single 
analysis, including different detection modes, by combining qualitative and quantitative 
information from the HPTLC fingerprints and PPI (Figure 8.2). Peak profiles from scanner 
densitometry (PPSD) can offer complementary, spectrally selective information but are 
beyond the scope to this work.  
The possibilities of applying the concept to identify an herbal drug, detect mixtures with 
related species (purity), and develop a minimum content test of an analytical marker, using 
a single analysis, were explored for Angelica gigas root in a case study described in 





chapter 4.  
First, the criteria for identification of roots of A. gigas by HPTLC fingerprints were 
established based on the evaluation of multiple batches of cultivated plant material that 
met the current quality specifications of the Korean Pharmacopoeia. Five detection modes 
were included. An average fingerprint representing the typical characteristics of the drug 
was generated by pooling multiple batches of plant material to yield a single sample. The 
specificity of the HPTLC method was tested with an analysis of twenty-eight related 
species, side-by-side. All species were distinguishable. 
 
 
Figure 8.2. Representation of the concept “comprehensive HPTLC fingerprinting”, using a sample 
of Angelica gigas root in different detection modes. 
For the purity test, two potential confounding species, Chinese angelica (A. sinensis) and 
Japanese angelica (A. acutiloba), which have the same common name (Danggui) as A. 
gigas (Koran angelica), were chosen. Their powdered roots were physically mixed with 
powdered root of A. gigas in different proportions. Mixtures of Angelica gigas with 
adulterants could be detected at levels as low as 1% based on the presence of the zone 
of Z-ligustilide. This is a blue zone under UV 366 nm prior to derivatization (at RF 0.58), 
which is characteristic for the investigated and nine other related species, but is absent in 
A. gigas. The determination of purity was performed visually, based on the electronic 
image, and using the PPI. 
The third part of the study demonstrated the use of PPI for determining the “minimum 
content” of the analytical markers decursin plus decursinol angelate in A. gigas root. These 
substances co-migrate as the most prominent blue zone (RF 0.27) of the fingerprint. For 
this determination, a quantified reference material of plant material (RMPM) for A. gigas 
root, distributed by the Forum for the Harmonization of Herbal Medicines (FHH), was used 
in a single-level calibration. The intent behind that was to avoid the use of expensive and 
commercially unavailable chemical standards for quantification and to provide a single 
reference material for identity and purity at the same time. 
For the test for minimum content test, the RMPM solution was prepared at a concentration 
of decursin plus decursinol angelate equivalent to the minimum content previously esta-
blished as the acceptance criterion (3.0%). After converting HPTLC fingerprints (images) 





into peak profiles (PPI), the height (intensity) of the zone at RF 0.27 in the samples was 
compared to the corresponding zone in the RMPM. Interpretation of the results (Figure 
8.3) was performed visually as a pass or fail test, where passing samples showed a higher 
peak than the RMPM. Failing samples showed a lower peak than the RMPM. The same 
data were also used for quantification of decursin plus decursinol angelate (absolute 
content) in the samples. Both evaluations are possible because the underlying quantitative 
method was validated using multilevel calibration and establishing a linear working range. 
The method was successfully tested in a collaborative trial involving three laboratories 
(Switzerland, South Korea, and Vietnam). 
This work is the proof of concept for the comprehensive HPTLC fingerprinting, demonstra-
ting that identity, presence of adulterants, and minimum content (either as pass/fail output 
or determining the percentage) for an herbal drug can be obtained from a single HPTLC 
analysis.  
An article was published in a special issue of Planta Medica dedicated to “Quality Control 
of Herbal Drugs and Preparations”: D. A. Frommenwiler, J. Kim, C.-S. Yook, T. T. T. Tran, 
S. Cañigueral, E. Reich. Comprehensive HPTLC fingerprinting for quality control of an 
herbal drug - the case of Angelica gigas root. Planta Medica 2018, 84, 06/07, p 465-474. 
The manuscript is shown in chapter 4.  
 
 
Figure 8.3. The test for minimum content of decursin plus decursinol angelate (DA) in 24 samples 
of A. gigas. Red bar: RMPM, equivalent to accepted minimum content. Green bars: passing 
samples (intensity decursin + DA peak ≥ RMPM); Grey bars: failing samples (intensity of decursin 
+ DA peak < RMPM. Values in the lower row of the table are the concentrations (%) of decursin + 
DA in the samples. 
8.2.3 Application of comprehensive HPTLC fingerprinting to the testing of 
purity of ginkgo products  
It has been shown that HPTLC fingerprints generated for identification can also be used 
to detect adulteration and for assaying markers. Within the concept “comprehensive 
HPTLC fingerprinting”, this section aims to go one step beyond in the test for adulterants 
and to evaluate the use of the HPTLC for purity limit tests. This approach was evaluated 
with samples of ginkgo leaf and extracts, as described in chapter 5.  
The USP monograph for ginkgo leaf extract [155] prescribes two HPTLC identifications 
(flavonoids and terpene lactones) two HPLC assays (flavonol glycosides and terpene 
lactones) and an HPLC limit test for rutin and quercetin in order to detect adulterations. 
The HPLC assay for total flavonol glycosides is somehow unspecific and can be easily 
fooled since a hydrolysis step is used to simplify the quantification. In this process, flavonol 





glycosides present in Gingko biloba L. leaf extract are converted into quercetin, 
kaempferol, and isorhamnetin. The quantification is done based on the sum of the peaks 
of these three substances. According to the monograph, the test solution should contain 
between 22 and 27% of flavonoids expressed as flavonol glycosides. Low levels of flavonol 
glycosides can be easily compensated by the addition of inexpensive rutin and quercetin 
bulk chemicals, or other inexpensive natural sources of these substances. Instead of 
looking for alternatives in the methods already existing in the monograph, USP included 
an additional one-hour HPLC limit test for rutin and quercetin to detect adulterations. 
The present study demonstrated that, with additional detection modes, the HPTLC finger-
prints produced during identification with an optimized USP method could detect mixtures 
of ginkgo products not only with rutin and quercetin but also with buckwheat herb and 
sophora (flower bud or fruit), as it is shown in Figure 8.4. 
 
Figure 8.4. Fingerprints of ginkgo leaf extract, buckwheat herb, sophora fruit, and flower with 
different detection modes. Arrows point to zones that are positive markers for adulterants in ginkgo 
samples. Buckwheat herb: red zones (green arrow); Sophora fruit: quenching zones (orange arrow 
and bracket) and a green zone (white arrow); Sophora flower:  two purple zones above and below 
rutin (black arrows). 
Additionally, the same HPTLC method proved suitable for verifying levels of rutin and quer-
cetin, providing information similar to that of the HPLC limit test. Instead of assigning 
values for these substances in the samples, the HPTLC limit test evaluates whether their 
levels are below the limits of the USP monograph. The test is performed on the PPI from 
images before and after derivatization. The peak heights of the test solutions were 
compared to those of the reference solutions prepared at concentrations equivalent to the 
acceptance criteria in the monograph. For adulterated samples, peaks due to rutin and/or 
quercetin are greater than those of the reference solutions (Figure 8.5). HPLC data was 
used to support the validity of the HPTLC limit test. A good correlation was obtained in 
98% of the cases for quercetin and 100% of the cases for rutin. 
Only eleven of fifty-nine analyzed products gave HPTLC fingerprints similar to that of 
ginkgo refined extract or ginkgo leaf, compliant with pharmacopoeial standards. The other 
forty-eight products showed at least one of the adulterants. Eight samples had more than 
4% of rutin, and thirty had more than 0.5% of quercetin. One contained no ginkgo at all. 
To the best of our knowledge, this is the first time that a single HPTLC was used for suc-
cessfully determining identity, purity, and limits of rutin and quercetin in ginkgo products. 
Thus, if a sample fails the tests for identity and purity test based on high levels of rutin 
and/or quercetin during comprehensive HPTLC fingerprinting (as proposed in this section), 





it will consequently fail the HPLC limit test for these adulterants. Conversely, a sample that 
passes comprehensive HPTLC fingerprinting will likely pass the HPLC assay and limit 
tests. Because problems with content can be detected during identification with the HPTLC 
method, the additional HPLC tests become redundant. Consequently, the HPTLC method 
may save costs and time by reducing the number of experiments. To assist the analyst 
during HPTLC experiments, a decision tree was proposed (Figure 5.7 in chapter 5).  
This work was published in the following paper: D. A. Frommenwiler, A. Booker, R. Vila, 
M. Heinrich, E. Reich, and S. Cañigueral. Comprehensive HPTLC fingerprinting as a tool 
for a simplified analysis of the purity of ginkgo products. Journal of Ethnopharmacology 
2019, 243, 112084. The manuscript is shown in Chapter 5. 
 
 
Figure 8.5. HPTLC limit tests for rutin and quercetin in 7 GB samples (GB20, 23, 32, 26, 1, 2, and 
4). Images with the bars represent intensities of rutin and quercetin in the reference and test 
solutions after integration of the peaks of the PPI. Red bar: peak of rutin in the reference solution; 
orange bar: peak of quercetin in the reference extract solution; green bars: passing samples; gray 
bars: failing samples. The concentration of reference solutions is equivalent to the acceptance 
criteria of the limit test. 
8.2.4 Comprehensive HPTLC fingerprinting in the Ph. Eur. monographs for 
Traditional Chinese Medicine (TCM) drugs 
The European Pharmacopoeia is an important instrument for quality control of Traditional 
Chinese Medicine (TCM) herbal drugs in the western world. The 10th edition includes 73 
monographs on TCM herbal drugs.  
The development of monographs for the quality control of these herbal drugs is particularly 
challenging due to the limited availability of commercial and reference samples of herbal 
drugs and adulterants in Europe. Additionally, the constituents responsible for the efficacy 
of the TCM herbal drugs are often only partially known or not at all. Consequently, most 





TCM monographs use the analytical marker approach to evaluate the content of the herbal 
drug. This type of assay is usually performed by HPLC, in addition to other tests (e.g., 
identity test by HPTLC). However, there have been some critical remarks from the TCM 
wholesalers regarding the costs associated with testing herbal drugs according to the Ph. 
Eur., particularly for TCM drugs with limited trade volume in Europe. Because of this 
problem, the TCM working party of the EDQM launched the project “alternatives to 
assays”. This project aimed at simplifying the determination of content and reducing the 
number of tests to be performed during quality control of TCM herbal drugs.  
Due to the quantitative features of HPTLC images, this technique was considered as a 
candidate for the pilot study, based on the comparison of peak heights (intensities) from 
the PPI. The suitability of HPTLC as an alternative to assays was evaluated in two case 
studies, chosen by the experts of the TCM working party: Fritillaria thunbergii bulbs (FTB) 
and Corydalis rhizome (CYR). In both cases, the concept “comprehensive HPTLC 
fingerprinting” was applied for identification and minimum content.  
In the first step, it was necessary to optimize the existing pharmacopoeial (HP)TLC 
methods for both TCM drugs, in order to improve their reproducibility and quantitative 
outcomes. The new methods were then applied to multiple samples. During this step, the 
acceptance criteria for the identification were set. Reference solutions, used as SST and 
intensity markers, were established following chapter 2.8.25.  
In the second part of the work, the test for minimum content by HPTLC was developed. 
The content of the markers was assessed in representative samples of FTB and CYR 
against a five-level calibration curve of standards. Based on the outcome of these assays, 
a minimum content was established for each marker. For simplicity in the routine 
application, reference solutions were prepared at a single concentration, within the linear 
range and equivalent to the minimum content in the sample. The intensity of the zone in 
the fingerprints of samples and reference are then compared. The test gives a pass or fail 
result rather than a content, and can be performed visually (on the images) or by software 
(using PPI). Outcomes of the two interpretations are in agreement, as shown in Figure 8.6 
for FTB.  
 
Figure 8.6. Visual and software interpretations of the test for minimum content of peimine and 
peiminine in FTB samples. Visual interpretation: passing samples are marked with a green check, 
while the failing sample is marked with an x. Software interpretation: orange and red bars: peiminine 
in the reference solution h and peimine in the reference solution g, respectively; green bars: passing 
samples; gray bar: failing sample. 
Finally, the reproducibility of the HPTLC methods was evaluated in a collaborative trial 
including six laboratories. The outcomes are presented in chapter 6. In summary, results 





for FTB from five laboratories were in agreement. The remaining laboratory did not pass 
the identification of the samples. For CYR, all laboratories presented the same results for 
SST, intensity markers, and identification. In the test for minimum content, one borderline 
sample passed in 4 laboratories and failed in two. All laboratories reached similar 
conclusions for the other seven samples. 
The HPTLC methods proposed to the Ph. Eur. offer a simplified approach to evaluating 
identity and minimum content of TCM drugs in a single analysis. They are suitable for any 
type of laboratory: from those performing HPTLC manually to laboratories equipped with 
HPTLC instruments and software. Thus, laboratories on a low budget have a better chance 
to comply with the pharmacopoeia. 
The manuscript presented in chapter 6 was submitted to Pharmeuropa Bio & Scientific 
Notes: D. A. Frommenwiler, C. Sabatini-Samori, E. Reich, S. Cañigueral and U. Rose. An 
alternative and simplified approach to identification and test for minimum content of TCM 
herbal drugs.  
8.2.5 The quantification of a group of constituents with comprehensive 
HPTLC fingerprinting 
Since the introduction of “comprehensive HPTLC fingerprinting”, the quantitative aspect of 
this concept has been focused on the assessment of individual markers against a 
reference solution (either from a chemical reference substance or an herbal reference 
material). However, herbal drugs and preparations often contain a complex mixture of 
substances, and thus, monitoring a group of constituents may be preferable for assuring 
their quality.  
For example, the USP recently adopted a monograph for Ganoderma lucidum fruiting body 
(GLFB) [156], which includes an assay of triterpenoic acids (ten peaks of ganoderic and 
ganoderenic acids). This analysis presents an extra challenge because it requires an unu-
sual long UHPLC column, and consequently, a stronger pump and a gradient run of 1 hour 
per sample. 
In this work, the applicability of the comprehensive HPTLC fingerprinting concept to deter-
mine the content of a group of constituents in an herbal drug was investigated using the 
example of GLFB. The goal was to propose a single HPTLC analysis, which combines the 
identification of GLFB with a test for adulteration and determination of the content of total 
triterpenoic acids expressed as ganoderic acid A.  
First, the mobile phase, the sample preparation method, and derivatization procedure of 
the existing USP HPTLC method for identification were optimized for simplicity and 
robustness. The specificity of the method was evaluated by comparing the fingerprints of 
GLFB with those of nine related mushroom species in different detection modes. 
Triterpenoic acids (yellow and green zones between RF 0.1 and 0.5, Figure 8.7) were 
specific for GLFB and absent in the fingerprints of all other species.  
The quantitative part of this work aimed at using a single reference solution for the quantifi-
cation of a group of substances. During method development, the zones due to triterpenoic 
acids (between RF 0.1 and 0.5, Figure 8.7) were identified in the fingerprint of the sample. 
That was accomplished by comparing their RF position, color before and after 
derivatization, and UV spectra before derivatization with those of reference substances. 
Some zones were also classified as triterpenoic acids based on their similarities in color 
and UV spectra with those of ganoderic acids A and D. The choice of a suitable detection 
mode was made based on the signal response of the peaks from PPI in different detection 
modes. UV 254 nm was chosen because the peaks were best detected and had a low 
coefficient of variation during quantification.  






Figure 8.7. HPTLC fingerprints of ergosterol, ganoderic acids D, B, A. G and C2 (prepared at 1 
mg/mL) and two samples of G. lucidum fruiting body (GL13 and GL12, respectively) under UV 254 
nm prior to derivatization (left) and UV 366 nm after derivatization (right). Standards on tracks 1, 3, 
and 6 show more than one zone due to impurities. 
The other important step for the quantification was to ensure that all PPI peaks to be quan-
tified were within the linear range allowing calculation with a single level calibration. For 
that, different dilutions of a pooled sample were analyzed, calibration curves for each of 
the selected peaks were established, and a suitable concentration of the test solution was 
chosen. A representation of this process is shown in section 8.3.8.3. 
The new quantitative method was then applied to the determination of triterpenoic acids in 
fifty samples. This was done by integrating all peaks between RF 0.1 and 0.5 as one peak, 
and calculating the total area against a single level calibration point of ganoderic acid A 
(as shown in Figure 8.8). Based on the lowest value for total triterpenoic acids in samples 
considered of acceptable quality, the minimum content expressed as ganoderic acid A 
was proposed at 0.25%. 
 
Figure 8.8 Representation of quantification of total triterpenoic acids by integrating all peaks 
between RF 0.1 and 0.5 in the test solution, using a single level calibration of ganoderic acid A at 
0.1 mg/mL, and expressing results as ganoderic acid A. 
The new method is a simpler yet efficient way to perform quality control of GLFB. In com-
parison to the method proposed by USP, the new HPTLC method is also an economic 
alternative. The analysis of one sample with the new method costs approximately 27.00 
Swiss Francs (CHF) in comparison to approximately 74.00 CHF for the USP method 
(combined HPTLC plus UHPLC). 
Furthermore, this work shows the application of two pattern recognition tools that could be 





used in routine quality control: peak recognition and acceptance range. With peak recogni-
tion, the existing descriptions of the zones in the HPTLC fingerprints, e.g., those in the 
style of the European Pharmacopoeia, can be imported into suitable software (e.g., a 
prototype functionality of the visionCATS software). The software checks the presence or 
absence of required peaks and automatically passes or fails samples. The other tool 
(acceptance range) describes the quality of an herbal more comprehensively, taking into 
account its entire fingerprint. In this assessment, the presence or absence of peaks and 
their intensities are compared with specifications, which were displayed in the shape of a 
“window” (Figure 8.9).  
 
Figure 8.9. Acceptance window model for evaluation of quality of Ganoderma lucidum fruiting body. 
A: Example of GIe – passes the test. B: two examples that fail tests (GL1 and 39). Arrows indicate 
zones of profiles that are outside of the acceptance criteria. PPI from the image after derivatization 
under UV 366 nm. 
This window contains for each RF line a maximum and minimum allowed intensity (or 
values of arbitrary units (a.u.)), which were set based on the evaluation of good GLFB 
samples. Samples compliant with the model show a fingerprint within the window. Non-
compliant samples present > 5% of their chromatogram outside of the window (above or 
below the acceptable ranges). Samples evaluated with both methods show the same 





passing/failing results as the visual evaluation.  
This case study offers an example of an economic yet powerful HPTLC method for 
comprehensively describing the quality of an herbal drug, combining identification and 
quantitative assessment of a group of zones in a single analysis. 
This work has been published in the following paper: D. A. Frommenwiler, D. Trefzer, M. 
Schmid, S. Cañigueral, and E. Reich. Comprehensive HPTLC fingerprinting: A novel eco-
nomic approach to evaluating the quality of Ganoderma lucidum fruiting body. Journal of 
Liquid Chromatography & Related Technologies, 2020. Published online, DOI: 10.1080/1 
0826076.2020.172 5560. The manuscript is shown in Chapter 7. 
8.3 How to develop a method for comprehensive HPTLC finger-
printing  
With the experience gained from different applications of comprehensive HPTLC finger-
printing, this section provides general guidance for the development of comprehensive 
HPTLC methods suitable for the analysis of herbal drugs, preparations, and products.  
8.3.1 Procurement of samples 
Comprehensive HPTLC methods must take the natural variability of herbals into account. 
For that, it is crucial to work with at least 5-10 samples of representative quality. If possible, 
at least 10 g of each sample, including botanical reference material (BRM), should be 
obtained. 
In addition, a minimum of 2-10 g of each known adulterants or related species should be 
included. Additional information can be obtained from SOP 013 of the HPTLC Association 
[157].  
8.3.2 Sample preparation 
Sample preparation should be kept as short and straightforward as possible. If available, 
sample preparation methods from the literature for the target herbal drug can be evaluated. 
A general method is sonication or shaking of the powdered sample with a suitable solvent 
(e.g. methanol) for 10 min at room temperature or 60°C.  
The efficiency of the sample preparation can be evaluated semi-quantitatively by 
comparing the intensity of the zones of the fingerprints, based on their PPI in different 
detection modes. 
Once the sample preparation method is established, precise weighing and exact volumes 
of solvents are required for quantitative analysis. Additional information can be found in 
SOP 005 [158]. 
8.3.3 Chromatographic setup  
For general guidance on the HPTLC procedure, the following SOP and chapters are 
recommended: USP 203 [142] Ph. Eur. 2.8.25 [143] SOP 001 General Methodology for 
HPTLC, from the HPTLC Association [159]. Additional important parameters are 
emphasized below. 
8.3.3.1 Stationary phase 
For most analyses, 20x10 cm HPTLC glass plates Si 60 F254 (e.g., Merck) are used. It is 
crucial to notice that plates from different manufacturers may have different selectivity, 
which can affect the reproducibility of the method.  
8.3.3.2 Reagents and solvents 
If possible, reagents and solvents of a high grade or purity should be used to ensure the 
reproducibility of the method.  





8.3.3.3 Sample application 
For ensuring quantitative results, the syringe should be rinsed twice with the rinsing solvent 
(e.g., methanol) and filled twice with the test/reference solution. This step should be re-
peated for each solution to be analyzed. Application volumes lower than 2 µL (reproduci-
bility) and greater than 10 µL (time, band broadening) should be avoided. 
8.3.3.4 Selection of the developing solvent 
Before developing a method from scratch, the existing literature should be considered. 
Good sources of methods are Ph. Eur., USP, and other pharmacopoeias, the USP Dietary 
Supplement Compendium (DSC), USP Herbal Medicines Compendium [160], Hong Kong 
Chinese Materia Medica Standards [161], Plant Drug Analysis [162], the HPTLC 
Association [163]. Additionally, the HPTLC Association offers a guideline on the selection 
and optimization of developing solvents [157].  
The selection of an optimal developing solvent is the core step of a comprehensive HPTLC 
method. During this evaluation, the analyst should take into account: 
 The class(es) of compound(s) targeted for analysis and the selection of a 
compatible chromatographic system.  
 That even if multiple classes of compounds are targeted, a single development, 
possibly combined with multiple detections, should be employed (e.g., evaluation 
of proanthocyanidins and flavonoids in cranberry can be performed with a single 
developing solvent [164]).  
 The capability of the method to detect adulterants (see section 8.3.7). 
 For harmonization purposes, a method applicable to the related and target herbal 
drug is preferred.  
 That the developing solvent can separate with baseline resolution the analytical 
marker(s) if they are separately quantified. 
 That the method fulfills the validation requirements (see section 8.3.5). 
8.3.3.5 Preparation of developing solvent and development 
For this step, it is crucial to ensure that: 
 In order to minimize volume error, a quantity of developing solvent sufficient for a 
working day should be prepared. 
 The twin through chamber contains no residual solvent. 
 If applicable, the development instrument should be rinsed appropriately with 
developing solvent prior to the development. 
 For development in a saturated chamber, the filter paper used is of the correct 
weight and free of residual solvents. 
Development in a saturated chamber: 10 mL of developing solvent are used in the front 
through affording a level of 5 mm depth for development, and 25 mL of developing solvent 
are used in the rear through for the saturation, together with filter paper. The chamber 
should be saturated for 20 minutes. Prior to development, plates are conditioned with a 
saturated salt solution (e.g., MgCl2) for 10 minutes. Developing distance is 70 mm from 
the lower edge of the plate. After development, the plate is dried for 5 minutes with air at 
room temperature. 
Development in an unsaturated chamber: Prior to development, plates are conditioned 
with a salt solution for 10 minutes. Then 10 mL of developing solvent are poured in the 
front through affording a level of 5 mm depth for development, just before introducing the 
plate into the chromatographic chamber. The rear through is left empty. Plates are 
developed to 70 mm from the lower edge. After development, they are dried for 5 minutes 
with air at room temperature. 





8.3.3.6 Detection and documentation 
Detection can be performed prior to and/or after derivatization. Derivatization is an 
important step in HPTLC analysis and part of the majority of the HPTLC methods. If not 
executed in an automated manner, derivatization can lead to reproducibility problems. It is 
important to highlight that subsequent derivatization steps can be performed on the same 
plate, offering additional information (e.g., detection of sophora flower in ginkgo leaf 
products). A documentation step is added after each derivatization. Examples of 
compatible reagents are natural products and anisaldehyde reagents, or natural products 
and fast blue salt B reagents. Additional details on the execution of the derivatization step 
are found in SOP 001 of the HPTLC association [159]. The preparation of the derivatization 
reagents is shown in SOP 006 [165]. If applicable, the post-derivatization reaction time 
and temperature should be investigated, using the PPI. The best combination of 
parameters will afford a higher response (e.g., more intense peaks).  
Plates should be documented with a digital documentation system under UV 254 nm and 
white light prior to application (for correction of the plate background); under UV 254 nm, 
UV 366 nm and white light after development; and under UV 366 nm and white light after 
derivatization. White light is used in combined absorption (from top) and transmission 
(from below) mode. Additionally, the post-chromatographic stability of the color and 
intensity of the zones with time can be evaluated. For that, after derivatization, images of 
the plate are recorded at different intervals of time (e.g., at 3, 6, 9, and 12 minutes). 
Evaluation is done with images plus PPI. A stable fingerprint is reached when the color 
and intensity of the peaks/zones changed only marginally or not at all. The time for 
reaching stability  should be considered in the description of the documentation (e.g., as 
shown in chapter 7).  
8.3.3.7 Converting images into peak profiles (PPI) 
For generating PPI, the luminance is calculated as L = (1/3 R) + (1/3 G) + (1/3 B) from the 
red (R), green (G), and blue (B) channel for each pixel line of the track. L in fluorescence 
mode, respectively 1-L in absorption mode, is then plotted as a function of the RF value. 
8.3.4 Defining a system suitability test SST 
In HPTLC analysis, the SST has two functions: (1) to verify and qualify the 
chromatography, and (2) to normalize the intensity of the images under UV 366 nm.  
The quality of the chromatography is evaluated with the SST reference solution either by 
judging the separation of two very close zones or comparing the RF of the zones with the 
acceptance criteria. The ∆RF should not be greater than 0.02 for analyses performed on 
the same day, and 0.05 for analyses performed on different days and in different 
laboratories.  
The SST is also useful for the normalizing of the image background. An example is shown 
in Figure 8.10, the plate background of the raw data can be different from plate to plate 
(upper images of the plates). These differences are caused by different exposure times 
during image capturing in high-dynamic-range imaging (HDRI) mode. An HDRI contains 
multiple ranges of luminance levels at different exposures to capture details in shadows or 
highlights. When normalized over a common intensity (e.g., SST), the backgrounds of dif-
ferent plates look similar, as in the three plates at the bottom of the image. Therefore, with 
software correction, it is possible to compare images captured with different exposures. 
SST can be: (a) chemical reference substances, or (b) reference extracts. Chemical refe-
rence substances as SST are used by most pharmacopoeias and the HPTLC Association, 
while reference extracts as SST are more common in the USP.  






Figure 8.10 Normalization of background based on SST in HPTLC analysis. Images of three plates 
(1-3) before and after plate background normalization over the SST (actein and isoferulic acid). 
The choice of chemical markers for SST is related to the targeted class of compound, and 
their distribution in the chromatogram (ideally between RF 0.2 and 0.8) [157]. Ideally, 5-10 
compounds of the targeted class should be prepared at 1 mg/mL and analyzed in individual 
tracks, including one test solution for comparison. From this experiment, 2-4 markers are 
chosen. In a second experiment, their concentration is optimized. The intensity should 
resemble those of the corresponding or similar zones in the test solutions to avoid underex-
posure or overexposure of an image. Reference extracts used as SST should be prepared 
in a concentration resembling that of the samples.  
8.3.5 Validation of comprehensive HPTLC methods  
General guidance on validation of qualitative HPTLC methods is presented by Koll et al. 
in [137]. For the quantitative assessment, it is recommended to take into account the ICH 
guideline [166]. The minimum validation requirements for the quantitative assessment are 
emphasized below.  
 The specificity of the method: to ensure the identity of the analyte, it is 
recommended to record UV spectra of the zones used in the quantification and 
compare them to the UV spectra of the reference standards.  
 Linearity: needs to be established before the precision. It is discussed in section 
III. 
 The precision of the method: can be evaluated through repeatability (evaluation in 
a short interval of time in the same laboratory) with six replicates, intermediate 
precision (evaluation within days and in the same laboratory), and if possible, 
reproducibility (evaluation in different laboratories).  
 Accuracy of the method: can be assessed through the recovery tests. For that, it is 
recommended to perform nine determinations using a sample spiked with three 
concentration levels of the marker, and each level prepared in triplicate. The 
analyst should ensure that the added amount of marker will not be outside of the 
linear range.  
8.3.6 Identity  
The HPTLC method for identification should deliver a binary outcome: YES, the tested 
sample corresponds to the target herbal drug, or NO, it is not the targeted herbal drug. 
The decision is based on acceptance criteria. 
8.3.6.1 Guidance for the establishment of acceptance criteria 
In order to set acceptance criteria for the identification of an herbal drug, the description 
of the HPTLC fingerprint should consider the following aspects: 
 The color of the zones and their RF, in different detection modes. 





 The natural variability should be considered in the description of the intensity of the 
zones. For that, a representative number of samples should be evaluated. The 
resulting description can include a range of intensity (e.g., faint to equivalent zone). 
 Description of intensity can be done more objectively with PPI, and minimum or 
maximum peak height/areas could be defined.  
 The entire fingerprint should be considered, including zones that are often ignored 
(e.g., fatty acids or chlorophylls). Zones that are barely detectable may be 
excluded. 
 It is recommended to include the evaluation of identity in different detection modes. 
 If the analysis is based on an existing standardized HPTLC method, the fingerprint 
images from a databank can be used for comparison (e.g., methods from HPTLC 
atlas of the HPTLC association, https://www.hptlc-association.org/atlas/hptlc-
atlas.cfm, or the CAMAG HPTLC method library, 
https://www.camag.com/products/ software). 
Identification can be automated by using suitable software and pattern recognition tools. 
However, specific acceptance criteria need to be set. These include the RF position of 
characteristic zones, acceptable ∆RF, color appearance value (Hue), variation in color 
appearance (∆Hue), and intensity. An example of its application is shown in chapter 7, 
section 7.3.13. 
8.3.7  Purity 
A purity test is performed to check the presence of non-target material (adulterants) in the 
herbal drug, preparation, or product. The method chosen for identification should also be 
suitable for checking purity. 
First, literature research should be performed to identify possible adulterants. After the 
procurement of representative samples, these should be analyzed side by side with the 
target herbal drug. A suitable method shows clear differences between the fingerprints of 
the different herbal drugs, as illustrated in Figure 8.11. In situation A, target and 
confounding herbal drugs show very similar fingerprints and cannot be distinguished with 
method 1, while in situation B, the use of method 2 allows discrimination of the herbal 
drugs.  
 
Figure 8.11 Schematic example for choosing a suitable HPTLC method for the identification and 
detection of adulteration. A: unsuitable method for distinguishing target herbal drug and the adulte-
rant; B: suitable method; C: illustration of a zone used to detect the adulterant; D: systematic 
mixtures of target herbal drug and adulterant.  
If the sample contains an admixture of an adulterant, a suitable method should be capable 
of detecting their presence based on the detection of at least one positive marker (zone). 
Positive zones are characteristic of the adulterant and absent or much fainter in the target 
herbal drug. For example, in Figure 8.11 C, the positive zone for detecting a mixture with 





an adulterant is the yellow zone just above the application position (blue arrow). This kind 
of evaluation is also applicable to detecting the addition of chemical substances (e.g., dyes 
in saffron stigma).  
8.3.7.1 The detection limit of the admixtures 
The detection limit of the admixtures should be investigated as well. For that, it is recom-
mended to prepare individual physical mixtures of 1, 5, 10, 25, 40 and 50% of the 
adulterant with 99, 95, 90, 75, 60 and 50% of the target herbal drug, as shown in Figure 
8.11 D. Different detection modes should be evaluated, as shown in chapter 5. The 
evaluation of Figure 8.11 D can also be performed in a more objective way using the PPI 
(not shown in this figure). It helps to better visualize zones that are very faint in the image 
(e.g., yellow zone, 1% of the adulterant in the target herbal drug).  
8.3.7.2 Limit test 
The limit test assesses whether the level of an impurity in the sample meets the 
acceptance criterion. The method must give a pass/fail result based on the quantification 
of the present impurity. It can be performed using the PPI. After localizing a positive marker 
in the chromatogram, its identity can be confirmed against a chemical reference standard. 
The scenarios illustrated in Figure 8.12 apply: 
 If the identity of the zone is known and the corresponding chemical reference stan-
dard is available, a standard solution is used with a concentration equivalent to the 
maximum acceptable amount of the impurity in the mixture. For example, in Figure 
8.12 A, the reference solution of substance x is prepared at a concentration corre-
sponding to the intensity of the yellow zone when 5% of the adulterant is in the 
herbal drug (when 5% is the maximum accepted). If the chemical reference 
standard is not available, approaches 2 and 3 can be followed. 
 If the identity of the zone is not known, a surrogate standard with a similar response 
can be used (see example in Figure 8.12 B). The same procedure should be fol-
lowed as in scenario A. 
 If a reference herbal drug/extract of the adulterant is available, this can be used for 
preparing a reference solution for the limit test (see example in Figure 8.12 C). In 
this case, the solution should be prepared at a concentration giving an intensity of 
substance x equivalent to the maximum accepted.  
If a test for purity already exists, its specifications can be applied (e.g., the limit test of rutin 
and quercetin in ginkgo products in the USP monograph, chapter 5). 
 
Figure 8.12 Schematic example of a limit test using an identified reference solution (A), a surrogate 
standard (B), and a reference herbal drug (C). 





I. How to perform the limit test using PPI 
First, the images are converted into peak profiles. Then, the heights of the target peaks 
of the reference and test solutions are compared. Passing samples are less intense than 
the reference while failing samples are more intense than the reference. A representation 
of this process is shown in Figure 8.13. Such evaluation is semi quantitative because 
these are plots of the peak heights (non-calibrated data). 
 
Figure 8.13. Use of peak profiles from images (PPI) in the limit test for rutin in ginkgo extract. A: 
Fingerprint of ginkgo extract under UV 254 nm prior to derivatization; B: Fingerprint converted into 
PPI; C: peak due to rutin in the sample, after the integration range was adjusted to exclude other 
peaks; D: bar graph showing the peak heights for rutin (red bar), and passing (green and blue bars) 
or failing (gray bar) samples. The intensity of rutin is equivalent to the maximum accepted in the 
extract. 
Same result can also be based on peak data (height and/or area) calculated by single level 
calibration. Nevertheless, it requires development of a quantitative method as will be 
shown in the next section.  
8.3.8 Content 
When coming to determination of content, it is important to ensure that the integrated and 
calibrated data is used. Therefore, in this section, the bar graph images are expressing 
the content of marker(s) after quantification rather than relative peak heights as shown in 
purity test. 
The content of an herbal drug / herbal drug preparation can be assessed based on 
individual markers or a group determination against a chemical substance or quantified 
herbal drug or extract. In the individual marker approach, individual peaks of the fingerprint 
are assayed against a corresponding reference peak. For group determination, in which a 
range of peaks due to the same class of compounds in the sample is used, the total area 
of the range is evaluated against a single chemical refence or a single peak in the 
reference extract. The results of the test for content of both approaches can be expressed 
in two manners: as a pass/fail (minimum content test) or the content in % of markers 
(assay). A third possibility is the group determination quantification with the corresponding 
range of a reference extract. This alternative was not pursued because a fully 
characterized reference extract is needed, which was not available.  Applying the 
comprehensive HPTLC fingerprinting concept means that the method used for 
identification and test for purity is also used for testing the content. If necessary, the con-
centration of the test solution is adjusted to fit the linear working range for quantification. 





Certain cases may require two concentrations of the test solution, e.g. if the concentration 
needed for quantification produces fingerprints that are too faint for use in identification. 
These can still be evaluated in a single analysis. To save time, the test solution prepared 
for the identification and test for purity can be suitably diluted for quantification. 
The steps for assessment of content by HPTLC are discussed in the next sections. The 
common steps for the two approaches (individual marker and group determination) are 
explained in section 8.3.8.1, and their individual cases are shown in sections 8.3.8.2 and 
8.3.8.3. 
8.3.8.1 Common steps 
II. Choice of the detection mode for quantitative assessment 
The selection of the most suitable detection for quantification should be based on the re-
sponse (shown in the PPI) of the target substance in different detection modes, prior to 
and after derivatization. Optionally, the PPSD at multiple wavelengths can be considered. 
Two elements are verified: the intensity of the signal, and the coefficient of variance (CV) 
for the same test solution, applied at several positions on the plate. For this test, a 
reference solution should be prepared in a single concentration (for example, one that 
contains the target compound(s) at 20 µg/mL) and applied at 4-8 different positions on the 
plate.  
The detection mode giving the highest response, either as peak area or as peak height, 
should be chosen, but the lowest CV of the 4-8 zones should also be considered. If 
possible, detection modes before derivatization should be preferred for quantification, in 
order to minimize possible errors introduced by additional steps of the method. 
III. Linear working range of the method 
In order to produce quantitative results, the linear working range of the method has to be 
investigated. First, the linearity of the calibration curve should be examined. As a rule of 
thumb, most of the chemical substances are within the linear working range when 
prepared at concentrations between 50 µg/mL and 1 µg/mL, with an application volume of 
2 µL (for absorption and fluorescence modes). In order to save time, it is recommended to 
prepare 10-15 concentrations within this range and analyze them on one plate (as shown 
in the example of Figure 8.14 A). 
The linearity study also applies if a quantified reference herbal drug/extract is used instead 
of a chemical reference substance. The concentrations of the solutions used for the 
calibration curve should be calculated based on the content of the target compound in the 
reference herbal drug/extract. For example, if 10 mg of an extract contains 40 µg of a 
substance x, then reference solutions of this extract can be prepared at concentrations of 
1.25, 2.5, 3.75, 5.0 mg/mL, to contain 5, 10, 15, 20 µg/mL of substance x, and so on 
(Figure 8.14 B). 
The test for linearity in the PPI can be performed based on the area (if baseline separation 
of the substance is achieved in the sample) or height of the target peak(s). A suitable linear 
working rage needs to be selected, as shown in Figure 8.14 C. Acceptable regression 
modes are linear and linear forced through zero. 
Once linearity is established, the quantitative method can be further validated (see recom-
mendations in section 8.3.5).  





Figure 8.14 Schematic example for determination of the linear working range of a reference solution 
or a given zone in a reference herbal drug or extract.  
8.3.8.2 Individual marker approach 
IV. Adjustment of the test solution to the linear working range 
After establishing the linear working range, the concentration of the test solution needs to 
be adjusted to fit this model. Usually, herbal drugs, at concentrations between 100 mg/mL 
and 10 mg/mL, and extracts between 50 mg/mL and 1 mg/mL, present zones in the linear 
range, using application volumes of 2 µL. In order to save time, it is recommended to 
prepare ten concentrations of a sample within these ranges and analyze them against a 
five-level calibration curve established in the previous step. A suitable concentration of the 
test solution would have the targeted marker(s) in the middle of the linear working range. 
V. Selection of concentration of the reference solution for routine assay 
For simplification of the assay, quantification with single level calibration is desirable. In 
this case, a reference solution should be prepared at the highest level of the linear range 
established in section III. The use of this calibration level also allows the quantification of 
samples that exceed the upper limit of the linear working range. 
For methods that use linear calibration functions not forced through zero, at least two 
reference points should be used for quantification. These are the lowest and highest levels 
of the linear range established in section III. 
VI. Setting acceptance criteria for minimum content  
In this step, the acceptance criteria for minimum content is established based on the lowest 
amount of the marker(s) considered appropriate for “good” samples of the herbal drug, 





preparation, or product, ± the error of the method, determined during validation. For this 
experiment, it is recommended to have at least ten samples of the herbal drug, which 
comply with the specifications for identity and purity. The samples are prepared at the 
concentration established during the linearity study (section IV), and the content of 
maker(s) is determined against the reference solution established in section V. 
VII. Selection of concentration of the reference solution for the test of 
minimum content 
The test for minimum content can be performed visually or with PPI. For this, a chemical 
reference substance or a quantified herbal drug/extract can be used at a concentration 
matching the intensity of a test solution with minimum content. 
VIII. Content: assay versus minimum content test  
Interpretation of the data can be performed in two ways:  
 Test for minimum content: the intensity of the target zones (Figure 8.15 A and B) 
or their content in % (Figure 8.15 C) in the reference and test solutions are 
compared. Passing samples have zones equally or more intense (or have equal or 
higher concentration) than the reference while failing samples have zones less 
intense (or have a lower concentration) than the reference.  
 Assay: the contents of the markers in the samples are calculated in % of the dried 
weight of the dried herbal drug, preparation, or product (Figure 8.15 C).  
 
Figure 8.15 Expression of the content. A: fingerprints of the chemical reference and samples solu-
tions under white light after derivatization; B: a pass/fail test comparing the intensity of the 
respective zones in reference solution and test solution; C: expression of the content of substance 
z in samples 1-3 in %. 
8.3.8.3 Group determination approach 
This approach uses a chemical reference substance or a quantified marker in a refence 
herbal drug or extract (e.g., Figure 8.14 B) to quantify a range of peaks in the samples. In 
this specific case, only peak area is used.  
IX. Identification of the zones in the fingerprint 
Although this step belongs to the investigation of specificity, this evaluation is different in 
the case of multiple markers and thus is highlighted here. To perform a quantitative 
assessment of a group of substances, first, it is recommended to identify the zones in the 
chromatogram by comparing their RF position, color, and UV spectra to those of reference 
substances.  





However, in most cases, not all reference standards are available, and thus the identity of 
the zones is difficult to verify. Nevertheless, it is possible to characterize zones against a 
reference substance as part of a class of compounds based on their similarities in RF posi-
tion, color, UV spectra, and, if necessary, MS analysis. In the example of Figure 8.16 B, 
the UV spectra of the zones due to flavonoids of St. John’s wort (quercetin, quercitrin, 
isoquercetin, hyperoside, and rutin) show shapes similar to a rutin standard solution. 
Conversely, in Figure 8.16 C, the spectrum of hypericin shows a shape different from the 
rutin standard.  
 
Figure 8.16 Comparison of UV spectra of different flavonoids of St. John’s wort (quercetin, 
quercitrin, isoquercetin, hyperoside, and rutin). Data recorded prior to derivatization. A: rutin 
reference solution and St. John’s wort sample under UV 366 nm after derivatization with NP 
reagent; B: spectra overlapping of zones due to flavonoids in the sample and rutin standard; C: 
spectra overlapping of zones due to hypericin in the sample and rutin standard. 
X. Adjustment of the test solution to the linear working range 
In this case, the linear working range for each of the main peaks within the selected range 
of the fingerprint should be determined to find a common suitable concentration of the test 
solution for quantification. The goal is to obtain a fingerprint in which all main peaks are 
within the linear range, and their sum can be calculated based on the same single level 
calibration.  
First, aliquots of samples available in large quantities, and compliant with the specification 
set during tests for identity and purity are pooled to create an average sample. The pooled 
sample is prepared according to the method for identification, and then fifteen dilutions are 
prepared from this stock solution. Recommended concentrations are shown in section IV. 
After the analysis of the test solutions, evaluations are performed on PPI (Figure 8.17) in 
the detection mode chosen in section 8.3.8.1. 
In the PPI, each peak within the selected range should be manually integrated using the 
perpendicular drop method, and the baseline should be corrected for all the peaks within 
the range. Both examples are shown in Figure 8.17 C and D).  
Because the concentrations of the target zones in the samples might not be known, the 
concentration of the test solutions can be assigned to the peaks when building the 
calibration curve. For example, in Figure 8.18, peaks 1-7 are labeled with the 
concentrations between 6-80 mg/mL according to the corresponding concentration of the 
test solution and plotted against the peak area. In Figure 8.18, the sample prepared at 80 
mg/mL has all the seven peaks within the linear range, and thus this concentration was 
selected for the assessment of content. 
It is also important to ensure that all selected peaks are within the linear working range of 
the chemical marker. For that, each peak of the sample is evaluated against the calibration 
curve set in section III. 
 






Figure 8.17 Determination of the linear working range for several peaks in a test solution of 
Ganoderma lucidum fruiting body, prepared in different concentrations.  A: image of the plate under 
UV 254 nm prior to derivatization; B: PPI of image A, without baseline correction; C: image B with 
baseline correction between RF 0.1 and 0.5; D: manual integration of each peak (peaks 1-7) in the 
PPI of the sample prepared at 80 mg/mL. 
 
 
Figure 8.18 Linear calibration for each of the seven peaks of Figure 8.17. 
 





XI. Selection of concentration of the reference solution for routine assay 
For simplification of the assay, a single level calibration of reference solution is used, equi-
valent to the middle concentration of the linear range, established in section III. This ap-
proach applies to linear function forced through zero.  
For methods that use linear functions not forced through zero, at least two reference points 
should be used for direct quantification. These are the lowest and highest levels of the 
linear range established in section III. 
XII. Setting acceptance criteria for minimum content  
In this step, the acceptance criterion for minimum content is established based on the 
lowest amount of the combined content of markers within a range, obtained in 
representative samples. For this experiment, it is recommended to have at least ten 
samples of the herbal drug, which comply with the specifications set during tests for identity 
and purity. They are prepared at concentration established during the linearity study 
(section X), and the maker(s) content is determined against the reference solution 
established in section XI. 
For calculation of the content, the range of zones in the PPI is integrated as one peak 
(Figure 8.19 A), and the total area is used in the linear equation. Most likely, the concentra-
tion of the test solutions will be displayed out of the linear range, because its signal is due 
to all added peaks. Therefore, it is important to extrapolate the calibration curve (Figure 
8.19 B). 
The content of the combined peaks in the samples is given in % of the dried weight of the 
herbal drug, preparation, or product.  
 
Figure 8.19 Integration of peaks as a total area of the peaks within the RF range (left image), and 
the calculation of its concentration against an extrapolated two-level calibration curve, which is not 













In this work, HPTLC proved to be a useful technique for routine quality control of herbal 
drugs, preparations and products. As demonstrated, it can simplify this process by per-
forming identity, purity and content testing in a single analysis, applying the concept of 
comprehensive HPTLC fingerprinting. This is afforded by rigorous standardization and 
qualification of the HPTLC data.  
Comprehensive HPTLC fingerprinting is a concept developed in the present thesis, which 
allies the qualitative and quantitative information of HPTLC images and can be performed 
with the standard instrument set up paired with suitable software. This gives opportunities 
to laboratories with different budgets to evaluate the quality of herbals in a less-costly way.  
This concept also proved to be suitable for the quality control of herbals, regardless of their 
regulatory category. In fact, if comprehensive HPTLC fingerprinting is adopted for this 
purpose, quality problems, such as adulteration and lower potency, can be detected 
already at early stages of the quality control process. It can also help other non-medicine 
industries to deliver higher quality herbals products.  
The specific conclusions of this work are the following:  
1.  In all market studies presented in this work, herbal products regulated under different 
categories had different qualities, where those regulated as non-medicines often 
showed one or more quality issues. Of the products evaluated in chapter 3, 52.4% of 
the milk thistle food supplements (FS), 33.3% of the coneflower FS, 45.5% of the black 
cohosh FS and 66.6% of black cohosh preparations showed quality problems. All 
THMP products were compliant with their label claim. Of the ginkgo products 
evaluated in chapter 5, approximately 81% presented at least one type of adulteration. 
These products were all commercialized as FS. 
2. The application of existing HPTLC methods, but including visual evaluation of the 
entire fingerprint and several detection modes, allows rapid identification of quality 
issues, especially adulterations. 
3.  The new concept comprehensive HPTLC fingerprinting allies for the first time the 
qualitative and quantitative aspects of HPTLC fingerprints in a single analysis, which 
permits performing tests for identity, purity, and content of markers in a straight 
forward and cost-efficient way. The concept was demonstrated using the example of 
Angelica gigas root. Based on the analysis of multiple batches of cultivated A. gigas 
root, the acceptance criteria for identification were established. The HPTLC method 
was capable of distinguishing 27 related species, detect the presence of mixtures of 
A. gigas with two other Angelica species traded as “Dang gui”. The method was also 
shown to be suitable for quantitative assessment of the sum of decursin and 
decursinol angelate as a pass/fail test (by visual evaluation or using PPI) and for 
content determination (using PPI or PPSD). 
4.  The comprehensive HPTLC fingerprinting concept demonstrated to be useful for 
detecting adulteration with herbal drugs and/or chemical substances, and for 
quantitatively performing limit tests, using the images generated during identification. 
This was demonstrated in the case of ginkgo products. The most common 
adulterations found were the presence of undeclared sophora fruit and/or high levels 
of rutin and/or quercetin. HPTLC and HPLC limit tests for rutin and quercetin were in 
agreement 100% or 98% of the cases, respectively. It, therefore, helped to reduce the 
number of analyses prescribed in the USP monograph for ginkgo dry extract. A 
decision tree showing the sequence of interpretation of the fingerprints obtained with 
different detections is included. It is a practical tool for helping the analyst in the 
routinary application of the HPTLC method. 
5. Comprehensive HPTLC fingerprinting methods, including a test for minimum content, 
proved to be a suitable and simpler alternative to the assay of markers. After proper 
validation, the simplification of the qualitative/quantitative HPTLC method enables 





laboratories to perform the analysis manually or with instruments and to interpret the 
results visually or using a software. Based on this approach, low-budget laboratories 
have a better chance of complying with the pharmacopoeia. With this approach, 
methods for Fritillaria thunbergii bulbs and corydalis rhizome were developed and 
validated, also showing good performance in interlaboratory trials. 
6. The application of the new concept for the quantification of a group of markers and 
the use of pattern recognition tools for the identity represents a step toward a more 
holistic and automated approach to quality for herbals. This was clearly shown for 
Ganoderma lucidum fruiting body. The new HPTLC method, which combined the tests 
for identification and the content determination of triterpenoic acids (ganoderic and 
ganoderenic acids), is an economic alternative to the USP method (27.00 CHF of a 
single HPTLC method versus approximately 74.00 CHF for the combined HPTLC plus 
UHPLC USP methods). Additionally, the use of pattern recognition tools allows 
simplification and automatization of the identification of this herbal drug.  
7.  The development of a detailed guideline is an important outcome of this work because 
it enables laboratories to develop, validate, and apply comprehensive HPTLC 
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